Original Article
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
N Engl J Med 2001; 344:783-792March 15, 2001
- Abstract
Background
The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor.
Methods
We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).
Results
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), longer survival (median survival, 25.1 vs. 20.3 months; P=0.046), and a 20 percent reduction in the risk of death. The most important adverse event was cardiac dysfunction, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone. Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management.
Conclusions
Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Progression-free Survival, According to Whether Patients Were Randomly Assigned to Receive Chemotherapy plus Trastuzumab or Chemotherapy Alone (Panel A), and Whether Chemotherapy Consisted of Either a Combination of an Anthracycline and Cyclophosphamide (Panel B) or Paclitaxel (Panel C).Figure 2
Kaplan–Meier Estimates of Overall Survival, According to Whether Patients Were Randomly Assigned to Receive Chemotherapy plus Trastuzumab or Chemotherapy Alone (Panel A) and Whether Chemotherapy Consisted of Either a Combination of an Anthracycline and Cyclophosphamide (Panel B) or Paclitaxel (Panel C).Article Activity
- Article
Despite advances in the diagnosis and treatment of breast cancer, more than 44,000 women in the United States will die this year of metastatic disease.1,2 Although objective responses to some chemotherapy regimens are common, few patients with metastatic disease are cured,3,4 and treatments frequently cause substantial adverse effects.
A growth factor receptor gene,5-7 human epidermal growth factor receptor (HER2), is amplified in 25 to 30 percent of breast cancers and in these cases the encoded protein is present in abnormally high levels in the malignant cells.8,9 Women with breast cancers that overexpress HER2 have an aggressive form of the disease with significantly shortened disease-free survival and overall survival.8-12 Laboratory studies indicate that amplification of HER2 has a direct role in the pathogenesis of these cancers,13-17 thereby providing investigators with an opportunity to target a therapeutic agent directly against the alteration.
Several murine monoclonal antibodies against the extracellular domain of the HER2 protein were found to inhibit the proliferation of human cancer cells that overexpressed HER2, both in vitro and in vivo.18-20 To minimize immunogenicity, the antigen-binding region of one of the more effective antibodies was fused to the framework region of human IgG21 and tested against breast-cancer cells that overexpressed HER2 in vitro and in vivo.21,22 This antibody, called trastuzumab, inhibited tumor growth when used alone4 but had synergistic effects20,22-24 when used in combination with cisplatin and carboplatin,20,23 docetaxel,24 and ionizing radiation25 and additive effects when used with doxorubicin, cyclophosphamide, methotrexate, and paclitaxel.22-26
Phase 1 clinical trials showed that the antibody is safe and confined to the tumor (unpublished data). Subsequent phase 2 trials demonstrated that many women with HER2-positive metastatic disease who had relapsed after chemotherapy had a response to trastuzumab27,28; as suggested by the preclinical data, the efficacy of trastuzumab when given with chemotherapy was superior to its effectiveness when used alone.28,29 We report the results of a phase 3 trial in which women with cancers that overexpressed HER2 who had not previously received chemotherapy for metastatic disease were randomly assigned to receive either chemotherapy alone or chemotherapy plus trastuzumab. The primary end points of the study were the time to disease progression and the incidence of adverse effects. Secondary end points were the rates and the duration of responses, the time to treatment failure, and overall survival.
Methods
Patients
Women with progressive metastatic breast cancer that overexpressed HER2 who had not previously received chemotherapy for metastatic disease were eligible for the study. Written informed consent was obtained from all patients. The level of expression of HER2 was determined by immunohistochemical analysis in a central laboratory. Only patients who had weak-to-moderate staining of the entire tumor-cell membrane for HER2 (referred to as a score of 2+) or more than moderate staining (referred to as a score of 3+) in more than 10 percent of tumor cells on immunohistochemical analysis were eligible for the study.
Patients were excluded if they had bilateral breast cancer, untreated brain metastases, osteoblastic bone metastases, pleural effusion or ascites as the only evidence of disease, a second type of primary cancer, or a Karnofsky score of less than 60. Patients were also excluded if they were pregnant or had received any type of investigational agent within 30 days before the study began.
Treatments
Patients were randomly assigned to receive either chemotherapy alone or chemotherapy plus trastuzumab. Chemotherapy consisted of an anthracycline (doxorubicin at a dose of 60 mg per square meter of body-surface area or epirubicin at a dose of 75 mg per square meter) plus cyclophosphamide (at a dose of 600 mg per square meter) for patients who had never before received an anthracycline, or paclitaxel (at a dose of 175 mg per square meter) for patients who had received adjuvant (postoperative) anthracycline. Doxorubicin or epirubicin plus cyclophosphamide or paclitaxel was administered once every three weeks for six cycles, and additional cycles were administered at the investigator's discretion. Trastuzumab was administered intravenously in a loading dose of 4 mg per kilogram of body weight, followed by a dose of 2 mg per kilogram once a week, until there was evidence of disease progression. On the detection of disease progression, patients were given the option of entering a nonrandomized, open-label study in which trastuzumab was administered at the same doses alone or in combination with other therapies. Sixty-six percent of such patients elected to do so.
Efficacy
Patients were evaluated for a response at weeks 8 and 20 and then at 12-week intervals. The determinations were made by the members of an independent response-evaluation committee, who were unaware of the patients' treatment assignments. A complete response was defined as the disappearance of all tumor on the basis of radiographic evidence, visual inspection, or both. A partial response was defined as a decrease of more than 50 percent in the dimensions of all measurable lesions. Disease progression was defined as an increase of more than 25 percent in the dimensions of any measurable lesion. The primary study end point was the time to disease progression. Prespecified secondary end points were the rate of objective response, the duration of a response, the time to treatment failure (a composite of disease progression, death, discontinuation of treatment, and the use of other types of antitumor therapy), and survival as of October 1999.
Adverse Events
Clinical assessments were performed at base line, at specified times, and at the time the patient was removed from the study. Adverse events were classified as mild, moderate, or severe. An independent cardiac evaluation committee whose members were unaware of patients' treatment assignments assessed the incidence, severity, treatment, and outcome of cardiac dysfunction. Abnormalities in laboratory values were classified by the grading system of the World Health Organization and cardiac dysfunction by the criteria of the New York Heart Association.
Statistical Analysis
We estimated that 450 patients would be needed in order for the study to detect at a power of 90 percent a 50 percent increase in the median time to disease progression, given a median time to progression of eight months in the subgroups receiving chemotherapy alone and a significance level of 0.05 with the use of a two-tailed log-rank test. All end points were analyzed according to the intention-to-treat principle. The primary analysis of all efficacy variables was performed on data pooled from both chemotherapy regimens. Additional analyses were performed within each chemotherapy group. The time to the various end points was analyzed with the use of Kaplan–Meier methods, and a two-sided log-rank test was used to compare the groups. The rate of objective response was analyzed with the use of normal approximation methods; a two-sided chi-square test was used to compare the groups.
Results
Characteristics of the Patients
We enrolled 469 patients between June 1995 and March 1997 (Table 1Table 1
Base-Line Characteristics of the Patients.); 5 patients were never treated: 2 declined treatment, 1 died before treatment was begun, 1 had disease progression at enrollment, and 1 was enrolled inadvertently. The median time in the study was 40 weeks (range, 1 to 127) in the group given chemotherapy plus trastuzumab, as compared with 25 weeks (range, 1 to 131) in the group given chemotherapy alone, reflecting the longer time to disease progression in the group that received combination treatment. The median number of doses of trastuzumab was 36 (range, 1 to 98).The base-line characteristics of the patients were similar among the treatment groups. Stratification on the basis of a history of adjuvant anthracycline treatment resulted in differences between the subgroups given an anthracycline and cyclophosphamide and the subgroups given paclitaxel. Patients who received paclitaxel had more involved lymph nodes at diagnosis and were more likely to have received adjuvant high-dose chemotherapy with stem-cell or marrow support than patients who received an anthracycline and cyclophosphamide. Of the 235 patients who received trastuzumab, 216 (92 percent) received at least 80 percent of the planned infusions and fewer than 5 percent required a delay in treatment or a reduction in doses of the chemotherapy. The final analysis of the primary end points was performed nine months after the enrollment of the last patient. Survival was analyzed 31 months after enrollment ended. The median duration of follow-up was 30 months (range, 30 to 51).
Efficacy
The median time to disease progression in the group assigned to chemotherapy plus trastuzumab was 7.4 months, whereas in the group given chemotherapy alone it was 4.6 months (P<0.001) (Table 2Table 2
Results of an Intention-to-Treat Analysis of the End Points. and Figure 1Figure 1Kaplan–Meier Estimates of Progression-free Survival, According to Whether Patients Were Randomly Assigned to Receive Chemotherapy plus Trastuzumab or Chemotherapy Alone (Panel A), and Whether Chemotherapy Consisted of Either a Combination of an Anthracycline and Cyclophosphamide (Panel B) or Paclitaxel (Panel C).). This difference was evident in both the subgroup that received an anthracycline, cyclophosphamide, and trastuzumab (median time to progression, 7.8 months, as compared with 6.1 months in the subgroup given only an anthracycline and cyclophosphamide; P<0.001) and the subgroup that received paclitaxel and trastuzumab (median time to progression, 6.9 months, as compared with 3.0 months in the group given paclitaxel alone; P<0.001) (Figure 1).As compared with chemotherapy alone, treatment with chemotherapy plus trastuzumab was associated with a significantly higher rate of overall response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), and a longer time to treatment failure (median, 6.9 vs. 4.5 months; P<0.001) (Table 2 and Table 3Table 3
Rates and Durations of Responses.). Statistically significant differences in the overall rates of response, the duration of response, and time to treatment failure were also found in the subgroup treated with an anthracycline, cyclophosphamide, and trastuzumab and the subgroup treated with paclitaxel and trastuzumab, as compared with the subgroups treated with an anthracycline and cyclophosphamide alone or paclitaxel alone, respectively (Table 2 and Table 3).The addition of trastuzumab was also associated with a significantly lower rate of death at one year (22 percent, as compared with 33 percent in the group given chemotherapy alone; P=0.008). The median survival was 25.1 months in the group given chemotherapy plus trastuzumab and 20.3 months in the group that received chemotherapy alone (P=0.046) (Table 2 and Figure 2Figure 2
Kaplan–Meier Estimates of Overall Survival, According to Whether Patients Were Randomly Assigned to Receive Chemotherapy plus Trastuzumab or Chemotherapy Alone (Panel A) and Whether Chemotherapy Consisted of Either a Combination of an Anthracycline and Cyclophosphamide (Panel B) or Paclitaxel (Panel C).). This calculation included patients in the group given chemotherapy alone who received open-label trastuzumab after the occurrence of disease progression. The risk of death was reduced by 18 to 20 percent in the subgroups given trastuzumab (Table 2). The efficacy of trastuzumab was consistently observed in both subgroups; however, patients with a score of 3+ for the overexpression of HER2 benefited to a greater degree from such treatment than those with a score of 2+.Deaths
As of October 1999, 314 patients had died (149 in the group given chemotherapy plus trastuzumab and 165 in the group given chemotherapy alone); 95 percent of these deaths were attributed to progressive disease. Two deaths, both in patients who had received an anthracycline, cyclophosphamide, and trastuzumab, were possibly related to trastuzumab therapy: one patient died of sepsis after 2 doses of trastuzumab, and the second died of hepatitis B–related hepatorenal syndrome after 11 doses of trastuzumab.
Adverse Events
Approximately 25 percent of patients had chills, fever, or both during the initial infusion of trastuzumab. Slowing the infusion rate ameliorated these symptoms. No episodes of frank anaphylaxis occurred, but one patient had moderate hypotension, and three had mild bronchospasm, all of which resolved without treatment.
Infection occurred in 47 percent of patients who were given chemotherapy plus trastuzumab and in 29 percent of those treated with chemotherapy alone (Table 4Table 4
Adverse Events That Occurred in More Than 10 Percent of Patients as a Group.). These infections consisted of mild-to-moderate infections of the upper respiratory tract in 72 percent of cases, catheter-related infections in 9 percent, a viral syndrome in 3 percent, and other types of infections in 16 percent. Of the 14 catheter-related infections among patients who received trastuzumab, 3 were severe, 13 required treatment, and 4 required surgical removal of the catheter. The incidence of sepsis was low and evenly distributed among the four subgroups. The addition of trastuzumab to the chemotherapy regimen increased the frequency of leukopenia and anemia (Table 4). These cases of cytopenia were mild to moderate in severity and did not necessitate the discontinuation of trastuzumab or withdrawal from the study.Twenty-five patients (19 in the subgroup given an anthracycline, cyclophosphamide, and trastuzumab and 6 in the subgroup given paclitaxel and trastuzumab) stopped taking trastuzumab because of adverse events. Eighteen patients (15 in the subgroup given an anthracycline, cyclophosphamide, and trastuzumab and 3 in the subgroup given paclitaxel and trastuzumab) had clinical signs of cardiac dysfunction. Two additional adverse events were attributed to trastuzumab therapy: an embolic stroke as a possible complication of cardiac dysfunction and chest pain after 49 doses of trastuzumab and six cycles of an anthracycline and cyclophosphamide. The events in the remaining five patients were not considered to be related to trastuzumab.
Cardiotoxicity
The adverse cardiac events prompted a retrospective analysis of all cases of cardiac dysfunction by an independent cardiac review and evaluation committee. This review identified 63 patients with symptomatic or asymptomatic cardiac dysfunction: 39 of 143 patients had received an anthracycline, cyclophosphamide, and trastuzumab (accounting for 27 percent of this subgroup); 11 of 135 had received an anthracycline and cyclophosphamide alone (incidence, 8 percent); 12 of 91 had received paclitaxel and trastuzumab (incidence, 13 percent); and 1 of 95 had received paclitaxel alone (incidence, 1 percent). Among these patients, the incidence of cardiac dysfunction of New York Heart Association class III or IV was highest among patients who had received an anthracycline, cyclophosphamide, and trastuzumab (16 percent, as compared with 3 percent among patients who had received an anthracycline and cyclophosphamide alone, 2 percent among those who had received paclitaxel and trastuzumab, and 1 percent among those who had received paclitaxel alone).
Of the 63 patients with cardiac dysfunction, 44 received standard medical treatment. The condition improved in 33 of these 44 patients, did not change in 5, and worsened in 4. One patient in the group given an anthracycline, cyclophosphamide, and trastuzumab died of cardiac dysfunction, as did one in the group given an anthracycline and cyclophosphamide alone. Among the five patients with persistent class III or IV cardiac dysfunction, three were in the group given an anthracycline, cyclophosphamide, and trastuzumab. Increasing age was the only base-line characteristic that was a significant risk factor for cardiac dysfunction in patients who were receiving the combination of an anthracycline, cyclophosphamide, and trastuzumab. The cumulative dose of anthracycline was not identified as a risk factor, but this finding should be interpreted with caution, since the majority of patients received all six cycles of an anthracycline and cyclophosphamide as specified in the protocol. Adding trastuzumab to the chemotherapy regimen did not increase the risk of other adverse events related to chemotherapy, and in no patient were antibodies against trastuzumab detected.
Discussion
We found that trastuzumab-based combination therapy was effective in that it reduced the relative risk of death by 20 percent at a median follow-up of 30 months. Few studies of metastatic breast cancer have demonstrated a survival advantage of this magnitude in association with the addition of a single agent.30,31 Particularly noteworthy is that two thirds of patients who were initially assigned to receive chemotherapy alone began, after disease progression, to receive open-label trastuzumab alone or with chemotherapy. Such a crossover design would generally reduce the likelihood that a survival advantage would be found. Significant increases in the time to disease progression, the rates of response, the duration of responses, and the time to treatment failure were observed in both subgroups that were given chemotherapy plus trastuzumab. These results increased survival, an end point free of ascertainment bias.
The benefit of trastuzumab plus paclitaxel does not appear to be attributable to the poor outcomes in the group given paclitaxel alone. The rate of response of 17 percent among patients who were given paclitaxel alone is lower than the rate previously reported for paclitaxel as an initial therapy for metastatic breast cancer.32 Our patients, however, had a particularly poor prognosis related to the overexpression of HER2, the progression of disease after adjuvant therapy that included an anthracycline, and the receipt of prior treatment with high-dose chemotherapy followed by hematopoietic stem-cell rescue (in 22 percent).
The most troubling adverse effect of trastuzumab was cardiac dysfunction, a complication that had not been anticipated on the basis of the results of preclinical or early clinical studies.20,23-29 We found that concurrent treatment with an anthracycline, cyclophosphamide, and trastuzumab significantly increased the risk of cardiac dysfunction, as compared with treatment with only an anthracycline and cyclophosphamide. A smaller increase in risk also occurred with treatment with paclitaxel and trastuzumab, as compared with treatment with paclitaxel alone, but all these patients had previously received an anthracycline. The 27 percent incidence of cardiac dysfunction among patients who were given an anthracycline, cyclophosphamide, and trastuzumab and the 13 percent incidence among those who were given paclitaxel and trastuzumab exceeded the expected incidence of less than 7 percent associated with cumulative doses of doxorubicin of up to 550 mg per square meter.33
Trastuzumab was discontinued because of cardiac dysfunction in 18 of 235 patients (8 percent) overall, and most of these patients received an anthracycline, cyclophosphamide, and trastuzumab. Continued use of trastuzumab did not cause further cardiac deterioration in most patients, and cardiac function improved in 75 percent of patients after the initiation of standard medical care. Among 81 patients who were assigned to receive an anthracycline and cyclophosphamide alone and who later received trastuzumab in an open-label fashion, clinically significant cardiac dysfunction developed in 7 (9 percent). The only significant risk factor associated with cardiac dysfunction was older age. The mechanism of the cardiotoxicity of trastuzumab is unknown.
Given the extremely poor prognosis of patients with HER2-positive metastatic breast cancer, the cardiotoxicity of trastuzumab must be weighed against its potential clinical benefit. We recommend a cautious approach to the use of trastuzumab in patients who have previously received anthracyclines and in those who are currently receiving anthracyclines. The adjuvant (postoperative) use of trastuzumab will be an important research topic, but since many patients with early-stage breast cancer can be cured by surgery and radiotherapy, the cardiotoxicity of trastuzumab will be a critical consideration. In this context, the risks of trastuzumab will necessitate great caution in its use, especially when it is combined with an anthracycline. Indeed, one large upcoming trial of adjuvant trastuzumab will evaluate a non-anthracycline-based regimen for this reason.22-24
The results of this phase 3 clinical trial indicate that trastuzumab, when added to conventional chemotherapy, can benefit patients with metastatic breast cancer that overexpresses HER2. As compared with the best available standard chemotherapy, concurrent treatment with trastuzumab and first-line chemotherapy was associated with a significantly longer time to disease progression, a higher rate of response, a longer duration of response, and improved overall survival. If confirmed in additional studies of patients with HER2-positive metastatic breast cancer, our results may affect treatment of this disease.
Supported by Genentech.
Dr. Slamon has received speakers' honorariums from Genentech. Drs. Leyland-Jones and Pegram have served as consultants to Genentech. Dr. Bajamonde is an employee of and a stockholder in Genentech. Drs. Shak and Fuchs are former employees of and stockholders in Genentech. Dr. Paton is a former employee of Genentech. Drs. Fleming and Eiermann have served on advisory boards for Genentech.
We are indebted to the members of the response-evaluation committee, which was chaired by Robert Ozols (Fox Chase Cancer Center) and Robert Heelan (Memorial Sloan-Kettering Cancer Center), for their independent assessment of tumor response; to the members of the cardiac review and evaluation committee, which included Andrew Seidman, Clifford Hudis, and Deborah Keefe (all of Memorial Sloan-Kettering Cancer Center), for their independent assessment of adverse cardiac events; to the staff of the contract research organization, Covance, as well as to the National Breast Cancer Coalition, both of which had an important role in the conduct of this large, multinational clinical trial; to the Genentech staff, including Tom Twadell, who initiated this study, for their efforts during the past decade; to Gracie Lieberman, Gwen Fyfe, Bob Cohen, Sue Hellmann, Mark Sliwkowski, Dave Stump, Corsee Sanders, and Janet Garman for their review of the manuscript; to the members of Breast Cancer Patient Advocates who contributed to the study design, participated in the data safety and monitoring committee, and assisted in patient outreach, education, and enrollment; and to the women who volunteered to participate in the trial.
Source Information
From the Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles (D.J.S., M.P.); the Department of Oncology, McGill University, Montreal (B.L.-J.): Medical Affairs, Genentech, South San Francisco, Calif. (S.S., V.P., A.B.); IntraBiotics, Mountain View, Calif. (H.F.); the Department of Biostatistics, University of Washington, Seattle (T.F.); the Department of Obstetrics and Gynecology, Frauenklinik vom Roten Kreuz, Munich, Germany (W.E.); the Department of Oncology, Rush–Presbyterian–St. Luke's Medical Center, Chicago (J.W.); the Department of Oncology, Hospital General Universitari Vall d'Hebron, Barcelona, Spain (J.B.); and the Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York (L.N.).
Address reprint requests to Dr. Slamon at UCLA School of Medicine, Division of Hematology/Oncology, 11-244 Factor Bldg., 10833 Le Conte, Los Angeles, CA 90095-1678, or at dslamon@mednet.ucla.edu.
Additional study investigators are listed in the Appendix.
Appendix
The following investigators and institutions also participated in the study: H. Allen, Las Vegas; A. Arnold, Hamilton Regional Cancer Centre, Hamilton, Ont., Canada; M. Azemar, Klinik für Tumorbiologie, Freiburg, Germany; P. Barrett-Lee, Velindre Hospital, Whitchurch, Cardiff, United Kingdom; J. Ellerton, Southern Nevada Cancer Research Foundation, Las Vegas; C. Fabian, University of Kansas Medical Center, Kansas City; J. Figueroa, Texas A&M University, Temple; F. Foss, Boston University Medical Center, Boston; P. Flynn, Minnesota Hematology/Oncology, Minneapolis; A. Goldrick, Cancer Therapy Center, Liverpool, N.S.W., Australia; P. Gonzalez, University of North Carolina Hospital, Chapel Hill; J. Graham, Bristol Oncology Centre, Bristol, United Kingdom; D. Grimes, Royal Brisbane Hospital, Herston, Australia; J. Gutheil, Sydney Kimmel Cancer Center, San Diego, Calif.; T. Hadley, Brown Cancer Center, University of Louisville, Louisville, Ky.; L. Harris, Duke University Medical Center, Durham, N.C.; R. Hart, Oncology of Wisconsin, Milwaukee; V. Harvey, Auckland Hospital, Grafton, Auckland, New Zealand; R. Hawkins, Addenbrooke's Hospital, Cambridge, United Kingdom; R. Herrmann, Abtl. Onkologie/Innere Medizin, Basel, Switzerland; Hoeffken Klinik für Innere Medizin, Jena, Germany; R. Jakesz, Allgemeines Krankenhause der Stadt Wien, Vienna, Austria; M. Jahanzeb, JFK Comprehensive Cancer Center, Atlantis, Fla.; C. Jones, Phoebe Cancer Center, Albany, Ga.; L. Kaizer, Mississauga, Ont., Canada; J. Kaufmann, Johann-Wolfgang-Goethe-Universitat Frankfurt, Frankfurt, Germany; Meden, Frauenklinik de Georg-August-Universitat, Gottingen, Germany; D. Merkel, Kellogg Cancer Center, Evanston, Ill.; A. Keller, Warren Cancer Research Foundation, Tulsa, Okla.; I. Kennedy, Waikato Hospital, Hamilton, New Zealand; I. Kuter, Massachusetts General Hospital, Boston; R. Leonard, Western General Hospital, Edinburgh, Scotland; G. Litton, Salt Lake City; S. Madajewicz, State University of New York at Stony Brook, Stony Brook, N.Y.; M. Martinez-Rio, Parkway Regional Medical Center, North Miami Beach, Fla.; R. Michaelson, West Orange, N.Y.; M. Modiano, Arizona Clinical Research Center, Tucson; M. Moore, Georgia Cancer Specialists, Dunwoody, Ga.; J. Mortimer, Washington University School of Medicine, St. Louis; R. Mowat, Toledo Clinic, Toledo, Ohio; L. Murray, M.D. Anderson Cancer Center, Houston; M. O'Rourke, Greenville Memorial Medical Center, Greenville, S.C.; D. Pasquale, St. Francis Hospital Medical Center, Hartford, Conn.; D. Patel, Rhinelander Medical Center, Rhinelander, Wis.; R. Patel, Bakersfield, Calif.; A. Paterson, Tom Baker Cancer Centre, Calgary, Alta., Canada; C. Perkins, Cancer Care Associates of Fresno, Fresno, Calif.; T. Perren, St. James University Hospital, Leeds, United Kingdom; K. Phadke, St. George Hospital, St. George, Australia; E. Reed, University of Nebraska, Omaha; D. Reding, Marshfield Clinic, Marshfield, Wis.; S. Rifkin, Tumor Institute of Swedish Hospital Medical Center, Seattle; N. Robert, Fairfax Hematology/Oncology Associates, Annandale, Va.; D. Rovira, University of Colorado Health Science Center, Denver; K. Rowland, Carle Cancer Center, Urbana, Ill.; M. Saley, Comprehensive Cancer Center, Birmingham, Ala.; B. Samuels, Lutheran General Hospital, Park Ridge, Ill.; G. Schaller, Frauenklinik, Universitätsklinikum B. Franklin, Berlin, Germany; M. Schonfelder, Tumorzentrum Leipzig Chirurgisches Krankenhaus, Leipzig, Germany; A. Schott, University of Michigan, Comprehensive Cancer Center, Ann Arbor; M. Schreeder, Comprehensive Cancer Center, Huntsville, Ala.; S. Schultz, Indianapolis; L. Schwartzberg, West Clinic, Memphis, Tenn.; S. Sedlacek, Colorado Cancer Research Program, Denver; P. Silverman, Ireland Cancer Center, University Hospitals of Cleveland, Cleveland; R. Snyder, St. Vincent's Hospital, Fitzroy, Australia; M. Spielmann, Institut Gustave Roussy, Villejuif, France; J. Sporn, University of Connecticut Health Center, Farmington; L. Stolbach, St. Vincent Hospital, Worcester, Mass.; D. Sutherland, Toronto Bayview Regional Cancer Center, Toronto; K. Tkaczuk, University of Maryland Cancer Center, Baltimore; D. Tripathy, Mt. Zion Cancer Center, San Francisco; F. Turpin, Centre René Huguenin, Saint-Cloud, France; M. Theodoulu, Memorial Sloan-Kettering Cancer Center, New York; M. Untch, Klinikum Großhadem, Munich, Germany; S. Verma, Ottawa Regional Cancer Center, Ottawa, Ont., Canada; C. Vogel, Aventura Concorde Center II, Aventura, Fla.; T. Weisberg, Maine Center for Cancer Medicine and Blood Disorders, Scarborough; H. Wheeler, Royal North Shore Hospital, Sydney, Australia; H. Wilke, Universitatsklinikum Essen, Essen, Germany; B. Yu, Henry Ford Hospital, Detroit.
- References
References
1
Landis SH, Murray T, Bolder S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999:49:8-31.
2
Hortobagyi GN . Treatment of breast cancer. N Engl J Med 1998;339:974-984
Full Text | Web of Science | Medline3
A'Hern RP ,Smith IE ,Ebbs SR . Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805
CrossRef | Web of Science | Medline4
Greenberg PA ,Hortobagyi GN ,Smith TL ,Ziegler LD ,Frye DK ,Buzdar AU . Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205
Web of Science | Medline5
Coussens L ,Yang-Feng TL ,Liao YC , et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139
CrossRef | Web of Science | Medline6
King CR ,Kraus MH ,Aaronson SA . Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-976
CrossRef | Web of Science | Medline7
Akiyama T ,Sudo C ,Ogawara H ,Toyoshima K ,Yamamoto T . The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646
CrossRef | Web of Science | Medline8
Slamon DJ ,Clark GM ,Wong SG ,Levin WJ ,Ullrich A ,McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline9
Slamon DJ ,Godolphin W ,Jones LA , et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
CrossRef | Web of Science | Medline10
Seshadri R ,Firgaira FA ,Horsfall DJ ,McCaul K ,Setlur V ,Kitchen P . Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-1942
Web of Science | Medline11
Press MF ,Pike MC ,Chazin VR , et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970
Web of Science | Medline12
Ravdin PM ,Chamness GC . The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers -- a review. Gene 1995;159:19-27
CrossRef | Web of Science | Medline13
Hudziak RM ,Schlessinger J ,Ulrich A . Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159-7163
CrossRef | Web of Science | Medline14
Di Fiore PP ,Pierce JH ,Krasu MH ,Segatto O ,King CR ,Aaronson SA . erbB-2 Is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182
CrossRef | Web of Science | Medline15
Guy CT ,Webster MA ,Schaller M ,Parsons TJ ,Cardiff RD ,Muller WJ . Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-10582
CrossRef | Web of Science | Medline16
Chazin VR ,Kaleko M ,Miller AD ,Slamon DJ . Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859-1866
Web of Science | Medline17
Pietras RJ ,Arboleda J ,Reese DM , et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-2446
Web of Science | Medline18
Hudziak RM ,Lewis GD ,Winget M ,Fendly BM ,Shepard HM ,Ullrich A . p185HER2 Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172
Web of Science | Medline19
Shepard HM ,Lewis GD ,Sarup JC , et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117-127
CrossRef | Web of Science | Medline20
Pietras RJ ,Fendly BM ,Chazin VR ,Pegram MD ,Howell SB ,Slamon DJ . Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838
Web of Science | Medline21
Carter P ,Presta L ,Gorman CM , et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-4289
CrossRef | Web of Science | Medline22
Pietras RJ ,Pegram MD ,Finn RS ,Maneval DA ,Slamon DJ . Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249
CrossRef | Web of Science | Medline23
Pegram M ,Hsu S ,Lewis G , et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251
CrossRef | Web of Science | Medline24
Konecny G ,Pegram MD ,Beryt M , et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999;57:114-11425
Pietras RJ ,Poen JC ,Gallardo D ,Wongvipat PN ,Lee HJ ,Slamon DJ . Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999;59:1347-1355
Web of Science | Medline26
Baselga J ,Norton L ,Albanell J ,Kim YM ,Mendelsohn J . Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831[Erratum, Cancer Res 1999;59:2020.]
Web of Science | Medline27
Baselga J ,Tripathy D ,Mendelsohn J , et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744
Web of Science | Medline28
Cobleigh MA ,Vogel CL ,Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
Web of Science | Medline29
Pegram MD ,Lipton A ,Hayes DF , et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671
Web of Science | Medline30
Smith G ,Henderson JC . New treatments for breast cancer. Semin Oncol 1996;23:506-528
Web of Science | Medline31
Fossati R ,Confalonieri C ,Torri V , et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460
Web of Science | Medline32
Sledge GW Jr ,Neuberg D ,Ingle J ,Martino S ,Wood W . Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Prog Proc Am Soc Clin Oncol 1997;16:1a-1a abstract.33
Von Hoff DD ,Layard MW ,Basa P , et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717
Web of Science | Medline
- Citing Articles (2149)
Citing Articles
1
Gary J. Kelloff, Caroline C. Sigman. (2012) Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery
CrossRef2
Forrest M. Kievit, Zachary R. Stephen, Omid Veiseh, Hamed Arami, Tingzhong Wang, Vy P. Lai, James O. Park, Richard G Ellenbogen, Mary L. Disis, Miqin Zhang. (2012) Targeting of Primary Breast Cancers and Metastases in a Transgenic Mouse Model Using Rationally Designed Multifunctional SPIONs. ACS Nano120210120621000
CrossRef3
T. Akiba, E. Kunieda, A. Kogawa, T. Komatsu, Y. Tamai, Y. Ohizumi. (2012) Re-irradiation for Metastatic Brain Tumors with Whole-brain Radiotherapy. Japanese Journal of Clinical Oncology
CrossRef4
L. Benjamin, F.-E. Cotté, F. Mercier, A. Vainchtock, G. Vidal-Trécan, I Durand-Zaleski. (2012) Burden of breast cancer with brain metastasis: a French national hospital database analysis. Journal of Medical Economics1-22
CrossRef5
Robert Whitfield, James Kollias, Primali De Silva, Helen Zorbas, Guy Maddern. (2012) Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit. ANZ Journal of Surgeryno-no
CrossRef6
E. Kouvaras, C.N. Papandreou, D.D. Daliani, A. Athanasiadis, G.K. Koukoulis. (2012) Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in “thin” and “thick” tissue sections. The Breast 21:1, 34-39
CrossRef7
Janet E. Dancey, Philippe L. Bedard, Nicole Onetto, Thomas J. Hudson. (2012) The Genetic Basis for Cancer Treatment Decisions. Cell 148:3, 409-420
CrossRef8
Ahmad Awada, Ivana Bozovic-Spasojevic, Louis Chow. (2012) New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?. Cancer Treatment Reviews
CrossRef9
Carole Gourmelon, Jean Sébastien Frenel, Mario Campone. (2012) What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?. Expert Review of Anticancer Therapy 12:2, 195-201
CrossRef10
Donald R.J. Singer, Andrew Marsh. (2012) Challenges and solutions for personalizing medicines. Health Policy and Technology
CrossRef11
Zohreh Hojati, Elham Orangi. (2012) HER-2/neu gene amplification assessment in breast cancer patients in Isfahan Province by Real Time PCR, differential PCR and immonohistochemistry. Gene
CrossRef12
Manuel Chiusa, Sara-Lynn Hool, Petra Truetsch, Siamak Djafarzadeh, Stephan M. Jakob, Franziska Seifriz, Stefan J. Scherer, Thomas M. Suter, Christian Zuppinger, Stephan Zbinden. (2012) Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes. Journal of Molecular and Cellular Cardiology
CrossRef13
Bin Wu, Ming Ye, Huafeng Chen, Jinfang F. Shen. (2012) Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clinical Therapeutics 34:2, 468-479
CrossRef14
Natalie Cook, Duncan I. Jodrell, David A. Tuveson. (2012) Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today
CrossRef15
Stefan A. Lange, Bernd Ebner, Astrid Wess, Matthias Kögel, Mieczyslaw Gajda, Thomas Hitschold, Jens Jung. (2012) Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clinical Research in Cardiology
CrossRef16
Y Gao, P Whitaker-Dowling, J A Griffin, I Bergman. (2012) Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Therapy
CrossRef17
T Doi, H Takiuchi, A Ohtsu, N Fuse, M Goto, M Yoshida, N Dote, Y Kuze, F Jinno, M Fujimoto, T Takubo, N Nakayama, R Tsutsumi. (2012) Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer
CrossRef18
Gradishar, William J., . (2012) HER2 Therapy — An Abundance of Riches. New England Journal of Medicine 366:2, 176-178
Full Text19
Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M., . (2012) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine 366:2, 109-119
Full Text20
Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale. (2012) HER2 testing in gastric cancer: a practical approach. Modern Pathology
CrossRef21
X. Pivot, M. Jary, E. Dobi, F. Bazan, L. Chaigneau, L. Cals, H. Almotlak, P. Montcuquet, N. Meneveau, C. Villanueva. (2012) Cancer du sein métastatique surexprimant HER2: évolutions des thérapeutiques. Oncologie
CrossRef22
R Y Tsang, R S Finn. (2012) Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. British Journal of Cancer 106:1, 6-13
CrossRef23
Sean Warsch, Alberto J. Montero, Stefan Glück. (2012) Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer. Current Breast Cancer Reports
CrossRef24
Elham Fakhrejahani, Masakazu Toi. (2012) Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored. Journal of Oncology 2012, 1-10
CrossRef25
K.A.B. Goddard, S. Weinmann, K. Richert-Boe, C. Chen, J. Bulkley, C. Wax. (2012) <i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions. Public Health Genomics 15:1, 1-10
CrossRef26
Hung-Wen Lai, Su-Yu Chien, Shou-Jen Kuo, Ling-Ming Tseng, Hui-Yi Lin, Chin-Wen Chi, Dar-Ren Chen. (2012) The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin. Evidence-Based Complementary and Alternative Medicine 2012, 1-12
CrossRef27
Karim S El-Sahwi, Peter E Schwartz, Alessandro D Santin. (2012) Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review of Anticancer Therapy 12:1, 41-49
CrossRef28
José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Kunz, Joo Hyuk Sohn, Vladimir Semiglazov, Guillermo Lerzo, Marketa Palacova, Volodymyr Probachai, Lajos Pusztai, Michael Untch, Richard D Gelber, Martine Piccart-Gebhart. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet
CrossRef29
Paolo Carli, Elisa Turchet, Daniela Quitadamo, Antonella Spada, Gianmaria Miolo, Elda Lamaj, Simon Spazzapan, Vincenzo Di Lauro, Riccardo Dolcetti, Andrea Veronesi, Diana Crivellari. (2012) Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology
CrossRef30
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 13:1, 25-32
CrossRef31
Alexandra V. Lucs, Benjamin Saltman, Christine H. Chung, Bettie M. Steinberg, David L. Schwartz, Jeffrey N. Myers. (2012) Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head & Neckn/a-n/a
CrossRef32
Casey Shuptrine, Rishi Surana, Louis M. Weiner. (2012) Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology
CrossRef33
Daniel E. Abbott, Antoine Brouquet, Elizabeth A. Mittendorf, Andreas Andreou, Funda Meric-Bernstam, Vicente Valero, Marjorie C. Green, Henry M. Kuerer, Steven A. Curley, Eddie K. Abdalla, Kelly K. Hunt, Jean-Nicolas Vauthey. (2012) Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery
CrossRef34
Gopa Iyer, Matthew I. Milowsky. (2012) Fibroblast growth factor receptor-3 in urothelial tumorigenesis
. Urologic Oncology: Seminars and Original Investigations
CrossRef35
Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens-Uwe Blohmer, Jörn Hilfrich, Dirk Strumberg, Peter A Fasching, Rolf Kreienberg, Hans Tesch, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Christian Jackisch, Jens Huober, Thorsten Kühn, Valentina Nekljudova, Gunter von Minckwitz. (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology
CrossRef36
Enrico Pegolo, Piernicola Machin, Franca Riosa, Anna Bassini, Laura Deroma, Carla Di Loreto. (2012) Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma. Cancer Cytopathologyn/a-n/a
CrossRef37
Giulio Casi, Dario Neri. (2012) Antibody-drug conjugates: Basic concepts, examples and future perspectives. Journal of Controlled Release
CrossRef38
Yoshinori Ito. (2011) Should we treat minimal breast cancer lesions?. Breast Cancer
CrossRef39
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef40
Cody P. Coyne, Toni Jones, Ryan Bear. (2011) Synthesis of a Covalent Epirubicin-(C 3 - amide )-Anti-HER2/ neu Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate. Cancer Biotherapy & Radiopharmaceuticals111222115845002
CrossRef41
Bryan Hoang, Raymond M Reilly, Christine Allen. (2011) Block Copolymer Micelles Target Auger Electron Radiotherapy to the Nucleus of HER2-Positive Breast Cancer Cells. Biomacromolecules111222104513009
CrossRef42
Dorothy M. K. Keefe, Emma H. Bateman. (2011) Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology
CrossRef43
Guopei Luo, Jiang Long, Bo Zhang, Chen Liu, Shunrong Ji, Jin Xu, Xianjun Yu, Quanxing Ni. (2011) Quantum dots in cancer therapy. Expert Opinion on Drug Delivery47-58
CrossRef44
J. D. Jensen, A. Knoop, A. V. Laenkholm, M. Grauslund, M. B. Jensen, E. Santoni-Rugiu, M. Andersson, M. Ewertz. (2011) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology
CrossRef45
Emanuel Raschi, Fabrizio Ponti. (2011) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Internal and Emergency Medicine
CrossRef46
D. J. Snodin, A. Suitters. 2011. Toxicology and Adverse Drug Reactions. , 157-214.
CrossRef47
E. A. Perez, A. C. Dueck, A. E. McCullough, M. M. Reinholz, K. S. Tenner, N. E. Davidson, J. Gralow, L. N. Harris, L. A. Kutteh, D. W. Hillman, R. B. Jenkins, B. Chen. (2011) Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. JNCI Journal of the National Cancer Institute
CrossRef48
Flora Zagouri, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Dimitrios Pectasides. (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treatment Reviews 37:8, 599-610
CrossRef49
C.B. Moelans, R.A. de Weger, E. Van der Wall, P.J. van Diest. (2011) Current technologies for HER2 testing in breast cancer. Critical Reviews in Oncology/Hematology 80:3, 380-392
CrossRef50
Nagi S. El Saghir, Arafat Tfayli, Hassan A. Hatoum, Zahi Nachef, Phuong Dinh, Ahmad Awada. (2011) Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives. Critical Reviews in Oncology/Hematology 80:3, 433-449
CrossRef51
Dionysis Papadatos-Pastos, Udai Banerji. (2011) Revisiting the role of molecular targeted therapies in patients with brain metastases. Journal of Neuro-Oncology 105:3, 467-474
CrossRef52
Christine H. Chung, Paula R. Pohlmann, Mace L. Rothenberg, Brian B. Burkey, Joel Parker, Kevin Palka, Joseph Aulino, Igor Puzanov, Barbara Murphy, Eben L. Rosenthal. (2011) Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head & Neck 33:12, 1804-1808
CrossRef53
Stephane Ederhy, Hassan Izzedine, Christophe Massard, Ghislaine Dufaitre, Jean Philippe Spano, Gerard Milano, Catherine Meuleman, Benjamin Besse, Franck Boccara, David Kahyat, Ariel Cohen, Jean Charles Soria. (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 80:3, 369-379
CrossRef54
Davendra PS Sohal, Weijing Sun. (2011) What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?. Expert Review of Anticancer Therapy 11:12, 1843-1850
CrossRef55
Jing Zhao, Yu Mi, Yutao Liu, Si-Shen Feng. (2011) Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials
CrossRef56
Pilar Eroles, Ana Bosch, J. Alejandro Pérez-Fidalgo, Ana Lluch. (2011) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews
CrossRef57
Steven A. Rosenzweig. (2011) Acquired resistance to drugs targeting receptor tyrosine kinases. Biochemical Pharmacology
CrossRef58
Heiner Schäfer, Chantal Dieckmann, Olena Korniienko, Gerhard Moldenhauer, Helena Kiefel, Alexey Salnikov, Achim Krüger, Peter Altevogt, Susanne Sebens. (2011) Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Letters
CrossRef59
Hye Jin Kim, Hwang-Phill Kim, Young-Kwang Yoon, Maeng-Sup Kim, Gwan-Sun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang. (2011) Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-Cancer Drugs1
CrossRef60
Sian E. Harding. (2011) Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling. Annals of the New York Academy of Sciences 1245:1, 48-49
CrossRef61
Mio Furuya, Jun Horiguchi, Hiroki Nakajima, Yoshikatsu Kanai, Tetsunari Oyama. (2011) Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Scienceno-no
CrossRef62
Clara Alsinet, Augusto Villanueva. (2011) Pronóstico genómico en el carcinoma hepatocelular. Gastroenterología y Hepatología
CrossRef63
M. Pegram, J. Liao. (2011) Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions. Clinical Breast Cancer
CrossRef64
Seigo Nakamura, Masashi Ando, Norikazu Masuda, Kenjiro Aogi, Hiroyo Ino, Hiroji Iwata, Yutaka Tokuda, Naohito Yamamoto, Hiroi Kasai, Masahiko Takeuchi, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yasuhiro Fujiwara. (2011) Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer. Clinical Breast Cancer
CrossRef65
Hidetoshi Hayashi, Junji Tsurutani, Taro Satoh, Norikazu Masuda, Wataru Okamoto, Ryotaro Morinaga, Masaaki Terashima, Masaki Miyazaki, Isamu Okamoto, Yukihiro Nishida, Shusei Tominaga, Yukihiko Tokunaga, Masahide Yamaguchi, Junichi Sakamoto, Takahiro Nakayama, Kazuhiko Nakagawa. (2011) Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer
CrossRef66
Serena Di Cosimo. (2011) Heart to heart with trastuzumab: a review on cardiac toxicity. Targeted Oncology
CrossRef67
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology
CrossRef68
Cagatay Arslan, Kadri Altundag, Omer Dizdar. (2011) Emerging drugs in metastatic breast cancer: an update. Expert Opinion on Emerging Drugs1-21
CrossRef69
J Gillibert-Duplantier, B Duthey, V Sisirak, D Salaün, T Gargi, O Trédan, P Finetti, F Bertucci, D Birnbaum, N Bendriss-Vermare, A Badache. (2011) Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene
CrossRef70
Luc Ceugnart, Bruno Coudert, Florence Dalenc, Jean-Marc Guinebretiere, Philippe Rouanet, Alain Toledano. (2011) Les traitements néoadjuvants (hors cancer du sein inflammatoire). Oncologie
CrossRef71
Nadine Dohollou, Gérard Ganem, Jean-Paul Guastalla, Rémy Salmon. (2011) Cancer du sein méta-analyse en première ligne. Oncologie
CrossRef72
Seock-Ah Im, Keun Seok Lee, Jungsil Ro, Eun Sook Lee, Youngmee Kwon, Jin-Hee Ahn, Jin Seok Ahn, Jee Hyun Kim, Han Sung Kang, Kyung Hwan Shin, Dong-Young Noh, In-Ae Park, Sung-Bae Kim, Young Hyuck Im, Sung Whan Ha. (2011) Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01. Breast Cancer Research and Treatment
CrossRef73
T. Hatschek, L. Carlsson, Z. Einbeigi, E. Lidbrink, B. Linderholm, B. Lindh, N. Loman, M. Malmberg, S. Rotstein, M. Söderberg, M. Sundquist, T. M. Walz, M. Hellström, H. Svensson, G. Åström, Y. Brandberg, J. Carstensen, M. Fernö, J. Bergh. (2011) Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Research and Treatment
CrossRef74
Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono, Aniruddha Choudhury, Rolf Kiessling, Hideki Fujii. (2011) Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. International Journal of Cancer 129:10, 2408-2416
CrossRef75
Miriam Martini, Loredana Vecchione, Salvatore Siena, Sabine Tejpar, Alberto Bardelli. (2011) Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology
CrossRef76
Giampietro Gasparini, Raffaele Longo. (2011) The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets1-10
CrossRef77
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology
CrossRef78
Yuling Wang, Jiji Chen, Joseph Irudayaraj. (2011) Nuclear Targeting Dynamics of Gold Nanoclusters for Enhanced Therapy of HER2 + Breast Cancer. ACS Nano111111085359008
CrossRef79
Agustí Barnadas, Laura G. Estévez, Ana Lluch-Hernández, Álvaro Rodriguez-Lescure, César Rodriguez-Sanchez, Pedro Sanchez-Rovira. (2011) An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. Advances in Therapy
CrossRef80
D. M. Collins, N. O'Donovan, P. M. McGowan, F. O'Sullivan, M. J. Duffy, J. Crown. (2011) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology
CrossRef81
D. Rayson, T. M. Suter, C. Jackisch, S. van der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. L. Canon, G. Ferrandina, S. Srinivasan, L. Zhang, D. J. Richel. (2011) Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology
CrossRef82
Geoffrey P. Luke, Doug Yeager, Stanislav Y. Emelianov. (2011) Biomedical Applications of Photoacoustic Imaging with Exogenous Contrast Agents. Annals of Biomedical Engineering
CrossRef83
Sara A. Hurvitz. (2011) Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. Cancer Treatment Reviews 37:7, 495-504
CrossRef84
Gaetana Di Fede, Giuseppe Bronte, Sergio Rizzo, Christian Rolfo Cervetto, Gianfranco Cocorullo, Gaspare Gulotta, Viviana Bazan, Antonio Russo. (2011) Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy 11:11, 1433-1445
CrossRef85
Sarah Barton, Charles Swanton. (2011) Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs 71:16, 2099-2113
CrossRef86
Cyrus Chargari, Hind Riahi Idrissi, Jean-Yves Pierga, Marc A. Bollet, Véronique Diéras, François Campana, Paul Cottu, Alain Fourquet, Youlia M. Kirova. (2011) Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics 81:3, 631-636
CrossRef87
Robert B. Livingston, William E. Barlow, Joseph J. Kash, Kathy S. Albain, Julie R. Gralow, Danika L. Lew, Lawrence E. Flaherty, Melanie E. Royce, Gabriel N. Hortobagyi. (2011) SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment 130:1, 123-131
CrossRef88
Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril Benes, Jeffrey Settleman, Kwok-Kin Wong, Lewis C. Cantley, Jeffrey A. Engelman. (2011) Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation 121:11, 4311-4321
CrossRef89
Yu Mi, Kai Li, Yutao Liu, Kan-Yi Pu, Bin Liu, Si-Shen Feng. (2011) Herceptin functionalized polyhedral oligomeric silsesquioxane – conjugated oligomers – silica/iron oxide nanoparticles for tumor cell sorting and detection. Biomaterials 32:32, 8226-8233
CrossRef90
Richard L Schilsky. (2011) Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine 8:6, 633-640
CrossRef91
Cheng-Cheng Hwang, Mariann Pintye, Liang-Che Chang, Huang-Yang Chen, Kun-Yan Yeh, Hui-Ping Chein, Nin Lee, Jim-Ray Chen. (2011) Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology 59:5, 984-992
CrossRef92
Min A Kim, Hyuk-Joon Lee, Han-Kwang Yang, Yung-Jue Bang, Woo Ho Kim. (2011) Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59:5, 822-831
CrossRef93
Anne-Sofie Schrohl, Hans Christian Pedersen, Sussie Steen Jensen, Signe Lykke Nielsen, Nils Brünner. (2011) Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 59:5, 975-983
CrossRef94
Sonia Servitja, Manuel Ramos, Miguel Gil, Pedro Sánchez-Rovira, Sergio Vázquez-Estevez, José Antonio Virizuela, Laura García-Estevez, Amalia Velasco, Ignacio Tusquets. (2011) Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Anti-Cancer Drugs1
CrossRef95
G. Somlo, C. L. Martel, S. K. Lau, P. Frankel, C. Ruel, L. Gu, A. Hurria, C. Chung, T. Luu, R. Morgan, L. Leong, M. Koczywas, M. McNamara, C. A. Russell, S. E. Kane. (2011) A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef96
Michael L. Maitland, Richard L. Schilsky. (2011) Clinical trials in the era of personalized oncology. CA: A Cancer Journal for Clinicians 61:6, 365-381
CrossRef97
Javier Cortés, Maurizio Scaltriti. 2011. Targeting HER2 + and trastuzumab-resistant metastatic breast cancer. , 035-049.
CrossRef98
Roberta Ferraldeschi, Gerhardt Attard. 2011. Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer. , 165-181.
CrossRef99
Charles Swanton. 2011. Chemotherapy and metastatic breast cancer. , 67-92.
CrossRef100
Andrew J. Armstrong, Mario A. Eisenberger, Susan Halabi, Stephane Oudard, David M. Nanus, Daniel P. Petrylak, A. Oliver Sartor, Howard I. Scher. (2011) Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. European Urology
CrossRef101
Mark R. Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht, Abhijit Mazumder, Judy Milloy, Peter M. Shaw, David Swank, Jian Wang, Ernst R. Berndt, Federico Goodsaid, Michael C. Palmer. (2011) Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery 10:11, 817-833
CrossRef102
S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi, D. Crivellari. (2011) Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of Oncology
CrossRef103
Rebecca L. Hirsh, Angela DeMichele. (2011) The Role of Lapatinib in the Preoperative Therapy of Breast Cancer. Current Oncology Reports
CrossRef104
T Shiroiwa, T Fukuda, K Shimozuma. (2011) Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. British Journal of Cancer 105:9, 1273-1278
CrossRef105
Kunal S. Taskar, Vinay Rudraraju, Rajendar K. Mittapalli, Ramakrishna Samala, Helen R. Thorsheim, Julie Lockman, Brunilde Gril, Emily Hua, Diane Palmieri, Joseph W. Polli, Stephen Castellino, Stephen D. Rubin, Paul R. Lockman, Patricia S. Steeg, Quentin R. Smith. (2011) Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research
CrossRef106
John C. Chang, Sanjiv S. Gambhir, Jürgen K. Willmann. 2011. Imaging Techniques in Drug Development and Clinical Practice. , 187-224.
CrossRef107
Stephen C. Alley, Simone Jeger, Robert P. Lyon, Django Sussman, Peter D. Senter. 2011. Empowered Antibodies for Cancer Therapy. , 289-323.
CrossRef108
Andrew V. Schally, Gabor Halmos. 2011. Targeting to Peptide Receptors. , 1219-1261.
CrossRef109
Ben Tran, Scott Kopetz, Jeanne Tie, Peter Gibbs, Zhi-Qin Jiang, Christopher H. Lieu, Atin Agarwal, Dipen M. Maru, Oliver Sieber, Jayesh Desai. (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:20, 4623-4632
CrossRef110
Cormac Sheridan. (2011) Pertuzumab to bolster Roche/Genentech's breast cancer franchise?. Nature Biotechnology 29:10, 856-858
CrossRef111
Mark Basik, Lodovico Balducci, Marco Bregni. (2011) Personalized medicine: a comprehensive approach in oncology. Journal of Medicine and the Person
CrossRef112
Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John, . (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine 365:14, 1273-1283
Full Text113
Nicholas R. Bertos, Morag Park. (2011) Breast cancer — one term, many entities?. Journal of Clinical Investigation 121:10, 3789-3796
CrossRef114
Kenji Tomizawa, Kenichi Suda, Ryoichi Onozato, Takayuki Kosaka, Hideki Endoh, Yoshitaka Sekido, Hisayuki Shigematsu, Hiroyuki Kuwano, Yasushi Yatabe, Tetsuya Mitsudomi. (2011) Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74:1, 139-144
CrossRef115
Douglas B. Sawyer, Anthony Caggiano. (2011) Neuregulin-1β for the treatment of systolic heart failure. Journal of Molecular and Cellular Cardiology 51:4, 501-505
CrossRef116
Nehmat Houssami, Petra Macaskill, Rosemary L. Balleine, Michael Bilous, Mark D. Pegram. (2011) HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment 129:3, 659-674
CrossRef117
Frederieke H van der Baan, Olaf H Klungel, Antoine CG Egberts, Hubert G Leufkens, Diederick E Grobbee, Kit CB Roes, Mirjam J Knol. (2011) Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics 12:10, 1485-1492
CrossRef118
Kab Choong Kim, Young Wha Koh, Heung-Moon Chang, Tae Hwan Kim, Jeong Hwan Yook, Byung Sik Kim, Se Jin Jang, Young Soo Park. (2011) Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays. Annals of Surgical Oncology 18:10, 2833-2840
CrossRef119
J. Chirgwin, S.L. Chua. (2011) Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review. The Breast 20:5, 394-406
CrossRef120
G. Damia, M. Broggini, S. Marsoni, S. Venturini, D. Generali. (2011) New Omics Information for Clinical Trial Utility in the Primary Setting. JNCI Monographs 2011:43, 128-133
CrossRef121
Alessandra Gennari, Mauro D'Amico. (2011) Anthracyclines in the management of metastatic breast cancer: state of the art. European Journal of Cancer Supplements 9:2, 11-15
CrossRef122
Jacob Mathew, Edith A. Perez. (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology1
CrossRef123
Matti Aapro. (2011) SIOG (International Society of Geriatric Oncology) and anthracycline use in the elderly. European Journal of Cancer Supplements 9:2, 30-35
CrossRef124
Elena B. Elkin, Deborah A. Marshall, Nathalie A. Kulin, Ilia L. Ferrusi, Michael J. Hassett, Uri Ladabaum, Kathryn A. Phillips. (2011) Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine 13:10, 853-860
CrossRef125
V. Semiglazov, W. Eiermann, M. Zambetti, A. Manikhas, A. Bozhok, A. Lluch, S. Tjulandin, M.D. Sabadell, A. Caballero, P. Valagussa, J. Baselga, L. Gianni. (2011) Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. European Journal of Surgical Oncology (EJSO) 37:10, 856-863
CrossRef126
Sita Subbaram, C Michael DiPersio. (2011) Integrin α3β1 as a breast cancer target. Expert Opinion on Therapeutic Targets 15:10, 1197-1210
CrossRef127
Zhiyuan Xu, Nicholas F. Marko, Sam T. Chao, Lilyana Angelov, Michael A. Vogelbaum, John H. Suh, Gene H. Barnett, Robert J. Weil. (2011) Relationship Between HER2 Status and Prognosis in Women with Brain Metastases from Breast Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef128
Laura Bourdeanu, Przemyslaw Twardowski, Sumanta Kumar Pal. (2011) Nursing Considerations With Pazopanib Therapy. Clinical Journal of Oncology Nursing 15:5, 513-517
CrossRef129
Kamal S. Saini, Hatem A. Azim Jr, Otto Metzger-Filho, Sherene Loi, Christos Sotiriou, Evandro de Azambuja, Martine Piccart. (2011) Beyond trastuzumab: New treatment options for HER2-positive breast cancer. The Breast 20, S20-S27
CrossRef130
Robert A. Beckman, Jason Clark, Cong Chen. (2011) Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Reviews Drug Discovery 10:10, 735-748
CrossRef131
Eugene R. Ahn, Charles L. Vogel. (2011) Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment
CrossRef132
Carmine Fedele, Gennaro Riccio, Carmela Coppola, Antonio Barbieri, Maria Gaia Monti, Claudio Arra, Carlo G. Tocchetti, Giuseppe D’Alessio, Nicola Maurea, Claudia De Lorenzo. (2011) Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Research and Treatment
CrossRef133
Claudia Rossig, Heribert Juergens, Wolfgang E. Berdel. (2011) New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. Pediatric Hematology-Oncology 28:7, 539-555
CrossRef134
Isaac S. Chan, Geoffrey S. Ginsburg. (2011) Personalized Medicine: Progress and Promise. Annual Review of Genomics and Human Genetics 12:1, 217-244
CrossRef135
Robert I. Griffiths, Deepa Lalla, Robert J. Herbert, Justin F. Doan, Melissa G. Brammer, Mark D. Danese. (2011) Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation110919072343009
CrossRef136
Jiyuan Yang, Hesheng Luo, Yan Li, Junchuan Li, Zhiqiang Cai, Xiaoyan Su, Danqing Dai, Wei Du, Tingxuan Chen, Ming Chen. (2011) Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens. Cell Biochemistry and Biophysics
CrossRef137
Laura J. Tafe, Gregory J. Tsongalis. (2011) The human epidermal growth factor receptor 2 (HER2). Clinical Chemistry and Laboratory Medicine---
CrossRef138
Ya Cao, Ronald A. DePinho, Matthias Ernst, Karen Vousden. (2011) Cancer research: past, present and future. Nature Reviews Cancer
CrossRef139
Alexandre Cochet, Gaetan Quilichini, Inna Dygai-Cochet, Claude Touzery, Michel Toubeau, Alina Berriolo-Riedinger, Bruno Coudert, Yves Cottin, Pierre Fumoleau, François Brunotte. (2011) Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment
CrossRef140
P Todeschini, E Cocco, S Bellone, J Varughese, K Lin, L Carrara, F Guzzo, N Buza, P Hui, D-A Silasi, E Ratner, M Azodi, P E Schwartz, T J Rutherford, S Pecorelli, A D Santin. (2011) Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal of Cancer
CrossRef141
Francesca Bonura, Daniela Di Lisi, Salvatore Novo, Natale D’Alessandro. (2011) Timely Recognition of Cardiovascular Toxicity by Anticancer Agents: A Common Objective of the Pharmacologist, Oncologist and Cardiologist. Cardiovascular Toxicology
CrossRef142
Gunter Minckwitz, Sibylle Loibl, Andrea Maisch, Michael Untch. (2011) Incorporating Agents that Target HER2 in the Neoadjuvant Setting. Current Breast Cancer Reports
CrossRef143
Devika Gajria, Joseph Gonzalez, Kimberly Feigin, Sujata Patil, Carol Chen, Maria Theodoulou, Pamela Drullinsky, Gabriella D’Andrea, Diana Lake, Larry Norton, Clifford A. Hudis, Tiffany A. Traina. (2011) Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef144
M. Bates, J. Sperinde, W. J. Kostler, S. M. Ali, K. Leitzel, E. M. Fuchs, A. Paquet, Y. Lie, T. Sherwood, R. Horvat, C. F. Singer, J. Winslow, J. M. Weidler, W. Huang, A. Lipton. (2011) Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology 22:9, 2014-2020
CrossRef145
Rashmita Sahoo, Vidya Harini V, V. Chitti Babu, Geeta V. Patil Okaly, Smitha Rao, Ashwini Nargund, E. Venkataswamy, Raghavendra Rao, B.S. Ajai Kumar. (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73:3, 316-319
CrossRef146
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvão de Castro, Gilberto Schwartsmann, Algemir Lunardi Brunetto. (2011) The process of drug development in pediatric oncology: a review of basic principals and a look into the future. Clinical Investigation 1:9, 1237-1249
CrossRef147
Galina Denisova, Kristina Jenkins, Carole Evelegh, Jonathan Bramson. (2011) Novel method for differentiation between Trastuzumab and host adaptive response. Molecular Immunology 48:15-16, 1882-1885
CrossRef148
H. Joensuu, J. Sperinde, M. Leinonen, W. Huang, J. Weidler, P. Bono, V. Kataja, R. Kokko, T. Turpeenniemi-Hujanen, S. Jyrkkio, J. Isola, P.- L. Kellokumpu-Lehtinen, A. Paquet, Y. Lie, M. Bates. (2011) Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology 22:9, 2007-2013
CrossRef149
Y. Saito, R. Oshitanai, M. Terao, M. Terada, B. Tsuda, T. Okamura, Y. Suzuki, Y. Tokuda. (2011) Post-marketing Safety Evaluation of S-1 in Patients with Inoperable or Recurrent Breast Cancer: Especially in Patients Treated with S-1 + Trastuzumab. Japanese Journal of Clinical Oncology 41:9, 1051-1058
CrossRef150
Adriana Albini, Eugenio Cesana, Francesco Donatelli, Rosaria Cammarota, Eraldo O Bucci, Massimo Baravelli, Claudio Anzà, Douglas M Noonan. (2011) Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiology 7:5, 693-704
CrossRef151
Stephen R.D. Johnston. (2011) The role of chemotherapy and targeted agents in patients with metastatic breast cancer. European Journal of Cancer 47, S38-S47
CrossRef152
Tsuyoshi Suzuki, Akihiro Fujii, Hiroshi Ochi, Hideo Nakamura. (2011) Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells. Journal of Cellular Biochemistry 112:9, 2279-2286
CrossRef153
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef154
Shilpen Patel, Reshma Jagsi, Natalie Cook, Luke Hughes-Davies, Christine Parkinson. (2011) The International Core Literature Consensus (ICLC): an Alternative Curriculum for Oncologists. Journal of Cancer Education 26:3, 420-426
CrossRef155
C. K. Lee, M. Hudson, M. Stockler, A. S. Coates, S. Ackland, V. Gebski, S. Lord, M. Friedlander, F. Boyle, R. J. Simes. (2011) A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment 129:2, 467-476
CrossRef156
F. Cardoso, L. Fallowfield, A. Costa, M. Castiglione, E. Senkus, . (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22:Supplement 6, vi25-vi30
CrossRef157
Filip Janku, Ignacio Garrido-Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock. (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1601-1612
CrossRef158
D. Amadori, C. Milandri, G. Comella, S. Saracchini, S. Salvagni, C. Barone, R. Bordonaro, V. Gebbia, A. Barbato, P. Serra, D. Gattuso, O. Nanni, B. Baconnet, G. Gasparini. (2011) A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. European Journal of Cancer 47:14, 2091-2098
CrossRef159
Mohamed B Satti. (2011) Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia. Histopathology 59:3, 537-542
CrossRef160
Hiromasa Horiguchi, Hideo Yasunaga, Hideki Hashimoto, Shinya Matsuda. (2011) Incidence of Severe Adverse Events Requiring Hospital Care after Trastuzumab Infusion for Metastatic Breast Cancer: A Nationwide Survey using an Administrative Claim Database. The Breast Journalno-no
CrossRef161
Bakheet Elsadek, Felix Kratz. (2011) Impact of albumin on drug delivery — New applications on the horizon. Journal of Controlled Release
CrossRef162
Alberto Gabizon, Hilary Shmeeda, Tal Grenader. (2011) Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy. European Journal of Pharmaceutical Sciences
CrossRef163
J. Huober, P.A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener, C. Thomssen, T. Reimer, S. Paepke, H.A. Azim, V. Ragosch, E. Kubista, A.K. Baumgärtner, M.W. Beckmann, C. May, I. Nimmrich, N. Harbeck. (2011) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial. The Breast
CrossRef164
Jasgit C. Sachdev, Mohammad Jahanzeb. (2011) Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer
CrossRef165
Brian M Zeglis, Priya Mohindra, Gabriel I Weissmann, Vadim Divilov, Scott Alan Hilderbrand, Ralph Weissleder, Jason S. Lewis. (2011) A Modular Strategy for the Construction of Radiometallated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry. Bioconjugate Chemistry110831040206032
CrossRef166
Thomas Hogberg. (2011) What is the Role of Chemotherapy in Endometrial Cancer?. Current Oncology Reports
CrossRef167
Nicholas B. La Thangue, David J. Kerr. (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology 8:10, 587-596
CrossRef168
Han-Peng Kuo, Tzu-Chao Chuang, Ming-Han Yeh, Shih-Chung Hsu, Tzong-Der Way, Po-Yuan Chen, Shan-Shue Wang, Yung-Hsien Chang, Ming-Ching Kao, Jah-Yao Liu. (2011) Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway. Journal of Agricultural and Food Chemistry 59:15, 8216-8224
CrossRef169
C. Serrano, J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, C. Saura, J. Perez, M. Vidal, E. Munoz-Couselo, M. J. Carreras, G. Sanchez-Olle, J. Tabernero, J. Baselga, S. Di Cosimo. (2011) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals of Oncology
CrossRef170
Shinichirou Izawa, Koji Kono, Kousaku Mimura, Yoshihiko Kawaguchi, Mitsuaki Watanabe, Takanori Maruyama, Hideki Fujii. (2011) H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. Cancer Immunology, Immunotherapy
CrossRef171
Erin M. Olson, Nancy U. Lin, Ian E. Krop, Eric P. Winer. (2011) The ethical use of mandatory research biopsies. Nature Reviews Clinical Oncology 8:10, 620-625
CrossRef172
X.-F. Le, W. Mao, G. He, F.-X. Claret, W. Xia, A. A. Ahmed, M.-C. Hung, Z. H. Siddik, R. C. Bast. (2011) The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. JNCI Journal of the National Cancer Institute
CrossRef173
Ignacio Garrido-Laguna, Manuel Hidalgo, Razelle Kurzrock. (2011) The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology 8:9, 562-566
CrossRef174
J.- C. Soria, J. Y. Blay, J. P. Spano, X. Pivot, Y. Coscas, D. Khayat. (2011) Added value of molecular targeted agents in oncology. Annals of Oncology 22:8, 1703-1716
CrossRef175
Christine L. MANDRAWA, Josephine STEWART, Gavin C. FABINYI, Susan P. WALKER. (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Australian and New Zealand Journal of Obstetrics and Gynaecology 51:4, 372-376
CrossRef176
Virginia Arrazubi, Roberto Pazo, Dolores Isla, José Luis Pérez Gracia. (2011) SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology 13:8, 587-591
CrossRef177
Zoe Kemp, Alison Jones. (2011) A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Advances in Therapy 28:8, 603-614
CrossRef178
Christina B Ching, Mahul B Amin, Raymond R Tubbs, Paul Elson, Eric Platt, Robert Dreicer, Amr Fergany, Donna E Hansel. (2011) HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Modern Pathology 24:8, 1111-1119
CrossRef179
Yaojun Feng, Xinhong Wu, Cuiping Pan, Juan Xu, Wei Zhong, Jun Shao, Biao Ma. (2011) HER-2 expression after neoadjuvant chemotherapy of the breast cancers. The Chinese-German Journal of Clinical Oncology 10:8, 476-479
CrossRef180
Kerrington R. Molhoek, Amber L. Shada, Mark Smolkin, Sudhir Chowbina, Jason Papin, David L. Brautigan, Craig L. Slingluff. (2011) Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Research 21:4, 274-284
CrossRef181
Ingo K. Mellinghoff, Andrew B. Lassman, Patrick Y. Wen. (2011) Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 59:8, 1205-1212
CrossRef182
Timothy R. Wilson, Diana Y. Lee, Leanne Berry, David S. Shames, Jeff Settleman. (2011) Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers. Cancer Cell 20:2, 158-172
CrossRef183
Shivani Rai Paliwal, Rishi Paliwal, Govind P Agrawal, Suresh P Vyas. (2011) Liposomal nanomedicine for breast cancer therapy. Nanomedicine 6:6, 1085-1100
CrossRef184
Roscoe Atkinson, Jens Mollerup, Anne-Vibeke Lænkholm, Mark Verardo, Debra Hawes, Deborah Commins, Birte Engvad, Adrian Correa, Charlotte Cort Ehlers, Kirsten Vang Nielsen. (2011) Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation. Archives of Pathology & Laboratory Medicine 135:8, 1010-1016
CrossRef185
Xiaoping Huang, Shuiliang Wang, Choon-Kee Lee, XiaoHe Yang, Bolin Liu. (2011) HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 307:1, 72-79
CrossRef186
Ryohei Adachi, Shota Horiuchi, Yoshiyuki Sakurazawa, Takuya Hasegawa, Koji Sato, Toshiyuki Sakamaki. (2011) ErbB2 down-regulates microRNA-205 in breast cancer. Biochemical and Biophysical Research Communications 411:4, 804-808
CrossRef187
Soheir R. Demian, Mona Hamdy, Inas M. Ali. (2011) The regulatory effects of interleukin-12 on interleukin-18 and interferon-γ production in Egyptian breast cancer patients. Alexandria Journal of Medicine
CrossRef188
Young Soo Park, Hee Sang Hwang, Hye Jin Park, Min-Hee Ryu, Heung-Moon Chang, Jeong Hwan Yook, Byung Sik Kim, Se Jin Jang, Yoon-Koo Kang. (2011) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. Human Pathology
CrossRef189
H. K. Chew, G. Somlo, P. C. Mack, B. Gitlitz, R. Gandour-Edwards, S. Christensen, H. Linden, L. J. Solis, X. Yang, A. M. Davies. (2011) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology
CrossRef190
S. M. Amos, C. P. M. Duong, J. A. Westwood, D. S. Ritchie, R. P. Junghans, P. K. Darcy, M. H. Kershaw. (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118:3, 499-509
CrossRef191
L. Rubinstein, M. LeBlanc, M. A. Smith. (2011) More Randomization in Phase II Trials: Necessary but not Sufficient. JNCI Journal of the National Cancer Institute 103:14, 1075-1077
CrossRef192
Yozo Nakazawa, Leslie E Huye, Vita S Salsman, Ann M Leen, Nabil Ahmed, Lisa Rollins, Gianpietro Dotti, Stephen M Gottschalk, Matthew H Wilson, Cliona M Rooney. (2011) PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. Molecular Therapy
CrossRef193
Balázs Győrffy, Zsombor Benke, András Lánczky, Bálint Balázs, Zoltán Szállási, József Timár, Reinhold Schäfer. (2011) RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Research and Treatment
CrossRef194
C-R Pradeep, W J Köstler, M Lauriola, R Z Granit, F Zhang, J Jacob-Hirsch, G Rechavi, H B Nair, B T Hennessy, A M Gonzalez-Angulo, R R Tekmal, I Ben-Porath, G B Mills, E Domany, Y Yarden. (2011) Modeling ductal carcinoma in situ: a HER2–Notch3 collaboration enables luminal filling. Oncogene
CrossRef195
DG Hicks, BF Boyce. (2011) The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotechnic & Histochemistry1-4
CrossRef196
J G C van Hasselt, A H Boekhout, J H Beijnen, J H M Schellens, A D R Huitema. (2011) Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity. Clinical Pharmacology & Therapeutics 90:1, 126-132
CrossRef197
Ronald M. Witteles, Michael B. Fowler, Melinda L. Telli. (2011) Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?. Heart Failure Clinics 7:3, 333-344
CrossRef198
Teresa Alonso Gordoa, José Ángel García-Sáenz, Juan Francisco Rodríguez Moreno, Francisco José Hernández Pérez, Eduardo Díaz-Rubio. (2011) Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?. Clinical and Translational Oncology 13:7, 451-459
CrossRef199
Y Chen, Y Xie, T Chan, A Sami, S Ahmed, Q Liu, J Xiang. (2011) Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice. Cancer Gene Therapy 18:7, 489-499
CrossRef200
Michael S. Ewer, Daniel D. Von Hoff, Robert S. Benjamin. (2011) A Historical Perspective of Anthracycline Cardiotoxicity. Heart Failure Clinics 7:3, 363-372
CrossRef201
Marina Pajic, Christopher J. Scarlett, David K. Chang, Robert L. Sutherland, Andrew V. Biankin. (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics 130:1, 93-101
CrossRef202
Jayashree P. Joshi, Nicole E. Brown, Samantha E. Griner, Rita Nahta. (2011) Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochemical Pharmacology
CrossRef203
Akm Hossain, Alice Chen, Percy Ivy, Daniel J. Lenihan, Jonathan Kaltman, Wendy Taddei-Peters, Scot C. Remick. (2011) The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting. Heart Failure Clinics 7:3, 373-384
CrossRef204
Krishna K. Singh, Praphulla C. Shukla, Adrian Quan, Fina Lovren, Yi Pan, Jesse I. Wolfstadt, Milan Gupta, Mohammed Al-Omran, Howard Leong-Poi, Hwee Teoh, Subodh Verma. (2011) Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications 411:2, 421-426
CrossRef205
Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, Thomas Bachelot, Isabelle Ray-Coquard, Olivier Tredan, Pierre Biron, Jean-François Latour, Jean-Yves Blay, Jean-Paul Guastalla, Bertrand Favier. (2011) Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006. Breast Cancer Research and Treatment 128:1, 187-195
CrossRef206
E. Voulgaris, G. Pentheroudakis, N. Pavlidis. (2011) Cancer and pregnancy: A comprehensive review. Surgical Oncology
CrossRef207
Sylvie Lorenzen, Florian Lordick. (2011) How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Current Opinion in Oncology 23:4, 396-402
CrossRef208
Bonnie Ky, Joseph R. Carver. (2011) Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy. Heart Failure Clinics 7:3, 323-331
CrossRef209
Ragavendra R. Baliga, James B. Young. (2011) Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemotherapy: Is It Time to Change Tracks?. Heart Failure Clinics 7:3, xiii-xix
CrossRef210
E. Razis, M. Bobos, V. Kotoula, A. G. Eleftheraki, H. P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K. T. Kalogeras, D. Skarlos, G. Fountzilas. (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Research and Treatment 128:2, 447-456
CrossRef211
Elda Tagliabue, Manuela Campiglio, Serenella M. Pupa, Sylvie Ménard, Andrea Balsari. (2011) Activity and resistance of trastuzumab according to different clinical settings. Cancer Treatment Reviews
CrossRef212
Glenn Liu, Yu-Hui Chen, Jill Kolesar, Wei Huang, Robert DiPaola, Michael Pins, Michael Carducci, Mark Stein, Glenn J. Bubley, George Wilding. (2011) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer,. Urologic Oncology: Seminars and Original Investigations
CrossRef213
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef214
C. Xiao, Y. Gong, E. Y. Han, A. M. Gonzalez-Angulo, N. Sneige. (2011) Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Annals of Oncology 22:7, 1547-1553
CrossRef215
Giuseppe Bogina, Laura Bortesi, Marcella Marconi, Marco Venturini, Gianluigi Lunardi, Francesca Coati, Alberto Massocco, Erminia Manfrin, Cristina Pegoraro, Giuseppe Zamboni. (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Archiv 459:1, 1-10
CrossRef216
Carsten Denkert, Silvia Darb-Esfahani, Sibylle Loibl, Ioannis Anagnostopoulos, Korinna Jöhrens. (2011) Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Seminars in Immunopathology 33:4, 341-351
CrossRef217
Khusru Asadullah, Frank Kramer. (2011) Biomarkers for intensive care medicine patients: the (stony) path into a bright future?. Biomarkers 16:S1, S1-S4
CrossRef218
Manuela Campiglio, Rosaria Bufalino, Marco Sandri, Elisa Ferri, Rosa Anna Aiello, Andrea Matteis, Marcella Mottolese, Sabino Placido, Patrizia Querzoli, Antonio Jirillo, Alberto Bottini, Manuela Fantini, Andrea Bonetti, Fulvia Pedani, Maria Mauri, Annamaria Molino, Antonella Ferro, Serenella M. Pupa, Marianna Sasso, Sylvie Ménard, Andrea Balsari, Elda Tagliabue. (2011) Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Research and Treatment 128:1, 147-154
CrossRef219
Teemu T. Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X. Sliwkowski. (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment 128:2, 347-356
CrossRef220
Brigitte Rack, Julia Jückstock, Maria Günthner-Biller, Ulrich Andergassen, Julia Neugebauer, Philip Hepp, Alexandra Schoberth, Doris Mayr, Thomas Zwingers, Christian Schindlbeck, Klaus Friese, Wolfgang Janni. (2011) Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics
CrossRef221
Caterina Nardella, John G. Clohessy, Andrea Alimonti, Pier Paolo Pandolfi. (2011) Pro-senescence therapy for cancer treatment. Nature Reviews Cancer 11:7, 503-511
CrossRef222
Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, Dominy Browning, Mayur M. Amonkar, Jon Karnon, Mel D. Walker, David Cameron. (2011) Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. The European Journal of Health Economics
CrossRef223
D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross, J. Baselga. (2011) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology
CrossRef224
Yu Kataoka, Toru Mukohara, Hideo Tomioka, Yohei Funakoshi, Naomi Kiyota, Yutaka Fujiwara, Masakazu Yashiro, Kosei Hirakawa, Midori Hirai, Hironobu Minami. (2011) Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Investigational New Drugs
CrossRef225
Pierantonio Menna, Odalys Gonzalez Paz, Massimo Chello, Elvio Covino, Emanuela Salvatorelli, Giorgio Minotti. (2011) Anthracycline cardiotoxicity. Expert Opinion on Drug Safety1-16
CrossRef226
K. Tamura, C. Shimizu, T. Hojo, S. Akashi-Tanaka, T. Kinoshita, K. Yonemori, T. Kouno, N. Katsumata, M. Ando, K. Aogi, F. Koizumi, K. Nishio, Y. Fujiwara. (2011) Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Annals of Oncology 22:6, 1302-1307
CrossRef227
C. A. Harris, R. L. Ward, T. A. Dobbins, A. K. Drew, S. Pearson. (2011) The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of Oncology 22:6, 1308-1317
CrossRef228
Aaron G Mammoser, David E Blas-Boria, Mark R Gilbert. (2011) Novel clinical trials in neuro-oncology. Clinical Investigation 1:6, 781-794
CrossRef229
Pablo Uribe, Sergio Gonzalez. (2011) Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathology - Research and Practice 207:6, 337-342
CrossRef230
Maureen Cronin, Jeffrey S Ross. (2011) Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomarkers in Medicine 5:3, 293-305
CrossRef231
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef232
M.Z. Ladjemi, W. Jacot, A. Pèlegrin, I. Navarro-Teulon. (2011) Vaccination anti-HER2 : l’avenir du ciblage immunologique de HER2 ?. Pathologie Biologie 59:3, 173-182
CrossRef233
Betsy Ramsey, Tao Bai, Amy Hanlon Newell, Megan Troxell, Byung Park, Susan Olson, Edward Keenan, Shiuh-Wen Luoh. (2011) GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Research and Treatment 127:3, 659-669
CrossRef234
Mafalda Oliveira, Sofia Braga, José Luís Passos-Coelho, Ricardo Fonseca, João Oliveira. (2011) Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Research and Treatment 127:3, 841-844
CrossRef235
Harold J. Burstein. (2011) Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer. Seminars in Oncology 38, S1-S2
CrossRef236
Jonathan Krell, Colin R. James, Deep Shah, Ondrej Gojis, Adrian Lim, Pippa Riddle, Riz Ahmad, Andreas Makris, Andrew Cowdray, Angela Chow, Tamerlan Babayev, Peter Madden, Robert Leonard, Susan Cleator, Carlo Palmieri. (2011) Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome. Clinical Breast Cancer 11:3, 153-160
CrossRef237
C.A. Geisberg, D.J. Lenihan. (2011) Neuregulin in heart failure. Herz 36:4, 306-310
CrossRef238
James A Lee, Megan Shaheen, Thomas Walke, Matt Daly. (2011) Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, 325-341
CrossRef239
A. Wittig, R. Engenhart-Cabillic. (2011) Cardiac side effects of conventional and particle radiotherapy in cancer patients. Herz 36:4, 311-324
CrossRef240
Patrick G. Morris, Clifford A. Hudis. (2011) Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter. Breast Cancer Research and Treatment 127:2, 585-586
CrossRef241
N. Harbeck, M. S. Ewer, M. De Laurentiis, T. M. Suter, S. M. Ewer. (2011) Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology 22:6, 1250-1258
CrossRef242
Paula M. Fracasso, Kerry J. Williams, Ronald C. Chen, Joel Picus, Cynthia X. Ma, Matthew J. Ellis, Benjamin R. Tan, Timothy J. Pluard, Douglas R. Adkins, Michael J. Naughton, Janet S. Rader, Matthew A. Arquette, James W. Fleshman, Allison N. Creekmore, Sherry A. Goodner, Lisa P. Wright, Zhanfang Guo, Christine E. Ryan, Yu Tao, Eliane M. Soares, Shi-rong Cai, Li Lin, Janet Dancey, Michelle A. Rudek, Howard L. McLeod, Helen Piwnica-Worms. (2011) A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology 67:6, 1225-1237
CrossRef243
Shinji Ohno, Kimihiro Tanaka, Chinami Koga, Sumiko Nishimura, Hiroshi Yamaguchi, Hidetoshi Kawaguchi, Tomoyuki Yoshiyama, Yoshiaki Nakamura. (2011) Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?. Breast Cancer
CrossRef244
Y. Shi, M. Moon, S. Dawood, B. McManus, P.P. Liu. (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36:4, 296-305
CrossRef245
Tao Chen, Tao Xu, Yang Li, Chun Liang, Juxiang Chen, Yicheng Lu, Zonggui Wu, Shenhong Wu. (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis. Cancer Treatment Reviews 37:4, 312-320
CrossRef246
Young Wha Koh, Hee Jin Lee, Jong Won Lee, Jun Kang, Gyungyub Gong. (2011) Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Modern Pathology 24:6, 794-800
CrossRef247
Xiaoli Zhu, Yongming Lu, Hongfen Lu, Wentao Yang, Xiaoyu Tu, Xu Cai, Xiaoyan Zhou. (2011) Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Human Pathology
CrossRef248
Elżbieta Senkus, Jacek Jassem. (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews 37:4, 300-311
CrossRef249
Nagahiro Saijo. (2011) Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treatment Reviews
CrossRef250
Theodoros Foukakis, Tommy Fornander, Tobias Lekberg, Henrik Hellborg, Jan Adolfsson, Jonas Bergh. (2011) Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Research and Treatment
CrossRef251
J.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R. E. Martell, J. Baselga. (2011) Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology
CrossRef252
Thomas J. Hudson. (2011) Cancer genome variation in children, adolescents, and young adults. Cancer 117:S10, 2262-2267
CrossRef253
Rajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah, Liang Cheng, Peter Crooks, Sundar Neelakantan, Tyler Peat, James Klaunig, William Matthews, Harikrishna Nakshatri, Christopher J. Sweeney. (2011) A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. International Journal of Cancer 128:10, 2481-2494
CrossRef254
Mitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki Arima, Hirotaka Iwase, Reiki Nishimura. (2011) Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. International Journal of Clinical Oncology
CrossRef255
Javier Cortés, Cristina Saura, Meritxell Bellet, Eva Muñoz-Couselo, Natalia Ramírez-Merino, Virginia Calvo, Jose Pérez, María Vidal. (2011) HER2 and hormone receptor-positive breast cancer—blocking the right target. Nature Reviews Clinical Oncology 8:5, 307-311
CrossRef256
Juan C. Plana. (2011) La quimioterapia y el corazón. Revista Española de Cardiología 64:5, 409-415
CrossRef257
Antonino Musolino, Laura Ciccolallo, Michele Panebianco, Elisa Fontana, Daniele Zanoni, Cecilia Bozzetti, Maria Michiara, Enrico Maria Silini, Andrea Ardizzoni. (2011) Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer. Cancer 117:9, 1837-1846
CrossRef258
Francesca Orlandi, José A. Guevara-Patiño, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton, Polly D. Gregor. (2011) Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine 29:20, 3646-3654
CrossRef259
Jane Fridlyand, Lee D. Kaiser, Gwen Fyfe. (2011) Analysis of tumor burden versus progression-free survival for Phase II decision making. Contemporary Clinical Trials 32:3, 446-452
CrossRef260
Howard A. Burris, Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, Gail D. Lewis Phillips. (2011) Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer. Clinical Breast Cancer
CrossRef261
Jennifer Levin Carter, Sheryl Elkin, Joan Barton. (2011) Company Profile: N-of-One: realizing personalized medicine. Personalized Medicine 8:3, 311-315
CrossRef262
Robert Amato. (2011) Everolimus for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy 12:7, 1143-1155
CrossRef263
H. Roche, L. T. Vahdat. (2011) Treatment of metastatic breast cancer: second line and beyond. Annals of Oncology 22:5, 1000-1010
CrossRef264
G. Yavas, F. Yildiz, S. Guler, M. F. Sargon, D. Yildiz, T. Yolcu, M. Tuncer, F. H. Akyol. (2011) Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. Annals of Oncology 22:5, 1120-1126
CrossRef265
Nazanin Fallah-Rad, Jonathan R. Walker, Anthony Wassef, Matthew Lytwyn, Sheena Bohonis, Tielan Fang, Ganhong Tian, Iain D.C. Kirkpatrick, Pawan K. Singal, Marianne Krahn, Debjani Grenier, Davinder S. Jassal. (2011) The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy. Journal of the American College of Cardiology 57:22, 2263-2270
CrossRef266
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef267
Paul J. Carter. (2011) Introduction to current and future protein therapeutics: A protein engineering perspective. Experimental Cell Research 317:9, 1261-1269
CrossRef268
Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike. (2011) New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs 20:5, 595-604
CrossRef269
Konstantin J. Dedes, Daniel Wetterskog, Alan Ashworth, Stan B. Kaye, Jorge S. Reis-Filho. (2011) Emerging therapeutic targets in endometrial cancer. Nature Reviews Clinical Oncology 8:5, 261-271
CrossRef270
S. Guiu, I. Adoubi, J. C. Kouassi Comoe, P. Fumoleau, B. Coudert. (2011) Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif. Journal Africain du Cancer / African Journal of Cancer 3:2, 128-140
CrossRef271
Chisako Yamauchi, Satoshi Fujii, Taichi Kimura, Takeshi Kuwata, Noriaki Wada, Hirofumi Mukai, Naoki Matsumoto, Masashi Fukayama, Atsushi Ochiai. (2011) E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells. International Journal of Cancer 128:9, 2125-2137
CrossRef272
Jon O. Wee, Yolonda L. Colson. (2011) Invited Commentary. The Annals of Thoracic Surgery 91:5, 1538
CrossRef273
Roger Y. Tsang, Richard S. Finn. (2011) HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. Drug Discovery Today: Therapeutic Strategies
CrossRef274
H. J. Chang, S.-W. Han, D.-Y. Oh, S.-A. Im, Y. K. Jeon, I. A. Park, W. Han, D.-Y. Noh, Y.-J. Bang, T.-Y. Kim. (2011) Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. Japanese Journal of Clinical Oncology 41:5, 593-599
CrossRef275
Yoshinori Ito, Takuji Iwase, Kiyohiko Hatake. (2011) Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?. Breast Cancer
CrossRef276
Anja Brügmann, Mikkel Eld, Giedrius Lelkaitis, Søren Nielsen, Michael Grunkin, Johan D. Hansen, Niels T. Foged, Mogens Vyberg. (2011) Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains. Breast Cancer Research and Treatment
CrossRef277
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Edhery, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria. (2011) Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs
CrossRef278
C Giordano, S Catalano, S Panza, D Vizza, I Barone, D Bonofiglio, L Gelsomino, P Rizza, S A W Fuqua, S Andò. (2011) Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene
CrossRef279
Alicia Okines, David Cunningham, Ian Chau. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 8:8, 492-503
CrossRef280
Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac, Myo Min. (2011) A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer. Clinical Breast Cancer 11:2, 121-128
CrossRef281
Shom Goel, Jacquie Chirgwin, Prudence Francis, Robin Stuart-Harris, Joanna Dewar, Linda Mileshkin, Ray Snyder, Michael Michael, Bogda Koczwara. (2011) Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. The Breast 20:2, 101-110
CrossRef282
Nupura S Bhise, Ron B Shmueli, Joel C Sunshine, Stephany Y Tzeng, Jordan J Green. (2011) Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery 8:4, 485-504
CrossRef283
R. Tanz, T. Mahfoud, A. Bazine, R. Khmamouch, Y. Bensouda, N. Ismaili, N. Benjaafar, B.K. El Gueddari, M. Ichou, H. Errihani. (2011) Tolérance cardiaque du trastuzumab en adjuvant : revue à travers 53 observations. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 40:2, 144-148
CrossRef284
Eric A Collisson, Anguraj Sadanandam, Peter Olson, William J Gibb, Morgan Truitt, Shenda Gu, Janine Cooc, Jennifer Weinkle, Grace E Kim, Lakshmi Jakkula, Heidi S Feiler, Andrew H Ko, Adam B Olshen, Kathleen L Danenberg, Margaret A Tempero, Paul T Spellman, Douglas Hanahan, Joe W Gray. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine 17:4, 500-503
CrossRef285
L. Staudacher, P. H. Cottu, V. Dieras, A. Vincent-Salomon, M. N. Guilhaume, L. Escalup, T. Dorval, P. Beuzeboc, L. Mignot, J. Y. Pierga. (2011) Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology 22:4, 848-856
CrossRef286
Madhuri V Warren, WY Iris Chan, John M Ridley. (2011) Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis. Biomarkers in Medicine 5:2, 227-248
CrossRef287
Senthil K Muthuswamy. (2011) Trastuzumab resistance: all roads lead to SRC. Nature Medicine 17:4, 416-418
CrossRef288
Alberto Zambelli, Matteo Giovanni Della Porta, Ermanno Eleuteri, Luciana De Giuli, Oronzo Catalano, Carlo Tondini, Alberto Riccardi. (2011) Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. The Breast 20:2, 176-183
CrossRef289
Carlo Palmieri, Deep Shah, Jonathan Krell, Ondrej Gojis, Katy Hogben, Pippa Riddle, Riz Ahmad, Tri Tat, Kevin Fox, Andrew Porter, Sarah Mahmoud, Stephanie Kirschke, Sami Shousha, Mihir Gudi, R. Charles Coombes, Robert Leonard, Susan Cleator. (2011) Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era. Clinical Breast Cancer 11:2, 93-102
CrossRef290
Paul Hamberg, Monique M.E.M. Bos, Hans J.J. Braun, Jacqueline M.L. Stouthard, Gert A. van Deijk, Frans L.G. Erdkamp, Iris N. van der Stelt-Frissen, Marijke Bontenbal, Geert-Jan M. Creemers, Johanneke E.A. Portielje, Johannes F.M. Pruijt, Olaf J.L. Loosveld, Willem M. Smit, Erik W. Muller, Paul I.M. Schmitz, Caroline Seynaeve, Jan G.M. Klijn. (2011) Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial. Clinical Breast Cancer 11:2, 103-113
CrossRef291
Christopher M. Booth, Pavlo Ohorodnyk, Liting Zhu, Dongsheng Tu, Ralph M. Meyer. (2011) Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. European Journal of Cancer 47:6, 854-863
CrossRef292
D H Roukos. (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. The Pharmacogenomics Journal 11:2, 81-92
CrossRef293
Richat Abbas, Bruce A. Hug, Cathie Leister, Jaime Burns, Daryl Sonnichsen. (2011) Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. British Journal of Clinical Pharmacology 71:4, 522-527
CrossRef294
Timo T. Purmonen, Emma Pänkäläinen, Juha H. O. Turunen, Christian Asseburg, Janne A. Martikainen. (2011) Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologica 50:3, 344-352
CrossRef295
Siyuan Zhang, Wen-Chien Huang, Ping Li, Hua Guo, Say-Bee Poh, Samuel W Brady, Yan Xiong, Ling-Ming Tseng, Shau-Hsuan Li, Zhaoxi Ding, Aysegul A Sahin, Francisco J Esteva, Gabriel N Hortobagyi, Dihua Yu. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine 17:4, 461-469
CrossRef296
Timothy M. Clay, Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, H. Kim Lyerly. (2011) Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunologic Research 49:1-3, 235-247
CrossRef297
J A Forster, A B Paul, P Harnden, M A Knowles. (2011) Expression of NRG1 and its receptors in human bladder cancer. British Journal of Cancer 104:7, 1135-1143
CrossRef298
Feero, W. Gregory, Guttmacher, Alan E., , Wang, Liewei, McLeod, Howard L., Weinshilboum, Richard M., . (2011) Genomics and Drug Response. New England Journal of Medicine 364:12, 1144-1153
Full Text299
F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L. G. T. Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S. B. Baylin, N. Ahuja, A. Viale, J. Massague, L. Norton, L. T. Vahdat, M. E. Moynahan, T. A. Chan. (2011) Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine 3:75, 75ra25-75ra25
CrossRef300
M. Martin, P. Sanchez-Rovira, M. Munoz, J. M. Baena-Canada, J. R. Mel, M. Margeli, M. Ramos, E. Martinez, J. A. Garcia-Saenz, A. Casado, A. M. Jaen, X. Gonzalez-Farre, M. J. Escudero, C. Rodriguez-Martin, E. Carrasco, . (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Annals of Oncology
CrossRef301
Alfonso De Stefano, Chiara Carlomagno, Stefano Pepe, Roberto Bianco, Sabino De Placido. (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemotherapy and Pharmacology
CrossRef302
Stephen R. Grobmyer, David L. Morse, Bradley Fletcher, Luke G. Gutwein, Parvesh Sharma, Vijay Krishna, Susan C. Frost, Brij M. Moudgil, Scott C. Brown. (2011) The promise of nanotechnology for solving clinical problems in breast cancer. Journal of Surgical Oncology 103:4, 317-325
CrossRef303
M. N. Fornier, P. G. Morris, A. Abbruzzi, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, A. D. Seidman, N. Sklarin, J. Chang, L. Norton, C. A. Hudis. (2011) A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of Oncology
CrossRef304
Y. Wu, M. M. Amonkar, B. H. Sherrill, J. O'Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, H. J. Burstein. (2011) Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of Oncology
CrossRef305
Roshawn G. Watson, Howard L. McLeod. (2011) Pharmacogenomic Contribution to Drug Response. The Cancer Journal 17:2, 80-88
CrossRef306
Pyung-Hwan Kim, Joo-Hyuk Sohn, Joung-Woo Choi, Yukyung Jung, Sung Wan Kim, Seungjoo Haam, Chae-Ok Yun. (2011) Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 32:9, 2314-2326
CrossRef307
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef308
Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Aron Goldhirsch, Michael Untch, Ian Smith, José Baselga, Christian Jackisch, David Cameron, Max Mano, José Luiz Pedrini, Andrea Veronesi, Cesar Mendiola, Anna Pluzanska, Vladimir Semiglazov, Eduard Vrdoljak, Michael J Eckart, Zhenzhou Shen, George Skiadopoulos, Marion Procter, Kathleen I Pritchard, Martine J Piccart-Gebhart, Richard Bell. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 12:3, 236-244
CrossRef309
Elena Geuna, Andrea Milani, Stefania Redana, Valentina Rossi, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro. (2011) Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy 12:4, 549-565
CrossRef310
Antonio C. Wolff. (2011) Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez). Current Breast Cancer Reports 3:1, 1-3
CrossRef311
Ivana Bozovic-Spasojevic, Hatem A Azim, Marianne Paesmans, Thomas Suter, Martine J Piccart, Evandro de Azambuja. (2011) Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. The Lancet Oncology 12:3, 209-211
CrossRef312
Lynda Chin, Jannik N Andersen, P Andrew Futreal. (2011) Cancer genomics: from discovery science to personalized medicine. Nature Medicine 17:3, 297-303
CrossRef313
Drew Pardoll. (2011) Timeline: a decade of advances in immunotherapy. Nature Medicine 17:3, 296-296
CrossRef314
Ian J Majewski, René Bernards. (2011) Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine304-312
CrossRef315
Ebru Sari, Gulnur Guler, Mutlu Hayran, Ibrahim Gullu, Kadri Altundag, Yavuz Ozisik. (2011) Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Medical Oncology 28:1, 57-63
CrossRef316
Brian Leyland-Jones, Brian R Smith. (2011) Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. The Lancet Oncology 12:3, 286-295
CrossRef317
J. -P. Spano, J. -C. Thery. (2011) Place des thérapies ciblées chez la patiente âgée atteinte de cancer du sein. Oncologie 13:2-3, 97-101
CrossRef318
Vishal Rana, Ramona F. Swaby. (2011) Targeted Therapies for HER2 Breast Cancer: A View of the Landscape. Current Breast Cancer Reports 3:1, 55-62
CrossRef319
M. Scaltriti, P. J. Eichhorn, J. Cortes, L. Prudkin, C. Aura, J. Jimenez, S. Chandarlapaty, V. Serra, A. Prat, Y. H. Ibrahim, M. Guzman, M. Gili, O. Rodriguez, S. Rodriguez, J. Perez, S. R. Green, S. Mai, N. Rosen, C. Hudis, J. Baselga. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences 108:9, 3761-3766
CrossRef320
Richard H DE BOER, Arlene CHAN, Ben TRAN, Nicholas WILCKEN. (2011) Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology 7:1, 4-10
CrossRef321
Guodong Shen, Hui Huang, Anli Zhang, Ting Zhao, Siyi Hu, Liansheng Cheng, Jing Liu, Weihua Xiao, Bin Ling, Qiang Wu, Lihua Song, Wei Wei. (2011) In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer Immunology, Immunotherapy 60:3, 339-348
CrossRef322
Marc Buyse, Stefan Michiels, Daniel J Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2011) Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 11:2, 171-182
CrossRef323
Julie A. Margenthaler. (2011) The Cancer Genome: Translating Sequences into Patient Therapeutics. Journal of Surgical Research
CrossRef324
Motoi Tobiume, Yoshiaki Yamada, Kogenta Nakamura, Shigeyuki Aoki, Kenji Zennami, Yoshiharu Kato, Genya Nishikawa, Toyoharu Yokoi, Nobuaki Honda. (2011) Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer. The Prostate 71:4, 385-393
CrossRef325
B. Besse, C. Massard, V. Haddad, F. Andre, A. Dunant, R. Pirker, K. A. Olaussen, E. Brambilla, P. Fouret, J. C. Soria. (2011) ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of Oncology 22:3, 575-581
CrossRef326
Valentina Rossi, Stefania Redana, Andrea Milani, Elena Geuna, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro. (2011) Trastuzumab in the adjuvant setting: a practical review. Therapy 8:2, 161-177
CrossRef327
Virginia G. Kaklamani, Kalliopi Siziopikou, Denise Scholtens, Mario Lacouture, Jennifer Gordon, Regina Uthe, Caitlin Meservey, Nora Hansen, Seema A. Khan, Jacqueline S. Jeruss, Kevin Bethke, Mary Cianfrocca, Steven Rosen, Jamie Roenn, Jeffrey Wayne, Vamsi Parimi, Borko Jovanovic, William Gradishar. (2011) Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Research and Treatment
CrossRef328
Rupninder Sandhu, Ashley G. Rivenbark, William B. Coleman. (2011) Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Research and Treatment
CrossRef329
Sandra Van Schaeybroeck, Wendy L. Allen, Richard C. Turkington, Patrick G. Johnston. (2011) Implementing prognostic and predictive biomarkers in CRC clinical trials. Nature Reviews Clinical Oncology 8:4, 222-232
CrossRef330
Hideya Onishi, Takashi Morisaki, Yuji Nakafusa, Yutaka Nakashima, Kazunori Yokohata, Mitsuo Katano. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. International Journal of Clinical Oncology
CrossRef331
Yan-Xia Shi, Yu-Ting Tan, Zhong-Yu Yuan, Shu-Sen Wang, Rou-Jun Peng, Xin An, Ye Cao, Ying Jin, Xiu-Yu Cai, Yue-Li Sun, Xiao-Yu Teng, Dong-Geng Liu. (2011) Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Medical Oncology
CrossRef332
J. Lemieux, P. J. Goodwin, L. J. Bordeleau, S. Lauzier, V. Theberge. (2011) Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001-2009). JNCI Journal of the National Cancer Institute 103:3, 178-231
CrossRef333
T. Iwamoto, G. Bianchini, D. Booser, Y. Qi, C. Coutant, C. Ya-Hui Shiang, L. Santarpia, J. Matsuoka, G. N. Hortobagyi, W. F. Symmans, F. A. Holmes, J. O'Shaughnessy, B. Hellerstedt, J. Pippen, F. Andre, R. Simon, L. Pusztai. (2011) Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. JNCI Journal of the National Cancer Institute 103:3, 264-272
CrossRef334
Sabine Riethdorf, Bernhard Hoegel, Birgit John, German Ott, Peter Fritz, Susanne Thon, Thomas Loening, Klaus Pantel. (2011) Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. Journal of Cancer Research and Clinical Oncology 137:2, 261-269
CrossRef335
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef336
Devika Gajria, Sarat Chandarlapaty. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy 11:2, 263-275
CrossRef337
Márk Barok, János Szöllősi. (2011) Steps in metastasis research: Analyzing, collecting, and culturing circulating tumor cells. Cytometry Part A 79A:2, 93-94
CrossRef338
Pamela J. Goodwin, Vuk Stambolic, Julie Lemieux, Bingshu E. Chen, Wendy R. Parulekar, Karen A. Gelmon, Dawn L. Hershman, Timothy J. Hobday, Jennifer A. Ligibel, Ingrid A. Mayer, Kathleen I. Pritchard, Timothy J. Whelan, Priya Rastogi, Lois E. Shepherd. (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment 126:1, 215-220
CrossRef339
S. Guiu, M. Liegard, L. Favier, I. van Praagh, R. Largillier, B. Weber, D. Coeffic, L. Moreau, F. Priou, M. Campone, J. Gligorov, L. Vanlemmens, V. Trillet-Lenoir, L. Arnould, B. Coudert. (2011) Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology 22:2, 321-328
CrossRef340
George C Zografos, Dimitrios H Roukos. (2011) Innovative biomarker development for personalized medicine in breast cancer care. Biomarkers in Medicine 5:1, 73-78
CrossRef341
Florian Lordick. (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncology 7:2, 187-199
CrossRef342
Rena Callahan, Sara Hurvitz. (2011) Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion in Obstetrics and Gynecology 23:1, 37-43
CrossRef343
Shaheenah Dawood, Rong Hu, Michelle D. Homes, Laura C. Collins, Stuart J. Schnitt, James Connolly, Graham A. Colditz, Rulla M. Tamimi. (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment 126:1, 185-192
CrossRef344
Paul Workman. (2011) Drugging the Cancer Genome. Annual Review of Pharmacology and Toxicology 52:1, 110301101444027
CrossRef345
Kousaku Mimura, Takashi Ando, Isabel Poschke, Dimitrios Mougiakakos, C. Christian Johansson, Jiro Ichikawa, Riki Okita, Michael I. Nishimura, Diana Handke, Nancy Krug, Aniruddha Choudhury, Barbara Seliger, Rolf Kiessling. (2011) T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. International Journal of Cancer 128:2, 390-401
CrossRef346
Naoki Hayashi, Seigo Nakamura, Hiroshi Yagata, Yuji Shimoda, Hidekazu Ota, Gabriel N. Hortobagyi, Massimo Cristofanilli, Naoto T. Ueno. (2011) Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology
CrossRef347
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef348
Anthony S.-Y. Leong, Zhengping Zhuang. (2011) The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. Pathobiology 78:2, 99-114
CrossRef349
Ali Naderi, Kee Ming Chia, Ji Liu. (2011) Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Research 13:2, R36
CrossRef350
Laura Bourdeanu, Przemyslaw Twardowski, Sumanta Kumar Pal. (2011) Nursing Considerations With Pazopanib Therapy : Focus on Metastatic Renal Cell Carcinoma. Clinical Journal of Oncology Nursing 15:5, 513
CrossRef351
Edith Pituskin, Mark Haykowsky, John R Mackey, Richard B Thompson, Justin Ezekowitz, Sheri Koshman, Gavin Oudit, Kelvin Chow, Joseph J Pagano, Ian Paterson. (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11:1, 318
CrossRef352
Cathy B. Moelans, Paul J. van Diest, Anya N. A. Milne, G. Johan A. Offerhaus. (2011) HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma. Pathology Research International 2011, 1-10
CrossRef353
Rangaiah Shashidharamurthy, Erica N. Bozeman, Jaina Patel, Ramneet Kaur, Jeyandra Meganathan, Periasamy Selvaraj. (2011) Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Medicinal Research Reviewsn/a-n/a
CrossRef354
Sejal Shah, Beiyun Chen. (2011) Testing for HER2 in Breast Cancer: A Continuing Evolution. Pathology Research International 2011, 1-16
CrossRef355
C.P. Coyne, Toni Jones, Todd Pharr. (2011) Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorganic & Medicinal Chemistry 19:1, 67-76
CrossRef356
Gabriel L. Fiszman, María A. Jasnis. (2011) Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. International Journal of Breast Cancer 2011, 1-11
CrossRef357
Qingguo Li, Daorong Wang, Jing Li, Ping Chen. (2011) Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 11:1, 277
CrossRef358
Shaheenah Dawood, Asim Jamal Shaikh, Thomas A. Buchholz, Javier Cortes, Massimo Cristofanilli, Sudeep Gupta, Ana M. Gonzalez-Angulo. (2011) The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancern/a-n/a
CrossRef359
David Parada, Karla Peña, Francesc Riu, Pilar Hernandez. (2011) Triple Negative Breast Carcinoma: A Comparative Study between Breast Lesion and Lymph Node Metastases: A Preliminary Study. ISRN Pathology 2011, 1-6
CrossRef360
Anthony Jarkowski, Ashley E Glode, Edward J Spangenthal, Michael K. K Wong. (2011) Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy 31:1, 62-75
CrossRef361
A. Jo Chien, Mark M. Moasser. (2011) New Insights into Human Epidermal Growth Factor Receptor 2 Blockade–What Agents and Combinations Work Best?. Breast Diseases: A Year Book Quarterly 22:3, 243-249
CrossRef362
Thommey P. Thomas, Yu-Chung Chang, Jing Yong Ye, Alina Kotlyar, Zhengyi Cao, Rameshwer Shukla, Suyang Qin, Theodore B. Norris, James R. Baker. (2011) Optical fiber-based in vivo quantification of growth factor receptors. Cancern/a-n/a
CrossRef363
Toru Mukohara. (2011) Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice 2011, 1-12
CrossRef364
Wen-Yen Huang, Jason J. Davis. (2011) Multimodality and nanoparticles in medical imaging. Dalton Transactions 40:23, 6087
CrossRef365
Sarah Lee, Woohee Jung, Soon-Won Hong, Ja Seung Koo. (2011) Evaluation of Intratumoral HER-2 Heterogeneity by Fluorescence In Situ Hybridization in Invasive Breast Cancer: A Single Institution Study. Journal of Korean Medical Science 26:8, 1001
CrossRef366
Immacolata Andolfo, Giuseppe Petrosino, Loredana Vecchione, Pasqualino De Antonellis, Mario Capasso, Donatella Montanaro, Marica Gemei, Giancarlo Troncone, Achille Iolascon, Michele Orditura, Fortunato Ciardiello, Fernando De Vita, Massimo Zollo. (2011) Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer 11:1, 126
CrossRef367
Dina Preise, Avigdor Scherz, Yoram Salomon. (2011) Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochemical & Photobiological Sciences 10:5, 681
CrossRef368
Mark Barok, Minna Tanner, Katri Köninki, Jorma Isola. (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Research 13:2, R46
CrossRef369
Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac, Myo Min. (2011) A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer. Clinical Breast Cancer 1:-1, 1-8
CrossRef370
Rohit Bhargava, Nicole N. Esposito, David J. Dabbs. 2011. Immunohistology of the Breast. , 763-819.
CrossRef371
M. Sánchez-Martín, A. Pandiella. (2011) Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications. International Journal of Cancern/a-n/a
CrossRef372
Sashikanth Banappagari, Sharon Ronald, Seetharama D. Satyanarayanajois. (2011) Structure–activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. MedChemComm 2:8, 752
CrossRef373
Leiping Wang, Qunling Zhang, Jian Zhang, Si Sun, Haiyi Guo, Zhen Jia, Biyun Wang, Zhimin Shao, Zhonghua Wang, Xichun Hu. (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:1, 248
CrossRef374
Jens Huober, Michael Baumann, Christoph Rochlitz, Stefan Aebi, Uwe Güth, Roger von Moos, Andreas Müller, Lukas von Rohr, Isabelle Widmer, Beat Thürlimann. (2011) Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology 81:3-4, 160-166
CrossRef375
Bohuslav Melichar, Mario Plebani. (2011) Targeted therapy for HER-2: personalized medicine for <i>her, too</i>. Clinical Chemistry and Laboratory Medicine-
CrossRef376
Karim S. ElSahwi, Alessandro D. Santin. (2011) erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics and Gynecology International 2011, 1-5
CrossRef377
Luca Albarello, Lorenza Pecciarini, Claudio Doglioni. (2011) HER2 Testing in Gastric Cancer. Advances in Anatomic Pathology 18:1, 53-59
CrossRef378
Hideo Shigematsu, Hidetoshi Kawaguchi, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno. (2011) Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 11:1, 118
CrossRef379
Isabell Witzel, Eva Johanna Kantelhardt, Karin Milde-Langosch, Maike Ihnen, Julia Zeitz, Nadia Harbeck, Fritz Jänicke, Volkmar Müller. (2011) Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer. Onkologie 34:6, 304-308
CrossRef380
Yu Rim Lee, Seok Jae Huh, Dong Hyun Lee, Hyun Hwa Yoon, Young-Mi Seol, Young-Jin Choi, Kyung A Kwon, Suee Lee, Sung Yong Oh, Sung-Hyun Kim, Hyo-Jin Kim, Hyuk-Chan Kwon. (2011) Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Journal of Breast Cancer 14:2, 140
CrossRef381
Toru Mukohara. (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science 102:1, 1-8
CrossRef382
A. von Drygalski, T. B. Tran, K. Messer, M. Pu, S. Corringham, C. Nelson, E. D. Ball. (2011) Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support. International Journal of Breast Cancer 2011, 1-8
CrossRef383
Kai-xin Zhang, Connie Kim, Elaine Chow, Irvin S. Y. Chen, William Jia, Paul S. Rennie. (2011) Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2. Breast Cancer Research and Treatment 125:1, 89-97
CrossRef384
Semir Vranic, Bryan Teruya, Susan Repertinger, Pamela Ulmer, Jill Hagenkord, Zoran Gatalica. (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:1, 48-53
CrossRef385
Ronald M. Witteles. (2011) Radiation Therapy for Breast Cancer. Journal of the American College of Cardiology 57:4, 453-454
CrossRef386
Anthony G Clementz, Allison Rogowski, Kinnari Pandya, Lucio Miele, Clodia Osipo. (2011) NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Research 13:3, R63
CrossRef387
Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin, Funda Meric-Bernstam. (2011) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancern/a-n/a
CrossRef388
Jiyoung Rhee, Sae-Won Han, Yongjun Cha, Hye Seon Ham, Hwang-phill Kim, Do-Youn Oh, Seock-Ah Im, Jong-Wan Park, Jungsil Ro, Keun Seok Lee, In Hae Park, Young-Hyuck Im, Yung-Jue Bang, Tae-You Kim. (2011) High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Research and Treatment 125:1, 107-114
CrossRef389
Carolin M. Grimminger, Peter V. Danenberg. (2011) Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. European Archives of Oto-Rhino-Laryngology 268:1, 5-16
CrossRef390
Edith A. Perez, Jean-Philippe Spano. (2011) Current and emerging targeted therapies for metastatic breast cancer. Cancern/a-n/a
CrossRef391
Eun-Jung Jung, Libero Santarpia, Juyeon Kim, Francisco J. Esteva, Erica Moretti, Aman U. Buzdar, Angelo Di Leo, Xiao-Feng Le, Robert C. Bast, Soon-Tae Park, Lajos Pusztai, George A. Calin. (2011) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancern/a-n/a
CrossRef392
Ulla Wilking, Eva Karlsson, Lambert Skoog, Thomas Hatschek, Elisabet Lidbrink, Goran Elmberger, Hemming Johansson, Linda Lindström, Jonas Bergh. (2011) HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Research and Treatment 125:2, 553-561
CrossRef393
Cun Liao, Fang Yin, Ping Huang, Yunfei Cao, Feng Gao. (2011) A Meta-Analysis of Randomized Controlled Trials Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Alone in HER-2-Positive Advanced Breast Cancer. The Breast Journal 17:1, 109-111
CrossRef394
Guy Jerusalem, Angelica Fasolo, Veronique Dieras, Fatima Cardoso, Jonas Bergh, Luc Vittori, Yufen Zhang, Cristian Massacesi, Tarek Sahmoud, Luca Gianni. (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment 125:2, 447-455
CrossRef395
Jesús Pérez-Losada, Andrés Castellanos-Martín, Jian-Hua Mao. (2011) Cancer evolution and individual susceptibility. Integrative Biology 3:4, 316
CrossRef396
Masahiro Takada, Hiroshi Terunuma, Xuewen Deng, Md. Zahidunnabi Dewan, Shigehira Saji, Katsumasa Kuroi, Naoki Yamamoto, Masakazu Toi. (2011) Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18:1, 64-67
CrossRef397
David Khayat. (2011) Innovative cancer therapies. Cancern/a-n/a
CrossRef398
Dok Hyun Yoon, Yoon-Koo Kang. (2011) Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. Clinical Investigation 1:1, 87-95
CrossRef399
Jae Hyun Choi, Hye-Suk Han, Ho-chang Lee, Ok-Jun Lee, Jeong Tae Kim, Sung-Nam Lim, Ki Hyeong Lee, Seung Taik Kim. (2011) Positive Response to Trastuzumab in a Case of HER2-Overexpressing Metastatic Gastric Cancer that Presented as Severe Thrombocytopenia. Onkologie 34:11, 621-624
CrossRef400
Jan Hysing, Erik Wist. (2011) Kardiotoksiske effekter av trastuzumab. Tidsskrift for Den norske legeforening 131:22, 2239-2241
CrossRef401
Terence C. Chua, Neil D. Merrett. (2011) Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival outcomes - a systematic review. International Journal of Cancern/a-n/a
CrossRef402
Hideo Shigematsu, Takayuki Kadoya, Yoshie Kobayashi, Keiko Kajitani, Tatsunari Sasada, Akiko Emi, Norio Masumoto, Rumi Haruta, Tsuyoshi Kataoka, Miyo Oda, Kouji Arihiro, Morihito Okada. (2011) A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer. World Journal of Surgical Oncology 9:1, 146
CrossRef403
F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi, C. Barone. (2011) The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical and Developmental Immunology 2011, 1-12
CrossRef404
Thomas Bachelot, Olivier Tredan. 2011. Cancers du sein métastatiques. , 129-136.
CrossRef405
Filippo Montemurro, Valentina Rossi, Maria Cossu Rocca, Rossella Martinello, Elena Verri, Stefania Redana, Laura Adamoli, Giorgio Valabrega, Anna Sapino, Massimo Aglietta, Giuseppe Viale, Aron Goldhirsch, Franco Nolè. (2011) Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancern/a-n/a
CrossRef406
Nicholas F. Marko, Zhiyuan Xu, Tianming Gao, Michael W. Kattan, Robert J. Weil. (2011) Predicting survival in women with breast cancer and brain metastasis. Cancern/a-n/a
CrossRef407
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef408
Ben Tran, Philippe L Bedard. (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research 13:6, 221
CrossRef409
Hyeong Chan Shin, Young Kyung Bae, Aeri Kim, Seok Ju Park. (2011) HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing. The Korean Journal of Pathology 45:6, 665
CrossRef410
Jeffrey L Nordstrom, Sergey Gorlatov, Wenjun Zhang, Yinhua Yang, Ling Huang, Steve Burke, Hua Li, Valentina Ciccarone, Tengfei Zhang, Jeffrey Stavenhagen, Scott Koenig, Stanford J Stewart, Paul A Moore, Syd Johnson, Ezio Bonvini. (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties. Breast Cancer Research 13:6, R123
CrossRef411
N. C. Turner, M. J. Seckl. (2010) A Therapeutic Target for Smoking-Associated Lung Cancer. Science Translational Medicine 2:62, 62ps56-62ps56
CrossRef412
J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schottle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansen, D. Rauh, I. Baessmann, J. Altmuller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sanger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nurnberg, S. Perner, R. K. Thomas. (2010) Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine 2:62, 62ra93-62ra93
CrossRef413
A. Chan, D. W. Miles, X. Pivot. (2010) Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Annals of Oncology 21:12, 2305-2315
CrossRef414
Mu-Tai Liu, Wen-Tao Huang, Ai-Yih Wang, Chia-Chun Huang, Chao-Yuan Huang, Tung-Hao Chang, Chu-Pin Pi, Hao-Han Yang. (2010) Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Supportive Care in Cancer 18:12, 1553-1564
CrossRef415
Guo-hong Song, Jun Ren, Lijun Di, Jing Yu, Jie Zhang, Bin Shao, Jun Jia, Wei Sun. (2010) Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dentritic cells immunomodulation among metastatic breast cancer patients. Chinese Journal of Cancer Research 22:4, 310-315
CrossRef416
Nicola Maurea, Carmela Coppola, Gianluca Ragone, Giuseppe Frasci, Annamaria Bonelli, Carmela Romano, Rosario Vincenzo Iaffaioli. (2010) Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Journal of Cardiovascular Medicine 11:12, 861-868
CrossRef417
N. S. Bese, C. Umay, S. Serdengecti, N. Kepil, N. Sut, T. Altug, A. Ober. (2010) The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. Medical Oncology 27:4, 1415-1419
CrossRef418
Nadia Hedhli, Kerry Strong Russell. (2010) Cytostatic Drugs, Neuregulin Activation of ErbB Receptors, and Angiogenesis. Current Hypertension Reports 12:6, 411-417
CrossRef419
Jung Sik Jang, Eun Jeong Jang, Ji-Young Park. (2010) HER2 expression in breast cancer: Comparisons of fluorescence in situ hybridization and silver in situ hybridization, and immunohistochemical staining using monoclonal antibody and polyclonal antibody. Basic and Applied Pathology 3:4, 115-120
CrossRef420
Susana Banerjee, Ian E Smith. (2010) Management of small HER2-positive breast cancers. The Lancet Oncology 11:12, 1193-1199
CrossRef421
Rosalba Torrisi, Anna Cardillo, Giuseppe Cancello, Silvia Dellapasqua, Alessandra Balduzzi, Raffaella Ghisini, Alberto Luini, Paolo Veronesi, Giuseppe Viale, Aron Goldhirsch, Marco Colleoni. (2010) Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. Clinical Breast Cancer 10:6, 483-488
CrossRef422
L. Tookman, R. Roylance. (2010) New drugs for breast cancer. British Medical Bulletin 96:1, 111-129
CrossRef423
Álvaro Pinto Marín, Enrique Espinosa Arranz, Andrés Redondo Sánchez, Pilar Zamora Auñón, Manuel González Barón. (2010) Role of anti-Her-2 therapy in bladder carcinoma. Journal of Cancer Research and Clinical Oncology 136:12, 1915-1920
CrossRef424
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef425
R. Bartsch, R. Ziebermayr. (2010) Metastatic breast cancer – ASCO 2010. memo - Magazine of European Medical Oncology 3:4, 159-162
CrossRef426
Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat. (2010) Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?. Critical Reviews in Oncology/Hematology 76:3, 186-195
CrossRef427
D. Herr, I. Bekes, R. Kreienberg. (2010) Antikörper und Tyrosinkinaseinhibitoren. Der Gynäkologe 43:12, 996-1001
CrossRef428
Hideo Shigematsu, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Hidetoshi Kawaguchi, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno. (2010) A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. International Journal of Clinical Oncology 15:6, 615-620
CrossRef429
Pablo Sanchez-Soria, Todd D. Camenisch. (2010) ErbB signaling in cardiac development and disease. Seminars in Cell & Developmental Biology 21:9, 929-935
CrossRef430
Tamás Nagykálnai. (2010) A nem pegilált liposzomális doxorubicin (Myocet®), mint a szabad doxorubicin kevésbé kardiotoxikus alternatívája. Magyar Onkológia 54:4, 359-367
CrossRef431
Chengyin Min, Yingshe Zhao, Mathilde Romagnoli, Philip C. Trackman, Gail E. Sonenshein, Kathrin H. Kirsch. (2010) Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. Journal of Cellular Biochemistry 111:5, 1160-1168
CrossRef432
Teresa Gilewski. (2010) Targeting the Immune System as a Therapeutic Strategy for Patients with Breast Cancer. Current Breast Cancer Reports 2:4, 214-221
CrossRef433
Debora Fumagalli, Christine Desmedt, Martine Piccart, Christos Sotiriou. (2010) Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. Current Breast Cancer Reports 2:4, 208-213
CrossRef434
Gelareh Farshid, Jane E. Armes, Richard Bell, Margaret Cummings, Stephen Fox, Glenn Francis, Martin Haswell, Adrienne Morey, Glenda McCue, Wendy Raymond, Peter Robbins, Michael Bilous. (2010) Establishment of the Australian In Situ Hybridization Program for the Assessment of HER2 Amplification in Breast Cancer. Diagnostic Molecular Pathology 19:4, 187-193
CrossRef435
J Dhillon, A Astanehe, C Lee, A Fotovati, K Hu, S E Dunn. (2010) The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 29:47, 6294-6300
CrossRef436
Allan Lipton, Wolfgang J. Köstler, Kim Leitzel, Suhail M. Ali, Jeff Sperinde, Jodi Weidler, Agnes Paquet, Thomas Sherwood, Weidong Huang, Michael Bates. (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116:22, 5168-5178
CrossRef437
Maximilian G. Posch, Anna Panek, Andrea Kersten, Santhosh Kumar Ghadge, Christian Geier, Silke Richter, Andreas Perrot, Mudather Gailani, Rainer Dietz, Diana Lüftner. (2010) Plasma HER2 levels are not associated with cardiac function or hypertrophy in control subjects and heart failure patients. International Journal of Cardiology 145:1, 105-106
CrossRef438
Huguette Albrecht. (2010) Trastuzumab (Herceptin ® ): overcoming resistance in HER2 -overexpressing breast cancer models. Immunotherapy 2:6, 795-798
CrossRef439
Cara L. Ferreira, Donald T. T. Yapp, Sarah Crisp, Brent W. Sutherland, Sylvia S. W. Ng, Martin Gleave, Corinne Bensimon, Paul Jurek, Garry E. Kiefer. (2010) Comparison of bifunctional chelates for 64Cu antibody imaging. European Journal of Nuclear Medicine and Molecular Imaging 37:11, 2117-2126
CrossRef440
Andreas H. Marx, Eike C. Burandt, Matthias Choschzick, Ronald Simon, Emre Yekebas, Jussuf T. Kaifi, Martina Mirlacher, Djordje Atanackovic, Carsten Bokemeyer, Walter Fiedler, Luigi Terracciano, Guido Sauter, Jakob R. Izbicki. (2010) Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology 41:11, 1577-1585
CrossRef441
Stacy Moulder. (2010) Intrinsic resistance to chemotherapy in breast cancer. Women's Health 6:6, 821-830
CrossRef442
Eran R. Andrechek, Joseph R. Nevins. (2010) Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. Journal of Molecular Medicine 88:11, 1095-1100
CrossRef443
K. W. Matter-Walstra, K. J. Dedes, M. Schwenkglenks, P. Brauchli, T. D. Szucs, B. C. Pestalozzi. (2010) Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology 21:11, 2161-2168
CrossRef444
Christos Katsios, Dimosthenis E. Ziogas, Theodore Liakakos, Odysseas Zoras, Dimitrios H. Roukos. (2010) Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. Journal of Surgical Research
CrossRef445
Claudia Andreetta, Alessandro M. Minisini, Manuela Miscoria, Fabio Puglisi. (2010) First-line chemotherapy with or without biologic agents for metastatic breast cancer. Critical Reviews in Oncology/Hematology 76:2, 99-111
CrossRef446
Baohui Liu, Daofeng Tian, Wei Yi, Liquan Wu, Qiang Cai, Huimin Dong, Heng Shen, Baowei Ji, Long Wang, Shenqi Zhang, Dong Ruan, Qianxue Chen. (2010) Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251. Cell Biochemistry and Biophysics 58:2, 91-96
CrossRef447
William Shingler, Richard Harrop. (2010) Targeting targeted therapies. Immunotherapy 2:6, 745-748
CrossRef448
Ad Geurts van Kessel. (2010) The ‘omics’ of cancer. Cancer Genetics and Cytogenetics 203:1, 37-42
CrossRef449
R. B. Costa, G. Kurra, L. Greenberg, C. E. Geyer. (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of Oncology 21:11, 2153-2160
CrossRef450
Dimitrios H Roukos. (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Review of Medical Devices 7:6, 723-726
CrossRef451
Fredika M. Robertson, Melissa Bondy, Wei Yang, Hideko Yamauchi, Shannon Wiggins, Samira Kamrudin, Savitri Krishnamurthy, Huong Le-Petross, Luc Bidaut, Audrey N. Player, Sanford H. Barsky, Wendy A. Woodward, Thomas Buchholz, Anthony Lucci, Naoto Ueno, Massimo Cristofanilli. (2010) Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. CA: A Cancer Journal for Clinicians 60:6, 351-375
CrossRef452
Bart Spiessens, Muriel Debois. (2010) Adjusted significance levels for subgroup analyses in clinical trials. Contemporary Clinical Trials 31:6, 647-656
CrossRef453
C. Vogel, A. Chan, B. Gril, S.-B. Kim, J. Kurebayashi, L. Liu, Y.-S. Lu, H. Moon. (2010) Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib. Japanese Journal of Clinical Oncology 40:11, 999-1013
CrossRef454
Geoffrey J. Yoon, Melinda L. Telli, David P. Kao, Kelly Y. Matsuda, Robert W. Carlson, Ronald M. Witteles. (2010) Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. Journal of the American College of Cardiology 56:20, 1644-1650
CrossRef455
Rebecca A. Burrell, Nicolai Juul, Stephen R. Johnston, Jorge S. Reis-Filho, Zoltan Szallasi, Charles Swanton. (2010) Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Journal of Cellular Biochemistry 111:4, 782-790
CrossRef456
Alastair J Munro, Paddy G Niblock. (2010) Trastuzumab for gastric cancer treatment – Authors' reply. The Lancet 376:9754, 1736-1737
CrossRef457
Isabel Álvarez López, Juan Haba Rodríguez, Amparo Ruiz Simón, Meritxell Bellet Ezquerra, Lourdes Calvo Martínez, Laura García Estévez, Álvaro Rodríguez Lescure, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of metastatic breast cancer. Clinical and Translational Oncology 12:11, 719-723
CrossRef458
A. Santoro, G. Gullo. (2010) Trastuzumab beyond progression: a challenge to translational oncology?. Annals of Oncology 21:11, 2131-2134
CrossRef459
V. Guarneri, E. Barbieri, M.V. Dieci, F. Piacentini, P. Conte. (2010) Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treatment Reviews 36, S62-S66
CrossRef460
Yvonne Kienast, Frank Winkler. (2010) Therapy and prophylaxis of brain metastases. Expert Review of Anticancer Therapy 10:11, 1763-1777
CrossRef461
Patricia R. Blank, Matthias Schwenkglenks, Holger Moch, Thomas D. Szucs. (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment 124:2, 497-507
CrossRef462
Hatem A Azim Jr, Hamdy Azim, Fedro A Peccatori. (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Review of Clinical Immunology 6:6, 821-826
CrossRef463
Rita Nahta, Ruth M. O'Regan. (2010) Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway. Clinical Breast Cancer 10:0, S72-S78
CrossRef464
S. Dawood, K. Broglio, J. Ensor, G. N. Hortobagyi, S. H. Giordano. (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Annals of Oncology 21:11, 2169-2174
CrossRef465
Ke Liang, Francisco J. Esteva, Constance Albarracin, Katherine Stemke-Hale, Yang Lu, Giampaolo Bianchini, Ching-Yi Yang, Yong Li, Xinqun Li, Chun-Te Chen, Gordon B. Mills, Gabriel N. Hortobagyi, John Mendelsohn, Mien-Chie Hung, Zhen Fan. (2010) Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell 18:5, 423-435
CrossRef466
Alicia FC Okines, Alice Dewdney, Ian Chau, Sheela Rao, David Cunningham. (2010) Trastuzumab for gastric cancer treatment. The Lancet 376:9754, 1736
CrossRef467
Y C Cheng, V Valero, M L Davis, M C Green, A M Gonzalez-Angulo, R L Theriault, J L Murray, G N Hortobagyi, N T Ueno. (2010) Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. British Journal of Cancer 103:9, 1331-1334
CrossRef468
S Guiu, M Gauthier, B Coudert, F Bonnetain, L Favier, S Ladoire, H Tixier, B Guiu, F Penault-Llorca, F Ettore, P Fumoleau, L Arnould. (2010) Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. British Journal of Cancer 103:9, 1335-1342
CrossRef469
Xianglin L. Du, Rui Xia, Keith Burau, Chih-Chin Liu. (2010) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncology
CrossRef470
Changfei Li, Sheng Cao, Zhen Liu, Xin Ye, Lizhao Chen, Songdong Meng. (2010) RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. International Journal of Cancer 127:7, 1507-1516
CrossRef471
C. Oakman, A. Sapino, C. Marchio, M. Pestrin, L. Biganzoli, A. Di Leo. (2010) Chemotherapy with or without trastuzumab. Annals of Oncology 21:Supplement 7, vii112-vii119
CrossRef472
Lori M. Minasian, William R. Carpenter, Bryan J. Weiner, Darrell E. Anderson, Worta McCaskill-Stevens, Stefanie Nelson, Cynthia Whitman, Joseph Kelaghan, Ann M. O'Mara, Arnold D. Kaluzny. (2010) Translating research into evidence-based practice. Cancer 116:19, 4440-4449
CrossRef473
Anna Emde, Wolfgang J. Köstler, Yosef Yarden. (2010) Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical Reviews in Oncology/Hematology
CrossRef474
M. Venturini, C. Bighin, F. Puglisi, N. Olmeo, E. Aitini, G. Colucci, O. Garrone, A. Paccagnella, G. Marini, L. Crinò. (2010) A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. The Breast 19:5, 333-338
CrossRef475
Jason A. Wilken, Nita J. Maihle. (2010) Primary trastuzumab resistance: new tricks for an old drug. Annals of the New York Academy of Sciences 1210:1, 53-65
CrossRef476
Chuandong Ma, Xiuqing Niu, Jianmin Luo, Zhimin Shao, Kunwei Shen. (2010) Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer Science 101:10, 2220-2226
CrossRef477
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, 303-316
CrossRef478
Masataka Sawaki, Hiroji Iwata, Yasuyuki Sato, Masaki Wada, Tatsuya Toyama, Eiichi Sasaki, Yasushi Yatabe, Tsuneo Imai, Yasuo Ohashi. (2010) Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. The Breast 19:5, 370-376
CrossRef479
Elisabetta Munzone, Franco Nolé, Aron Goldhirsch, Edoardo Botteri, Angela Esposito, Laura Zorzino, Giuseppe Curigliano, Ida Minchella, Laura Adamoli, Maria Cristina Cassatella, Chiara Casadio, Maria Teresa Sandri. (2010) Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. Clinical Breast Cancer 10:5, 392-397
CrossRef480
Alfonso Sánchez-Muñoz, R. Dueñas-García, A. Jaén-Morago, E. Carrasco, I. Chacón, A. M. García-Tapiador, A. L. Ortega-Granados, E. Martínez-Ortega, N. Ribelles, M. Fernández-Navarro, C. de la Torre-Cabrera, B. Dueñas, A. I. Rueda, J. Martínez, C. Ramírez Tortosa, M. D. Martín-Salvago, P. Sánchez-Rovira. (2010) Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?. American Journal of Clinical Oncology 33:5, 432-437
CrossRef481
Cynthia Frankel. (2010) Trastuzumab Cardio-Oncology: Lessons Learned. Clinical Journal of Oncology Nursing 14:5, 630-640
CrossRef482
Michael S. Ewer, Steven M. Ewer. (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nature Reviews Cardiology 7:10, 564-575
CrossRef483
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Bio tribune magazine 36:1, 30-35
CrossRef484
J. Baselga. (2010) Treatment of HER2-overexpressing breast cancer. Annals of Oncology 21:Supplement 7, vii36-vii40
CrossRef485
J. S. de Bono, Alan Ashworth. (2010) Translating cancer research into targeted therapeutics. Nature 467:7315, 543-549
CrossRef486
S. Seoane, J. C. Montero, A. Ocana, A. Pandiella. (2010) Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. JNCI Journal of the National Cancer Institute 102:18, 1432-1446
CrossRef487
A Chakrabarty, B N Rexer, S E Wang, R S Cook, J A Engelman, C L Arteaga. (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29:37, 5193-5203
CrossRef488
Soumitra Basu, Adegboyega Oyelere. 2010. The Application of Recombinant DNA Technology in Medicinal Chemistry and Drug Discovery. .
CrossRef489
Birgitta Schlüter, Roswitha Gerhards, Dirk Strumberg, Rudolf Voigtmann. (2010) Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. Journal of Cancer Research and Clinical Oncology 136:9, 1389-1400
CrossRef490
Maha Zohra Ladjemi, William Jacot, Thierry Chardès, André Pèlegrin, Isabelle Navarro-Teulon. (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunology, Immunotherapy 59:9, 1295-1312
CrossRef491
Andrés García Palomo. (2010) Therapeutic approaches in young women with advanced or metastatic breast cancer. Breast Cancer Research and Treatment 123:S1, 49-52
CrossRef492
Richard Simon. (2010) Moving from correlative science to predictive oncology. The EPMA Journal 1:3, 377-387
CrossRef493
Sheng-Xiang Lin, Jiong Chen, Mausumi Mazumdar, Donald Poirier, Cheng Wang, Arezki Azzi, Ming Zhou. (2010) Molecular therapy of breast cancer: progress and future directions. Nature Reviews Endocrinology 6:9, 485-493
CrossRef494
Sally Greenberg, Hope S. Rugo. (2010) Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. Clinical Breast Cancer 10:0, S20-S29
CrossRef495
Douglas B. Sawyer, Xuyang Peng, Billy Chen, Laura Pentassuglia, Chee Chew Lim. (2010) Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?. Progress in Cardiovascular Diseases 53:2, 105-113
CrossRef496
Otto Metzger Filho, Kamal S. Saini, Hatem A. Azim, Ahmad Awada. (2010) Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology
CrossRef497
Jean-Philippe Theurillat, Birgit Dreier, Gabriela Nagy-Davidescu, Burkhardt Seifert, Silvia Behnke, Ursina Zürrer-Härdi, Fabienne Ingold, Andreas Plückthun, Holger Moch. (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Modern Pathology 23:9, 1289-1297
CrossRef498
Gerald M Higa, Vikramjit Singh, Jame Abraham. (2010) Biological considerations and clinical applications of new HER2-targeted agents. Expert Review of Anticancer Therapy 10:9, 1497-1509
CrossRef499
Stacy L. Moulder. (2010) Novel Cytotoxic Backbones and Targeted Therapies: Recent Data and Ongoing Clinical Trials. Clinical Breast Cancer 10:0, S30-S40
CrossRef500
Francisco Javier Andreu. (2010) Histologic diagnosis in young women with breast cancer. Breast Cancer Research and Treatment 123:S1, 15-18
CrossRef501
N. Saijo. (2010) Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology 40:9, 855-862
CrossRef502
Elizabeth A. Comen, Monica N. Fornier. (2010) Algorithms for the Treatment of Patients With Metastatic Breast Cancer and Prior Exposure to Taxanes and Anthracyclines. Clinical Breast Cancer 10:0, S7-S19
CrossRef503
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef504
T. Horie, K. Ono, H. Nishi, K. Nagao, M. Kinoshita, S. Watanabe, Y. Kuwabara, Y. Nakashima, R. Takanabe-Mori, E. Nishi, K. Hasegawa, T. Kita, T. Kimura. (2010) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovascular Research 87:4, 656-664
CrossRef505
Joseph R. Carver. (2010) Management of Trastuzumab-Related Cardiac Dysfunction. Progress in Cardiovascular Diseases 53:2, 130-139
CrossRef506
Josef Rüschoff, Manfred Dietel, Gustavo Baretton, Susanne Arbogast, Axel Walch, Geneviéve Monges, Marie-Pierre Chenard, Frédérique Penault-Llorca, Iris Nagelmeier, Werner Schlake, H. Höfler, H. H. Kreipe. (2010) HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 457:3, 299-307
CrossRef507
R A Jones, J J Petrik, R A Moorehead. (2010) Preneoplastic changes persist after IGF-IR downregulation and tumor regression. Oncogene 29:34, 4779-4786
CrossRef508
C A Purdie, L Baker, A Ashfield, S Chatterjee, L B Jordan, P Quinlan, D J A Adamson, J A Dewar, A M Thompson. (2010) Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. British Journal of Cancer 103:4, 475-481
CrossRef509
Daniel S.-W. Tan, Marco Gerlinger, Bin-Tean Teh, Charles Swanton. (2010) Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer 46:12, 2166-2177
CrossRef510
Christian Zuppinger, Thomas M Suter. (2010) Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium. Journal of Cardiovascular Pharmacology 56:2, 141-146
CrossRef511
Juan de la Haba-Rodriguez, Rosario González Mancha, Gumersindo Pérez Manga, Enrique Aranda Aguilar, José Manuel Baena Cañada, Pedro Sánchez Rovira, Emilio Alba Conejo. (2010) Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study. Clinical Breast Cancer 10:4, 313-317
CrossRef512
Neil K. Taunk, Sharad Goyal, Meena S. Moran, Qifeng Yang, Rahul Parikh, Bruce G. Haffty. (2010) Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy
CrossRef513
Rajiv Dua, Jianhuan Zhang, Phets Nhonthachit, Elicia Penuel, Chris Petropoulos, Gordon Parry. (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Research and Treatment 122:3, 685-697
CrossRef514
Cynthia Moreira, Virginia Kaklamani. (2010) Lapatinib and breast cancer: current indications and outlook for the future. Expert Review of Anticancer Therapy 10:8, 1171-1182
CrossRef515
Hirofumi Mukai. (2010) Treatment strategy for HER2-positive breast cancer. International Journal of Clinical Oncology 15:4, 335-340
CrossRef516
Ulla Wilking, Bengt Jönsson, Nils Wilking, Jonas Bergh. (2010) Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncologica 49:6, 844-850
CrossRef517
H. Mukai. (2010) Targeted Therapy in Breast Cancer: Current Status and Future Directions. Japanese Journal of Clinical Oncology 40:8, 711-716
CrossRef518
Jolien Tol, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Iris D. Nagtegaal, Cornelis J.A. Punt, Johan H.J.M. Van Krieken, Marjolijn J.L. Ligtenberg. (2010) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. Journal of Cellular and Molecular Medicine 14:8, 2122-2131
CrossRef519
Katri Köninki, Mark Barok, Minna Tanner, Synnöve Staff, Jukka Pitkänen, Päivikki Hemmilä, Joanna Ilvesaro, Jorma Isola. (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Letters 294:2, 211-219
CrossRef520
Hatem A Azim Jr, Martine J Piccart. (2010) Simultaneous targeting of estrogen receptor and HER2 in breast cancer. Expert Review of Anticancer Therapy 10:8, 1255-1263
CrossRef521
Ben Tallon, Elizabeth Blanchard, Lynne J. Goldberg. (2010) Permanent chemotherapy-induced alopecia: Case report and review of the literature. Journal of the American Academy of Dermatology 63:2, 333-336
CrossRef522
Susana M. Campos, Suzanne T. Berlin, Leroy M. Parker, Wendy Y. Chen, Craig A. Bunnell, Tina Atkinson, Julie Lee, Ursula Matulonis, Michelle S. Hirsch, Lyndsay Harris, Carolyn N. Krasner. (2010) Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International Journal of Clinical Oncology 15:4, 390-398
CrossRef523
Dimitrios H Roukos. (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:8, 1039-1043
CrossRef524
Sophie Otter, Alistair Ring. (2010) Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly. Expert Review of Anticancer Therapy 10:8, 1265-1272
CrossRef525
Patricia R. Blank, Konstantin J. Dedes, Thomas D. Szucs. (2010) Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer. PharmacoEconomics 28:8, 629-647
CrossRef526
Ron J. Keizer, Alwin D.R. Huitema, Jan H.M. Schellens, Jos H. Beijnen. (2010) Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics 49:8, 493-507
CrossRef527
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376:9742, 687-697
CrossRef528
K. Tsujino, J. Shiraishi, T. Tsuji, T. Kurata, T. Kawaguchi, A. Kubo, M. Takada. (2010) Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?. Annals of Oncology 21:8, 1668-1674
CrossRef529
Hope Rugo, Melissa Brammer, Fan Zhang, Deepa Lalla. (2010) Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. Clinical Breast Cancer 10:4, 288-293
CrossRef530
Alison K. Conlin, Andrew D. Seidman, Ariadne Bach, Diana Lake, Maura Dickler, Gabriella D'Andrea, Tiffany Traina, Michael Danso, Adam M. Brufsky, Mansoor Saleh, Alicia Clawson, Clifford A. Hudis. (2010) Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer 10:4, 281-287
CrossRef531
Andre T Brunetto, Rebecca S Kristeleit, Johann S de Bono. (2010) Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncology 6:8, 1339-1352
CrossRef532
Jeffrey Y.C. Wong, Andrew Raubitschek, Dave Yamauchi, Lawrence E. Williams, Anna M. Wu, Paul Yazaki, John E. Shively, David Colcher, George Somlo. (2010) A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer. Cancer Biotherapy & Radiopharmaceuticals 25:4, 387-394
CrossRef533
D.G. Power, J.V. Reynolds. (2010) Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. Cancer Treatment Reviews 36:5, 400-409
CrossRef534
L. Bergmann, B. Berns, A. G. Dalgleish, M. von Euler, T. T. Hecht, G. L. Lappin, N. Reed, S. Palmeri, J. Smyth, S. Embacher-Aichorn, H. Zwierzina, . (2010) Investigator-initiated trials of targeted oncology agents: why independent research is at risk?. Annals of Oncology 21:8, 1573-1578
CrossRef535
S Wang, X Huang, C-K Lee, B Liu. (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29:29, 4225-4236
CrossRef536
B. C. Browne, J. Crown, N. Venkatesan, M. J. Duffy, M. Clynes, D. Slamon, N. O'Donovan. (2010) Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals of Oncology
CrossRef537
K. Kast, W. Distler. (2010) ErbB2 (HER2)-positives Mammakarzinom. Der Gynäkologe 43:7, 574-578
CrossRef538
Timothy A. Yap, Shahneen K. Sandhu, Paul Workman, Johann S. de Bono. (2010) Envisioning the future of early anticancer drug development. Nature Reviews Cancer 10:7, 514-523
CrossRef539
Monique P. Curran. (2010) Lapatinib. Drugs 70:11, 1411-1422
CrossRef540
K. Aoyama, T. Kamio, T. Nishikawa, S. Kameoka. (2010) A Comparison of HER2/neu Gene Amplification and Its Protein Overexpression Between Primary Breast Cancer and Metastatic Lymph Nodes. Japanese Journal of Clinical Oncology 40:7, 613-619
CrossRef541
Lynette M. Sholl, Neal I. Lindeman. (2010) Molecular Diagnostics Testing for Lung Adenocarcinoma. Pathology Case Reviews 15:4, 103-110
CrossRef542
István Peták, Richárd Schwab, László Őrfi, László Kopper, György Kéri. (2010) Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 9:7, 523-535
CrossRef543
Shaheenah Dawood. (2010) Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics 10:5, 581-590
CrossRef544
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Oncologie 12:7, 416-421
CrossRef545
Patricia S Kho, Wei Chua, Melissa M Moore, Stephen J Clarke. (2010) Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine 7:4, 387-397
CrossRef546
Sandra Geiger, Veronika Lange, Patricia Suhl, Volker Heinemann, Hans-Joachim Stemmler. (2010) Anticancer therapy induced cardiotoxicity: review of the literature. Anti-Cancer Drugs 21:6, 578-590
CrossRef547
Nicholas J. Robert. (2010) Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint. Breast Cancer Research and Treatment 122:1, 9-10
CrossRef548
Lynne Dobson, Catherine Conway, Alan Hanley, Alex Johnson, Sean Costello, Anthony O’Grady, Yvonne Connolly, Hilary Magee, Daniel O’Shea, Michael Jeffers, Elaine Kay. (2010) Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology 57:1, 27-38
CrossRef549
Nobuaki Kato, Hitoshi Itoh, Akihiko Serizawa, Yutaka Hatanaka, Shinobu Umemura, R. Yoshiyuki Osamura. (2010) Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathology International 60:7, 510-515
CrossRef550
George W. Sledge, Aparna C. Jotwani, Lida Mina. (2010) Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises. Surgical Oncology Clinics of North America 19:3, 669-679
CrossRef551
C. G. Murphy, M. Khasraw, A. D. Seidman. (2010) Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment 122:1, 177-179
CrossRef552
Anne H. Blaes, Philippe Gaillard, Bruce A. Peterson, Douglas Yee, Beth Virnig. (2010) Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment 122:2, 585-590
CrossRef553
Valentina Macrinici, Edward Romond. (2010) Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E38-E46
CrossRef554
Anna Niwińska, Małgorzata Tacikowska, Magdalena Murawska. (2010) The Effect of Early Detection of Occult Brain Metastases in HER2-Positive Breast Cancer Patients on Survival and Cause of Death. International Journal of Radiation Oncology*Biology*Physics 77:4, 1134-1139
CrossRef555
Heidrun Karlic, Harald Herrmann, Axel Schulenburg, Thomas W. Grunt, Sylvia Laffer, Irina Mirkina, Rainer Hubmann, Medhat Shehata, Brigitte Marian, Edgar Selzer, Michael Pfeilstöcker, Elisabeth Pittermann, Ulrich Jäger, Hubert Pehamberger, Christoph Zielinski, Peter Valent. (2010) Tumor-Stammzellforschung – Basis und Herausforderung für Diagnostik und Therapie. Wiener klinische Wochenschrift 122:13-14, 423-436
CrossRef556
Stefan Stortecky, Thomas M Suter. (2010) Insights into cardiovascular side-effects of modern anticancer therapeutics. Current Opinion in Oncology 22:4, 312-317
CrossRef557
Cathy B Moelans, Roel A de Weger, Hanneke N Monsuur, Raymon Vijzelaar, Paul J van Diest. (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Modern Pathology 23:7, 1029-1039
CrossRef558
Heather L. McArthur, Clifford A. Hudis. (2010) Chemotherapy: Neoadjuvant trial design: time for a brave new world?. Nature Reviews Clinical Oncology 7:7, 359-360
CrossRef559
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef560
Alicia F.C. Okines, David Cunningham. (2010) Trastuzumab in gastric cancer. European Journal of Cancer 46:11, 1949-1959
CrossRef561
H. M. Horlings, C. D. Savci-Heijink, M. J. van de Vijver. (2010) Translating the Genomic Architecture of Breast Cancer into Clinical Applications. Science Translational Medicine 2:38, 38ps32-38ps32
CrossRef562
Ho-Young Yhim, Sae-Won Han, Do-Youn Oh, Wonshik Han, Seock-Ah Im, Tae-You Kim, Young Tae Kim, Dong-Young Noh, Eui Kyu Chie, Sung Whan Ha, In Ae Park, Yung-Jue Bang. (2010) Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer 116:12, 2890-2901
CrossRef563
Helena R. Chang. (2010) Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 116:12, 2856-2867
CrossRef564
Marc Buyse, Daniel J. Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology 7:6, 309-317
CrossRef565
Carin A Uyl-de Groot, Saskia de Groot, Adri Steenhoek. (2010) The economics of improved cancer survival rates: better outcomes, higher costs. Expert Review of Pharmacoeconomics & Outcomes Research 10:3, 283-292
CrossRef566
Dominika Nowis, Michał Mączewski, Urszula Mackiewicz, Marek Kujawa, Anna Ratajska, Mariusz R. Wieckowski, Grzegorz M. Wilczyński, Monika Malinowska, Jacek Bil, Paweł Salwa, Marek Bugajski, Cezary Wójcik, Maciej Siński, Piotr Abramczyk, Magdalena Winiarska, Anna Dąbrowska-Iwanicka, Jerzy Duszyński, Marek Jakóbisiak, Jakub Golab. (2010) Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. The American Journal of Pathology 176:6, 2658-2668
CrossRef567
Javier Rodríguez, Antonio Viúdez, Mariano Ponz-Sarvisé, Isabel Gil-Aldea, Ana Chopitea, Jesús García-Foncillas, Ignacio Gil-Bazo. (2010) Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Critical Reviews in Oncology/Hematology 74:3, 193-202
CrossRef568
Christina A. Saurel, Tejal A. Patel, Edith A. Perez. (2010) Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review. Clinical Breast Cancer 10:3, 196-208
CrossRef569
F. Grudé, M. Campone, A. Lortholary, R. Delva, P. Soulie, P. Kerbrat, G. Ganem, H. Bourgeois, S. Hulst, E. Vuillemin, A.-C. Hardy-Bessard, M.-J. Goudier, H. Simon, B. Lucas, F. Priou, C. Riché, E. Gamelin. (2010) Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l’Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL). Oncologie 12:5-6, 362-368
CrossRef570
Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Begoña Martin-Castillo, Silvia Cufí, Sonia Del Barco, Eugeni Lopez-Bonet, Joan Brunet, Javier A. Menendez. (2010) Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications 397:1, 27-33
CrossRef571
Connie G. Chiu, Hamid Masoudi, Samuel Leung, David K. Voduc, Blake Gilks, David G. Huntsman, Sam M. Wiseman. (2010) HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. Annals of Surgery 251:6, 1107-1116
CrossRef572
Massimo Cristofanilli. (2010) Novel targeted therapies in inflammatory breast cancer. Cancer 116:S11, 2837-2839
CrossRef573
Jane Hurtig. (2010) Managing Patients With Advanced and Metastatic Breast Cancer. Clinical Journal of Oncology Nursing 14:3, 313-323
CrossRef574
S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri, G. Cicero, C. La Mendola, G. Guggino, M. D'Asaro, V. Orlando, F. Scarpa, A. Roberts, N. Caccamo, G. Stassi, F. Dieli, A. C. Hayday. (2010) In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clinical & Experimental Immunologyno-no
CrossRef575
Guenther G. Steger, Jitka Abrahámová, Florin Bacanu, Stephen Brincat, Arija Brize, Alvydas Česas, Tanja Čufer, Magdolna Dank, Renata Duchnowska, Alexandru Eniu, Jacek Jassem, Zsuzsanna Kahán, Erika Matos, Peeter Padrik, Signe Plāte, Helis Pokker, Gunta Purkalne, Constanta Timcheva, Valentina Tzekova, Rostislav Vyzula, Christoph C. Zielinski. (2010) Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener klinische Wochenschrift 122:11-12, 368-379
CrossRef576
Patrice Viens, Carole Tarpin, Henri Roche, François Bertucci. (2010) Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies. Cancer 116:S11, 2829-2836
CrossRef577
Frances M. Palmieri, Charlyn V. Myatt, Edith A. Perez. (2010) Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer. Clinical Journal of Oncology Nursing 14:3, 326-336
CrossRef578
Per E. Lønning. (2010) Molecular basis for therapy resistance. Molecular Oncology 4:3, 284-300
CrossRef579
L. Del Mastro, C. Bighin, G. Bini, S. Giraudi, P. Taveggia, A. Levaggi, G. Canavese, G. Rescinito, P. Pronzato. (2010) Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?. Annals of Oncology 21:6, 1376-1377
CrossRef580
Bettina G. Papouchado, Jonathan Myles, Ricardo V. Lloyd, Mark Stoler, Andre M. Oliveira, Erinn Downs-Kelly, Adrienne Morey, Michael Bilous, Ray Nagle, Nichole Prescott, Lin Wang, Lidija Dragovich, Abigail McElhinny, Carole Ferrell Garcia, Jim Ranger-Moore, Heather Free, William Powell, Margaret Loftus, James Pettay, Fabien Gaire, Christopher Roberts, Manfred Dietel, Patrick Roche, Thomas Grogan, Raymond Tubbs. (2010) Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma. The American Journal of Surgical Pathology 34:6, 767-776
CrossRef581
Colin A Purdie, Lee B Jordan, Jean B McCullough, Sharon L Edwards, Joan Cunningham, Miriam Walsh, Andrew Grant, Norman Pratt, Alastair M Thompson. (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56:6, 702-707
CrossRef582
F Stegmeier, M Warmuth, W R Sellers, M Dorsch. (2010) Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clinical Pharmacology & Therapeutics 87:5, 543-552
CrossRef583
Louis M. Weiner, Rishi Surana, Shangzi Wang. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 10:5, 317-327
CrossRef584
Lucy Gossage, Tim Eisen. (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature Reviews Clinical Oncology 7:5, 277-288
CrossRef585
Carlos H. Barrios, Mei-Ching Liu, Soo Chin Lee, Laurence Vanlemmens, Jean-Marc Ferrero, Toshio Tabei, Xavier Pivot, Hiroji Iwata, Kenjiro Aogi, Roberto Lugo-Quintana, Nadia Harbeck, Marla J. Brickman, Ke Zhang, Kenneth A. Kern, Miguel Martin. (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment 121:1, 121-131
CrossRef586
S.G. Coulson, V.S. Kumar, I.M. Manifold, M.Q. Hatton, S. Ramakrishnan, K.S. Dunn, O.P. Purohit, C. Bridgewater, R.E. Coleman. (2010) Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?. Clinical Oncology 22:4, 289-293
CrossRef587
Richard L. Schilsky. (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9:5, 363-366
CrossRef588
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef589
Antonio C. Wolff, Molin Wang, Hailun Li, Michael R. Pins, Florence J. Pretorius, Kendrith M. Rowland, Joseph A. Sparano, Nancy E. Davidson. (2010) Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. Breast Cancer Research and Treatment 121:1, 111-120
CrossRef590
S. F. Schoppmann, D. Tamandl, L. Roberts, G. Jomrich, A. Schoppmann, R. Zwrtek, P. Dubsky, M. Gnant, R. Jakesz, P. Birner. (2010) HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Annals of Oncology 21:5, 955-960
CrossRef591
E C Dijkers, T H Oude Munnink, J G Kosterink, A H Brouwers, P L Jager, J R de Jong, G A van Dongen, C P Schröder, M N Lub-de Hooge, E G de Vries. (2010) Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer. Clinical Pharmacology & Therapeutics 87:5, 586-592
CrossRef592
T. Pienkowski, C. C. Zielinski. (2010) Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Annals of Oncology 21:5, 917-924
CrossRef593
F. Cardoso, E. Senkus-Konefka, L. Fallowfield, A. Costa, M. Castiglione, . (2010) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v15-v19
CrossRef594
H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhonen, T. Turpeenniemi-Hujanen, R. Asola, M. Leinonen, M. Hahka-Kemppinen, P. Kellokumpu-Lehtinen. (2010) Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of Oncology 21:5, 968-973
CrossRef595
Daniel Serin. (2010) Cancer du sein avancé ou métastatique HER2+: évolution de la prise en charge. Oncomagazine 4:2, 16-18
CrossRef596
Edgardo Rivera. (2010) Implications of Anthracycline-Resistant and Taxane-Resistant Metastatic Breast Cancer and New Therapeutic Options. The Breast Journal 16:3, 252-263
CrossRef597
Thomas J. Hudson (Chairperson), Warwick Anderson, Axel Aretz, Anna D. Barker, Cindy Bell, Rosa R. Bernabé, M. K. Bhan, Fabien Calvo, Iiro Eerola, Daniela S. Gerhard, Alan Guttmacher, Mark Guyer, Fiona M. Hemsley, Jennifer L. Jennings, David Kerr, Peter Klatt, Patrik Kolar, Jun Kusuda, David P. Lane, Frank Laplace, Youyong Lu, Gerd Nettekoven, Brad Ozenberger, Jane Peterson, T.S. Rao, Jacques Remacle, Alan J. Schafer, Tatsuhiro Shibata, Michael R. Stratton, Joseph G. Vockley, Koichi Watanabe, Huanming Yang, Matthew M. F. Yuen, Bartha M. Knoppers (Leader), Martin Bobrow, Anne Cambon-Thomsen, Lynn G. Dressler, Stephanie O. M. Dyke, Yann Joly, Kazuto Kato, Karen L. Kennedy, Pilar Nicolás, Michael J. Parker, Emmanuelle Rial-Sebbag, Carlos M. Romeo-Casabona, Kenna M. Shaw, Susan Wallace, Georgia L. Wiesner, Nikolajs Zeps, Peter Lichter (Leader), Andrew V. Biankin, Christian Chabannon, Lynda Chin, Bruno Clément, Enrique de Alava, Françoise Degos, Martin L. Ferguson, Peter Geary, D. Neil Hayes, Thomas J. Hudson, Amber L. Johns, Arek Kasprzyk, Hidewaki Nakagawa, Robert Penny, Miguel A. Piris, Rajiv Sarin, Aldo Scarpa, Tatsuhiro Shibata, Marc van de Vijver, P. Andrew Futreal (Leader), Hiroyuki Aburatani, Mónica Bayés, David D.L. Bowtell, Peter J. Campbell, Xavier Estivill, Daniela S. Gerhard, Sean M. Grimmond, Ivo Gut, Martin Hirst, Carlos López-Otín, Partha Majumder, Marco Marra, John D. McPherson, Hidewaki Nakagawa, Zemin Ning, Xose S. Puente, Yijun Ruan, Tatsuhiro Shibata, Michael R. Stratton, Hendrik G. Stunnenberg, Harold Swerdlow, Victor E. Velculescu, Richard K. Wilson, Hong H. Xue, Liu Yang, Paul T. Spellman (Leader), Gary D. Bader, Paul C. Boutros, Peter J. Campbell, Paul Flicek, Gad Getz, Roderic Guigó, Guangwu Guo, David Haussler, Simon Heath, Tim J. Hubbard, Tao Jiang, Steven M. Jones, Qibin Li, Nuria López-Bigas, Ruibang Luo, Lakshmi Muthuswamy, B. F. Francis Ouellette, John V. Pearson, Xose S. Puente, Victor Quesada, Benjamin J. Raphael, Chris Sander, Tatsuhiro Shibata, Terence P. Speed, Lincoln D. Stein, Joshua M. Stuart, Jon W. Teague, Yasushi Totoki, Tatsuhiko Tsunoda, Alfonso Valencia, David A. Wheeler, Honglong Wu, Shancen Zhao, Guangyu Zhou, Lincoln D. Stein (Leader), Roderic Guigó, Tim J. Hubbard, Yann Joly, Steven M. Jones, Arek Kasprzyk, Mark Lathrop, Nuria López-Bigas, B. F. Francis Ouellette, Paul T. Spellman, Jon W. Teague, Gilles Thomas, Alfonso Valencia, Teruhiko Yoshida, Karen L. Kennedy (Leader), Myles Axton, Stephanie O. M. Dyke, P. Andrew Futreal, Daniela S. Gerhard, Chris Gunter, Mark Guyer, Thomas J. Hudson, John D. McPherson, Linda J. Miller, Brad Ozenberger, Kenna M. Shaw, Arek Kasprzyk (Leader), Lincoln D. Stein (Leader), Junjun Zhang, Syed A. Haider, Jianxin Wang, Christina K. Yung, Anthony Cross, Yong Liang, Saravanamuttu Gnaneshan, Jonathan Guberman, Jack Hsu, Martin Bobrow (Leader), Don R. C. Chalmers, Karl W. Hasel, Yann Joly, Terry S. H. Kaan, Karen L. Kennedy, Bartha M. Knoppers, William W. Lowrance, Tohru Masui, Pilar Nicolás, Emmanuelle Rial-Sebbag, Laura Lyman Rodriguez, Catherine Vergely, Teruhiko Yoshida, Sean M. Grimmond (Leader), Andrew V. Biankin, David D. L. Bowtell, Nicole Cloonan, Anna deFazio, James R. Eshleman, Dariush Etemadmoghadam, Brooke A. Gardiner, James G. Kench, Aldo Scarpa, Robert L. Sutherland, Margaret A. Tempero, Nicola J. Waddell, Peter J. Wilson, John D. McPherson (Leader), Steve Gallinger, Ming-Sound Tsao, Patricia A. Shaw, Gloria M. Petersen, Debabrata Mukhopadhyay, Lynda Chin, Ronald A. DePinho, Sarah Thayer, Lakshmi Muthuswamy, Kamran Shazand, Timothy Beck, Michelle Sam, Lee Timms, Vanessa Ballin, Youyong Lu (Leader), Jiafu Ji, Xiuqing Zhang, Feng Chen, Xueda Hu, Guangyu Zhou, Qi Yang, Geng Tian, Lianhai Zhang, Xiaofang Xing, Xianghong Li, Zhenggang Zhu, Yingyan Yu, Jun Yu, Huanming Yang, Mark Lathrop (Leader), Jörg Tost, Paul Brennan, Ivana Holcatova, David Zaridze, Alvis Brazma, Lars Egevad, Egor Prokhortchouk, Rosamonde Elizabeth Banks, Mathias Uhlén, Anne Cambon-Thomsen, Juris Viksna, Fredrik Ponten, Konstantin Skryabin, Michael R. Stratton (Leader), P. Andrew Futreal, Ewan Birney, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Sancha Martin, Jorge S. Reis-Filho, Andrea L. Richardson, Christos Sotiriou, Hendrik G. Stunnenberg, Gilles Thomas, Marc van de Vijver, Laura van’t Veer, Fabien Calvo (Leader), Daniel Birnbaum, Hélène Blanche, Pascal Boucher, Sandrine Boyault, Christian Chabannon, Ivo Gut, Jocelyne D. Masson-Jacquemier, Mark Lathrop, Iris Pauporté, Xavier Pivot, Anne Vincent-Salomon, Eric Tabone, Charles Theillet, Gilles Thomas, Jörg Tost, Isabelle Treilleux, Fabien Calvo (Leader), Paulette Bioulac-Sage, Bruno Clément, Thomas Decaens, Françoise Degos, Dominique Franco, Ivo Gut, Marta Gut, Simon Heath, Mark Lathrop, Didier Samuel, Gilles Thomas, Jessica Zucman-Rossi, Peter Lichter (Leader), Roland Eils (Leader), Benedikt Brors, Jan O. Korbel, Andrey Korshunov, Pablo Landgraf, Hans Lehrach, Stefan Pfister, Bernhard Radlwimmer, Guido Reifenberger, Michael D. Taylor, Christof von Kalle, Partha P. Majumder (Leader), Rajiv Sarin, T. S. Rao, M. K. Bhan, Aldo Scarpa (Leader), Paolo Pederzoli, Rita T. Lawlor, Massimo Delledonne, Alberto Bardelli, Andrew V. Biankin, Sean M. Grimmond, Thomas Gress, David Klimstra, Giuseppe Zamboni, Tatsuhiro Shibata (Leader), Yusuke Nakamura, Hidewaki Nakagawa, Jun Kusuda, Tatsuhiko Tsunoda, Satoru Miyano, Hiroyuki Aburatani, Kazuto Kato, Akihiro Fujimoto, Teruhiko Yoshida, Elias Campo (Leader), Carlos López-Otín, Xavier Estivill, Roderic Guigó, Silvia de Sanjosé, Miguel A. Piris, Emili Montserrat, Marcos González-Díaz, Xose S. Puente, Pedro Jares, Alfonso Valencia, Heinz Himmelbaue, Victor Quesada, Silvia Bea, Michael R. Stratton (Leader), P. Andrew Futreal, Peter J. Campbell, Anne Vincent-Salomon, Andrea L. Richardson, Jorge S. Reis-Filho, Marc van de Vijver, Gilles Thomas, Jocelyne D. Masson-Jacquemier, Samuel Aparicio, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Hendrik G. Stunnenberg, Laura van’t Veer, Douglas F. Easton, Paul T. Spellman, Sancha Martin, Anna D. Barker, Lynda Chin, Francis S. Collins, Carolyn C. Compton, Martin L. Ferguson, Daniela S. Gerhard, Gad Getz, Chris Gunter, Alan Guttmacher, Mark Guyer, D. Neil Hayes, Eric S. Lander, Brad Ozenberger, Robert Penny, Jane Peterson, Chris Sander, Kenna M. Shaw, Terence P. Speed, Paul T. Spellman, Joseph G. Vockley, David A. Wheeler, Richard K. Wilson, Thomas J. Hudson (Chairperson), Lynda Chin, Bartha M. Knoppers, Eric S. Lander, Peter Lichter, Lincoln D. Stein, Michael R. Stratton, Warwick Anderson, Anna D. Barker, Cindy Bell, Martin Bobrow, Wylie Burke, Francis S. Collins, Carolyn C. Compton, Ronald A. DePinho, Douglas F. Easton, P. Andrew Futreal, Daniela S. Gerhard, Anthony R. Green, Mark Guyer, Stanley R. Hamilton, Tim J. Hubbard, Olli P. Kallioniemi, Karen L. Kennedy, Timothy J. Ley, Edison T. Liu, Youyong Lu, Partha Majumder, Marco Marra, Brad Ozenberger, Jane Peterson, Alan J. Schafer, Paul T. Spellman, Hendrik G. Stunnenberg, Brandon J. Wainwright, Richard K. Wilson, Huanming Yang. (2010) International network of cancer genome projects. Nature 464:7291, 993-998
CrossRef598
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef599
Rebecca Scully, Steven E. Lipshultz. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children. , 97-126.
CrossRef600
Pierantonio Menna, Emanuela Salvatorelli, Carlo Salsano, Luca Gianni, Giorgio Minotti. 2010. Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts. , 223-256.
CrossRef601
Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 120:2, 293-308
CrossRef602
Mauro Ferrari. (2010) Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends in Biotechnology 28:4, 181-188
CrossRef603
Maneerat Koohapitagtam, Suang Rungpragayphan, Ratchanee Hongprayoon, Wichai Kositratana, Theerapol Sirinarumitr. (2010) Efficient amplification of light and heavy chain variable regions and construction of a non-immune phage scFv library. Molecular Biology Reports 37:4, 1677-1683
CrossRef604
Mikael Hartman, En Yun Loy, Chee Seng Ku, Kee Seng Chia. (2010) Molecular epidemiology and its current clinical use in cancer management. The Lancet Oncology 11:4, 383-390
CrossRef605
Pramila Paudyal, Bishnuhari Paudyal, Hirofumi Hanaoka, Noboru Oriuchi, Yashuhiko Iida, Hiroki Yoshioka, Hideyuki Tominaga, Satoshi Watanabe, Shigeki Watanabe, Noriko S Ishioka, Keigo Endo. (2010) Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET. Cancer Science 101:4, 1045-1050
CrossRef606
Stig Linder, Maria Hägg Olofsson, Richard Herrmann, Engin Ulukaya. (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Review of Molecular Diagnostics 10:3, 353-359
CrossRef607
Beth Sherrill, Angelo Di Leo, Mayur M. Amonkar, Yun Wu, Zanete Zvirbule, Zeba Aziz, Jose Bines, Henry L. Gomez. (2010) Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion 26:4, 767-775
CrossRef608
Jonathan M. Street, James W. Dear. (2010) The application of mass-spectrometry-based protein biomarker discovery to theragnostics. British Journal of Clinical Pharmacology 69:4, 367-378
CrossRef609
Keiko USUI, Toyoko OCHIAI, Ikuko ABE, Haruko NISHIO, Kana TOGO, Motoo YAMAGATA. (2010) Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon. The Journal of Dermatology 37:4, 350-354
CrossRef610
Denise A. Yardley. (2010) Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety. Clinical Breast Cancer 10:2, 119-129
CrossRef611
M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, A. Vieillefond. (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Annals of Oncology 21:4, 815-819
CrossRef612
B. Tran, M.A. Rosenthal. (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. Journal of Clinical Neuroscience 17:4, 417-421
CrossRef613
Richard A Morgan, James C Yang, Mio Kitano, Mark E Dudley, Carolyn M Laurencot, Steven A Rosenberg. (2010) Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy 18:4, 843-851
CrossRef614
Tim J. Kruser, Deric L. Wheeler. (2010) Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research 316:7, 1083-1100
CrossRef615
B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, J. Baselga. (2010) Status of PI3K inhibition and biomarker development in cancer therapeutics. Annals of Oncology 21:4, 683-691
CrossRef616
Enrique Barrajón-Catalán, María P. Menéndez-Gutiérrez, Alberto Falco, Alfredo Carrato, Miguel Saceda, Vicente Micol. (2010) Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. Cancer Letters 290:2, 192-203
CrossRef617
Fabrício F T Barros, Desmond G Powe, Ian O Ellis, Andrew R Green. (2010) Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 56:5, 560-572
CrossRef618
S Sutherland, S Ashley, D Miles, S Chan, A Wardley, N Davidson, R Bhatti, M Shehata, H Nouras, T Camburn, S R D Johnston. (2010) Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. British Journal of Cancer 102:6, 995-1002
CrossRef619
Janet K. Horton, Jan Halle, Madlyn Ferraro, Lisa Carey, Dominic T. Moore, David Ollila, Carolyn I. Sartor. (2010) Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer With Trastuzumab: A Phase II Trial. International Journal of Radiation OncologyBiologyPhysics 76:4, 998-1004
CrossRef620
S Kulkarni, K B Reddy, F J Esteva, H C F Moore, G T Budd, R R Tubbs. (2010) Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 29:9, 1339-1350
CrossRef621
G. Capri, J. Chang, S.-C. Chen, P. Conte, K. Cwiertka, G. Jerusalem, Z. Jiang, S. Johnston, B. Kaufman, J. Link, J. Ro, J. Schutte, C. Oliva, R. Parikh, A. Preston, J. Rosenlund, M. Selzer, D. Zembryki, S. De Placido. (2010) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology 21:3, 474-480
CrossRef622
Wasif Riaz, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman. (2010) Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research 46:1-3, 192-205
CrossRef623
Serena T. Wong, Deborah Toppmeyer. (2010) Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions. Current Breast Cancer Reports 2:1, 16-24
CrossRef624
Arpad Z. Barabas, Chad D. Cole, Arpad D. Barabas, Richard M. Graeff, Rene Lafreniere, Donald M. Weir. (2010) Modified Vaccination Technique for Prophylactic and Therapeutic Applications to Combat Endogenous Antigen-Induced Disorders. Scandinavian Journal of Immunology 71:3, 125-133
CrossRef625
Austin Tanney, Richard D Kennedy. (2010) Developing mRNA-based biomarkers from formalin-fixed paraffin-embedded tissue. Personalized Medicine 7:2, 205-211
CrossRef626
N. Patani, K. Mokbel. (2010) Herceptin and breast cancer: An overview for surgeons. Surgical Oncology 19:1, e11-e21
CrossRef627
Tomás García-Caballero, Dorthe Grabau, Andrew R Green, John Gregory, Arno Schad, Elke Kohlwes, Ian O Ellis, Sarah Watts, Jens Mollerup. (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:4, 472-480
CrossRef628
W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez. (2010) N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Annals of Oncology 21:3, 493-497
CrossRef629
Tamás Nagykálnai, László Landherr, Edina Mészáros. (2010) Lehetőségek anthracyclin- és/vagy taxánkezelések után progrediáló emlőrákban. Magyar Onkológia 54:1, 9-16
CrossRef630
Windy Dean-Colomb, Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2:1, 42-52
CrossRef631
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef632
Brigette BY Ma, Herbert Loong. (2010) Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine 7:2, 121-124
CrossRef633
April Davoli, Barbara A. Hocevar, Thomas L. Brown. (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology 65:4, 611-623
CrossRef634
E C Merkhofer, P Cogswell, A S Baldwin. (2010) Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα. Oncogene 29:8, 1238-1248
CrossRef635
Gaurav D. Shah, Nick Loizos, Hagop Youssoufian, Jonathan D. Schwartz, Eric K. Rowinsky. (2010) Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α. Cancer 116:S4, 1018-1026
CrossRef636
M Watanabe, K Kono, Y Kawaguchi, Y Mizukami, K Mimura, T Maruyama, H Fujii. (2010) Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. British Journal of Cancer 102:3, 520-529
CrossRef637
T Gelardi, V Damiano, R Rosa, R Bianco, R Cozzolino, G Tortora, P Laccetti, G D'Alessio, C De Lorenzo. (2010) Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. British Journal of Cancer 102:3, 513-519
CrossRef638
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, H. Minami. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annals of Oncology 21:2, 255-262
CrossRef639
Francisco J. Esteva, Dihua Yu, Mien-Chie Hung, Gabriel N. Hortobagyi. (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews Clinical Oncology 7:2, 98-107
CrossRef640
James Korkola, Joe W Gray. (2010) Breast cancer genomes—form and function. Current Opinion in Genetics & Development 20:1, 4-14
CrossRef641
M. Schmidt, M. E. Scheulen, C. Dittrich, P. Obrist, N. Marschner, L. Dirix, M. Schmidt, D. Ruttinger, M. Schuler, C. Reinhardt, A. Awada. (2010) An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology 21:2, 275-282
CrossRef642
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef643
Hiroshi Ishiguro, Masahide Kondo, Shu-Ling Hoshi, Masahiro Takada, Seigo Nakamura, Satoshi Teramukai, Kazuhiro Yanagihara, Masakazu Toi. (2010) Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clinical Therapeutics 32:2, 311-326
CrossRef644
Saranya Chumsri, Stacie Jeter, Lisa K. Jacobs, Hind Nassar, Deborah K. Armstrong, Leisha A. Emens, John H. Fetting, Julie R. Lange, Carol Riley, Theodore N. Tsangaris, Antonio C. Wolff, Richard Zellars, Zhe Zhang, Vered Stearns. (2010) Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer. Clinical Breast Cancer 10:1, 40-45
CrossRef645
Patricia A. Deverka, John Vernon, Howard L. McLeod. (2010) Economic Opportunities and Challenges for Pharmacogenomics. Annual Review of Pharmacology and Toxicology 50:1, 423-437
CrossRef646
Eleni Andreopoulou, Massimo Cristofanilli. (2010) Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert Review of Anticancer Therapy 10:2, 171-177
CrossRef647
Alba A Brandes, Enrico Franceschi, Alicia Tosoni, Roberta Degli Esposti. (2010) Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Review of Anticancer Therapy 10:2, 179-184
CrossRef648
Laura Ottini, Domenico Palli, Sergio Rizzo, Mario Federico, Viviana Bazan, Antonio Russo. (2010) Male breast cancer. Critical Reviews in Oncology/Hematology 73:2, 141-155
CrossRef649
Yolanda Fernández, Juan Cueva, Andrés G. Palomo, Manuel Ramos, Ana de Juan, Lourdes Calvo, Jesús García-Mata, Paula García-Teijido, Ignacio Peláez, Laura García-Estévez. (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treatment Reviews 36:1, 33-42
CrossRef650
Cimona V. Hinton, Shalom Avraham, Hava Karsenty Avraham. (2010) Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clinical & Experimental Metastasis 27:2, 97-105
CrossRef651
Alejandra T. Perez, Banu Arun, Debu Tripathy, Mary A. Tagliaferri, Heather S. Shaw, Gretchen G. Kimmick, Isaac Cohen, Emma Shtivelman, Katherine A. Caygill, Deborah Grady, Mark Schactman, Charles L. Shapiro. (2010) A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Research and Treatment 120:1, 111-118
CrossRef652
Cathy B. Moelans, Roel A. Weger, Paul J. Diest. (2010) Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment 120:1, 1-7
CrossRef653
Joseph A. Sparano, Gabriel N. Hortobagyi, Julie R. Gralow, Edith A. Perez, Robert L. Comis. (2010) Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Research and Treatment 119:3, 511-527
CrossRef654
Stacy Moulder, Hailun Li, Molin Wang, William J. Gradishar, Edith A. Perez, Joseph A. Sparano, Michael Pins, Ximing Yang, George W. Sledge. (2010) A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Research and Treatment 119:3, 663-671
CrossRef655
Tristin Abair, Kristin Garcia, Timothy Quill. (2010) The 2009 San Antonio Breast Cancer Symposium. Clinical Breast Cancer 10:1, 19-26
CrossRef656
Yeon Hee Park, Seung Tae Kim, Eun Yoon Cho, Yoon La Choi, Oh-Nam Ok, Hae Jin Baek, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Won Park, Doo Ho Choi, Seung Jae Huh, Jin Seok Ahn, Young-Hyuck Im. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Research and Treatment 119:3, 653-661
CrossRef657
Tommaso Susini, Cecilia Bussani, Giulia Marini, Jacopo Nori, Simone Olivieri, Cecilia Molino, Simonetta Bianchi, Vania Vezzosi, Milena Paglierani, Massimo Giachi, Elena Borrani, Gianfranco Scarselli. (2010) Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecologic Oncology 116:2, 234-239
CrossRef658
U. Dafni, I. Grimani, A. Xyrafas, A. G. Eleftheraki, G. Fountzilas. (2010) Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Research and Treatment 119:3, 621-631
CrossRef659
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef660
Shaheenah Dawood. (2010) Biology and management of inflammatory breast cancer. Expert Review of Anticancer Therapy 10:2, 209-220
CrossRef661
Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara. (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu -positive breast cancer. Cancer 116:2, 302-308
CrossRef662
A V Lucs, W J Muller, S K Muthuswamy. (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29:2, 174-187
CrossRef663
K El-Sahwi, S Bellone, E Cocco, M Cargnelutti, F Casagrande, M Bellone, M Abu-Khalaf, N Buza, F A Tavassoli, P Hui, D-A Silasi, M Azodi, P E Schwartz, T J Rutherford, S Pecorelli, A D Santin. (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal of Cancer 102:1, 134-143
CrossRef664
Kaori Fujimoto-Ouchi. (2010) Current status and prospects of antibody drugs—trastuzumab. Folia Pharmacologica Japonica 136:4, 210-214
CrossRef665
Koji Oda, Noriko Hosoda, Hiroshi Endo, Kunio Saito, Kenji Tsujihara, Michio Yamamura, Takeshi Sakata, Naohiko Anzai, Michael F. Wempe, Yoshikatsu Kanai, Hitoshi Endou. (2010) l-Type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Science 101:1, 173-179
CrossRef666
Sun Hee Kang, Jihyoung Cho, Jung Sook Ha, Sun Young Kwon. (2010) Evaluation of Serum HER-2/neu Extracelluar Domain in Breast Cancer Patients: Correlation with Tissue HER-2/neu Status and Clinicopathological Factors. Journal of the Korean Surgical Society 78:5, 271
CrossRef667
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Akihiro Hirakawa, Makiko Ono, Tsutomu Kouno, Noriyuki Katsumata, Masashi Ando, Kenji Tamura, Tadashi Hasegawa, Takayuki Kinoshita, Yasuhiro Fujiwara. (2010) Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. Journal of Surgical Oncologyn/a-n/a
CrossRef668
Yasunori SATO, Kengo NAGASHIMA, Chikuma HAMADA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:6, 291-300
CrossRef669
Michael S. Gordon, David S. Mendelson, Gerry Kato. (2010) Tumor angiogenesis and novel antiangiogenic strategies. International Journal of CancerNA-NA
CrossRef670
Agnieszka M. Rygiel, Francesca Milano, Fiebo J. ten Kate, Jacques J. G. H. M. Bergman, Kausillia K. Krishnadath. (2010) Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus. Journal of Oncology 2010, 1-8
CrossRef671
Charles W. Kanaly, Dale Ding, Amy B. Heimberger, John H. Sampson. (2010) Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. Neurosurgery Clinics of North America 21:1, 95-109
CrossRef672
E. D. Saad, A. Katz, P. M. Hoff, M. Buyse. (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Annals of Oncology 21:1, 7-12
CrossRef673
Ji Yeon Kim, Taeeun Kim, Eun Yoon Cho. (2010) Comparative Study of Metaplastic Breast Carcinoma and Triple-Negative Breast Carcinoma Using Histologic and Immunohistochemical Analyses. The Korean Journal of Pathology 44:6, 605
CrossRef674
Major Kenneth Lee IV, Anupama Sharma, Brian J Czerniecki. (2010) It’s all in for the HER family in tumorigenesis. Expert Review of Vaccines 9:1, 29-34
CrossRef675
Ya-Chen Tina Shih, Linda S. Elting, Alexandre L. Pavluck, Andrew Stewart, Michael T. Halpern. (2010) Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer. Cancer Investigation 28:1, 46-53
CrossRef676
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Rosa García-Martín, Lorenzo Alonso-Carrión, Cesar Mendiola, Eduardo Lanzós. (2010) Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:1, 164-172
CrossRef677
Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, Yasuo Hozumi, Yasuhiro Fujiwara, Norikazu Masuda, Fumine Tsukamoto, Mitsue Saito, Shigeto Miura, Kenji Eguchi, Tetsu Shinkai, Masashi Ando, Toru Watanabe, Noriyuki Masuda, Yasuo Ohashi, Muneaki Sano, Shinzaburo Noguchi. (2010) Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Research and Treatment 119:1, 127-136
CrossRef678
Sejal S. Shah, Rhett P. Ketterling, Matthew P. Goetz, James N. Ingle, Carol A. Reynolds, Edith A. Perez, Beiyun Chen. (2010) Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human Pathology 41:1, 103-106
CrossRef679
Jan Jørgensen. 2010. , 325.
CrossRef680
U. De Giorgi, V. Valero, E. Rohren, M. Mego, G. V. Doyle, M. C. Miller, N. T. Ueno, B. C. Handy, J. M. Reuben, H. A. Macapinlac, G. N. Hortobagyi, M. Cristofanilli. (2010) Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology 21:1, 33-39
CrossRef681
Sudong Kim, Hyung Joon Kim, Noo Li Jeon. (2010) Biological applications of microfluidic gradient devices. Integrative Biology 2:11-12, 584
CrossRef682
Woo Sang Ryu, Gil Soo Son. (2010) Cancer Vaccines Targeting HER2/neu for Early Breast Cancer. Journal of Breast Cancer 13:1, 5
CrossRef683
Manoj Garg, Deepika Kanojia, Amlesh Seth, Rajive Kumar, Anju Gupta, Avadhesha Surolia, Anil Suri. (2010) Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. European Journal of Cancer 46:1, 207-215
CrossRef684
Giulio Metro, Diana Giannarelli, Donatello Gemma, Gaetano Lanzetta, Mariangela Ciccarese, Paola Papaldo, Teresa Gamucci, Vito Lorusso, Marcella Mottolese, Emanuela Magnolfi, Francesco Cognetti, Alessandra Fabi. (2010) Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. The Breast Journal 16:1, 66-72
CrossRef685
Michael A. Morse, Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, Takuya Osada, Amy C. Hobeika, Sharon Peplinski, Haixiang Jiang, Gayathri R. Devi, Wei Chen, Neil Spector, Andrea Amalfitano, H. Kim Lyerly, Timothy M. Clay. (2010) Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of CancerNA-NA
CrossRef686
Cathy B Moelans, Roel A de Weger, Marja TM van Blokland, Elsken van der Wall, Paul J van Diest. (2010) Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Modern Pathology 23:1, 62-70
CrossRef687
Keisei Anan, Shoshu Mitsuyama, Kenichirou Koga, Reiko Tanabe, Michiyo Saimura, Yoshitaka Tanabe, Masato Watanabe, Nobuhiro Suehara, Hiroaki Matsunaga, Kazuyoshi Nishihara, Yuji Abe, Toru Nakano, Keiyoshi Tamae, Minoru Ono, Satoshi Toyoshima. (2010) Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 17:1, 48-55
CrossRef688
James L. Frazier, James E. Han, Michael Lim, Alessandro Olivi. (2010) Immunotherapy Combined with Chemotherapy in the Treatment of Tumors. Neurosurgery Clinics of North America 21:1, 187-194
CrossRef689
Brian Thiessen, Clinton Stewart, Ming Tsao, Suzanne Kamel-Reid, Paula Schaiquevich, Warren Mason, Jacob Easaw, Karl Belanger, Peter Forsyth, Lynn McIntosh, Elizabeth Eisenhauer. (2010) A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology 65:2, 353-361
CrossRef690
Ruchi Saxena, Anila Dwivedi. (2010) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviewsn/a-n/a
CrossRef691
Coral Omene, Amy Tiersten. 2010. The Differences between Male and Female Breast Cancer. , 459-472.
CrossRef692
Tatjana Ivkovic-Kapicl, Slavica Knezevic-Usaj. (2010) Human epidermal growth factor receptor 2 testing in breast cancer. Medicinski pregled 63:1-2, 69-74
CrossRef693
Richard D. Olson, Barry J. Cusack. 2009. Cardiac Toxicity of Anthracyclines. .
CrossRef694
Michael A. Tainsky. 2009. Oncology Biomarkers. .
CrossRef695
R. Sikorski, B. Yao. (2009) Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine 1:10, 10ps11-10ps11
CrossRef696
Alberto Ocaña, Eitan Amir. (2009) Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews 35:8, 685-691
CrossRef697
Austin Duffy, Shivaani Kummar. (2009) Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology 4:4, 267-273
CrossRef698
Julia Aigner, Andreas Schneeweiss. (2009) Systemtherapie des Mammakarzinoms. Onkopipeline 2:4, 171-184
CrossRef699
Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell. (2009) Immunotherapy of cancer. European Journal of Pharmacology 625:1-3, 41-54
CrossRef700
Michael A. Tainsky. (2009) Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 176-193
CrossRef701
Chad M Barnett. (2009) Survival Data of Patients with Anthracycline- or Taxane-Pretreated or Resistant Metastatic Breast Cancer. Pharmacotherapy 29:12, 1482-1490
CrossRef702
Béla Pikó. (2009) Lapatinib – kezelési lehetőség trastuzumab-rezisztens emlőrákban. Magyar Onkológia 53:4, 369-375
CrossRef703
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef704
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck. (2009) Triple-negative breast cancer--current status and future directions. Annals of Oncology 20:12, 1913-1927
CrossRef705
Thomas R. Geiger, Daniel S. Peeper. (2009) Metastasis mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 293-308
CrossRef706
Joshua M Lang, Adin-Cristian Andrei, Douglas G McNeel. (2009) Prioritization of cancer antigens: keeping the target in sight. Expert Review of Vaccines 8:12, 1657-1661
CrossRef707
Hwee Tong Tan, Jiayi Low, Seng Gee Lim, Maxey C. M. Chung. (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal 276:23, 6880-6904
CrossRef708
Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip, Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. (2009) Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1077-1085
CrossRef709
X Liu, J Wu, S Zhang, C Li, Q Huang. (2009) Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Therapy 16:11, 861-872
CrossRef710
D. Hölzel, G. Schubert-Fritschle, J. Engel. (2009) Ergebnisse der interdisziplinären onkologischen Versorgung. Der Onkologe 15:11, 1120-1133
CrossRef711
Y. Suzuki, Y. Tokuda, Y. Fujiwara, H. Iwata, Y. Sasaki, S. Saji, K. Aogi, Y. Nambu, A. Suri, T. Saeki, S. Takashima. (2009) Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment. Japanese Journal of Clinical Oncology 39:11, 699-706
CrossRef712
Sung Hee Yoon, Jin Myung Lee, Sun-Je Woo, Min-Ji Park, Jung-Sun Park, Hye-Sung Kim, Mi-Young Park, Hyun-Jung Sohn, Tai-Gyu Kim. (2009) Transfer of Her-2/neu Specificity into Cytokine-Induced Killer (CIK) Cells with RNA Encoding Chimeric Immune Receptor (CIR). Journal of Clinical Immunology 29:6, 806-814
CrossRef713
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, S. Van Belle, C. Vogel, N. Wilcken, C. Wiltschke, C. C. Zielinski, H. Zwierzina, . (2009) Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology 20:11, 1771-1785
CrossRef714
Douglas P Clark. (2009) Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Review of Molecular Diagnostics 9:8, 787-794
CrossRef715
Erin M. Goldblatt, Priscilla A. Erickson, Erin R. Gentry, Sergei M. Gryaznov, Brittney-Shea Herbert. (2009) Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Research and Treatment 118:1, 21-32
CrossRef716
Louis P. Garrison, David L. Veenstra. (2009) The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer. Value in Health 12:8, 1118-1123
CrossRef717
Karen Y. Wonders, David S. Hydock, Stephanie Greufe, Carole M. Schneider, Reid Hayward. (2009) Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974. Cancer Chemotherapy and Pharmacology 64:6, 1105-1113
CrossRef718
(2009) Cancer du sein métastatique. Oncologie 11:11, 552-588
CrossRef719
D. Collins, A.D.K. Hill, L. Young. (2009) Lapatinib: A competitor or companion to trastuzumab?. Cancer Treatment Reviews 35:7, 574-581
CrossRef720
Dale W. Garsed, Andrew J. Holloway, David M. Thomas. (2009) Cancer-associated neochromosomes: a novel mechanism of oncogenesis. BioEssays 31:11, 1191-1200
CrossRef721
Carol A. Parise, Katrina R. Bauer, Monica M. Brown, Vincent Caggiano. (2009) Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. The Breast Journal 15:6, 593-602
CrossRef722
Hamdy Azim, Hatem A. Azim, Bernard Escudier. (2009) Trastuzumab versus lapatinib: The cardiac side of the story. Cancer Treatment Reviews 35:7, 633-638
CrossRef723
Jessica C. Lawson, Gregory L. Blatch, Adrienne L. Edkins. (2009) Cancer stem cells in breast cancer and metastasis. Breast Cancer Research and Treatment 118:2, 241-254
CrossRef724
Stefan Glück, Aurelio Castrellon. (2009) Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain Metastases. American Journal of Therapeutics 16:6, 585-590
CrossRef725
J-S Frenel, E Bourbouloux, D Berton-Rigaud, S Sadot-Lebouvier, A Zanetti, M Campone. (2009) Lapatinib in metastatic breast cancer. Women's Health 5:6, 603-612
CrossRef726
Peter Barrett-Lee, François-Clément Bidard, Jean-Yves Pierga. (2009) Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. Cancer Treatment Reviews 35:7, 582-589
CrossRef727
Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta, Cynthia Bamdad. (2009) MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Research and Treatment 118:1, 113-124
CrossRef728
Timothy E. Kute, Lori Savage, John R. Stehle, Jung W. Kim-Shapiro, Michael J. Blanks, James Wood, James P. Vaughn. (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunology, Immunotherapy 58:11, 1887-1896
CrossRef729
Douglas P. Clark. (2009) Seize the opportunity. Cancer Cytopathology 117:5, 289-297
CrossRef730
Mohammad Vasei, Helmout Modjtahedi, Oreineb Ale-booyeh, Ahmad Mosallaei, Abdol Mohammad Kajbafzadeh, Mehdi Shahriari, Abbas Ali Ghaderi, Hossein Soleymanpour, Farid Kosari, Holger Moch. (2009) Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genetics and Cytogenetics 194:2, 88-95
CrossRef731
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Begoña Jiménez, Nuria Ribelles, Antonia Márquez, Isabel García-Ríos, Emilio Alba Conejo. (2009) Targeted therapy of metastatic breast cancer. Clinical and Translational Oncology 11:10, 643-650
CrossRef732
Maya Guglin, Gregory Hartlage, Christopher Reynolds, Ren Chen, Vinod Patel. (2009) Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study. Journal of Cardiac Failure 15:8, 651-657
CrossRef733
Mikiya Ishihara, Hirofumi Mukai, Shunji Nagai, Toru Mukohara. (2009) Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. International Journal of Clinical Oncology 14:5, 431-435
CrossRef734
Wendy A. Woodward, Massimo Cristofanilli. (2009) Inflammatory Breast Cancer. Seminars in Radiation Oncology 19:4, 256-265
CrossRef735
A. Cirstoiu-Hapca, F. Buchegger, L. Bossy, M. Kosinski, R. Gurny, F. Delie. (2009) Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. European Journal of Pharmaceutical Sciences 38:3, 230-237
CrossRef736
Ian E. Smith, Susana Banerjee. (2009) The follow-up of women at high risk for breast cancer relapse. The Breast 18, S74-S77
CrossRef737
Carole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, Michel Marty, Véronique Girre, Henri Roché, Etienne Brain, Jean-Paul Moatti, Patrice Viens, Anne-Gaëlle Le Corroller-Soriano. (2009) Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. American Journal of Clinical Oncology 32:5, 492-498
CrossRef738
E.A. te Velde, A.C. Franke, R. van Hillegersberg, S.M. Elshof, R.W. de Weger, I.H.M. Borel Rinkes, P.J. van Diest. (2009) HER-family gene amplification and expression in resected pancreatic cancer. European Journal of Surgical Oncology (EJSO) 35:10, 1098-1104
CrossRef739
Jyoti Nautiyal, Pralay Majumder, Bhaumik B. Patel, Francis Y. Lee, Adhip P.N. Majumdar. (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Letters 283:2, 143-151
CrossRef740
Xiaoli Shi, Li Xu, Junping Yu, Xiaohong Fang. (2009) Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy. Experimental Cell Research 315:16, 2847-2855
CrossRef741
Tobias Bäuerle, Wolfhard Semmler. (2009) Imaging response to systemic therapy for bone metastases. European Radiology 19:10, 2495-2507
CrossRef742
Elmar Stickeler, Maximilian Klar, Dirk Watermann, Annette Geibel, Martha Földi, Annette Hasenburg, Gerald Gitsch. (2009) Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Research and Treatment 117:3, 591-598
CrossRef743
Yutaka Tokuda, Yasuhiro Suzuki, Yuki Saito, Shinobu Umemura. (2009) The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 16:4, 295-300
CrossRef744
Luca Gianni. (2009) Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. Breast Cancer Research and Treatment 117:3, 599-601
CrossRef745
Hiroji Iwata. (2009) Neo(adjuvant) trastuzumab treatment: current perspectives. Breast Cancer 16:4, 288-294
CrossRef746
Nathan M. Shumway, Nuhad Ibrahim, Sathibalan Ponniah, George E. Peoples, James L. Murray. (2009) Therapeutic Breast Cancer Vaccines. BioDrugs 23:5, 277-287
CrossRef747
Felipe C. Geyer, Maria A. Lopez-Garcia, Maryou B. Lambros, Jorge S. Reis-Filho. (2009) Genetic characterization of breast cancer and implications for clinical management. Journal of Cellular and Molecular Medicine 13:10, 4090-4103
CrossRef748
Masafumi Kurosumi. (2009) Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer 16:4, 284-287
CrossRef749
Shani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, Lior Zach, Juri Kopolovic, Anna Kruglikova, Tami Modiano, Ady Yosepovich, Raphael Catane, Bella Kaufman. (2009) Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients. American Journal of Clinical Oncology 32:5, 504-508
CrossRef750
Rafal Zielinski, Ilya Lyakhov, Amy Jacobs, Oleg Chertov, Gabriela Kramer-Marek, Nicholas Francella, Andrew Stephen, Robert Fisher, Robert Blumenthal, Jacek Capala. (2009) Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors. Journal of Immunotherapy 32:8, 817-825
CrossRef751
Susan Bahl, Robert E. Roses, Anupama Sharma, Ursula Koldovsky, Shuwen Xu, Susan Weinstein, Harvey Nisenbaum, Kevin Fox, Theresa Pasha, Paul Zhang. (2009) Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu–pulsed dendritic cell vaccines. The American Journal of Surgery 198:4, 488-494
CrossRef752
Debra Josephs, James Spicer, Michael O’Doherty. (2009) Molecular imaging in clinical trials. Targeted Oncology 4:3, 151-168
CrossRef753
Aruna Mani, Julie Roda, Donn Young, Michael A. Caligiuri, Gini F. Fleming, Peter Kaufman, Adam Brufsky, Susan Ottman, William E. Carson, Charles L. Shapiro. (2009) A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Research and Treatment 117:1, 83-89
CrossRef754
Ya-Chen Tina Shih, Linda S. Elting, Michael T. Halpern. (2009) Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients. Medical Care 47:9, 948-958
CrossRef755
Hasan Senol COSKUN, Mustafa ALTINBAS, Ozlem ER, Figen OZTURK, Hatice KARAMAN, Serdar SOYUER, Metin OZKAN, Isin SOYUER. (2009) Human epidermal growth factor receptor 2 oncoprotein expression in breast cancer patients from central Anatolia, Turkey. Asia-Pacific Journal of Clinical Oncology 5:3, 206-211
CrossRef756
Elizabeth L. Strevel, Lillian L. Siu. (2009) Cardiovascular toxicity of molecularly targeted agents. European Journal of Cancer 45, 318-331
CrossRef757
G. Di Lorenzo, R. Autorino, G. Bruni, G. Carteni, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, M. Giuliano, A. Gonnella, C. De Nunzio, M. Rizzo, V. Montesarchio, M. Ewer, S. De Placido. (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology 20:9, 1535-1542
CrossRef758
Daniel S. W. Tan, George V. Thomas, Michelle D. Garrett, Udai Banerji, Johann S. de Bono, Stan B. Kaye, Paul Workman. (2009) Biomarker-Driven Early Clinical Trials in Oncology. The Cancer Journal 15:5, 406-420
CrossRef759
Elisa Rossi, Salvatore Grisanti, Vincenzo Villanacci, Domenico Della Casa, Paolo Cengia, Guido Missale, Luigi Minelli, Michela Buglione, Renzo Cestari, Gabrio Bassotti. (2009) HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. Journal of Cellular and Molecular Medicine 13:9b, 3826-3833
CrossRef760
Mi–Jin Lee, Gyung–Ran Yu, Hee–Jung Yoo, Jong–Hyun Kim, Byung–Il Yoon, Yang–Kyu Choi, Dae–Ghon Kim. (2009) ANXA8 Down-regulation by EGF-FOXO4 Signaling Is Involved in Cell Scattering and Tumor Metastasis of Cholangiocarcinoma. Gastroenterology 137:3, 1138-1150.e9
CrossRef761
Patrick G Morris, Clifford A Hudis. (2009) Personalizing therapy for metastatic breast cancer. Expert Review of Anticancer Therapy 9:9, 1223-1226
CrossRef762
Sabine C. Linn, Laura J. Van 't Veer. (2009) Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. European Journal of Cancer 45, 11-26
CrossRef763
Chung-Ming Tu, Kai-Ming Chu, Shin-Ping Yang, Shu-Mung Cheng, Wen-been Wang. (2009) Trastuzumab (Herceptin)–associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review. The American Journal of Emergency Medicine 27:7, 903.e1-903.e3
CrossRef764
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Kaoru Hashizume, Makiko Ono, Tsutomu Kouno, Masashi Ando, Kenji Tamura, Noriyuki Katsumata, Tadashi Hasegawa, Takayuki Kinoshita, Yasuhiro Fujiwara. (2009) Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Medical Oncology 26:3, 344-349
CrossRef765
Surojeet Sengupta, Rachel Schiff, Benita S. Katzenellenbogen. (2009) Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Research and Treatment 117:2, 243-251
CrossRef766
Tsuguo Kubota, Rinpei Niwa, Mitsuo Satoh, Shiro Akinaga, Kenya Shitara, Nobuo Hanai. (2009) Engineered therapeutic antibodies with improved effector functions. Cancer Science 100:9, 1566-1572
CrossRef767
R. J. Thomas, M. Williams, J. Glen, M. Callam. (2009) Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Research and Treatment 117:2, 289-295
CrossRef768
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef769
Deepa Wadhwa, Nazanin Fallah-Rad, Debjani Grenier, Marianne Krahn, Tielan Fang, Roien Ahmadie, Jonathan R. Walker, Danica Lister, Rakesh C. Arora, Ivan Barac, Andrew Morris, Davinder S. Jassal. (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Research and Treatment 117:2, 357-364
CrossRef770
Toru Mukohara, Hiroyuki Shimada, Naomi Ogasawara, Ryoko Wanikawa, Manami Shimomura, Tetsuya Nakatsura, Genichiro Ishii, Joon Oh Park, Pasi A. Jänne, Nagahiro Saijo, Hironobu Minami. (2009) Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Letters 282:1, 14-24
CrossRef771
Seetharama Satyanarayanajois, Stephanie Villalba, Liu Jianchao, Go Mei Lin. (2009) Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2-Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines. Chemical Biology & Drug Design 74:3, 246-257
CrossRef772
A Gualberto, M Pollak. (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28:34, 3009-3021
CrossRef773
Alvaro Moreno-Aspitia, Edith A. Perez. (2009) Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clinical Therapeutics 31:8, 1619-1640
CrossRef774
Bénédicte Poncet, Cyrille Colin, Thomas Bachelot, Isabelle Jaisson-Hot, Laure Derain, Laurent Magaud, Cécile Fournel-Federico, Mireille Mousseau, Jean-Dominique Tigaud, Jean-Philippe Jacquin, Véronique Trillet-Lenoir. (2009) Treatment of Metastatic Breast Cancer. American Journal of Clinical Oncology 32:4, 369-374
CrossRef775
Serena T Wong, Susan Goodin. (2009) Overcoming Drug Resistance in Patients with Metastatic Breast Cancer. Pharmacotherapy 29:8, 954-965
CrossRef776
Asahi Ito, Takashi Ishida, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Fumihiko Sato, Hisashi Takino, Fumiko Mori, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda. (2009) Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model. Cancer Immunology, Immunotherapy 58:8, 1195-1206
CrossRef777
Adam Brufsky. (2009) Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer. American Journal of Clinical Oncology1
CrossRef778
Sumanta Kumar Pal, Joanne Mortimer. (2009) Triple-negative breast cancer: Novel therapies and new directions. Maturitas 63:4, 269-274
CrossRef779
M. Untch, C. Jackisch. (2009) Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom. Der Onkologe 15:8, 811-826
CrossRef780
Michael Montejo, Theresa L. Werner, David Gaffney. (2009) Current challenges in clinical management of endometrial cancer. Advanced Drug Delivery Reviews 61:10, 883-889
CrossRef781
Ashok R. Venkitaraman. (2009) Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy. Cancer Cell 16:2, 89-90
CrossRef782
Riccardo Soffietti, Wallace Akerley, Randy L. Jensen, Joachim Bischoff, Anne Constanze Regierer. (2009) The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors. Seminars in Oncology 36, S55-S68
CrossRef783
R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros. (2009) Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™). The Breast 18:4, 218-224
CrossRef784
Dorte Aa. Olsen, Birthe Østergaard, Susanne Bokmand, Peter A. Wamberg, Erik H. Jakobsen, Anders Jakobsen, Ivan Brandslund. (2009) HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue. Clinical Chemistry and Laboratory Medicine 47:8, 977-984
CrossRef785
Shiang-Fu Huang, Wen-Yu Chuang, I-How Chen, Chun-Ta Liao, Hung-Ming Wang, Ling-Ling Hsieh. (2009) EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. Head & Neck 31:8, 1068-1077
CrossRef786
James L. Hare, Joseph K. Brown, Rodel Leano, Carly Jenkins, Natasha Woodward, Thomas H. Marwick. (2009) Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. American Heart Journal 158:2, 294-301
CrossRef787
Shunsuke TAKAHAGI, Hideki NODA, Akiko KAMEGASHIRA, Naoki MADOKORO, Ikuko HORI, Hajime SHINDO, Shouji MIHARA, Michihiro HIDE. (2009) Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy. The Journal of Dermatology 36:8, 457-461
CrossRef788
(2009) A comprehensive Analysis of a Large Panel of Cancer/Testis (CT) Antigens in Korea Breast Cancer. Journal of Life Science 19:7, 886-891
CrossRef789
José Baselga, Sandra M. Swain. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9:7, 463-475
CrossRef790
Jan Trøst Jørgensen, Henrik Winther. (2009) The new era of personalized medicine: 10 years later. Personalized Medicine 6:4, 423-428
CrossRef791
C. H. Barrios, C. Sampaio, J. Vinholes, R. Caponero. (2009) What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?. Annals of Oncology 20:7, 1157-1162
CrossRef792
Manuela Fiúza. (2009) Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Advances in Therapy 26:S1, 9-17
CrossRef793
Peter S Hall, Jaishree Bhosle, David A Cameron. (2009) Lapatinib in the management of breast cancer. Therapy 6:4, 553-568
CrossRef794
Carla M.L. van Herpen, Winette T.A. van der Graaf, Wim J.G. Oyen. (2009) Time to target evaluation criteria of targeted therapies. Nuclear Medicine Communications 30:7, 487-489
CrossRef795
Shelby D. Reed, Kevin A. Schulman. (2009) Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer. Value in Health 12:5, 637-640
CrossRef796
Bruce H Littman. (2009) Translational strategies to implement personalized medicine: rheumatoid arthritis examples. Personalized Medicine 6:4, 429-437
CrossRef797
Keith I. Block, Charlotte Gyllenhaal, Debu Tripathy, Sally Freels, Mark N. Mead, Penny B. Block, William C. Steinmann, Robert A. Newman, Jacob Shoham. (2009) Survival Impact of Integrative Cancer Care in Advanced Metastatic Breast Cancer. The Breast Journal 15:4, 357-366
CrossRef798
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef799
S. Barco, R. Colomer, L. Calvo, I. Tusquets, E. Adrover, P. Sánchez, J. Rifà, J. Haba, J. A. Virizuela. (2009) Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Research and Treatment 116:2, 351-358
CrossRef800
Chris Skedgel, Daniel Rayson, Tallal Younis. (2009) The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. Value in Health 12:5, 641-648
CrossRef801
Atsushi Inagaki, Takashi Ishida, Hiroki Yano, Toshihiko Ishii, Shigeru Kusumoto, Asahi Ito, Masaki Ri, Fumiko Mori, Jianmin Ding, Hirokazu Komatsu, Shinsuke Iida, Ryuzo Ueda. (2009) Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. International Journal of Cancer 125:1, 212-221
CrossRef802
David Jamieson, Nicola Cresti, Mark W Verrill, Alan V. Boddy. (2009) Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of Immunological Methods 345:1-2, 106-111
CrossRef803
D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, A. Rehemtulla, C. G. Kleer, D. F. Hayes, P. C. Lucas, S. Varambally, A. M. Chinnaiyan. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences 106:25, 10284-10289
CrossRef804
Thomas W. Flaig, Lih-Jen Su, Caroline McCoach, Yuan Li, David Raben, Marileila Varella-Garcia, Lynne T. Bemis. (2009) Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU International 103:12, 1729-1737
CrossRef805
Meili Zhang, Zhengsheng Yao, Kayhan Garmestani, Sarah Yu, Carolyn K. Goldman, Chang H. Paik, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann. (2009) Preclinical Evaluation of an Anti-CD25 Monoclonal Antibody, 7G7/B6, Armed with the β-Emitter, Yttrium-90, as a Radioimmunotherapeutic Agent for Treating Lymphoma. Cancer Biotherapy & Radiopharmaceuticals 24:3, 303-309
CrossRef806
I. Pauporté, C. Faure, X. Pivot. (2009) Impulser la recherche clinique française dans le cancer du sein: l’exemple de l’essai PHARE. Oncologie 11:6, 348-352
CrossRef807
Michael F. Berger, Levi A. Garraway. (2009) Applications of Genomics in Melanoma Oncogene Discovery. Hematology/Oncology Clinics of North America 23:3, 397-414
CrossRef808
Bingfeng Sun, Si-Shen Feng. (2009) Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine 4:4, 431-445
CrossRef809
K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, H. J. Burstein. (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Annals of Oncology 20:6, 1026-1031
CrossRef810
2009. Early Symptomatic Breast Cancer. , 1-67.
CrossRef811
Edward T.H. Yeh, Courtney L. Bickford. (2009) Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology 53:24, 2231-2247
CrossRef812
Joan Albanell, Xavier Andreu, María José Calasanz, Ángel Concha, José María Corominas, Tomás García-Caballero, José Antonio López, Fernando López-Ríos, Santiago Ramón y Cajal, Francisco J. Vera-Sempere, Ramón Colomer, Miguel Martín, Emilio Alba, Antonio González-Martín, Antonio Llombart, Ana Lluch, José Palacios. (2009) Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology 11:6, 363-375
CrossRef813
Saori Tomita, Zhenhuan Zhang, Masahiro Nakano, Mutsuko Ibusuki, Teru Kawazoe, Yutaka Yamamoto, Hirotaka Iwase. (2009) Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Science 100:6, 1012-1017
CrossRef814
Lin Wang, Xiaobei Wang, Xiu Nie, Ling Ma. (2009) Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients. Journal of Huazhong University of Science and Technology [Medical Sciences] 29:3, 354-358
CrossRef815
Evandro Azambuja, Philippe L. Bedard, Thomas Suter, Martine Piccart-Gebhart. (2009) Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. Targeted Oncology 4:2, 77-88
CrossRef816
Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Ullrich, Mirjam Koker, Florian Fischer, Takeshi Shimamura, Daniel Rauh, Craig Mermel, Stefanie Fischer, Isabel Stückrath, Stefanie Heynck, Rameen Beroukhim, William Lin, Wendy Winckler, Kinjal Shah, Thomas LaFramboise, Whei F. Moriarty, Megan Hanna, Laura Tolosi, Jörg Rahnenführer, Roel Verhaak, Derek Chiang, Gad Getz, Martin Hellmich, Jürgen Wolf, Luc Girard, Michael Peyton, Barbara A. Weir, Tzu-Hsiu Chen, Heidi Greulich, Jordi Barretina, Geoffrey I. Shapiro, Levi A. Garraway, Adi F. Gazdar, John D. Minna, Matthew Meyerson, Kwok-Kin Wong, Roman K. Thomas. (2009) Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation 119:6, 1727-1740
CrossRef817
Hilary Shmeeda, Dina Tzemach, Lidia Mak, Alberto Gabizon. (2009) Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage. Journal of Controlled Release 136:2, 155-160
CrossRef818
S H Yoon, J M Lee, H I Cho, E K Kim, H S Kim, M Y Park, T G Kim. (2009) Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Therapy 16:6, 489-497
CrossRef819
A. Moreno-Aspitia, E. A. Perez. (2009) Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane. Mayo Clinic Proceedings 84:6, 533-545
CrossRef820
R A Jones, C I Campbell, G A Wood, J J Petrik, R A Moorehead. (2009) Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 28:21, 2152-2162
CrossRef821
M. C. U. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P. S. Bernard, J. S. Parker, C. M. Perou, M. J. Ellis, T. O. Nielsen. (2009) Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI Journal of the National Cancer Institute 101:10, 736-750
CrossRef822
Cornelia Erfurt, Esther Müller, Sonja Emmerling, Claudia Klotz, Michael Hertl, Gerold Schuler, Erwin S. Schultz. (2009) Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4 + T cells in melanoma patients. International Journal of Cancer 124:10, 2341-2346
CrossRef823
D. J. Slamon, M. F. Press. (2009) Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers. JNCI Journal of the National Cancer Institute 101:9, 615-618
CrossRef824
Alessandra Gennari, Michele Tursi, Consiglia Carella, Enrico Ricevuto, Cinzia Orlandini, Antonio Frassoldati, Pierfranco Conte, Paolo Bruzzi, Stefano Iacobelli. (2009) Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Research and Treatment 115:1, 131-136
CrossRef825
Richard J. Epstein. (2009) TNM: Therapeutically Not Mandatory. European Journal of Cancer 45:7, 1111-1116
CrossRef826
P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, M. W. Verrill. (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology 20:5, 816-827
CrossRef827
X.Y. Hu, Y.M. Xu, Q. Fu, J.J. Yu, J. Huang. (2009) Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. European Journal of Surgical Oncology (EJSO) 35:5, 527-531
CrossRef828
Michael Z. Gilcrease, Wendy A. Woodward, Marlo M. Nicolas, Lynda J. Corley, Gregory N. Fuller, Francisco J. Esteva, Susan L. Tucker, Thomas A. Buchholz. (2009) Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer. The American Journal of Surgical Pathology 33:5, 759-767
CrossRef829
Hany Elsaleh, James J Farrell, Christopher H Crane. (2009) Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. Journal of Gastroenterology and Hepatology 24:5, 708-710
CrossRef830
BM Fine, L Amler. (2009) Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective. Clinical Pharmacology & Therapeutics 85:5, 535-538
CrossRef831
Mariantonietta Colozza, Elisa Minenza, Stefania Gori, Daniela Fenocchio, Cristina Paolucci, Cynthia Aristei, Piero Floridi. (2009) Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemotherapy and Pharmacology 63:6, 1157-1159
CrossRef832
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef833
John W. Rose, John F. Foley, Noel G. Carlson. (2009) Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology 11:3, 211-220
CrossRef834
Ming Hui Chen. (2009) Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Current Cardiology Reports 11:3, 167-174
CrossRef835
Andrea Nicolini, Angelo Carpi. (2009) Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology. Medicinal Research Reviews 29:3, 436-471
CrossRef836
Bin zhou, Li Rao, Ying Peng, Qiuping Zhang, Lin Zhang. (2009) Epidermal growth factor receptor gene polymorphisms, R497K, but not (CA)n repeat, is associated with dilated cardiomyopathy. Clinica Chimica Acta 403:1-2, 184-187
CrossRef837
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer. (2009) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment 115:1, 115-121
CrossRef838
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski. (2009) Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell 15:5, 429-440
CrossRef839
M. Wu, L. Jung, A. B. Cooper, C. Fleet, L. Chen, L. Breault, K. Clark, Z. Cai, S. Vincent, S. Bottega, Q. Shen, A. Richardson, M. Bosenburg, S. P. Naber, R. A. DePinho, C. Kuperwasser, M. O. Robinson. (2009) Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proceedings of the National Academy of Sciences 106:17, 7022-7027
CrossRef840
H. Agadjanian, J. Ma, A. Rentsendorj, V. Valluripalli, J. Y. Hwang, A. Mahammed, D. L. Farkas, H. B. Gray, Z. Gross, L. K. Medina-Kauwe. (2009) Tumor detection and elimination by a targeted gallium corrole. Proceedings of the National Academy of Sciences 106:15, 6105-6110
CrossRef841
Georgios Voidonikolas, Stephanie S. Kreml, Changyi Chen, William E. Fisher, F. Charles Brunicardi, Richard A. Gibbs, Marie-Claude Gingras. (2009) Basic Principles and Technologies for Deciphering the Genetic Map of Cancer. World Journal of Surgery 33:4, 615-629
CrossRef842
G. Schilling, M. Bruweleit, N. Harbeck, C. Thomssen, K. Becker, R. Hoffmann, C. Villena, M. Schütte, D. K. Hossfeld, C. Bokemeyer, M. Wit. (2009) Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Investigational New Drugs 27:2, 166-172
CrossRef843
Tianqian Zhang, Dorothee Herlyn. (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunology, Immunotherapy 58:4, 475-492
CrossRef844
Giuseppe Gullo, Daniela Bettio, Valter Torri, Giovanna Masci, Piermario Salvini, Armando Santoro. (2009) Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Investigational New Drugs 27:2, 179-183
CrossRef845
Dorte Lisbet Nielsen, Michael Andersson, Claus Kamby. (2009) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treatment Reviews 35:2, 121-136
CrossRef846
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef847
Hironori Hayashi, Mariko Kimura, Nobuyasu Yoshimoto, Masanori Tsuzuki, Nobuyuki Tsunoda, Takashi Fujita, Toshinari Yamashita, Hiroji Iwata. (2009) A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer 16:2, 136-140
CrossRef848
Nancy E Hynes, Gwen MacDonald. (2009) ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology 21:2, 177-184
CrossRef849
Laura Pentassuglia, Michael Graf, Heidi Lane, Yukio Kuramochi, Gregory Cote, Francesco Timolati, Douglas B. Sawyer, Christian Zuppinger, Thomas M. Suter. (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research 315:7, 1302-1312
CrossRef850
Christoph A. Klein. (2009) Parallel progression of primary tumours and metastases. Nature Reviews Cancer 9:4, 302-312
CrossRef851
Michael K. K Wong, Anthony Jarkowski. (2009) Response to Sorafenib After Sunitinib-Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. Pharmacotherapy 29:4, 473-478
CrossRef852
Vladimir Tolmachev, Eskender Mume, Stefan Sjöberg, Fredrik Y. Frejd, Anna Orlova. (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging 36:4, 692-701
CrossRef853
Don X. Nguyen, Paula D. Bos, Joan Massagué. (2009) Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer 9:4, 274-284
CrossRef854
Enrique Montero, Maikel Valdes, Janet Avellanet, Armando Lopez, Rolando Perez, Agustin Lage. (2009) Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 27:16, 2230-2239
CrossRef855
Heather-Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs. (2009) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Research and Treatment 114:3, 579-587
CrossRef856
Surabhi Amar, Vivek Roy, Edith A. Perez. (2009) Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Research and Treatment 114:3, 413-422
CrossRef857
Y H Park, M J Park, S H Ji, S Y Yi, D H Lim, D H Nam, J-I Lee, W Park, D H Choi, S J Huh, J S Ahn, W K Kang, K Park, Y-H Im. (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. British Journal of Cancer 100:6, 894-900
CrossRef858
John Mackey, Deanna McLeod, Joseph Ragaz, Karen Gelmon, Sunil Verma, Kathleen Pritchard, Kara Laing, Louise Provencher, Lauren F. Charbonneau. (2009) Adjuvant targeted therapy in early breast cancer. Cancer 115:6, 1154-1168
CrossRef859
A L Jones, M Barlow, P J Barrett-Lee, P A Canney, I M Gilmour, S D Robb, C J Plummer, A M Wardley, M W Verrill. (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 100:5, 684-692
CrossRef860
S Umemura, M Shirane, S Takekoshi, T Kusakabe, J Itoh, N Egashira, Y Tokuda, K Mori, Y R Osamura. (2009) Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. British Journal of Cancer 100:5, 764-771
CrossRef861
T Murayama, M Inokuchi, Y Takagi, H Yamada, K Kojima, J Kumagai, T Kawano, K Sugihara. (2009) Relation between outcomes and localisation of p-mTOR expression in gastric cancer. British Journal of Cancer 100:5, 782-788
CrossRef862
Christopher A. Maher, Chandan Kumar-Sinha, Xuhong Cao, Shanker Kalyana-Sundaram, Bo Han, Xiaojun Jing, Lee Sam, Terrence Barrette, Nallasivam Palanisamy, Arul M. Chinnaiyan. (2009) Transcriptome sequencing to detect gene fusions in cancer. Nature 458:7234, 97-101
CrossRef863
Louis M Weiner, Madhav V Dhodapkar, Soldano Ferrone. (2009) Monoclonal antibodies for cancer immunotherapy. The Lancet 373:9668, 1033-1040
CrossRef864
Bushra Haq, Charles E Geyer. (2009) Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women's Health 5:2, 135-147
CrossRef865
AP Chiang, AJ Butte. (2009) Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events. Clinical Pharmacology & Therapeutics 85:3, 259-268
CrossRef866
Dana Faratian, Ashley Graham, Frances Rae, Jeremy Thomas. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54:4, 428-432
CrossRef867
Sejal S. Shah, Yan Wang, Jamie Tull, Shengle Zhang. (2009) Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma. Diagnostic Molecular Pathology 18:1, 30-33
CrossRef868
Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin, Yuping Tan, Virginie Durbecq, Denis Larsimont, Rosa Giuliani, Colombe Chappey, Marc Buyse, John Winslow, Martine Piccart, Christos Sotiriou, Christos Petropoulos, Michael Bates. (2009) Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology 18:1, 22-29
CrossRef869
Dimiter V Tassev, Nai-Kong V Cheung. (2009) Monoclonal antibody therapies for solid tumors. Expert Opinion on Biological Therapy 9:3, 341-353
CrossRef870
F.C. Geyer, T. Decker, J.S. Reis-Filho. (2009) Genomweite Expressionsprofile als klinische Entscheidungshilfe. Der Pathologe 30:2, 141-146
CrossRef871
Christian Jackisch. (2009) Role of cytotoxics in combination with targeted agents. European Journal of Cancer Supplements 7:1, 19-22
CrossRef872
Philippe L. Bedard, Fatima Cardoso, Martine J. Piccart-Gebhart. (2009) Stemming Resistance to HER-2 Targeted Therapy. Journal of Mammary Gland Biology and Neoplasia 14:1, 55-66
CrossRef873
Elizabeth M.H. Kim, Catherine Lobocki, Linda Dubay, Vijay K. Mittal. (2009) A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines. The American Journal of Surgery 197:3, 331-336
CrossRef874
Raymond D SNYDER, Frances M BOYLE, Arlene CHAN, Paul S CRAFT, Richard DE BOER, Paul N MAINWARING, Nicole J McCARTHY, Nicholas R WILCKEN. (2009) Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology 5:1, 4-16
CrossRef875
Yining Shi, Weidong Huang, Yuping Tan, Xueguang Jin, Rajiv Dua, Elicia Penuel, Ali Mukherjee, Jeff Sperinde, Herjit Pannu, Ahmed Chenna, Lisa DeFazio-Eli, Sailaja Pidaparthi, Youssouf Badal, Gerald Wallweber, Lili Chen, Steve Williams, Hasan Tahir, Jeff Larson, Laurie Goodman, Jeannette Whitcomb, Christos Petropoulos, John Winslow. (2009) A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue. Diagnostic Molecular Pathology 18:1, 11-21
CrossRef876
V. H. Schartinger, J. Schmutzhard, M. Wurm, I. M. Schwentner, P. Obrist, W. Oberaigner, G. M. Sprinzl. (2009) The expression of EGFR, HER2 and EpCam in Head and Neck squamous cell carcinomas. memo - Magazine of European Medical Oncology 2:1, 45-50
CrossRef877
Markus Stenner, J. Peter Klussmann. (2009) Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. European Archives of Oto-Rhino-Laryngology 266:3, 333-341
CrossRef878
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263-271
CrossRef879
Ilia L Ferrusi, Deborah A Marshall, Nathalie A Kulin, Natasha B Leighl, Kathryn A Phillips. (2009) Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Personalized Medicine 6:2, 193-215
CrossRef880
Frédéric Chibon, Isabelle de Mascarel, Ghislaine Sierankowski, Véronique Brouste, Hervé Bonnefoi, Marc Debled, Louis Mauriac, Gaëtan MacGrogan. (2009) Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Modern Pathology 22:3, 403-409
CrossRef881
Jun Zhao, Zhi-jie Wang, Jian-chun Duan, Qing-zhi Guo, Hua Bai, Lu Yang, Tong-tong An, Xin Wang, Yu-yan Wang, Mei-na Wu, Xu-yi Liu, Jie Wang. (2009) A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. Chinese Journal of Cancer Research 21:1, 1-12
CrossRef882
Teruhiko Fujii, Naoko Seki, Roka Namoto-Matsubayashi, Hiroki Takahashi, Yuka Inoue, Uhi Toh, Masayoshi Kage, Kazuo Shirouzu. (2009) YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells. Future Oncology 5:2, 153-156
CrossRef883
Claudia De Lorenzo, Giuseppe D’Alessio. (2009) Human anti-ErbB2 immunoagents - immunoRNases and compact antibodies. FEBS Journal 276:6, 1527-1535
CrossRef884
M Scaltriti, C Verma, M Guzman, J Jimenez, J L Parra, K Pedersen, D J Smith, S Landolfi, S Ramon y Cajal, J Arribas, J Baselga. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:6, 803-814
CrossRef885
J D Barros-Silva, D Leitão, L Afonso, J Vieira, M Dinis-Ribeiro, M Fragoso, M J Bento, L Santos, P Ferreira, S Rêgo, C Brandão, F Carneiro, C Lopes, F Schmitt, M R Teixeira. (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer 100:3, 487-493
CrossRef886
Laura Pentassuglia, Douglas B. Sawyer. (2009) The role of Neuregulin-1β/ErbB signaling in the heart. Experimental Cell Research 315:4, 627-637
CrossRef887
Makiko Ono, Masashi Ando, Mayu Yunokawa, Eriko Nakano, Kan Yonemori, Koji Matsumoto, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Noriyuki Katsumata, Yasuhiro Fujiwara. (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. International Journal of Clinical Oncology 14:1, 48-52
CrossRef888
Ashlynn L.Z. Lee, Yong Wang, Han Yin Cheng, Shazib Pervaiz, Yi Yan Yang. (2009) The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30:5, 919-927
CrossRef889
Gabriella Mariani, Angelica Fasolo, Elena De Benedictis, Luca Gianni. (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clinical Practice Oncology 6:2, 93-104
CrossRef890
Takemi Tanaka, Paolo Decuzzi, Massimo Cristofanilli, Jason H. Sakamoto, Ennio Tasciotti, Fredika M. Robertson, Mauro Ferrari. (2009) Nanotechnology for breast cancer therapy. Biomedical Microdevices 11:1, 49-63
CrossRef891
Lee B. Riley, Darius C. Desai. (2009) The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America 89:1, 1-15
CrossRef892
Melissa C. Hulvat, Nora M. Hansen, Jacqueline S. Jeruss. (2009) Multidisciplinary Care for Patients with Breast Cancer. Surgical Clinics of North America 89:1, 133-176
CrossRef893
Vishnu Chintalgattu, Shalin S. Patel, Aarif Y. Khakoo. (2009) Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America 23:1, 97-107
CrossRef894
Cecilia Nisticò, Emilio Bria, Vanja Vaccaro, Federica Cuppone, Monica Fornier, Isabella Sperduti, Armando Carpino, Fiorentino Izzo, Francesco Tropea, Francesco Cognetti, Edmondo Terzoli. (2009) Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anti-Cancer Drugs 20:2, 109-114
CrossRef895
M. J. Pepels, K. A. Boomars, R. Kimmenade, P. S. Hupperets. (2009) Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Research and Treatment 113:3, 609-612
CrossRef896
Patrick G Morris, Monica N Fornier. (2009) Novel anti-tubulin cytotoxic agents for breast cancer. Expert Review of Anticancer Therapy 9:2, 175-185
CrossRef897
Nathalie Wong, Winnie Yeo, Wai-Lap Wong, Navy L.-Y. Wong, Kathy Y.-Y. Chan, Frankie K.-F. Mo, Jane Koh, Stephan Lam Chan, Anthony T.-C. Chan, Paul B.-S. Lai, Arthur K.-K. Ching, Joanna H.-M. Tong, Ho-Keung Ng, Philip J. Johnson, Ka-Fai To. (2009) TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. International Journal of Cancer 124:3, 644-652
CrossRef898
Jeremy D. Gates, Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Matthew T. Hueman, Michael M. Woll, Constantine G. Ioannides, Craig H. Robson, David G. McLeod, Sathibalan Ponniah, George E. Peoples. (2009) Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients. Journal of the American College of Surgeons 208:2, 193-201
CrossRef899
A Jimeno, A Chan, G Cusatis, X Zhang, J Wheelhouse, A Solomon, F Chan, M Zhao, S C Cosenza, MV Ramana Reddy, M A Rudek, P Kulesza, R C Donehower, E P Reddy, M Hidalgo. (2009) Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 28:4, 610-618
CrossRef900
William W Chen, Birgit Schoeberl, Paul J Jasper, Mario Niepel, Ulrik B Nielsen, Douglas A Lauffenburger, Peter K Sorger. (2009) Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Molecular Systems Biology 5,
CrossRef901
S. Gori, A. Sidoni, M. Colozza, I. Ferri, M. G. Mameli, D. Fenocchio, L. Stocchi, J. Foglietta, V. Ludovini, E. Minenza, V. De Angelis, L. Crino. (2009) EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Annals of Oncology 20:4, 648-654
CrossRef902
Stefan Glück. (2009) NOAH Study: Is It Really Setting the New Standard for Preoperative Systemic Therapy in HER2-Positive Early Breast Cancer?. Breast Diseases: A Year Book Quarterly 20:2, 138-139
CrossRef903
David G. Hicks. 2009. Molecular Pathology of Breast Cancer. , 360-378.
CrossRef904
Daphne W Bell. (2009) Our changing view of the genomic landscape of cancer. The Journal of Pathologyn/a-n/a
CrossRef905
Véronique Baud, Michael Karin. (2009) Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery 8:1, 33-40
CrossRef906
Ian E. Krop, Eric P. Winer. (2009) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Research and Treatment 113:2, 207-209
CrossRef907
Richard Shaffer, Scott Tyldesley, Martin Rolles, Stephen Chia, Islam Mohamed. (2009) Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study. Radiotherapy and Oncology 90:1, 122-126
CrossRef908
David A. Katz, Anahita Bhathena. 2009. Overview of Pharmacogenetics. .
CrossRef909
Christine K. Cheng, Qi-Wen Fan, William A. Weiss. (2009) PI3K Signaling in Glioma-Animal Models and Therapeutic Challenges. Brain Pathology 19:1, 112-120
CrossRef910
Hye-Suk Han, Jin-Soo Kim, Jin Hyun Park, Yoon Kyung Jeon, Keun-Wook Lee, Do-Youn Oh, Jee Hyun Kim, So Yeon Park, Seock-Ah Im, Tae-You Kim, In Ae Park, Yung-Jue Bang. (2009) Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy. Journal of Korean Medical Science 24:5, 910
CrossRef911
Jun Kang, Gui Young Kwon, Young-Hee Lee, Gyungyub Gong. (2009) Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization for HER2 Gene Status in Breast Carcinomas. Journal of Breast Cancer 12:4, 235
CrossRef912
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber. (2009) Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009, 1-14
CrossRef913
Thomas A Miller, Basak Icli, Gregory M. Cote, Nathan K. LeBrasseur, Steve C. Borkan, David R. Pimentel, Xuyang Peng, Douglas B. Sawyer. (2009) Palmitate alters neuregulin signaling and biology in cardiac myocytes. Biochemical and Biophysical Research Communications 379:1, 32-37
CrossRef914
Kaichun Wu, Yongzhan Nie, Changcun Guo, Yu Chen, Jie Ding, Daiming Fan. (2009) Molecular basis of therapeutic approaches to gastric cancer. Journal of Gastroenterology and Hepatology 24:1, 37-41
CrossRef915
M. Arroyo Yustos, M. Martín Angulo, J.L. López González, R. Molina Villaverde. (2009) Cáncer de mama metastásico. Medicine - Programa de Formación Médica Continuada Acreditado 10:24, 1636.e1-1636.e3
CrossRef916
Peter S. Hall, David A. Cameron. (2009) Current perspective – Trastuzumab. European Journal of Cancer 45:1, 12-18
CrossRef917
Michelle E Melisko, Michael Glantz, Hope S Rugo. (2009) New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature Clinical Practice Oncology 6:1, 25-33
CrossRef918
Katherine H. Rak Tkaczuk. (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clinical Therapeutics 31, 2273-2289
CrossRef919
Takashi Temma, Kohei Sano, Yuji Kuge, Junko Kamihashi, Nozomi Takai, Yuki Ogawa, Hideo Saji. (2009) Development of a Radiolabeled Probe for Detecting Membrane Type-1 Matrix Metalloproteinase on Malignant Tumors. Biological & Pharmaceutical Bulletin 32:7, 1272-1277
CrossRef920
Jacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, Friedrich Kommoss, Philipp Harter, Jens Huober, Barbara Schmalfeldt, Nicole Burchardi, Norbert Arnold, Felix Hilpert. (2009) Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy. International Journal of Gynecological Cancer 19:1, 109-115
CrossRef921
Yeon Hee Park. (2009) Drug Therapy for Breast Cancer. Journal of the Korean Medical Association 52:10, 963
CrossRef922
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263
CrossRef923
Kristin McLarty, Bart Cornelissen, Deborah A. Scollard, Susan J. Done, Kathy Chun, Raymond M. Reilly. (2009) Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. European Journal of Nuclear Medicine and Molecular Imaging 36:1, 81-93
CrossRef924
Elyse E. Lower, Eleanor Glass, Robbin Blau, Stacy Harman. (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Research and Treatment 113:2, 301-306
CrossRef925
M. Arroyo Yustos, R. Molina Villaverde, J.L. López González, M. Álvarez-Mon Soto. (2009) Cáncer de mama (II). Tratamiento sistémico. Medicine - Programa de Formación Médica Continuada Acreditado 10:24, 1583-1590
CrossRef926
Marta Cuadros, Román Villegas. (2009) Systematic Review of HER2 Breast Cancer Testing. Applied Immunohistochemistry & Molecular Morphology 17:1, 1-7
CrossRef927
E. Montagna, G. Cancello, D. D’Agostino, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, A. Accurso, S. Placido, M. Laurentiis. (2009) Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemotherapy and Pharmacology 63:2, 275-280
CrossRef928
2009. BIBLIOGRAPHIE. , 176-189.
CrossRef929
D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, J. P. A. Ioannidis. (2008) Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer. JNCI Journal of the National Cancer Institute 100:24, 1780-1791
CrossRef930
Tristin Abair, Paul Card, Joyce O'Shaughnessy. (2008) Highlights from: The 33rd European Society of Medical Oncology Congress: September 2008; Stockholm, Sweden. Clinical Breast Cancer 8:6, 481-486
CrossRef931
David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment 112:3, 533-543
CrossRef932
(2008) News. Oncologie 10:S3, 389-418
CrossRef933
Yeon Hee Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im. (2008) Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications 377:2, 389-394
CrossRef934
Elisa Capizzi, Elisa Gruppioni, Antonia DʼErrico Grigioni, Elena Gabusi, Alberto Grassigli, Walter Franco Grigioni, Michelangelo Fiorentino. (2008) Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and Immunohistochemistry. Diagnostic Molecular Pathology 17:4, 220-226
CrossRef935
C. C. Zielinski. (2008) Treatment of metastatic breast cancer: a historical perspective. memo - Magazine of European Medical Oncology 1:4, 227-234
CrossRef936
Lester J. Layfield, Carlynn Willmore-Payne, Gary Isom, Joseph A. Holden. (2008) Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization. Applied Immunohistochemistry & Molecular Morphology 16:6, 562-567
CrossRef937
Toshiki Okasaka, Noriyasu Usami, Tetsuya Mitsudomi, Yasushi Yatabe, Keitaro Matsuo, Kohei Yokoi. (2008) Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. Journal of Surgical Oncology 98:7, 510-514
CrossRef938
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef939
Gianluca Tomasello, Evandro de Azambuja, Phuong Dinh, Natasa Snoj, Martine Piccart-Gebhart. (2008) Jumping higher: is it still possible? The ALTTO trial challenge. Expert Review of Anticancer Therapy 8:12, 1883-1890
CrossRef940
(2008) Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?. Asia-Pacific Journal of Clinical Oncology 4:4, 185-187
CrossRef941
Hyoungsuk Ko, Hyesil Seol, Wook Youn Kim, Seock-Ah Im, Wonshik Han, Dong-Young Noh, Yoon Kyung Jeon, In Ae Park. (2008) Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines. Basic and Applied Pathology 1:4, 182-188
CrossRef942
M. Gross-Goupil. (2008) Génomique, thérapie ciblée et CAPI: vers une prise en charge basée sur l’analyse moléculaire des CAPI ?. Oncologie 10:12, 718-721
CrossRef943
Yoshihiro Kikuchi, Masashi Takano, Kazuya Kudoh, Tsunekazu Kita, Kazuhiko Sato. (2008) Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 141:2, 189-191
CrossRef944
Djuana M. E. Harvell, Jennifer K. Richer, Meenakshi Singh, Nicole Spoelstra, Christina Finlayson, Virginia F. Borges, Anthony D. Elias, Kathryn B. Horwitz. (2008) Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment 112:3, 489-501
CrossRef945
Quanri Jin, Francisco J. Esteva. (2008) Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 13:4, 485-498
CrossRef946
Emilio Bria, Federica Cuppone, Michele Milella, Sunil Verma, Paolo Carlini, Cecilia Nisticò, Vanja Vaccaro, Antonio Rossi, Giuseppe Tonini, Francesco Cognetti, Edmondo Terzoli. (2008) Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opinion on Biological Therapy 8:12, 1963-1971
CrossRef947
Juan Bayo, María Lomas, Javier Salvador, Alberto Moreno, Manuel Ruiz, Alberto Rodríguez, José Fuentes, Ana Fernández-Freire, Reyes Bernabé, Andrea Fernández. (2008) A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. Clinical and Translational Oncology 10:12, 817-825
CrossRef948
Windy Dean-Colomb, Francisco J. Esteva. (2008) Her2-positive breast cancer: Herceptin and beyond. European Journal of Cancer 44:18, 2806-2812
CrossRef949
Reinhard von Wasielewski, Svenja Hasselmann, Josef Rüschoff, Annette Fisseler-Eckhoff, Hans Kreipe. (2008) Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Archiv 453:6, 537-543
CrossRef950
K. C. Jensen, D. A. Turbin, S. Leung, M. A. Miller, K. Johnson, B. Norris, T. Hastie, S. McKinney, T. O. Nielsen, D. G. Huntsman, C. B. Gilks, R. B. West. (2008) New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Research and Treatment 112:3, 453-459
CrossRef951
V WOLSTENHOLME, M HAWKINS, S ASHLEY, D TAIT, G ROSS. (2008) HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients
CrossRef952
Louis WC CHOW, Young-Hyuck IM. (2008) Current treatment of locally advanced and metastatic breast cancer in the Asia-Pacific region: Challenges and limitations. Asia-Pacific Journal of Clinical Oncology 4, S14-S23
CrossRef953
Wendell W. Weber. (2008) Pharmacogenetics: From Description to Prediction. Clinics in Laboratory Medicine 28:4, 499-511
CrossRef954
Deepali Sachdev. (2008) Regulation of Breast Cancer Metastasis by IGF Signaling. Journal of Mammary Gland Biology and Neoplasia 13:4, 431-441
CrossRef955
Shinji OHNO, Monica N FORNIER. (2008) Challenging patient populations in breast cancer: Taxane resistance and triple-negative receptor subtype. Asia-Pacific Journal of Clinical Oncology 4, S40-S48
CrossRef956
Serena Di Cosimo, José Baselga. (2008) Targeted therapies in breast cancer: Where are we now?. European Journal of Cancer 44:18, 2781-2790
CrossRef957
Christian F. Singer, Wolfgang J. Köstler, Gernot Hudelist. (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1786:2, 105-113
CrossRef958
A. Kruschinski, A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, J. Charo. (2008) Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proceedings of the National Academy of Sciences 105:45, 17481-17486
CrossRef959
B Sherrill, M Amonkar, Y Wu, C Hirst, S Stein, M Walker, J Cuzick. (2008) Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. British Journal of Cancer 99:10, 1572-1578
CrossRef960
M K Robinson, K M Hodge, E Horak, Å L Sundberg, M Russeva, C C Shaller, M von Mehren, I Shchaveleva, H H Simmons, J D Marks, G P Adams. (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. British Journal of Cancer 99:9, 1415-1425
CrossRef961
M. Ruiz, J. Salvador, J. Bayo, M. Lomas, A. Moreno, M. Valero, R. Bernabé, D. Vicente, J. Jiménez, A. Lopez-Ladrón. (2008) Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemotherapy and Pharmacology 62:6, 1085-1090
CrossRef962
Fátima Carneiro, Carla Oliveira, Marina Leite, Raquel Seruca. (2008) Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology 25:4, 274-287
CrossRef963
Saima Sharif, Ramesh K. Ramanathan, Douglas Potter, Kathleen Cieply, Alyssa M. Krasinskas. (2008) HER2 Gene Amplification and Chromosome 17 Copy Number Do Not Predict Survival of Patients with Resected Pancreatic Adenocarcinoma. Digestive Diseases and Sciences 53:11, 3026-3032
CrossRef964
Phuong Dinh, Evandro de Azambuja, Fatima Cardoso, Martine J Piccart-Gebhart. (2008) Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology 5:11, 645-654
CrossRef965
Aarif Y Khakoo, Edward TH Yeh. (2008) Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nature Clinical Practice Oncology 5:11, 655-667
CrossRef966
Daryl C. Drummond, Charles O. Noble, Mark E. Hayes, John W. Park, Dmitri B. Kirpotin. (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences 97:11, 4696-4740
CrossRef967
Guru Sonpavde. (2008) Neoadjuvant therapy as a paradigm to develop systemic cancer therapy. Drug Development Research 69:7, 388-397
CrossRef968
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef969
Jan Trøst Jørgensen. (2008) Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. Expert Review of Molecular Diagnostics 8:6, 689-695
CrossRef970
Don S Dizon, Sharmila Makhija. (2008) HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opinion on Drug Discovery 3:11, 1363-1369
CrossRef971
Yukio Kageyama. (2008) Development of drugs against hormone-refractory prostate cancer. Drug Development Research 69:7, 431-450
CrossRef972
Isao TABEI, Shigeki NISHIYAMA, Shigeo YAMASHITA, Hisashi HASHIMOTO, Toshiaki TACHIBANA, Ken UCHIDA, Hiroshi ISHIKAWA. (2008) Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma. Human Cell 21:4, 105-112
CrossRef973
Antonino Carbone, Gerardo Botti, Annunziata Gloghini, Gianni Simone, Mauro Truini, Maria Pia Curcio, Patrizia Gasparini, Anita Mangia, Tiziana Perin, Sandra Salvi, Adele Testi, Paolo Verderio. (2008) Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists. The Journal of Molecular Diagnostics 10:6, 527-536
CrossRef974
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Kaoru Hashizume, Makiko Ono, Yukihiro Nakanishi, Tadashi Hasegawa, Yasuji Miyakita, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara. (2008) Immunohistochemical profiles of brain metastases from breast cancer. Journal of Neuro-Oncology 90:2, 223-228
CrossRef975
P. SINGH, C.L. SMITH, G. CHEETHAM, T.J. DODD, M.L.J. DAVY. (2008) Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. International Journal of Gynecological Cancer 18:6, 1344-1351
CrossRef976
CA Haller, ME Cosenza, JT Sullivan. (2008) Safety Issues Specific to Clinical Development of Protein Therapeutics. Clinical Pharmacology & Therapeutics 84:5, 624-627
CrossRef977
J. Stagg, J. Sharkey, S. Pommey, R. Young, K. Takeda, H. Yagita, R. W. Johnstone, M. J. Smyth. (2008) Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences 105:42, 16254-16259
CrossRef978
E. D. Saad, A. Katz. (2008) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Annals of Oncology 20:3, 460-464
CrossRef979
A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, L. Fernandez. (2008) Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology 20:3, 454-459
CrossRef980
O N Ikediobi. (2008) Somatic pharmacogenomics in cancer. The Pharmacogenomics Journal 8:5, 305-314
CrossRef981
Sheila C. L. Wludarski, Carlos E. Bacchi. (2008) High Concordance of SP3 Rabbit Monoclonal Antibody With FISH to Evaluate HER2 in Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 16:5, 466-470
CrossRef982
Tallal Younis, Chris Skedgel. (2008) Is trastuzumab a cost-effective treatment for breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 8:5, 433-442
CrossRef983
John H. Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner. (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology 20:5, 267-275
CrossRef984
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef985
Alessandra Fabi, Giulio Metro, Gianluigi Ferretti, Diana Giannarelli, Serena Di Cosimo, Paola Papaldo, Marcella Mottolese, Paolo Carlini, Alessandra Felici, Michelangelo Russillo, Francesco Cognetti. (2008) Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. The Breast 17:5, 499-505
CrossRef986
Francesca Milano, Kausilia K. Krishnadath. (2008) Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens. Human Immunology 69:10, 614-624
CrossRef987
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef988
Philipp Kiewe, Eckhard Thiel. (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs 17:10, 1553-1558
CrossRef989
Giulio Metro, Marcella Mottolese, Alessandra Fabi. (2008) HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opinion on Pharmacotherapy 9:15, 2583-2601
CrossRef990
A. Heidenreich, D. Thüer, D. Pfister. (2008) Der Stellenwert der Tageted-Therapie beim Peniskarzinom. Der Urologe 47:10, 1320-1327
CrossRef991
D. Serin, A. Brédart, M. Debled, P. Fumoleau. (2008) Chimiothérapie et qualité de vie dans le cancer du sein métastatique: état des lieux. Oncologie 10:10, 580-590
CrossRef992
Y MADARNAS, M TRUDEAU, J FRANEK, D MCCREADY, K PRITCHARD, H MESSERSMITH. (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews 34:6, 539-557
CrossRef993
Rupert Bartsch, Catharina Wenzel, Simon P. Gampenrieder, Ursula Pluschnig, Gabriela Altorjai, Margaretha Rudas, Robert M. Mader, Peter Dubsky, Andrea Rottenfusser, Michael Gnant, Christoph C. Zielinski, Guenther G. Steger. (2008) Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 62:5, 903-910
CrossRef994
Emmanouel Saloustros, Dimitris Mavroudis, Vassilis Georgoulias. (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opinion on Pharmacotherapy 9:15, 2603-2616
CrossRef995
Jae-Hoon Jeong, Jee Young An, Yong Tae Kwon, Lu-Yuan Li, Yong J. Lee. (2008) Quercetin-induced ubiquitination and down-regulation of Her-2/ neu. Journal of Cellular Biochemistry 105:2, 585-595
CrossRef996
Alfonso Sánchez-Muñoz, Ana María García-Tapiador, Esther Martínez-Ortega, Rosario Dueñas-García, Ana Jaén-Morago, Ana Laura Ortega-Granados, Mónica Fernández-Navarro, Capilla Torre-Cabrera, Basilio Dueñas, Ana Isabel Rueda, Francisco Morales, César Ramírez-Torosa, María Dolores Martín-Salvago, Pedro Sánchez-Rovira. (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology 10:10, 646-653
CrossRef997
Peng H Tan, Amrit S Lota. (2008) Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opinion on Pharmacotherapy 9:15, 2639-2660
CrossRef998
PJ Wysocki, H Wysocki. (2008) Cardiovascular complications associated with biological therapies for breast cancer. Expert Opinion on Biological Therapy 8:10, 1551-1559
CrossRef999
Lye Lin Ho, James G. Kench, David J. Handelsman, George L. Scheffer, Phillip D. Stricker, John G. Grygiel, Robert L. Sutherland, Susan M. Henshall, John D. Allen, Lisa G. Horvath. (2008) Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. The Prostate 68:13, 1421-1429
CrossRef1000
Suhail M. Ali, Walter P. Carney, Francisco J. Esteva, Monica Fornier, Lyndsay Harris, Wolfgang. J. Köstler, Jean-Pierre Lotz, Diana Luftner, Marie-France Pichon, Allan Lipton, . (2008) Serum HER-2/ neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113:6, 1294-1301
CrossRef1001
J. Qin, R. C. Jones, R. Ramakrishnan. (2008) Studying copy number variations using a nanofluidic platform. Nucleic Acids Research 36:18, e116-e116
CrossRef1002
John W. Rose, John Foley, Noel Carlson. (2008) Monoclonal antibody treatments for multiple sclerosis. Current Neurology and Neuroscience Reports 8:5, 419-426
CrossRef1003
Belinda Sánchez Ramírez, Yeranddy Aguiar Alpízar, Diana Rosa Hernández Fernández, Greta Garrido Hidalgo, Ailem Rabasa Capote, Rolando Pérez Rodríguez, Luis Enrique Fernández. (2008) Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine. Vaccine 26:38, 4918-4926
CrossRef1004
Thorsten Wiech, Elisabeth Nikolopoulos, Michael Hausmann, Axel Walch, Martin Werner, Paul Fisch. (2008) A Case of Heterogeneous Breast Cancer with Clonally Expanded T-Cells in the HER2+ and Metastasis of the HER2− Tumor Cells. The Breast Journal 14:5, 487-491
CrossRef1005
Angela L.W. Meisner, M. Houman Fekrazad, Melanie E. Royce. (2008) Breast Disease: Benign and Malignant. Medical Clinics of North America 92:5, 1115-1141
CrossRef1006
Josep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, José Pérez, Marta Parera. (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:3, S72-S76
CrossRef1007
Thomas Force, Risto Kerkelä. (2008) Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem. Drug Discovery Today 13:17-18, 778-784
CrossRef1008
Aleix Prat, José Baselga. (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology 5:9, 531-542
CrossRef1009
Neesha Dhani, Lillian L. Siu. (2008) Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Cancer and Metastasis Reviews 27:3, 339-349
CrossRef1010
D SOMA, J KITAYAMA, H YAMASHITA, H MIYATO, M ISHIKAWA, H NAGAWA. (2008) Leptin Augments Proliferation of Breast Cancer Cells via Transactivation of HER2. Journal of Surgical Research 149:1, 9-14
CrossRef1011
Chao Hui Huang, Michael M. Millenson, Eric J. Sherman, Hossein Borghaei, David M. Mintzer, Roger B. Cohen, Arthur P. Staddon, Judi Seldomridge, Ocn Joseph Treat, Holly Tuttle, Karen J. Ruth, Corey J. Langer. (2008) Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. Journal of Thoracic Oncology 3:9, 1032-1038
CrossRef1012
Henry G. Kaplan, Judith A. Malmgren. (2008) Impact of Triple Negative Phenotype on Breast Cancer Prognosis. The Breast Journal 14:5, 456-463
CrossRef1013
Juan Haba-Rodriguez, Emilio Alba, Agustí Barnadas, Eloisa Bayo, Antonio Llombart, Ana Lluch, Miguel Martín, José Andrés Moreno-Nogueira, Gumersindo Pérez Manga, Álvaro Rodríguez-Lescure, Enrique Aranda. (2008) Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clinical and Translational Oncology 10:9, 552-559
CrossRef1014
David A Cameron, Steven Stein. (2008) Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nature Clinical Practice Oncology 5:9, 512-520
CrossRef1015
Alicia Lázaro, Javier Cassinello, Almudena Amorós, Miriam Heredia, Ana López-Alfonso. (2008) Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. Clinical and Translational Oncology 10:9, 587-590
CrossRef1016
P ATHANASSIADOU, D GRAPSA. (2008) Bone marrow micrometastases in different solid tumors: Pathogenesis and importance. Surgical Oncology 17:3, 153-164
CrossRef1017
C Osipo, P Patel, P Rizzo, A G Clementz, L Hao, T E Golde, L Miele. (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 27:37, 5019-5032
CrossRef1018
B. Xiang, K. Chatti, H. Qiu, B. Lakshmi, A. Krasnitz, J. Hicks, M. Yu, W. T. Miller, S. K. Muthuswamy. (2008) Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proceedings of the National Academy of Sciences 105:34, 12463-12468
CrossRef1019
B. Gril, D. Palmieri, J. L. Bronder, J. M. Herring, E. Vega-Valle, L. Feigenbaum, D. J. Liewehr, S. M. Steinberg, M. J. Merino, S. D. Rubin, P. S. Steeg. (2008) Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute 100:15, 1092-1103
CrossRef1020
Bénédicte Poncet, Thomas Bachelot, Cyrille Colin, Christell Ganne, Isabelle Jaisson-Hot, Hubert Orfeuvre, Pierre-Yves Peaud, Jean-Philippe Jacquin, Bruno Salles, Jean-Dominique Tigaud, Isabelle Mechin-Cretinon, François Marechal, Cécile Fournel, Véronique Trillet Lenoir. (2008) Use of the Monoclonal Antibody Anti-HER2 Trastuzumab in the Treatment of Metastatic Breast Cancer. American Journal of Clinical Oncology 31:4, 363-368
CrossRef1021
Michael Boyiadzis, Kenneth A Foon. (2008) Approved monoclonal antibodies for cancer therapy. Expert Opinion on Biological Therapy 8:8, 1151-1158
CrossRef1022
Brent Anderson, Douglas B Sawyer. (2008) Predicting and preventing the cardiotoxicity of cancer therapy. Expert Review of Cardiovascular Therapy 6:7, 1023-1033
CrossRef1023
R. S. Finn. (2008) Targeting Src in breast cancer. Annals of Oncology 19:8, 1379-1386
CrossRef1024
Nahomi Tokudome, Yoshinori Ito, Kiyohiko Hatake, Masakazu Toi, Muneaki Sano, Hiroji Iwata, Yasuyuki Sato, Toshiaki Saeki, Kenjiro Aogi, Shigemitsu Takashima. (2008) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Anti-Cancer Drugs 19:7, 753-759
CrossRef1025
Giuliana Cavalloni, Ivana Sarotto, Ymera Pignochino, Loretta Gammaitoni, Giorgia Migliardi, Luca Sgro, Wanda Piacibello, Mauro Risio, Massimo Aglietta, Francesco Leone. (2008) Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. Anti-Cancer Drugs 19:7, 689-696
CrossRef1026
Jing Qin, Penghai Zhang, Xinyu Qian, Aimin Li, Rongcheng Luo, Dingli Xu. (2008) Analysis of cardiotoxicity from rh-endostatin therapy combined with chemotherapy. Chinese Journal of Clinical Oncology 5:4, 290-293
CrossRef1027
Giovanni Tonon. (2008) From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncology 4:4, 569-577
CrossRef1028
AC Wu, AL Fuhlbrigge. (2008) Economic Evaluation of Pharmacogenetic Tests. Clinical Pharmacology & Therapeutics 84:2, 272-274
CrossRef1029
N WALJI, L BHATT, S DHALLU, I FERNANDO. (2008) Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure. The Breast 17:4, 423-425
CrossRef1030
F. Peintinger, A. U. Buzdar, H. M. Kuerer, J. A. Mejia, C. Hatzis, A. M. Gonzalez-Angulo, L. Pusztai, F. J. Esteva, S. S. Dawood, M. C. Green, G. N. Hortobagyi, W. F. Symmans. (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Annals of Oncology 19:12, 2020-2025
CrossRef1031
P Arora, B D Cuevas, A Russo, G L Johnson, J Trejo. (2008) Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 27:32, 4434-4445
CrossRef1032
I. H. Park, J. Ro, K. S. Lee, B. H. Nam, Y. Kwon, K. H. Shin. (2008) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Annals of Oncology 20:1, 56-62
CrossRef1033
Shinya Toyokuni. (2008) Molecular mechanisms of oxidative stress-induced carcinogenesis: From epidemiology to oxygenomics. IUBMB Life 60:7, 441-447
CrossRef1034
Mei Yu, David Zloty, Bryce Cowan, Jerry Shapiro, Anne Haegert, Robert H Bell, Larry Warshawski, Nicholas Carr, Kevin J McElwee. (2008) Superficial, Nodular, and Morpheiform Basal-Cell Carcinomas Exhibit Distinct Gene Expression Profiles. Journal of Investigative Dermatology 128:7, 1797-1805
CrossRef1035
V. González, E. Salgueiro, F. J. Jimeno, A. Hidalgo, T. Rubio, G. Manso. (2008) Post‐marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiology and Drug Safety 17:7, 714-721
CrossRef1036
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef1037
R EPSTEIN, B CHEUNG. (2008) Loading doses for costly cancer biologicals: Sound pharmacology or unnecessary extravagance?. European Journal of Cancer 44:11, 1488-1492
CrossRef1038
Sadaf Y Qureshi, Nadeem Qureshi. (2008) Genetic profiling in primary care can enhance personalized drug therapy: reality or myth?. Personalized Medicine 5:4, 311-316
CrossRef1039
Graziella Pratesi, Giovanna Petrangolini, Monica Tortoreto, Alessandro Addis, Franco Zunino, Claudia Calcaterra, Andrea Merlo, Elda Tagliabue, Sylvie Menard, Andrea Balsari. (2008) Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. Journal of Immunotherapy 31:6, 537-544
CrossRef1040
I HENNIG, C TWELVES. (2008) Loading doses for costly cancer biologicals: A cause for concern or tilting at windmills?. European Journal of Cancer 44:11, 1493-1496
CrossRef1041
Patrick R Benusiglio. (2008) Focus on ERBB2. Pharmacogenomics 9:7, 825-828
CrossRef1042
A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, A. Pandiella. (2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology 19:11, 1860-1869
CrossRef1043
A. Dutt, H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, W. Winckler, R. Grewal, M. Hanna, N. Wyhs, L. Ziaugra, D. J. Richter, J. Trovik, I. B. Engelsen, I. M. Stefansson, T. Fennell, K. Cibulskis, M. C. Zody, L. A. Akslen, S. Gabriel, K.-K. Wong, W. R. Sellers, M. Meyerson, H. Greulich. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences 105:25, 8713-8717
CrossRef1044
David R. Spigel, Ming Lin, Vincent O'Neill, John D. Hainsworth. (2008) Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 112:12, 2749-2755
CrossRef1045
M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, A. Lopez, R. Islam, V. Valero, G. N. Hortobagyi. (2008) Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations. Annals of Oncology 19:10, 1713-1719
CrossRef1046
Maya Guglin, Raymond Cutro, Joseph D. Mishkin. (2008) Trastuzumab-Induced Cardiomyopathy. Journal of Cardiac Failure 14:5, 437-444
CrossRef1047
Carmela Ricciardelli, Michael W. Jackson, Catherine S. Choong, Jürgen Stahl, Villis R. Marshall, David J. Horsfall, Wayne D. Tilley. (2008) Elevated levels of HER-2/ neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. The Prostate 68:8, 830-838
CrossRef1048
Tomo Osako, Yoshinori Ito, Shunji Takahashi, Nahomi Tokudome, Takuji Iwase, Kiyohiko Hatake. (2008) Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology 62:1, 159-164
CrossRef1049
H COLEY. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews 34:4, 378-390
CrossRef1050
Richard Simon. (2008) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opinion on Medical Diagnostics 2:6, 721-729
CrossRef1051
David N. Church, Ramayana Modgil, Sam Guglani, Amit Bahl, Kirsten Hopkins, Jeremy P. Braybrooke, Peter Blair, Chris G. A. Price. (2008) Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer. American Journal of Clinical Oncology 31:3, 250-254
CrossRef1052
Feng Guo, Stephen P. Letrent, Pamela N. Munster, Carolyn D. Britten, Karen Gelmon, Anthony W. Tolcher, Amarnath Sharma. (2008) Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemotherapy and Pharmacology 62:1, 97-109
CrossRef1053
R. Bartsch, G. G. Steger. (2008) Adjuvant chemotherapy in breast cancer. memo - Magazine of European Medical Oncology 1:2, 91-98
CrossRef1054
Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi, Kiichiro Tsutani. (2008) The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Research and Treatment 109:3, 559-566
CrossRef1055
Swati Kulkarni, David G. Hicks. (2008) HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective. Annals of Surgical Oncology 15:6, 1677-1688
CrossRef1056
A Brunello, A Jirillo, C Falci, S Lonardi, U Basso, S Monfardini. (2008) Treatment of advanced breast cancer in elderly women: medical approach. Aging Health 4:3, 267-277
CrossRef1057
Howard H. Bailey, Steven Attia, Richard R. Love, Terri Fass, Rick Chappell, Kendra Tutsch, Linda Harris, Alcee Jumonville, Richard Hansen, Gary R. Shapiro, James A. Stewart. (2008) Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemotherapy and Pharmacology 62:1, 149-157
CrossRef1058
Scott C. Mayer, Annette L. Banker, Frank Boschelli, Li Di, Mark Johnson, Cynthia Hess Kenny, Girija Krishnamurthy, Kristina Kutterer, Franklin Moy, Susan Petusky, Malini Ravi, Diane Tkach, Hwei-Ru Tsou, Weixin Xu. (2008) Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorganic & Medicinal Chemistry Letters 18:12, 3641-3645
CrossRef1059
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:7, 797-805
CrossRef1060
April F. Eichler, Irene Kuter, Paula Ryan, Lidia Schapira, Jerry Younger, John W. Henson. (2008) Survival in patients with brain metastases from breast cancer. Cancer 112:11, 2359-2367
CrossRef1061
J. M. Llovet, A. M. Di Bisceglie, J. Bruix, B. S. Kramer, R. Lencioni, A. X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, G. J. Gores, . (2008) Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute 100:10, 698-711
CrossRef1062
C. Gravalos, A. Jimeno. (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology 19:9, 1523-1529
CrossRef1063
F. Puglisi, G. G. Cardellino, D. Crivellari, C. Di Loreto, M. D. Magri, A. M. Minisini, M. Mansutti, C. Andreetta, S. Russo, D. Lombardi, T. Perin, G. Damante, A. Veronesi. (2008) Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Annals of Oncology 19:9, 1541-1546
CrossRef1064
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, T. Suter. (2008) Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Annals of Oncology 19:9, 1530-1539
CrossRef1065
M Hermes, W Schormann, M Brulport, K Uhlemann, F Lupatsch, L C Horn, A Schumann, C Allgaier, M Weishaupt, K Engeland, G A Müller, J Mössner, A Bauer, I B Schiffer, S Gebhard, M Schmidt, E Lausch, D Prawitt, C Wilhelm, J G Hengstler. (2008) Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. British Journal of Cancer 98:9, 1525-1532
CrossRef1066
Surabhi Amar, Alvaro Moreno-Aspitia, Edith A. Perez. (2008) Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Research and Treatment 109:1, 1-7
CrossRef1067
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, J. E. Payton, P. Westervelt, J. F. DiPersio, D. C. Link, M. J. Walter, T. A. Graubert, M. Watson, J. Baty, S. Heath, W. D. Shannon, R. Nagarajan, C. D. Bloomfield, E. R. Mardis, R. K. Wilson, T. J. Ley. (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111:9, 4797-4808
CrossRef1068
Yoshiya Ohno, Kentaro Suda, Kazue Masuko, Hideki Yagi, Yoshiyuki Hashimoto, Takashi Masuko. (2008) Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human l-type amino-acid transporter 1. Cancer Science 99:5, 1000-1007
CrossRef1069
Carsten T. Viehl, Daniel M. Frey, Chanpheng Phommaly, Tingting Chen, Timothy P. Fleming, William E. Gillanders, Timothy J. Eberlein, Peter S. Goedegebuure. (2008) Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. Breast Cancer Research and Treatment 109:2, 305-314
CrossRef1070
Li Yan, Karl Hsu, Robert A. Beckman. (2008) Antibody-Based Therapy for Solid Tumors. The Cancer Journal 14:3, 178-183
CrossRef1071
Anna M. Wu, Tove Olafsen. (2008) Antibodies for Molecular Imaging of Cancer. The Cancer Journal 14:3, 191-197
CrossRef1072
Shaheenah Dawood, Kristine Broglio, Yun Gong, Wei-Tse Yang, Massimo Cristofanilli, Shu-Wan Kau, Funda Meric-Bernstam, Thomas A. Buchholz, Gabriel N Hortobagyi, Ana M. Gonzalez-Angulo, . (2008) Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112:9, 1905-1911
CrossRef1073
Ruxandra Jurcut, Hans Wildiers, Javier Ganame, Jan D’hooge, Robert Paridaens, Jens-Uwe Voigt. (2008) Detection and monitoring of cardiotoxicity—what does modern cardiology offer?. Supportive Care in Cancer 16:5, 437-445
CrossRef1074
Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl. (2008) HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Research and Treatment 109:2, 351-357
CrossRef1075
N. V. Zhukov, S. A. Tjulandin. (2008) Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow) 73:5, 605-618
CrossRef1076
Emilio Bria, Federica Cuppone, Monica Fornier, Cecilia Nisticò, Paolo Carlini, Michele Milella, Isabella Sperduti, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Research and Treatment 109:2, 231-239
CrossRef1077
Tsukasa Nabekura, Toshiro Nagasawa, Hiromitsu Nakauchi, Masafumi Onodera. (2008) An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2. Cancer Immunology, Immunotherapy 57:5, 611-622
CrossRef1078
H.G. Sayer, F. Jänicke, W. Budach, K. Höffken. (2008) Therapie des metastasierten Mammakarzinoms. Der Onkologe 14:5, 514-519
CrossRef1079
Paul J. Carter, Peter D. Senter. (2008) Antibody-Drug Conjugates for Cancer Therapy. The Cancer Journal 14:3, 154-169
CrossRef1080
Stephen J. Fuller, Kenga Sivarajah, Peter H. Sugden. (2008) ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. Journal of Molecular and Cellular Cardiology 44:5, 831-854
CrossRef1081
Hitoshi Itoh, Yoko Miyajima, Shinobu Umemura, Robert Y. Osamura. (2008) Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers. Cancer 114:2, 134-140
CrossRef1082
Inés G. Muñoz, Francisco J. Blanco, Guillermo Montoya. (2008) On the relevance of defining protein structures in cancer research. Clinical and Translational Oncology 10:4, 204-212
CrossRef1083
Andrea Kiessling, Susanne Füssel, Rebekka Wehner, Michael Bachmann, Manfred P. Wirth, E. Peter Rieber, Marc Schmitz. (2008) Advances in Specific Immunotherapy for Prostate Cancer. European Urology 53:4, 694-708
CrossRef1084
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef1085
Andrea Kiessling, Susanne Füssel, Rebekka Wehner, Michael Bachmann, Manfred P. Wirth, E. Peter Rieber, Marc Schmitz. (2008) Rebuttal from Authors re: Christian Doehn. Immunotherapy of Prostate Cancer. Eur Urol 2008;53:681–3. European Urology 53:4, 684-685
CrossRef1086
Patricia S Steeg, Dan Theodorescu. (2008) Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology 5:4, 206-219
CrossRef1087
Isabel M. Chu, Ludger Hengst, Joyce M. Slingerland. (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews Cancer 8:4, 253-267
CrossRef1088
A.K Croker, A.L Allan. (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. Journal of Cellular and Molecular Medicine 12:2, 374-390
CrossRef1089
M.A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, V. Ambrosini, C. Nanni, S. Boschi, G. Biasco. (2008) Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treatment Reviews 34:2, 103-121
CrossRef1090
Q. Jing, Q. Xinyu, L. Rougcheng. (2008) Recombinant Human Endostatin-associated Acute Left Heart Failure. Clinical Oncology 20:3, 268
CrossRef1091
Peter Nygren, Rolf Larsson. (2008) Predictive tests for individualization of pharmacological cancer treatment. Expert Opinion on Medical Diagnostics 2:4, 349-360
CrossRef1092
Volker Heinemann. (2008) Review of bevacizumab in the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:8, 13-18
CrossRef1093
Barbara T. McGrogan, Breege Gilmartin, Desmond N. Carney, Amanda McCann. (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:2, 96-132
CrossRef1094
Gerald M. Higa. (2008) Targeting HER 1 and 2 in breast cancer with lapatinib. Oncology Reviews 2:1, 21-28
CrossRef1095
Victoria Moncada, Sudhir Srivastava. (2008) Biomarkers in oncology research and treatment: early detection research network: a collaborative approach. Biomarkers in Medicine 2:2, 181-195
CrossRef1096
Amer H. Zureikat, Mark D. McKee. (2008) Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America 17:2, 279-301
CrossRef1097
Pier Franco Conte. (2008) The 2007 Rome Forum on the Treatment of Breast Cancer: first-line treatment choices for metastatic breast cancer in Europe. European Journal of Cancer Supplements 6:8, 1-4
CrossRef1098
A. Schwalen. (2008) Herz-Lungen-Probleme bei und nach gynäkologisch-onkologischer Therapie. Der Gynäkologe 41:4, 262-268
CrossRef1099
Constantin N Baxevanis. (2008) Antibody-based cancer therapy. Expert Opinion on Drug Discovery 3:4, 441-452
CrossRef1100
K KNOBLOCH, J TEPE, R LICHTINGHAGEN, H LUCK, P VOGT. (2008) Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. International Journal of Cardiology 125:1, 113-115
CrossRef1101
Paik, Soonmyung, Kim, Chungyeul, Wolmark, Norman, . (2008) HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. New England Journal of Medicine 358:13, 1409-1411
Full Text1102
Sanjay Popat, Ian E Smith. (2008) Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature Clinical Practice Oncology
CrossRef1103
S. Dawood, K. Broglio, F. J. Esteva, N. K. Ibrahim, S.-W. Kau, R. Islam, K. D. Aldape, T.-K. Yu, G. N. Hortobagyi, A. M. Gonzalez-Angulo. (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Annals of Oncology 19:7, 1242-1248
CrossRef1104
J. King, J. Waxman, H. Stauss. (2008) Advances in tumour immunotherapy. QJM 101:9, 675-683
CrossRef1105
T Kidokoro, C Tanikawa, Y Furukawa, T Katagiri, Y Nakamura, K Matsuda. (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:11, 1562-1571
CrossRef1106
D CAMERON. (2008) Bevacizumab in the first-line treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 21-28
CrossRef1107
Erin Farrell, Jonathan Usuka. (2008) Pharmacogenomics and drug development: the impact of US FDA postapproval tracking on clinical pharmacology. Personalized Medicine 5:2, 133-139
CrossRef1108
Tait D. Shanafelt, Susan M. Geyer, Nancy D. Bone, Renee C. Tschumper, Tom E. Witzig, Greg S. Nowakowski, Clive S. Zent, Tim G. Call, Betsy LaPlant, Gordon W. Dewald, Diane F. Jelinek, Neil E. Kay. (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. British Journal of Haematology 140:5, 537-546
CrossRef1109
David Cameron. (2008) Promises borne out in clinical studies. European Journal of Cancer Supplements 6:5, 15-24
CrossRef1110
Pierre Fumoleau. (2008) Future options in the treatment of ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 25-31
CrossRef1111
Paul Wheatley-Price, Frances A Shepherd. (2008) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology 20:2, 162-175
CrossRef1112
Richard Bell, David Cameron. (2008) Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 1-6
CrossRef1113
Ahmad Awada, Martine J. Piccart-Gebhart. (2008) Management of HER-2/neu-positive metastatic breast cancer. European Journal of Cancer Supplements 6:4, 2-9
CrossRef1114
Alfredo Santinelli, Eleonora Pisa, Daniela Stramazzotti, Guidalberto Fabris. (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. International Journal of Cancer 122:5, 999-1004
CrossRef1115
Daigo Yamamoto, Satoru Iwase, Kaoru Kitamura, Hiroki Odagiri, Chizuko Yamamoto, Yoshinori Nagumo. (2008) A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemotherapy and Pharmacology 61:3, 509-514
CrossRef1116
N HARBECK. (2008) Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. European Journal of Cancer Supplements 6:6, 14-20
CrossRef1117
Christian Jackisch. (2008) Challenges in the treatment of ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 7-14
CrossRef1118
Monica Brown, Alex Tsodikov, Katrina R. Bauer, Carol A. Parise, Vincent Caggiano. (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer 112:4, 737-747
CrossRef1119
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef1120
Ian N Olver. (2008) Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when. Future Oncology 4:1, 125-131
CrossRef1121
Christoph C. Zielinski, Ahmad Awada, David A. Cameron, Tanja Cufer, Miguel Martin, Matti Aapro. (2008) The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. European Journal of Cancer 44:3, 353-365
CrossRef1122
Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl, Enikő Tóth, István Juhász, John W. Park, Jorma Isola, György Vereb, János Szöllősi. (2008) Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Letters 260:1-2, 198-208
CrossRef1123
T.K. Yau, I.S. Soong, K. Chan, A. Chang, H. Sze, M.W. Yeung, R. Tung, S. Lau, A. Lee. (2008) Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong. The Breast 17:1, 58-63
CrossRef1124
Marianna Zavodovskaya, Michael J. Campbell, Betty A. Maddux, Laura Shiry, Geoffrey Allan, Leslie Hodges, Peter Kushner, John A. Kerner, Jack F. Youngren, Ira D. Goldfine. (2008) Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. Journal of Cellular Biochemistry 103:2, 624-635
CrossRef1125
Shaheenah Dawood, Naoto T. Ueno, Massimo Cristofanilli. (2008) The Medical Treatment of Inflammatory Breast Cancer. Seminars in Oncology 35:1, 64-71
CrossRef1126
M. Anderssona, A. Awadab, P. Barrett-Leec, P. Ellisd, P. Hupperetse, C. Jackischf, E. Kubistag, H.-J. Lückh, C. Monnerati, U. Nitzj, M. Untchl. (2008) European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. The Breast 17, S1-S12
CrossRef1127
Partho P. Sengupta, Donald W. Northfelt, Federico Gentile, Jose L. Zamorano, Bijoy K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef1128
P. P. Sengupta, D. W. Northfelt, F. Gentile, J. L. Zamorano, B. K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef1129
F.E ODICINO, E BIGNOTTI, E ROSSI, B PASINETTI, R.A TASSI, C DONZELLI, M FALCHETTI, P FONTANA, P.G GRIGOLATO, S PECORELLI. (2008) HER-2/ neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. International Journal of Gynecological Cancer 18:1, 14-21
CrossRef1130
Jan Trøst Jørgensen. (2008) From blockbuster medicine to personalized medicine. Personalized Medicine 5:1, 55-63
CrossRef1131
Alice Ulhoa-Cintra, Larisa Greenberg, Charles E. Geyer. (2008) The emerging role of Lapatinib in HER2-positive breast cancer. Current Oncology Reports 10:1, 10-17
CrossRef1132
Anna Bafico, Luca Grumolato, Stuart A. Aaronson. 2008. Oncogenes and Signal Transduction. , 17-30.
CrossRef1133
J. Peppercorn. (2008) Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerBernhard J, Zahrieh D, Zhang JJ, et al (IBCSG Coordinating Ctr, Bern, Switzerland; IBCSG Statistical Ctr, Dana-Farber Cancer Inst, Boston; Harvard School of Public Health, Boston; et al) Br J Cancer 98:25-33, 2008§. Breast Diseases: A Year Book Quarterly 19:3, 279-280
CrossRef1134
N LIN. (2008) Treatment of HER2-Positive Breast Cancer: New Approaches, New Opportunities. Breast Diseases: A Year Book Quarterly 18:4, 336-338
CrossRef1135
María Sereno, Antonella Brunello, Alberto Chiappori, Jorge Barriuso, Enrique Casado, Cristóbal Belda, Javier Castro, Jaime Feliu, Manuel González-Barón. (2008) Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology 10:1, 35-46
CrossRef1136
Nadia Harbeck, Volker Heinemann, Sibylle Loibl, Michael Untch. (2008) Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care 3:1, 7-12
CrossRef1137
S J L Payne, R L Bowen, J L Jones, C A Wells. (2008) Predictive markers in breast cancer - the present. Histopathology 52:1, 82-90
CrossRef1138
Eun Yoon Cho, Jae Joon Han, Yoon-La Choi, Kyoung-Mee Kim, Young Lyun Oh. (2008) Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study. Journal of Korean Medical Science 23:6, 1053
CrossRef1139
Wai M. Liu, Katherine A. Scott, Jonathan Shamash, Simon Joel, Thomas B. Powles. (2008) Enhancing the in vitro cytotoxic activity of Δ 9 -tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leukemia & Lymphoma 49:9, 1800-1809
CrossRef1140
A Tefferi. (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:1, 3-13
CrossRef1141
Franklin L. Chen, Andrew J. Armstrong, Daniel J. George. (2008) Cell Signaling Modifiers in Prostate Cancer. The Cancer Journal 14:1, 40-45
CrossRef1142
Wolfgang Janni, Gunter von Minckwitz, Volker Möbus, Ulrike Nitz. (2008) Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care 3:1, 17-20
CrossRef1143
Reiki Nishimura, Yasuhiro Okumura, Nobuyuki Arima. (2008) Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 15:1, 57-64
CrossRef1144
Danielle M. Doyle, Kathy D. Miller. (2008) Development of new targeted therapies for breast cancer. Breast Cancer 15:1, 49-56
CrossRef1145
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef1146
Christian Jackisch, Josef Rüschoff, Axel Ullrich. (2008) Development of Targeted Therapies in ErbB2-Positive Breast Cancer. Breast Care 3:1, 3-6
CrossRef1147
Steven M Ewer, Michael S Ewer. (2008) Cardiotoxicity Profile of Trastuzumab. Drug Safety 31:6, 459-467
CrossRef1148
Julio Caballero, Michael Fernández, Mario Saavedra, Fernando D. González-Nilo. (2008) 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases’ inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. Bioorganic & Medicinal Chemistry 16:2, 810-821
CrossRef1149
Stephen E. Jones. (2008) Considerations in treatment choice for metastatic breast cancer. Breast Cancer 15:1, 35-39
CrossRef1150
Sharon Marsh, Michael S Phillips. (2008) Integrating pharmacogenomics into oncology clinical practice. Expert Review of Clinical Pharmacology 1:1, 73-80
CrossRef1151
Michael S. Gee, Rabi Upadhyay, Henry Bergquist, Ralph Weissleder, Lee Josephson, Umar Mahmood. (2007) Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. International Journal of Cancer 121:11, 2492-2500
CrossRef1152
Pankaj Singhal, Nana E Tchabo, Kunle Odunsi. (2007) Immunologic markers of cancer progression and prognosis. Expert Opinion on Medical Diagnostics 1:4, 439-450
CrossRef1153
Tammy F Chu, Maria A Rupnick, Risto Kerkela, Susan M Dallabrida, David Zurakowski, Lisa Nguyen, Kathleen Woulfe, Elke Pravda, Flavia Cassiola, Jayesh Desai, Suzanne George, Jeffrey A Morgan, David M Harris, Nesreen S Ismail, Jey-Hsin Chen, Frederick J Schoen, Annick D Van den Abbeele, George D Demetri, Thomas Force, Ming Hui Chen. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet 370:9604, 2011-2019
CrossRef1154
Kitty Pavlakis, Panteleimon Kountourakis, Efstathios Stathopoulos, Amanda Psyrri, Dimitra Rontogianni, Maria Kafousi, Maria Derivianaki, Nikolaos Xiros, Dimitrios Pectasides, Theofanis Economopoulos. (2007) Her-2 Protein Expression, Cellular Localization, and Gene Amplification in Colorectal Carcinoma. Applied Immunohistochemistry & Molecular Morphology 15:4, 441-445
CrossRef1155
Xiaoyun Cheng, Mien-Chie Hung. (2007) Breast cancer brain metastases. Cancer and Metastasis Reviews 26:3-4, 635-643
CrossRef1156
Marzia B. Gariboldi, Raffaella Ravizza, Roberta Molteni, Domenico Osella, Elisabetta Gabano, Elena Monti. (2007) Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Letters 258:2, 181-188
CrossRef1157
Patrick J Perik, Maarten Alexander de Korte, Dirk J van Veldhuisen, Jourik A Gietema, Dirk T Sleijfer, Elisabeth GE de Vries. (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7:12, 1763-1771
CrossRef1158
C De Lorenzo, F Troise, V Cafaro, G D'Alessio. (2007) Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. British Journal of Cancer 97:10, 1354-1360
CrossRef1159
Paul M. Armistead, Jason Salganick, Jae S. Roh, Dejka M. Steinert, Shreyaskumar Patel, Mark Munsell, Adel K. El-Naggar, Robert S. Benjamin, Wei Zhang, Jonathan C. Trent. (2007) Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma. Cancer 110:10, 2293-2303
CrossRef1160
Rupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, Karin Dieckmann, Ursula Pluschnig, Gabriela Altorjai, Margaretha Rudas, Robert M. Mader, Richard Poetter, Christoph C. Zielinski, Guenther G. Steger. (2007) Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. Journal of Neuro-Oncology 85:3, 311-317
CrossRef1161
Tao Yang, Min-Koo Choi, Fu-De Cui, Seung-Jin Lee, Suk-Jae Chung, Chang-Koo Shim, Dae-Duk Kim. (2007) Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells. Pharmaceutical Research 24:12, 2402-2411
CrossRef1162
Ying Chun Shen, Chiun Hsu, Ann Lii Cheng. (2007) Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology 2:4, 199-210
CrossRef1163
Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John Bishop. (2007) Trastuzumab not for ductal carcinoma in situ?. Anti-Cancer Drugs 18:10, 1231-1235
CrossRef1164
Z PALYIKREKK, M BAROK, J ISOLA, M TAMMI, J SZOLLOSI, P NAGY. (2007) Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. European Journal of Cancer 43:16, 2423-2433
CrossRef1165
H. Labrosse, B. Favier, J. Fayette. (2007) Pharmacologie des thérapeutiques ciblées. Oncologie 9:11, 773-777
CrossRef1166
Cynthia Frankel. (2007) Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient. Seminars in Oncology Nursing 23, S3-S9
CrossRef1167
Catalin S Buhimschi, Irina A Buhimschi. (2007) Proteomic biomarkers of adverse pregnancy outcome in preterm birth: a theranostics opportunity. Expert Review of Obstetrics & Gynecology 2:6, 743-753
CrossRef1168
James S. Welsh, Jeffrey P. Limmer. (2007) Image-Guided Hypofractionated Simultaneous In-Field Boost Breast IMRT: In Regard to Freedman et al. (Int J Radiat Oncol Biol Phys 2007;68:347–353). International Journal of Radiation Oncology*Biology*Physics 69:3, 962
CrossRef1169
Sean L. Petersen, Lai Wang, Asligul Yalcin-Chin, Lin Li, Michael Peyton, John Minna, Patrick Harran, Xiaodong Wang. (2007) Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis. Cancer Cell 12:5, 445-456
CrossRef1170
R TORRISI, N ROTMENSZ, V BAGNARDI, G VIALE, B CURTO, P DELLORTO, P VERONESI, A LUINI, C DALESSANDRO, A CARDILLO. (2007) HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. European Journal of Cancer 43:16, 2339-2344
CrossRef1171
Barbara Harkins, Charles E. Geyer. (2007) Overcoming Treatment Challenges in Advanced Breast Cancer. Seminars in Oncology Nursing 23, S10-S16
CrossRef1172
Edurne Arriola, Socorro Maria Rodriguez-Pinilla, Maryou B. K. Lambros, Robin L. Jones, Michelle James, Kay Savage, Ian E. Smith, Mitch Dowsett, Jorge S. Reis-Filho. (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Research and Treatment 106:2, 181-189
CrossRef1173
E. Ortega-Paino, J. Fransson, S. Ek, C. A. K. Borrebaeck. (2007) Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 111:3, 1617-1624
CrossRef1174
M M Moasser. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:46, 6577-6592
CrossRef1175
Sumanta Kumar Pal, Mark Pegram. (2007) HER2 targeted therapy in breast cancer...beyond Herceptin. Reviews in Endocrine and Metabolic Disorders 8:3, 269-277
CrossRef1176
C. Geier, M.G. Posch, R. Dietz, A.N. Garratt, C. Özcelik. (2007) Molekulare Mechanismen der Kardiotoxizität von Tyrosinkinaseinhibitoren. Der Kardiologe 1:3, 209-216
CrossRef1177
E Lacaná, S Amur, P Mummanneni, H Zhao, F W Frueh. (2007) The Emerging Role of Pharmacogenomics in Biologics. Clinical Pharmacology & Therapeutics 82:4, 466-471
CrossRef1178
Tristin Abair, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7–8, 2007. Clinical Breast Cancer 7:10, 734-738
CrossRef1179
Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards. (2007) A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell 12:4, 395-402
CrossRef1180
P A Deverka, T Doksum, R J Carlson. (2007) Integrating Molecular Medicine into the US Health-care System: Opportunities, Barriers, and Policy Challenges. Clinical Pharmacology & Therapeutics 82:4, 427-434
CrossRef1181
Kazuo Ogawa, Tetsuko Kojima, Chinami Matsumoto, Satoshi Kamegai, Takuya Oyama, Yukari Shibagaki, Hiroshi Muramoto, Tetsuo Kawasaki, Hiroshi Fujinaga, Kozo Takahashi, Hiroaki Hikiami, Hirozo Goto, Chizuru Kiga, Keiichi Koizumi, Hiroaki Sakurai, Yutaka Shimada, Masahiro Yamamoto, Katsutoshi Terasawa, Shuichi Takeda, Ikuo Saiki. (2007) Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clinical Biochemistry 40:15, 1113-1121
CrossRef1182
Vishad Nabili, Jesse W. Tan, Sunita Bhuta, Joel A. Sercarz, Christian S. Head. (2007) Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy. Head & Neck 29:10, 907-912
CrossRef1183
Jennifer K. Litton, Yesim Eralp, Ana M. Gonzalez-Angulo, Kristine Broglio, Anne Uyei, Gabriel N. Hortobagyi, Banu Arun. (2007) Multifocal breast cancer in women ≤35 years old. Cancer 110:7, 1445-1450
CrossRef1184
Daphne R. Friedman, Amy P. Abernethy. (2007) <I>REVIEW</I>. Progress in Palliative Care 15:5, 225-232
CrossRef1185
Arash Naeim, Rishi Sawhney, Catherine H. MacLean, Homayoon Sanati. (2007) Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. Journal of the American Geriatrics Society 55, S258-S269
CrossRef1186
Mikael Persson, Igor Sivaev, Karl Johan Winberg, Lars Gedda, Per-Uno Malmström, Vladimir Tolmachev. (2007) In Vitro Evaluation of Two Polyhedral Boron Anion Derivatives as Linkers for Attachment of Radioiodine to the Anti-HER2 Monoclonal Antibody Trastuzumab. Cancer Biotherapy & Radiopharmaceuticals 22:5, 585-596
CrossRef1187
Filippo G. Giancotti. (2007) Targeting integrin β4 for cancer and anti-angiogenic therapy. Trends in Pharmacological Sciences 28:10, 506-511
CrossRef1188
T. Mieghem, K. Leunen, N. Pochet, B. Moor, F. Smet, F. Amant, P. Berteloot, D. Timmerman, I. Vanden Bempt, R. Drijkoningen, H. Wildiers, R. Paridaens, A. Smeets, W. Hendrickx, E. Limbergen, M. R. Christiaens, I. Vergote, P. Neven. (2007) Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment 106:1, 127-133
CrossRef1189
Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment 105:3, 319-326
CrossRef1190
C Massard, J-J Voigt, A Laplanche, S Culine, A Lortholary, R Bugat, C Theodore, F Priou, M-C Kaminsky, T Lesimple, X Pivot, B Coudert, J-Y Douillard, Y Merrouche, K Fizazi. (2007) Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. British Journal of Cancer
CrossRef1191
Shaheenah Dawood, Ana M. Gonzalez-Angulo, Florentia Peintinger, Kristine Broglio, William F. Symmans, Shu-Wan Kau, Rabiul Islam, Gabriel N. Hortobagyi, Aman U. Buzdar. (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer 110:6, 1195-1200
CrossRef1192
Feng Guo, Stephen P. Letrent, Amarnath Sharma. (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemotherapy and Pharmacology 60:6, 799-809
CrossRef1193
Stefan Engelhardt. (2007) Alternative signaling: cardiomyocyte β1-adrenergic receptors signal through EGFRs. Journal of Clinical Investigation 117:9, 2396-2398
CrossRef1194
Min A Kim, Eun Ji Jung, Hye Seung Lee, Hee Eun Lee, Yoon Kyung Jeon, Han-Kwang Yang, Woo Ho Kim. (2007) Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Human Pathology 38:9, 1386-1393
CrossRef1195
Gaston Demonty. (2007) Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence. Women's Health 3:5, 523-528
CrossRef1196
Ruoyu Ni, Anna Marie Mulligan, Cherry Have, Frances P. O??Malley. (2007) PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer. Applied Immunohistochemistry & Molecular Morphology 15:3, 316-324
CrossRef1197
D.A. Cameron. (2007) Herceptin – from bedside to bench to clinic?. European Journal of Cancer Supplements 5:5, 372-374
CrossRef1198
Wenfang Shi, Cunye Qu, Qijun Qian. (2007) Trends in therapeutic monoclonal antibodies of cancer. Expert Opinion on Therapeutic Patents 17:9, 1047-1059
CrossRef1199
Maria Savino, Maria Garrubba, Paola Parrella, Filomena Baorda, Massimiliano Copetti, Roberto Murgo, Leopoldo Zelante, Massimo Carella, Vanna Maria Valori, Stefano Angelo Santini. (2007) Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer. Clinica Chimica Acta 384:1-2, 52-56
CrossRef1200
Gerald M Higa, Jame Abraham. (2007) Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy 7:9, 1183-1192
CrossRef1201
Jin DING, Yun FENG, Hong-yang WANG. (2007) From cell signaling to cancer therapy. Acta Pharmacologica Sinica 28:9, 1494-1498
CrossRef1202
Zhenping ZHU. (2007) Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacologica Sinica 28:9, 1476-1493
CrossRef1203
Valéry Renard, Dana R. Leach. (2007) Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 25, B17-B23
CrossRef1204
Louis M. Weiner. (2007) Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews Cancer 7:9, 701-706
CrossRef1205
Erika Matos, Tanja Čufer. (2007) Adjuvant treatment of breast cancer patients with trastuzumab. Radiology and Oncology 41:3, 115-122
CrossRef1206
Harold J. Burstein, Aparna Keshaviah, Ari D. Baron, Ronald D. Hart, Rosemary Lambert-Falls, P. Kelly Marcom, Rebecca Gelman, Eric P. Winer. (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 110:5, 965-972
CrossRef1207
Stephen K. Chia, Caroline H. Speers, Yulia D'yachkova, Anna Kang, Suzanne Malfair-Taylor, Jeff Barnett, Andy Coldman, Karen A. Gelmon, Susan E. O'Reilly, Ivo A. Olivotto. (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:5, 973-979
CrossRef1208
Evan Y Yu, David A Mankoff. (2007) Positron emission tomography imaging as a cancer biomarker. Expert Review of Molecular Diagnostics 7:5, 659-672
CrossRef1209
A MILANO, F LONGO, M BASILE, R IAFFAIOLI, F CAPONIGRO. (2007) Recent advances in the treatment of salivary gland cancers: Emphasis on molecular targeted therapy. Oral Oncology 43:8, 729-734
CrossRef1210
Louis M. Weiner. (2007) Emerging concepts in monocloal antibody therapy. European Journal of Cancer Supplements 5:5, 442-443
CrossRef1211
Michael S. Ewer. (2007) The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight. European Journal of Cancer 43:14, 2024-2025
CrossRef1212
M.A. de Korte, E.G.E. de Vries, M.N. Lub-de Hooge, P.L. Jager, J.A. Gietema, W.T.A. van der Graaf, W.J. Sluiter, D.J. van Veldhuisen, T.M. Suter, D.T. Sleijfer, P.J. Perik. (2007) 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. European Journal of Cancer 43:14, 2046-2051
CrossRef1213
Yang Song, George Y. H. Chi. (2007) A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26:19, 3535-3549
CrossRef1214
B Spänkuch, E Kurunci-Csacsko, M Kaufmann, K Strebhardt. (2007) Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26:39, 5793-5807
CrossRef1215
Amy Lin, Hope S. Rugo. (2007) The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations. Current Treatment Options in Oncology 8:1, 47-60
CrossRef1216
Jos Jonkers, Patrick W. B. Derksen. (2007) Modeling Metastatic Breast Cancer in Mice. Journal of Mammary Gland Biology and Neoplasia 12:2-3, 191-203
CrossRef1217
Sabine C Linn, Jos Jonkers. (2007) Treating the genetic make-up of breast cancer: a new fashion?. Expert Review of Anticancer Therapy 7:8, 1065-1067
CrossRef1218
Stephanie Roessler, Anuradha Budhu, Xin Wei Wang. (2007) Future of molecular profiling of human hepatocellular carcinoma. Future Oncology 3:4, 429-439
CrossRef1219
Mathias Lidgren, Nils Wilking, Bengt Jönsson, Clas Rehnberg. (2007) Health related quality of life in different states of breast cancer. Quality of Life Research 16:6, 1073-1081
CrossRef1220
Alice A Robinson, William J Watson, Kimberly K Leslie. (2007) Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. The Lancet Oncology 8:8, 738-743
CrossRef1221
P. Harter, A. Bois. (2007) Supportivmaßnahmen in der gynäkologischen Onkologie. Der Gynäkologe 40:8, 629-641
CrossRef1222
Maryou B.K. Lambros, Rachael Natrajan, Jorge S. Reis-Filho. (2007) Chromogenic and fluorescent in situ hybridization in breast cancer. Human Pathology 38:8, 1105-1122
CrossRef1223
Hongtao Zhang, Alan Berezov, Qiang Wang, Geng Zhang, Jeffrey Drebin, Ramachandran Murali, Mark I. Greene. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. Journal of Clinical Investigation 117:8, 2051-2058
CrossRef1224
Heather L McArthur, Clifford A Hudis. (2007) Has first-line therapy had an impact on general outcome in metastatic breast cancer?. Future Oncology 3:4, 411-418
CrossRef1225
Georgios Giamas, Justin Stebbing, Constantinos E Vorgias, Uwe Knippschild. (2007) Protein kinases as targets for cancer treatment. Pharmacogenomics 8:8, 1005-1016
CrossRef1226
Debu Tripathy, Debu Tripathy. (2007) 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. Clinical Breast Cancer 7:9, 660-669
CrossRef1227
E. D. Rossmann, A. Liljegren, J. Bergh. (2007) Male breast cancer – how to treat?. Breast Cancer Online 10:08,
CrossRef1228
Dany Gholam, Amale Chebib, Dominique Hauteville, Marie-Pierre Bralet, Claude Jasmin. (2007) Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anti-Cancer Drugs 18:7, 835-837
CrossRef1229
Louis P. Garrison, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck, Edith A. Perez. (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:3, 489-498
CrossRef1230
Per E. Lønning, Jürgen Geisler. (2007) Aromatase inhibitors—Socioeconomical issues. The Journal of Steroid Biochemistry and Molecular Biology 106:1-5, 55-61
CrossRef1231
S. Pruthi, K. R. Brandt, A. C. Degnim, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, G. K. Dy, J. N. Ingle. (2007) A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis. Mayo Clinic Proceedings 82:8, 999-1012
CrossRef1232
Hudis, Clifford A., . (2007) Trastuzumab — Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine 357:1, 39-51
Full Text1233
Yoshikazu Nakaoka, Keigo Nishida, Masahiro Narimatsu, Atsunori Kamiya, Takashi Minami, Hirofumi Sawa, Katsuya Okawa, Yasushi Fujio, Tatsuya Koyama, Makiko Maeda, Manami Sone, Satoru Yamasaki, Yuji Arai, Gou Young Koh, Tatsuhiko Kodama, Hisao Hirota, Kinya Otsu, Toshio Hirano, Naoki Mochizuki. (2007) Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. Journal of Clinical Investigation 117:7, 1771-1781
CrossRef1234
Satoko Morohashi, Hiroki Odagiri, Hajime Morohashi, Yutaka Kimura, Mutsuo Sasaki. (2007) Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab. Breast Cancer 14:3, 297-301
CrossRef1235
Christian Widakowich, Evandro de Azambuja, Thierry Gil, Fatima Cardoso, Phuong Dinh, Ahmad Awada, Martine Piccart-Gebhart. (2007) Molecular targeted therapies in breast cancer: Where are we now?. The International Journal of Biochemistry & Cell Biology 39:7-8, 1375-1387
CrossRef1236
Zhiming Mai, George L. Blackburn, Jin-Rong Zhou. (2007) Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Molecular Carcinogenesis 46:7, 534-542
CrossRef1237
Filippo Montemurro, Massimo Aglietta. (2007) Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. Nature Clinical Practice Oncology 4:7, 398-399
CrossRef1238
Jason Sakamoto, Ananth Annapragada, Paolo Decuzzi, Mauro Ferrari. (2007) Antibiological barrier nanovector technology for cancer applications. Expert Opinion on Drug Delivery 4:4, 359-369
CrossRef1239
Anne-Laure Goenaga, Yu Zhou, Christine Legay, Houcine Bougherara, Lan Huang, Bin Liu, Daryl C. Drummond, Dmitri B. Kirpotin, Christian Auclair, James D. Marks, Marie-Alix Poul. (2007) Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Molecular Immunology 44:15, 3777-3788
CrossRef1240
M. Dietel, I. O. Ellis, H. Höfler, H. Kreipe, H. Moch, A. Dankof, K. Kölble, G. Kristiansen. (2007) Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Archiv 451:1, 19-25
CrossRef1241
I Craig Henderson, Vinona Bhatia. (2007) Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Review of Anticancer Therapy 7:7, 919-943
CrossRef1242
Neal T. Holm, Kerry Byrnes, Benjamin D.L. Li, Richard H. Turnage, Fleurette Abreo, James M. Mathis, Quyen D. Chu. (2007) Elevated Levels of Chemokine Receptor CXCR4 in HER-2 Negative Breast Cancer Specimens Predict Recurrence. Journal of Surgical Research 141:1, 53-59
CrossRef1243
Lisa M. Davis, Cole Harris, Lei Tang, Patti Doherty, Peter Hraber, Yumiko Sakai, Therese Bocklage, Katie Doeden, Bryan Hall, John Alsobrook, Ian Rabinowitz, Thomas M. Williams, John Hozier. (2007) Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma. The Journal of Molecular Diagnostics 9:3, 327-336
CrossRef1244
R. Sánchez-Escribano Morcuende, J. E. Alés-Martínez, P. M. Aramburo González. (2007) Low dose Gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clinical and Translational Oncology 9:7, 459-464
CrossRef1245
Cecilia Nistic??, Emilio Bria, Federica Cuppone, Monica Fornier, Isabella Sperduti, Armando Carpino, Andrea Pace, Francesco Cognetti, Edmondo Terzoli. (2007) Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. Anti-Cancer Drugs 18:6, 687-692
CrossRef1246
Gustavo Helguera, José A. Rodríguez, Tracy R. Daniels, Manuel L. Penichet. (2007) Long-term immunity elicited by antibody–cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunology, Immunotherapy 56:9, 1507-1512
CrossRef1247
Kartik Mohanty, Asim Saha, Smarajit Pal, Palash Mallick, Sunil K. Chatterjee, Kenneth A. Foon, Malaya Bhattacharya-Chatterjee. (2007) Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Research and Treatment 104:1, 1-11
CrossRef1248
Inka Seil, Claudia Frei, Holger Sültmann, Shirley K. Knauer, Knut Engels, Elke Jäger, Kurt Zatloukal, Michael Pfreundschuh, Alexander Knuth, Yao Tseng-Chen, Achim A. Jungbluth, Roland H. Stauber, Dirk Jäger. (2007) The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. International Journal of Cancer 120:12, 2635-2642
CrossRef1249
Akiko Hori, Taro Shibata, Masahiro Kami, Eiji Kusumi, Hiroto Narimatsu, Yukiko Kishi, Naoko Murashige, Kazuhiko Mori. (2007) Age disparity between a cancer population and participants in clinical trials submitted as a new drug application of anticancer drugs in Japan. Cancer 109:12, 2541-2546
CrossRef1250
Christian Zuppinger, Francesco Timolati, Thomas M. Suter. (2007) Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovascular Toxicology 7:2, 61-66
CrossRef1251
Luca Gianni, Emanuela Salvatorelli, Giorgio Minotti. (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology 7:2, 67-71
CrossRef1252
Billy Chen, Xuyang Peng, Laura Pentassuglia, Chee Chew Lim, Douglas B. Sawyer. (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovascular Toxicology 7:2, 114-121
CrossRef1253
Patricia A. Fetsch, Andrea Abati. (2007) The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagnostic Cytopathology 35:6, 319-328
CrossRef1254
Charles Swanton, Michela Marani, Olivier Pardo, Patricia H. Warne, Gavin Kelly, Erik Sahai, Frédéric Elustondo, Jenny Chang, Jillian Temple, Ahmed A. Ahmed, James D. Brenton, Julian Downward, Barbara Nicke. (2007) Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell 11:6, 498-512
CrossRef1255
G. Sauer, N. Schneiderhan-Marra, C. Kurzeder, R. Kreienberg, T. Joos, H. Deissler. (2007) Molekulares Staging und Vorhersage von Therapieansprechen beim Mammakarzinom. Der Gynäkologe 40:6, 424-430
CrossRef1256
Tsipi Ben-Kasus, Bilha Schechter, Michael Sela, Yosef Yarden. (2007) Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology 1:1, 42-54
CrossRef1257
A PRAT. (2007) Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica 129:5, 184-193
CrossRef1258
Tao Zuo, Lizhong Wang, Carl Morrison, Xing Chang, Huiming Zhang, Weiquan Li, Yan Liu, Yin Wang, Xingluo Liu, Michael W.Y. Chan, Jin-Qing Liu, Richard Love, Chang-gong Liu, Virginia Godfrey, Rulong Shen, Tim H.-M. Huang, Tianyu Yang, Bae Keun Park, Cun-Yu Wang, Pan Zheng, Yang Liu. (2007) FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene. Cell 129:7, 1275-1286
CrossRef1259
Petros I. Rafailidis, Ourania K. Kakisi, Konstantinos Vardakas, Matthew E. Falagas. (2007) Infectious complications of monoclonal antibodies used in cancer therapy. Cancer 109:11, 2182-2189
CrossRef1260
A M Feldman, W J Koch, T L Force. (2007) Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences. Clinical Pharmacology & Therapeutics 81:6, 887-892
CrossRef1261
C. Kurzeder, G. Sauer, R. Kreienberg. (2007) Zielgerichtete Therapien. Der Gynäkologe 40:6, 448-454
CrossRef1262
S. R. D. Johnston. (2007) Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer. Breast Cancer Online 10:06,
CrossRef1263
Michela Maur, Cristiana Sessa. (2007) Review: new biological insights in early clinical studies. Hematological Oncology 25:2, 53-57
CrossRef1264
M.R. Raspollini, G.L. Taddei. (2007) Tumor markers in ovarian carcinoma. International Journal of Gynecology & Obstetrics 97:3, 175-181
CrossRef1265
L. G. Estévez, M. Martín, E. Alba, R. Colomer, F. Lobo, A. Lluch, E. Adrover, J. Albanell, A. Barnadas, J. García-Mata, A. Llombart, M. Muñoz, C. Rodríguez, P. Sánchez-Rovira, M. A. Seguí, I. Tusquets. (2007) Current controversies in the management of early breast cancer. Clinical and Translational Oncology 9:6, 375-384
CrossRef1266
R Nahta, F J Esteva. (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:25, 3637-3643
CrossRef1267
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, T. A. Waldmann. (2007) Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proceedings of the National Academy of Sciences 104:20, 8444-8448
CrossRef1268
Stephen R. Mattarollo, Tony Kenna, Mie Nieda, Andrew J. Nicol. (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunology, Immunotherapy 56:8, 1285-1297
CrossRef1269
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, R. Schiff. (2007) Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. JNCI Journal of the National Cancer Institute 99:9, 694-705
CrossRef1270
Thomas Force, Daniela S. Krause, Richard A. Van Etten. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 7:5, 332-344
CrossRef1271
T Macarulla, J Tabernero. 2007. Safety of targeted therapies. , 141-155.
CrossRef1272
Mitch Dowsett, Wedad M Hanna, Mark Kockx, Frederique Penault-Llorca, Josef Rüschoff, Thorsten Gutjahr, Kai Habben, Marc J van de Vijver. (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology 20:5, 584-591
CrossRef1273
Michael J. Duffy. (2007) Role of tumor markers in patients with solid cancers: A critical review. European Journal of Internal Medicine 18:3, 175-184
CrossRef1274
Don X. Nguyen, Joan Massagué. (2007) Genetic determinants of cancer metastasis. Nature Reviews Genetics 8:5, 341-352
CrossRef1275
Barbara S. Craft, Gabriel N. Hortobagyi, Stacy L. Moulder. (2007) Adjuvant Biologic Therapy for Breast Cancer. The Cancer Journal 13:3, 156-161
CrossRef1276
Robert A. Wolff. (2007) Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy. The Cancer Journal 13:3, 175-184
CrossRef1277
Laura Pentassuglia, Francesco Timolati, Franziska Seifriz, Kaisaier Abudukadier, Thomas M. Suter, Christian Zuppinger. (2007) Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Experimental Cell Research 313:8, 1588-1601
CrossRef1278
Hossein Borghaei, R. Katherine Alpaugh, Patricia Bernardo, Irma E. Palazzo, Janice P. Dutcher, Usha Venkatraj, William C. Wood, Lori Goldstein, Louis M. Weiner. (2007) Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy 30:4, 455-467
CrossRef1279
Raymond Ng, Michael D Green. (2007) Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opinion on Drug Safety 6:3, 315-321
CrossRef1280
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, J. Baselga. (2007) Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute 99:8, 628-638
CrossRef1281
Simon Chowdhury, Lisa M. Pickering, Paul A. Ellis. (2007) Lapatinib: a novel dual tyrosine kinase inhibitor. Targeted Oncology 2:2, 107-112
CrossRef1282
T NGUYEN, L ABREY. (2007) Brain Metastases: Old Problem, New Strategies. Hematology/Oncology Clinics of North America 21:2, 369-388
CrossRef1283
Nicholas J. Robert, Anne M. Favret. (2007) HER2-Positive Advanced Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 293-302
CrossRef1284
Hiroji Iwata. (2007) Perspective of trastuzumab treatment. Breast Cancer 14:2, 150-155
CrossRef1285
Lisa A. Newman, Eleftherios P. Mamounas. (2007) Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project. Surgical Clinics of North America 87:2, 279-305
CrossRef1286
Yoshinori Ito, Nahomi Tokudome, Tsutomu Sugihara, Shunji Takahashi, Kiyohiko Hatake. (2007) Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Cancer 14:2, 156-162
CrossRef1287
Jeffrey Peppercorn, Emily Blood, Eric Winer, Ann Partridge. (2007) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109:7, 1239-1246
CrossRef1288
G ISMAEL, D ROSA, E DEAZAMBUJA, S BRAGA, M PICCARTGEBHART. (2007) Trastuzumab (Herceptin) for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 239-256
CrossRef1289
Laura Biganzoli, Wederson M. Claudino, Marta Pestrin, Daniele Pozzessere, Angelo Di Leo. (2007) Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. Critical Reviews in Oncology/Hematology 62:1, 1-8
CrossRef1290
Hannah M Simonds, David Miles. (2007) Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opinion on Biological Therapy 7:4, 487-491
CrossRef1291
Larry E. Morrison, Susan S. Jewell, Lydia Usha, Beth A. Blondin, Ruta D. Rao, Bita Tabesh, Matthew Kemper, Marta Batus, John S. Coon. (2007) Effects ofERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes, Chromosomes and Cancer 46:4, 397-405
CrossRef1292
Jennifer Klem, Zachary Moore, Susan Peck, Debu Tripathy, Joyce O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, December 2006. Clinical Breast Cancer 7:7, 535-542
CrossRef1293
Rupert Bartsch, Catharina Wenzel, Gabriela Altorjai, Ursula Pluschnig, Thomas Bachleitner-Hoffmann, Gottfried J. Locker, Margaretha Rudas, Robert Mader, Christoph C. Zielinski, Guenther G. Steger. (2007) Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Research and Treatment 102:3, 375-381
CrossRef1294
Dong Il Park, Mun Su Kang, Suk Joong Oh, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Won Kon Han, Hungdai Kim, Seung Ho Ryu, Antonia R. Sepulveda. (2007) HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. International Journal of Colorectal Disease 22:5, 491-497
CrossRef1295
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Hideyuki Yasuno, Yoichiro Moriya, Kazushige Mori, Yutaka Tanaka. (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology 59:6, 795-805
CrossRef1296
F. Mancia, S. Brenner-Morton, R. Siegel, Z. Assur, Y. Sun, I. Schieren, M. Mendelsohn, R. Axel, W. A. Hendrickson. (2007) Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. Proceedings of the National Academy of Sciences 104:11, 4303-4308
CrossRef1297
S H Choi, J M Mendrola, M A Lemmon. (2007) EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26:11, 1567-1576
CrossRef1298
M.S. MANO, D.D. ROSA, E. AZAMBUJA, G. ISMAEL, S. BRAGA, V. D?HONDT, M. PICCART, A. AWADA. (2007) Current management of ovarian carcinosarcoma. International Journal of Gynecological Cancer 17:2, 316-324
CrossRef1299
Xiaoyan Wang, Gregory T. MacLennan, Antonio Lopez-Beltran, Liang Cheng. (2007) Small Cell Carcinoma of the Urinary Bladder???Histogenesis, Genetics, Diagnosis, Biomarkers, Treatment, and Prognosis. Applied Immunohistochemistry & Molecular Morphology 15:1, 8-18
CrossRef1300
William C. Powell, David G. Hicks, Nichole Prescott, Shannon M. Tarr, Simas Laniauskas, Tristin Williams, Sarah Short, James Pettay, Raymond B. Nagle, David J. Dabbs, Katherine M. Scott, Richard W. Brown, Thomas Grogan, Patrick C. Roche, Raymond R. Tubbs. (2007) A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility. Applied Immunohistochemistry & Molecular Morphology 15:1, 94-102
CrossRef1301
M.V. Seiden, H.A. Burris, U. Matulonis, J.B. Hall, D.K. Armstrong, J. Speyer, J.D.A. Weber, F. Muggia. (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecologic Oncology 104:3, 727-731
CrossRef1302
David A. Katz. 2007. Overview of Pharmacogenetics. .
CrossRef1303
Rebecca L. Olin, Shashank S. Desai, Kevin Fox, Rebecca Davidson. (2007) Non-Myopathic Cardiac Events in Two Patients Treated with Trastuzumab. The Breast Journal 13:2, 211-212
CrossRef1304
Rosa Giuliani, Virginie Durbecq, Angelo Di Leo, Marianne Paesmans, Denis Larsimont, Jean-Yves Leroy, Marleen Borms, Anita Vindevoghel, Guy Jerusalem, Veronique D’Hondt, Luc Dirix, Jean-Luc Canon, Vincent Richard, Veronique Cocquyt, Françoise Majois, Michel Reginster, Jan Demol, Jean-Pierre Kains, Paul Delree, Carine Keppens, Christos Sotiriou, Martine J. Piccart, Fatima Cardoso. (2007) Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). European Journal of Cancer 43:4, 725-735
CrossRef1305
Joseph Menczer, Letizia Schreiber, Esther Berger, Abraham Golan, Tally Levy. (2007) Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. Gynecologic Oncology 104:3, 675-679
CrossRef1306
Alper Çelik, I. Ebru Arabacı, Unal Erkorkmaz, Suat Kutun, Sabahattin Aslan, Isın Pak, Abdullah Çetin. (2007) Immunohistochemical determination and grading of CerbB-2 expression in breast cancer: correlation with interpectoral, apical nodal involvement and other prognostic factors. Central European Journal of Medicine 2:1, 1-11
CrossRef1307
Yiwen Li, Zhenping Zhu. (2007) Monoclonal antibody-based therapeutics for leukemia. Expert Opinion on Biological Therapy 7:3, 319-330
CrossRef1308
Bohuslav Melichar, Rebecca Patenia, Stacie Gallardo, Karolina Melicharová, Wei Hu, Ralph S. Freedman. (2007) Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecologic Oncology 104:3, 707-713
CrossRef1309
B. Poncet, T. Bachelot, C. Colin, H. Orfeuvre, C. Ganne, P.Y. Péaud, J.P. Jacquin, B. Salles, J.D. Tigaud, I. Méchin-Crétinon, F. Maréchal, V. Trillet-Lenoir. (2007) Use of the Monoclonal Antibody Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2), Trastuzumab, in the Treatment of Metastatic Breast Cancer: A Cost-effectiveness Analysis. Clinical Oncology 19:2, 162-163
CrossRef1310
Mitsuharu Hanada, Toshihiro Noguchi, Takashi Yamaoka. (2007) Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Science 98:3, 447-454
CrossRef1311
P. Kelly Marcom, Claudine Isaacs, Lyndsay Harris, Zee Wang Wong, Aruna Kommarreddy, Nellie Novielli, Gretchen Mann, Yu Tao, Matthew J. Ellis. (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Research and Treatment 102:1, 43-49
CrossRef1312
D Pils, A Pinter, J Reibenwein, A Alfanz, P Horak, B C Schmid, L Hefler, R Horvat, A Reinthaller, R Zeillinger, M Krainer. (2007) In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. British Journal of Cancer 96:3, 485-491
CrossRef1313
Dorte A. Olsen, Birthe Østergaard, Susanne Bokmand, Peter A. Wamberg, Erik H. Jakobsen, Ivan Brandslund. (2007) HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clinical Chemistry and Laboratory Medicine 45:2, 177-182
CrossRef1314
Thomas YK Lau, Darran P O’Connor, Donal J Brennan, Michael J Duffy, Stephen R Pennington, William M Gallagher. (2007) Breast cancer proteomics: clinical perspectives. Expert Opinion on Biological Therapy 7:2, 209-219
CrossRef1315
Aarati Ranganathan, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 2006. Clinical Breast Cancer 7:6, 445-454
CrossRef1316
Gurusher Singh Panjrath, Diwakar Jain. (2007) Trastuzumab-induced cardiac dysfunction. Nuclear Medicine Communications 28:2, 69-73
CrossRef1317
Gianluigi Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Francesco Cognetti. (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Current Opinion in Obstetrics and Gynecology 19:1, 56-62
CrossRef1318
Suresh Ramalingam, Chandra P Belani. (2007) Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets 11:2, 245-257
CrossRef1319
Filippo Montemurro, Giorgio Valabrega, Massimo Aglietta. (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy 7:2, 257-268
CrossRef1320
Kalliopi P. Siziopikou, Melody Cobleigh. (2007) The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. The Breast 16:1, 104-107
CrossRef1321
Frances M. Palmieri, Edith A. Perez. (2007) Managing High-Risk Breast Cancer. Seminars in Oncology Nursing 23:1, 29-36
CrossRef1322
Susan Moore, Melody A. Cobleigh. (2007) Targeting Metastatic and Advanced Breast Cancer. Seminars in Oncology Nursing 23:1, 37-45
CrossRef1323
Samuel Troadec, Myriam Chentouf, Martine C??rutti, Brigitte Nguyen, Daniel Olive, C??dric B??s, Thierry Chard??s. (2007) In Vitro Antitumoral Activity of Baculovirus-expressed Chimeric Recombinant Anti-CD4 Antibody 13B8.2 on T-cell Lymphomas. Journal of Immunotherapy 30:2, 190-202
CrossRef1324
Xiaoyan Wang, Timothy D Jones, Shaobo Zhang, John N Eble, David G Bostwick, Junqi Qian, Antonio Lopez-Beltran, Rodolfo Montironi, John J Harris, Liang Cheng. (2007) Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Modern Pathology 20:2, 175-182
CrossRef1325
Dianne S Hirsch, Wen Jin Wu. (2007) Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Review of Anticancer Therapy 7:2, 147-157
CrossRef1326
Qi Zhang, Guihua Chen, Xinyuan Liu, Qijun Qian. (2007) Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Research 17:2, 89-99
CrossRef1327
Max S. Mano, Daniela D. Rosa, Evandro De Azambuja, Gustavo F.V. Ismael, Virginie Durbecq. (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treatment Reviews 33:1, 64-77
CrossRef1328
S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, G. Halmos. (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proceedings of the National Academy of Sciences 104:6, 1943-1946
CrossRef1329
Giampietro Gasparini, Massimo Gion, Luigi Mariani, Paola Papaldo, Diana Crivellari, Gianfranco Filippelli, Alessandro Morabito, Vittorio Silingardi, Francesco Torino, Antonella Spada, Matelda Zancan, Livia Sio, Antonio Caputo, Francesco Cognetti, Antonio Lambiase, Dino Amadori. (2007) Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Research and Treatment 101:3, 355-365
CrossRef1330
Anna K. H. Hirsch, Felix R. Fischer, François Diederich. (2007) Molekulare Erkennung von Phosphaten in der Strukturbiologie. Angewandte Chemie 119:3, 342-357
CrossRef1331
Anna K. H. Hirsch, Felix R. Fischer, François Diederich. (2007) Phosphate Recognition in Structural Biology. Angewandte Chemie International Edition 46:3, 338-352
CrossRef1332
Pauline Athanassiadou, Dimitra Grapsa. (2007) Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature. Cancer and Metastasis Reviews 25:4, 507-519
CrossRef1333
Canfeza Sezgin, Ender Kurt, Turkan Evrensel, Necmettin Ozdemir, Osman Manavoglu, Erdem Goker. (2007) Efficacy of Lower Dose Capecitabine in Patients with Metastatic Breast Cancer and Factors Influencing Therapeutic Response and Outcome. Southern Medical Journal 100:1, 27-32
CrossRef1334
Hiroo NAKAJIMA, Naruhiko MIZUTA, Ikuya FUJIWARA, Koichi SAKAGUCHI, Katsuhiko NAKATSUKASA, Aya KOBAYASHI. (2007) Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 32:4, 643-647
CrossRef1335
Pier Franco Conte, Carmelo Bengala, Valentina Guarneri. (2007) Controversies of chemotherapy for the treatment of metastatic breast cancer. European Journal of Cancer Supplements 5:1, 11-16
CrossRef1336
Sith Sathornsumetee, Kaitlyn A Vredenburgh, Kathryn P Lattimore, Jeremy N Rich. (2007) Malignant glioma drug discovery ? targeting protein kinases. Expert Opinion on Drug Discovery 2:1, 1-17
CrossRef1337
Kousaku Mimura, Koji Kono, Akihiro Takahashi, Yoshihiko Kawaguchi, Yoshiki Mizukami, Hideki Fujii. (2007) Vascular Endothelial Growth Factor Partially Inhibits the Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity of Human Monocytes. Oncology 72:3-4, 172-180
CrossRef1338
J Alasdair Millar, Michael J Millward. (2007) Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer. PharmacoEconomics 25:5, 429-442
CrossRef1339
Carmel S. Verrier, Kimberly Blackwell. 2007. Is There a Role for ErbB Dual Kinase Inhibition?. , 203-212.
CrossRef1340
Ai-Li Shiau, Yu-Ping Lin, Gia-Shing Shieh, Chih-Hau Su, Wen-Luan Wu, Yuh-Shyan Tsai, Chih-Wei Cheng, Ming-Derg Lai, Chao-Liang Wu. (2007) Development of a Conditionally Replicating Pseudorabies Virus for HER-2/neu-overexpressing Bladder Cancer Therapy. Molecular Therapy 15:1, 131-138
CrossRef1341
Stefan Aebi, Olivia Pagani. (2007) Treatment of Premenopausal Women with Early Breast Cancer. Drugs 67:10, 1393-1401
CrossRef1342
Joseph Menczer, Letizia Schreiber, Bernard Czernobilsky, Esther Berger, Abraham Golan, Tally Levy. (2007) Is Her-2/neu expressed in nonepithelial ovarian malignancies?. American Journal of Obstetrics and Gynecology 196:1, 79.e1-79.e4
CrossRef1343
Hans-Joachim Stemmler, Manfred Schmitt, Amina Willems, Helga Bernhard, Nadia Harbeck, Volker Heinemann. (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood???brain barrier. Anti-Cancer Drugs 18:1, 23-28
CrossRef1344
Edith A. Perez, Mansoina. Baweja. 2007. HER2-Positive Breast Cancer: Current Treatment Strategies. , 189-202.
CrossRef1345
C KAMILA, B JENNY, H PER, B JONAS. (2007) How to treat male breast cancer. The Breast 16, 147-154
CrossRef1346
Kayo MIZUTANI, Masayuki UMEMURA, Masayuki MIYAZAKI, Yasuo KUMAKURA, Yoshiaki KATO, Yuichi ANDO, Toshitaka NABESHIMA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:1, 23-28
CrossRef1347
Rupert Bartsch, Catharina Wenzel, Christoph C Zielinski, Guenther G Steger. (2007) HER-2-Positive Breast Cancer. BioDrugs 21:2, 69-77
CrossRef1348
Michael F Press, Heinz-Josef Lenz. (2007) EGFR, HER2 and VEGF Pathways. Drugs 67:14, 2045-2075
CrossRef1349
Michael Braun, Bettina Schlehe, Andree Faridi, Uwe Heindrichs, Christian Rudlowski. (2007) Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study. Breast Care 2:4, 227-233
CrossRef1350
Douglas W Ball. (2007) Medullary thyroid cancer: therapeutic targets and molecular markers. Current Opinion in Oncology 19:1, 18-23
CrossRef1351
Damien Downing. (2007) Herceptin madness. Journal of Nutritional and Environmental Medicine 16:1, 1-9
CrossRef1352
Peter H. Johnson, Francisco J. Esteva. (2007) The use of HER2 modulation in the adjuvant setting. Current Oncology Reports 9:1, 9-16
CrossRef1353
Susana M. Campos. 2007. Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. , 213-234.
CrossRef1354
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369:9555, 29-36
CrossRef1355
Maria Lambropoulou, Dimitrios Stefanou, George Alexiadis, Demetrio Tamiolakis, Grigorios Tripsianis, Ekaterini Chatzaki, Gerasimos P. Vandoros, Anastasia Kiziridou, Evropi Papadopoulou, Nikolas Papadopoulos. (2007) Cytoplasmic Expression of c-erb-B2 in Endometrial Carcinomas. Onkologie 30:10, 495-500
CrossRef1356
G.B. Fogarty, N.M. Conus, J. Chu, G. McArthur. (2007) Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. British Journal of Dermatology 156:1, 92-98
CrossRef1357
Alison K. Conlin, Andrew D. Seidman. (2007) Taxanes in breast cancer: An update. Current Oncology Reports 9:1, 22-30
CrossRef1358
Matti S Aapro, Pierfranco Conte, Emilio Esteban Gonz??lez, V??ronique Trillet-Lenoir. (2007) Oral Vinorelbine. Drugs 67:5, 657-667
CrossRef1359
Gloria Peiró, Francisco I. Aranda, Encarnal Adrover, María Niveiro, Cristina Alenda, Artemio Payá, Javier Seguí. (2007) Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance. Human Pathology 38:1, 26-34
CrossRef1360
Karin Rennstam, Göran Jönsson, Minna Tanner, Pär-Ola Bendahl, Johan Staaf, Anita I. Kapanen, Ritva Karhu, Bo Baldetorp, Åke Borg, Jorma Isola. (2007) Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genetics and Cytogenetics 172:2, 95-106
CrossRef1361
Uriel M. Malyankar. (2007) Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy. International Reviews of Immunology 26:3-4, 223-247
CrossRef1362
Vera J. Suman, Amylou Dueck, Daniel J. Sargent. 2007. Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. , 1-10.
CrossRef1363
Keisei TAKU, Narikazu BOKU. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 393-400
CrossRef1364
Maria Rosaria Raspollini, Gian Luigi Taddei. (2007) Cyclooxygenase-2: A novel target in human solid tumors. Current Oncology Reports 9:2, 96-101
CrossRef1365
Ricardo J. Gonzalez, Aman U. Buzdar, W. Fraser Symmans, Tina W. Yen, Kristine R. Broglio, Anthony Lucci, Francisco J. Esteva, Guosheng Yin, Henry M. Kuerer. (2007) Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). The Breast Journal 13:1, 72-75
CrossRef1366
Robert J. Schulz, Dirk L. J. Verellen, Colin G. Orton. (2007) Future developments in external beam radiotherapy will be unlikely to significantly improve treatment outcomes over those currently achieved with 3D-conformal and IMRT treatments. Medical Physics 34:8, 3123
CrossRef1367
Syed A Hussain, Daniel H Palmer, David Spooner, Daniel W Rea. (2007) Molecularly Targeted Therapeutics for Breast Cancer. BioDrugs 21:4, 215-224
CrossRef1368
Jennifer Laudadio, Denise I Quigley, Raymond Tubbs, Daynna J Wolff. (2007) HER2 testing: a review of detection methodologies and their clinical performance. Expert Review of Molecular Diagnostics 7:1, 53-64
CrossRef1369
Geyer, Charles E., Forster, John, Lindquist, Deborah, Chan, Stephen, Romieu, C. Gilles, Pienkowski, Tadeusz, Jagiello-Gruszfeld, Agnieszka, Crown, John, Chan, Arlene, Kaufman, Bella, Skarlos, Dimosthenis, Campone, Mario, Davidson, Neville, Berger, Mark, Oliva, Cristina, Rubin, Stephen D., Stein, Steven, Cameron, David, . (2006) Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 355:26, 2733-2743
Full Text1370
R. T. Chlebowski, G. L. Blackburn, C. A. Thomson, D. W. Nixon, A. Shapiro, M. K. Hoy, M. T. Goodman, A. E. Giuliano, N. Karanja, P. McAndrew, C. Hudis, J. Butler, D. Merkel, A. Kristal, B. Caan, R. Michaelson, V. Vinciguerra, S. Del Prete, M. Winkler, R. Hall, M. Simon, B. L. Winters, R. M. Elashoff. (2006) Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI Journal of the National Cancer Institute 98:24, 1767-1776
CrossRef1371
Nancy D. Doolittle, David M. Peereboom, Gregory A. Christoforidis, Walter A. Hall, Diane Palmieri, Penelope R. Brock, Kathleen C. M. Campbell, D. Thomas Dickey, Leslie L. Muldoon, Brian Patrick O’Neill, Darryl R. Peterson, Brad Pollock, Carole Soussain, Quentin Smith, Rose Marie Tyson, Edward A. Neuwelt. (2006) Delivery of chemotherapy and antibodies across the blood–brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the eleventh annual blood–brain barrier consortium meeting. Journal of Neuro-Oncology 81:1, 81-91
CrossRef1372
P LEARN, N KRISHNEGOWDA, J TALAMANTEZ, M KAHLENBERG. (2006) Compensatory Increases in Her-2/neu Activation in Response to EGFR Tyrosine Kinase Inhibition in Colon Cancer Cell Lines. Journal of Surgical Research 136:2, 227-231
CrossRef1373
Fiamma Buttitta, Fabio Barassi, Giuseppina Fresu, Lara Felicioni, Antonio Chella, Diego Paolizzi, Giuseppe Lattanzio, Simona Salvatore, Pier P. Camplese, Sandra Rosini, Teodorico Iarussi, Felice Mucilli, Rocco Sacco, Andrea Mezzetti, Antonio Marchetti. (2006) Mutational analysis of theHER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. International Journal of Cancer 119:11, 2586-2591
CrossRef1374
Debajit K. Biswas, J. Dirk Iglehart. (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-κB) signaling in breast cancer. Journal of Cellular Physiology 209:3, 645-652
CrossRef1375
F. Stenner-Liewen, A. Zippelius, B. C. Pestalozzi, A. Knuth. (2006) Molekular zielgerichtete Therapie. Der Chirurg 77:12, 1118-1125
CrossRef1376
Christina C. Spevak, Eun-Hee Park, Adam P. Geballe, Jerry Pelletier, Matthew S. Sachs. (2006) her-2 upstream open reading frame effects on the use of downstream initiation codons. Biochemical and Biophysical Research Communications 350:4, 834-841
CrossRef1377
B YOU, V TRILLETLENOIR. (2006) Thérapeutiques anticancéreuses ciblées. La Revue de Médecine Interne 27, S285-S288
CrossRef1378
Thierry Dervieux, Mohan V Bala. (2006) Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 7:8, 1175-1184
CrossRef1379
T Ishida, T Ishii, A Inagaki, H Yano, S Kusumoto, M Ri, H Komatsu, S Iida, H Inagaki, R Ueda. (2006) The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 20:12, 2162-2168
CrossRef1380
Yuji Komizu, Yoko Matsumoto, Ryuichi Ueoka. (2006) Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis. Bioorganic & Medicinal Chemistry Letters 16:23, 6131-6134
CrossRef1381
J CROWE, R PATRICK, L RYBICKI, P ESCOBAR, D WENG, G THOMASBUDD, R TUBBS, G PROCOP, D HICKS. (2006) A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. The Breast 15:6, 728-735
CrossRef1382
Nicholas W Choong, Ezra EW Cohen. (2006) Forthcoming receptor tyrosine kinase inhibitors. Expert Opinion on Therapeutic Targets 10:6, 793-797
CrossRef1383
Christopher Y. Thomas, Dan Theodorescu. (2006) Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology 24:5, 565-578
CrossRef1384
Axel Schulenburg, Herbert Ulrich-Pur, Dietmar Thurnher, Boban Erovic, Stefan Florian, Wolfgang R. Sperr, Peter Kalhs, Brigitte Marian, Friedrich Wrba, Christoph C. Zielinski, Peter Valent. (2006) Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 107:10, 2512-2520
CrossRef1385
Michael Davies, Bryan Hennessy, Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, 2243-2261
CrossRef1386
Mitsuo Satoh, Shigeru Iida, Kenya Shitara. (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opinion on Biological Therapy 6:11, 1161-1173
CrossRef1387
Fruma Yehiely, Jose V. Moyano, Joseph R. Evans, Torsten O. Nielsen, Vincent L. Cryns. (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends in Molecular Medicine 12:11, 537-544
CrossRef1388
Robin L Jones, Charles Swanton, Michael S Ewer. (2006) Anthracycline cardiotoxicity. Expert Opinion on Drug Safety 5:6, 791-809
CrossRef1389
Jeffrey S Ross, W Fraser Symmans, Lajos Pusztai, Gabriel N Hortobagyi. (2006) Personalized medicine for breast cancer: moving forward and going back. Personalized Medicine 3:4, 363-370
CrossRef1390
T. INUI, A. ASAKAWA, Y. MORITA, S. MIZUNO, T. NATORI, A. KAWAGUCHI, M. MURAKAMI, Y. HISHIKAWA, A. INUI. (2006) HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. Journal of Internal Medicine 260:5, 484-487
CrossRef1391
Takashi Ishida, Ryuzo Ueda. (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science 97:11, 1139-1146
CrossRef1392
A NICOLINI, R GIARDINO, A CARPI, P FERRARI, L ANSELMI, S COLOSIMO, M CONTE, M FINI, G GIAVARESI, P BERTI. (2006) Metastatic breast cancer: an updating. Biomedecine & Pharmacotherapy 60:9, 548-556
CrossRef1393
Eric J. Duell. (2006) The future of epidemiology. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 49:11, 1179-1184
CrossRef1394
Filitsa A. Badra, Michalis V. Karamouzis, Panagiota Ravazoula, Eleni Likaki-Karatza, Evagelos Tzorakoleftherakis, Dimitrios Koukouras, Gregorios Iconomou, Nikolaos Xiros, Dimitrios Siablis, Athanasios G. Papavassiliou, Haralabos P. Kalofonos. (2006) Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. Cancer Letters 244:1, 34-41
CrossRef1395
G Frasci, G D'Aiuto, P Comella, R Thomas, G Botti, M Di Bonito, V De Rosa, G Iodice, M R Rubulotta, G Comella. (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. British Journal of Cancer 95:8, 1005-1012
CrossRef1396
James O. Armitage. (2006) Any drug that works has a target. Targeted Oncology 1:4, 179-180
CrossRef1397
M. Namer, J. Gligorov, E. Luporsi, D. Serin, . (2006) Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. Targeted Oncology 1:4, 228-238
CrossRef1398
A Chan, M Martin, M Untch, M G Gil, V Guillem-Porta, M Wojtukiewicz, P Kellokumpu-Lehtinen, H L Sommer, V Georgoulias, N Battelli, M Pawlicki, D Aubert, T Bourlard, J Gasmi, G Villanova, L Petruzelka. (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer 95:7, 788-793
CrossRef1399
Ozlem Canoz, Metin Ozkan, Vedat Arsav, Ozlem Er, H. Senol Coskun, Serdar Soyuer, Mustafa Altinbas. (2006) The Role of c-erbB-2 Expression on the Survival of Patients with Small-Cell Lung Cancer. Lung 184:5, 267-272
CrossRef1400
Garnet Suck. (2006) Novel approaches using natural killer cells in cancer therapy. Seminars in Cancer Biology 16:5, 412-418
CrossRef1401
Keiko Furukawa, Yoshinori Ito, Shunji Takahashi, Masataka Sawaki, Nobuyuki Mizunuma, Noboru Horikoshi, Fujio Kasumi, Futoshi Akiyama, Goi Sakamoto, Kiyonori Furukawa, Takashi Tajiri, Kiyohiko Hatake. (2006) Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience. Breast Cancer 13:4, 329-333
CrossRef1402
Yasuhiro Tsutani, Shozo Ohsumi, Kenjiro Aogi, Naruto Taira, Masaaki Kataoka, Yasushi Hamamoto, Rieko Nishimura, Shigemitsu Takashima. (2006) A case of metastatic Breast Cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer 13:4, 374-377
CrossRef1403
Neil J. Freedman, Geoffrey S. Ginsburg. (2006) Novel—and “Neu”—Therapeutic Possibilities for Heart Failure
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 48:7, 1448-1450
CrossRef1404
Miguel H. Bronchud. 2006. Oncology, Molecular. .
CrossRef1405
Nicholas B. La Thangue. 2006. Cancer Chemotherapy, Theoretical Foundations of. .
CrossRef1406
Li Yan, Zhenping Zhu. (2006) Development of antibody-based therapeutics for oncology indications. Drug Development Research 67:9, 699-728
CrossRef1407
Lecia V. Sequist, Rafal Dziadziuszko. (2006) Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology 1:7, 740-743
CrossRef1408
Michael C Cox, Tu D Dan, Sandra M Swain. (2006) Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opinion on Emerging Drugs 11:3, 489-501
CrossRef1409
Robin L Jones, Michael S Ewer. (2006) Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy 6:9, 1249-1269
CrossRef1410
Mu-Tai Liu, Chang-Yao Hsieh, Ai-Yih Wang, Tung-Hao Chang, Chu-Pin Pi, Chia-Chun Huang, Chao-Yuan Huang, Cheng-Hong Liou. (2006) Prognostic factors affecting the outcome of brain metastases from breast cancer. Supportive Care in Cancer 14:9, 936-942
CrossRef1411
Jose Baselga. (2006) Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics 1:3, 299-310
CrossRef1412
Karen Lisa Smith, Chau Dang, Andrew D Seidman. (2006) Cardiac dysfunction associated with trastuzumab. Expert Opinion on Drug Safety 5:5, 619-629
CrossRef1413
Richard M. Weinshilboum, Liewei Wang. (2006) Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Review of Genomics and Human Genetics 7:1, 223-245
CrossRef1414
J Shipley. (2006) Putting the colours into chromogenicin situ hybridization (CISH). The Journal of Pathology 210:1, 1-2
CrossRef1415
D. N. Church, A. Bahl, A. Jones, C. G. A. Price. (2006) HER2-positive Breast Cancer Brain Metastases: Multiple Responses to Systemic Chemotherapy and Trastuzumab—a Case Report. Journal of Neuro-Oncology 79:3, 289-292
CrossRef1416
David G. Hicks, Sarah M. Short, Nichole L. Prescott, Shannon M. Tarr, Kara A. Coleman, Brian J. Yoder, Joseph P. Crowe, Toni K. Choueiri, Andrea E. Dawson, G. Thomas Budd, Raymond R. Tubbs, Graham Casey, Robert J. Weil. (2006) Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR. The American Journal of Surgical Pathology1097-1104
CrossRef1417
Elisa Rossi, Vincenzo Villanacci, Gabrio Bassotti, Domenico Della Casa, Guido Missale, Luigi Minelli, Renzo Cestari. (2006) HER-2/neu in Barrett Esophagus. Diagnostic Molecular Pathology 15:3, 125-130
CrossRef1418
J.A. VILLELLA, S. COHEN, D.H. SMITH, H. HIBSHOOSH, D. HERSHMAN. (2006) HER-2/ neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. International Journal of Gynecological Cancer 16:5, 1897-1902
CrossRef1419
R.L. Dodd, N.J. Slevin. (2006) Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncology 42:8, 759-769
CrossRef1420
Michelle K. Bianco, Mohammad A. Vasef. (2006) HER-2 Gene Amplification in Paget Disease of the Nipple and Extramammary Site: A Chromogenic In Situ Hybridization Study. Diagnostic Molecular Pathology 15:3, 131-135
CrossRef1421
Maria M. Belimezi, Danai Papanastassiou, Efrossini Merkouri, Constantin N. Baxevanis, Avgi Mamalaki. (2006) Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunology, Immunotherapy 55:9, 1091-1099
CrossRef1422
Ranee Mehra, Barbara Burtness. (2006) Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion on Biological Therapy 6:9, 951-962
CrossRef1423
Eleanor E. R. Harris, Wei-Ting Hwang, Eric A. Lee, Keith A. Cengel, Michael D. Feldman, Angela DeMichele, Gary Kao, Lawrence J. Solin. (2006) The Impact of HER-2 Status on Local Recurrence in Women with Stage I?II Breast Cancer Treated with Breast-Conserving Therapy. The Breast Journal 12:5, 431-436
CrossRef1424
Donald J Buchsbaum, Tong Zhou, Albert F LoBuglio. (2006) TRAIL receptor-targeted therapy. Future Oncology 2:4, 493-508
CrossRef1425
Jan Norum. (2006) The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opinion on Pharmacotherapy 7:12, 1617-1625
CrossRef1426
Sabeeha Muneer, Joyce A. O'Shaughnessy. (2006) 2006 Highlights from: the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA, June 2006. Clinical Breast Cancer 7:3, 215-220
CrossRef1427
Jessica Kao, Jonathan R. Pollack. (2006) RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes, Chromosomes and Cancer 45:8, 761-769
CrossRef1428
Mark Pegram, Debbie Ngo. (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study. Advanced Drug Delivery Reviews 58:5-6, 723-734
CrossRef1429
I Bernard Weinstein, Andrew K Joe. (2006) Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 3:8, 448-457
CrossRef1430
Wenjun Guo, Yuliya Pylayeva, Angela Pepe, Toshiaki Yoshioka, William J. Muller, Giorgio Inghirami, Filippo G. Giancotti. (2006) β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell 126:3, 489-502
CrossRef1431
Douglas L Mann. (2006) Targeted cancer therapeutics: the heartbreak of success. Nature Medicine 12:8, 881-882
CrossRef1432
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein. (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology 24:8, 985-995
CrossRef1433
Dong Il Park, Jung Won Yun, Jung Ho Park, Suk Joong Oh, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Chang Hak Yoo, Byung Ho Son, Eun Yoon Cho, Seoung Wan Chae, Eo-Jin Kim, Jin Hee Sohn, Seung Ho Ryu, Antonia R. Sepulveda. (2006) HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences 51:8, 1371-1379
CrossRef1434
Sofia Braga, Lissandra dal Lago, Chantal Bernard, Fátima Cardoso, Martine Piccart. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy 6:8, 1153-1164
CrossRef1435
Elizabeth A. Mittendorf, Catherine E. Storrer, Craig D. Shriver, Sathibalan Ponniah, George E. Peoples. (2006) Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer. Annals of Surgical Oncology 13:8, 1085-1098
CrossRef1436
Antonio Jimeno, Manuel Hidalgo. (2006) Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology 59:2, 150-158
CrossRef1437
Sinto Sebastian, Jeffrey Settleman, Stephan J. Reshkin, Amalia Azzariti, Antonia Bellizzi, Angelo Paradiso. (2006) The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:1, 120-139
CrossRef1438
D K Wilkins, A Mayer. (2006) Development of antibodies for cancer therapy. Expert Opinion on Biological Therapy 6:8, 787-796
CrossRef1439
Paul M Waring. (2006) Matching patients with drugs: triumphs and challenges. Personalized Medicine 3:3, 335-344
CrossRef1440
Adrian M. Jubb, Adam J. Oates, Scott Holden, Hartmut Koeppen. (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nature Reviews Cancer 6:8, 626-635
CrossRef1441
Patricia S Steeg. (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine 12:8, 895-904
CrossRef1442
Janet E. Dancey, Helen X. Chen. (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Reviews Drug Discovery 5:8, 649-659
CrossRef1443
Alex Starr, Joel Greif, Akiva Vexler, Maia Ashkenazy-Voghera, Valery Gladesh, Chanan Rubin, Gabriele Kerber, Sylvia Marmor, Shahar Lev-Ari, Moshe Inbar, Yosef Yarden, Rami Ben-Yosef. (2006) ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. International Journal of Cancer 119:2, 269-274
CrossRef1444
Eriko Tokunaga, Eiji Oki, Kojiro Nishida, Tadashi Koga, Akinori Egashira, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara. (2006) Trastuzumab and breast cancer: developments and current status. International Journal of Clinical Oncology 11:3, 199-208
CrossRef1445
Kalliopi P. Siziopikou, Reshma Ariga, Kimon E. Proussaloglou, Paolo Gattuso, Melody Cobleigh. (2006) The Challenging Estrogen Receptor-Negative/ Progesterone Receptor-Negative/HER-2-Negative Patient: A Promising Candidate for Epidermal Growth Factor Receptor-Targeted Therapy?. The Breast Journal 12:4, 360-362
CrossRef1446
Magali Morelle, Elodie Haslé, Isabelle Treilleux, Jean-Philippe Michot, Thomas Bachelot, Frédérique Penault-Llorca, Marie-Odile Carrère. (2006) Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. International Journal of Technology Assessment in Health Care 22:03,
CrossRef1447
, Shinichi Wakamatsu, Shoshu Mitsuyama, Kiyoshi Nanba, Kiyoshi Nishimura, Yoshiatsu Sagara, Maki Tanaka, Nobumitsu Tamaki, Toshihiro Koga, Kazuo Tamura. (2006) Adjuvant therapy for Breast Cancer in Kyushu. Breast Cancer 13:3, 308-312
CrossRef1448
Hitoshi Tsuda. (2006) HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 13:3, 236-248
CrossRef1449
V. Heinemann. (2006) Systemische Chemotherapie beim metastasierten Mammakarzinom. Der Onkologe 12:7, 683-698
CrossRef1450
Melinda Epstein, Yanling Ma, Michael F. Press. (2006) Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. Advances in Anatomic Pathology 13:4, 200-201
CrossRef1451
Shinya Toyokuni. (2006) Novel Aspects of Oxidative Stress-Associated Carcinogenesis. Antioxidants & Redox Signaling 8:7-8, 1373-1377
CrossRef1452
Yoshitaka Nishio, Yoshiaki Yamada, Hiroto Kokubo, Kogenta Nakamura, Shigeyuki Aoki, Tomohiro Taki, Nobuaki Honda, Atsuko Nakagawa, Shinsuke Saga, Kazuo Hara. (2006) Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68:1, 110-115
CrossRef1453
Niklaus G Schaefer, Bernhard C Pestalozzi, Alexander Knuth, Christoph Renner. (2006) Potential use of humanized antibodies in the treatment of breast cancer. Expert Review of Anticancer Therapy 6:7, 1065-1074
CrossRef1454
Ami Citri, Yosef Yarden. (2006) EGF–ERBB signalling: towards the systems level. Nature Reviews Molecular Cell Biology 7:7, 505-516
CrossRef1455
Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y. Wu, Seungchan Yang, Graham Carpenter, Adi F. Gazdar, Senthil K. Muthuswamy, Carlos L. Arteaga. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:1, 25-38
CrossRef1456
Eric J. Duell. (2006) The future of epidemiology. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 49:7, 622-627
CrossRef1457
A S Doane, M Danso, P Lal, M Donaton, L Zhang, C Hudis, W L Gerald. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:28, 3994-4008
CrossRef1458
Daniel Von Hoff. 2006. Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 445-457.
CrossRef1459
Alberto Pinzon-Charry, Chris Schmidt, José Alejandro López. (2006) Dendritic cell immunotherapy for breast cancer. Expert Opinion on Biological Therapy 6:6, 591-604
CrossRef1460
C CABRERAMORALES. (2006) PCR frente a FISH en la determinación del estado de Her2/neu en tumores de mama. Medicina Clínica 127:1, 35-36
CrossRef1461
Benny Vittrup Jensen. (2006) Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. Seminars in Oncology 33, 15-21
CrossRef1462
Stan Kaye. (2006) Which drugs for which patients?. Future Oncology 2:3, 317-319
CrossRef1463
Ryan P. Million. (2006) Impact of genetic diagnostics on drug development strategy. Nature Reviews Cancer 5:6, 459-462
CrossRef1464
Jocelyn Holash, Gavin Thurston, John S. Rudge, George D. Yancopoulos, Alex A. Adjei, Gabriele Bergers, Bronislaw Pytowski, Mark Pegram, Michael S. Gordon. (2006) Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer and Metastasis Reviews 25:2, 243-252
CrossRef1465
Elisa Rossi, Alessandro Ubiali, Moris Cadei, Piera Balzarini, Ernestina Valagussa, Laura Lucini, Franco Alpi, Anna Galletti, Lucia Fontana, Chiara Tedoldi, Piergiovanni Grigolato. (2006) HER-2/neu in Breast Cancer. Applied Immunohistochemistry & Molecular Morphology 14:2, 127-131
CrossRef1466
R STAN. (2006) DNA Vaccines Against Cancer. Hematology/Oncology Clinics of North America 20:3, 613-636
CrossRef1467
Hugues Bourgeois, Aur??lie Ferru, Alain Lortholary, Thierry Delozier, Mich??le Boisdron-Celle, Sophie Abadie-Lacourtoisie, Florence Joly, St??phanie Chieze, Virginie Chabrun, Erick Gamelin, Jean-Marc Tourani. (2006) Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer. American Journal of Clinical Oncology 29:3, 267-275
CrossRef1468
Maria Rosaria Raspollini, Gianni Amunni, Alessandro Villanucci, Francesca Castiglione, Duccio Rossi Degl??Innocenti, Gianna Baroni, Milena Paglierani, Gian Luigi Taddei. (2006) HER-2/neu and bcl-2 in Ovarian Carcinoma. Applied Immunohistochemistry & Molecular Morphology 14:2, 181-186
CrossRef1469
Armando Ciampa, Bo Xu, Gamze Ayata, Daniel Baiyee, Jan Wallace, Michael Wertheimer, Kathryn Edmiston, Ashraf Khan. (2006) HER-2 Status in Breast Cancer. Applied Immunohistochemistry & Molecular Morphology 14:2, 132-137
CrossRef1470
Pritchard, Kathleen I., Shepherd, Lois E., O'Malley, Frances P., Andrulis, Irene L., Tu, Dongsheng, Bramwell, Vivien H., Levine, Mark N., . (2006) HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine 354:20, 2103-2111
Full Text1471
Makoto Suzuki, Hisayuki Shigematsu, Toshihiko Iizasa, Kenzo Hiroshima, Yukio Nakatani, John D. Minna, Adi F. Gazdar, Takehiko Fujisawa. (2006) Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106:10, 2200-2207
CrossRef1472
Kazuhiro Araki, Takafumi Sangai, Shin'ichi Miyamoto, Hiroyuki Maeda, Shi-Chuan Zhang, Michio Nakamura, Genichiro Ishii, Takahiro Hasebe, Hideaki Kusaka, Tadakazu Akiyama, Yoshimi Tokuda, Kanji Nagai, Hironobu Minami, Atsushi Ochiai. (2006) Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. International Journal of Cancer 118:10, 2602-2608
CrossRef1473
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, J. Zweit. (2006) Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies. JNCI Journal of the National Cancer Institute 98:9, 580-598
CrossRef1474
Alberto Serrano-Olvera, Alfonso Dueñas-González, Dolores Gallardo-Rincón, Myrna Candelaria, Jaime De la Garza-Salazar. (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treatment Reviews 32:3, 180-190
CrossRef1475
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva. (2006) Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:5, 269-280
CrossRef1476
Robert J Weil. (2006) Does trastuzumab increase the risk of isolated central nervous system metastases in patients with breast cancer?. Nature Clinical Practice Oncology 3:5, 236-237
CrossRef1477
E. JEWELL, A.A. SECORD, T. BROTHERTON, A. BERCHUCK. (2006) Use of trastuzumab in the treatment of metastatic endometrial cancer. International Journal of Gynecological Cancer 16:3, 1370-1373
CrossRef1478
John M Luk, Kwong-Fai Wong. (2006) MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA. Clinical and Experimental Pharmacology and Physiology 33:5-6, 482-488
CrossRef1479
Jean-Pierre Gillet, Françoise de Longueville, José Remacle. (2006) DualChip ® microarray as a new tool in cancer research. Expert Review of Molecular Diagnostics 6:3, 295-306
CrossRef1480
D R Emlet, R Schwartz, K A Brown, A A Pollice, C A Smith, S E Shackney. (2006) HER2 expression as a potential marker for response to therapy targeted to the EGFR. British Journal of Cancer 94:8, 1144-1153
CrossRef1481
C Bengala, C Zamagni, P Pedrazzoli, P Matteucci, A Ballestrero, G Da Prada, M Martino, G Rosti, M Danova, M Bregni, G Jovic, V Guarneri, M Maur, P F Conte. (2006) Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. British Journal of Cancer 94:7, 1016-1020
CrossRef1482
Nobuaki Sato, Muneaki Sano, Toshio Tabei, Taro Asaga, Jiro Ando, Hirofumi Fujii, Naohito Yamamoto, Masafumi Kurosumi, Kenichi Inoue, Morihiko Kimura. (2006) Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer: A multicenter, phase-II study. Breast Cancer 13:2, 166-171
CrossRef1483
Keith T. Flaherty, Marcia S. Brose. (2006) Her-2 targeted therapy: Beyond breast cancer and trastuzumab. Current Oncology Reports 8:2, 90-95
CrossRef1484
A. A. Joy, J. R. Mackey. (2006) The role of platinum-based therapy for HER-2-positive breast cancer. Breast Cancer Online 9:04,
CrossRef1485
Max Mano. (2006) Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treatment Reviews 32:2, 106-118
CrossRef1486
Sheila A Doggrell. (2006) ‘Simply stunning’ – trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy 7:5, 631-634
CrossRef1487
Wedad M Hanna, Kevin Kwok. (2006) Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Modern Pathology 19:4, 481-487
CrossRef1488
A. Tutt, J. Yarnold. (2006) Radiobiology of Breast Cancer. Clinical Oncology 18:3, 166-178
CrossRef1489
Lynn S. Ashby, Timothy C. Ryken. (2006) Management of malignant glioma: steady progress with multimodal approaches. Neurosurgical FOCUS 20:4, E3
CrossRef1490
Rebecca Dent, Mark Clemons. (2006) Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. Cancer Treatment Reviews 32:2, 144-148
CrossRef1491
Gordon Jayson, John Harris. (2006) How participants in cancer trials are chosen: ethics and conflicting interests. Nature Reviews Cancer 6:4, 330-336
CrossRef1492
Ruth E Board, Emma J Dean, Claire Mitchell, Andrew M Wardley. (2006) Second-line treatment of postmenopausal women with advanced breast carcinoma. Expert Review of Anticancer Therapy 6:4, 613-624
CrossRef1493
H STEMMLER, S KAHLERT, W SIEKIERA, M UNTCH, B HEINRICH, V HEINEMANN. (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. The Breast 15:2, 219-225
CrossRef1494
Cheng-long Huang, Hiroyasu Yokomise, Masakazu Fukushima, Moritoshi Kinoshita. (2006) Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncology 2:2, 289-299
CrossRef1495
Barbara Zsebik, Ami Citri, Jorma Isola, Yosef Yarden, János Szöllősi, György Vereb. (2006) Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters 104:1-2, 146-155
CrossRef1496
Heidi A. Lane, David Lebwohl. (2006) Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program. Seminars in Oncology 33, 18-25
CrossRef1497
Simon Chowdhury, Peter G. Harper. (2006) Aims and difficulties of targeting. Targeted Oncology 1:2, 69-70
CrossRef1498
Koji MATSUMOTO, Chikako SHIMIZU, Yasuhiro FUJIWARA. (2006) The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. Asia-Pacific Journal of Clinical Oncology 2:1, 6-8
CrossRef1499
Sarah-Jane DAWSON, Nadia F RANIERI, Raymond D SNYDER, Sue-Anne McLACHLAN, William I BURNS, Genni M NEWNHAM, Prudence A FRANCIS, Anthony J DOWLING. (2006) Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab. Asia-Pacific Journal of Clinical Oncology 2:1, 50-56
CrossRef1500
Gernot Hudelist, Wolfgang J. Köstler, Klaus Czerwenka, Ernst Kubista, Johannes Attems, Ruth Müller, Daphne Gschwantler-Kaulich, Mahmood Manavi, Isabell Huber, Heinz Hoschützky, Christoph C. Zielinski, Christian F. Singer. (2006) Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. International Journal of Cancer 118:5, 1126-1134
CrossRef1501
D Yee. (2006) Targeting insulin-like growth factor pathways. British Journal of Cancer 94:4, 465-468
CrossRef1502
Shuji Haraguchi, Masafumi Hioki, Takao Hisayoshi, Koji Yamashita, Yasuo Yamashita, Jun Kawamura, Tomomi Hirata, Shigeki Yamagishi, Kiyoshi Koizumi, Kazuo Shimizu. (2006) Resection of Sternal Tumors and Reconstruction of the Thorax: A Review of 15 Patients. Surgery Today 36:3, 225-229
CrossRef1503
Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Bono, Petri, Alanko, Tuomo, Kataja, Vesa, Asola, Raija, Utriainen, Tapio, Kokko, Riitta, Hemminki, Akseli, Tarkkanen, Maija, Turpeenniemi-Hujanen, Taina, Jyrkkiö, Sirkku, Flander, Martti, Helle, Leena, Ingalsuo, Seija, Johansson, Kaisu, Jääskeläinen, Anna-Stina, Pajunen, Marjo, Rauhala, Mervi, Kaleva-Kerola, Jaana, Salminen, Tapio, Leinonen, Mika, Elomaa, Inkeri, Isola, Jorma, . (2006) Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine 354:8, 809-820
Full Text1504
Ian Smith. (2006) Goals of Treatment for Patients With Metastatic Breast Cancer. Seminars in Oncology 33, 2-5
CrossRef1505
Alberto Oca??a, Juan J. Cruz, Atanasio Pandiella. (2006) Trastuzumab and Antiestrogen Therapy. American Journal of Clinical Oncology 29:1, 90-95
CrossRef1506
Sabeeha Muneer, Aarati Ranganathan, Susan Peck, Latha Shivakumar, Joyce A. O'Shaughnessy. (2006) 2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2005. Clinical Breast Cancer 6:6, 481-489
CrossRef1507
David B. Whyte, Susan L. Holbeck. (2006) Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochemical and Biophysical Research Communications 340:2, 469-475
CrossRef1508
Evan Matros, Gerald Bailey, Thomas Clancy, Michael Zinner, Stanley Ashley, Edward Whang, Mark Redston. (2006) Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer 106:3, 693-702
CrossRef1509
O W Tawfik, B F Kimler, M Davis, J K Donahue, D L Persons, F Fan, S Hagemeister, P Thomas, C Connor, W Jewell, C J Fabian. (2006) Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48:3, 258-267
CrossRef1510
Axel Mischo, Boris Kubuschok, Kubilay Ertan, Klaus-Dieter Preuss, Bernd Romeike, Evi Regitz, Claudia Schormann, Diederik de Bruijn, Andreas Wadle, Frank Neumann, Werner Schmidt, Christoph Renner, Michael Pfreundschuh. (2006) Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. International Journal of Cancer 118:3, 696-703
CrossRef1511
Tufia Haddad, Douglas Yee. (2006) Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncology 2:1, 101-110
CrossRef1512
Anne E. Kayl, Christina A. Meyers. (2006) Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Current Opinion in Obstetrics and Gynecology 18:1, 24-28
CrossRef1513
Raymond Ng, Nathan Better, Michael D. Green. (2006) Anticancer Agents and Cardiotoxicity. Seminars in Oncology 33:1, 2-14
CrossRef1514
Rita Nahta, Francisco J. Esteva. (2006) Herceptin: mechanisms of action and resistance. Cancer Letters 232:2, 123-138
CrossRef1515
L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, V Cabaret, V Fermeaux, P Bertheau, J Garnier, J-F Jeannin, B Coudert. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. British Journal of Cancer 94:2, 259-267
CrossRef1516
Robert L Strausberg. 2006. Cancer Genome Anatomy Project. .
CrossRef1517
Haiwei H Guo, John F Davidson, Lawrence A Loeb. 2006. Genomic and Chromosomal Instability. .
CrossRef1518
Hisayuki Shigematsu, Adi F. Gazdar. (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer 118:2, 257-262
CrossRef1519
Nancy E. Hynes, William Gullick. (2006) Therapeutic Targeting of Signal Transduction Pathways and Proteins in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 1-2
CrossRef1520
N. Bornfeld, A. Schüler, R. Bölöni, C. Jurklies, R. Wieland, W. Sauerwein, D. Lohmann. (2006) Retinoblastom. Der Ophthalmologe 103:1, 59-78
CrossRef1521
B. Michael Ghadimi, Heinz Becker. 2006. Chirurgische Onkologie. , 179-202.
CrossRef1522
Ramón Colomer, Javier A. Menéndez. (2006) Mediterranean diet, olive oil and cancer. Clinical and Translational Oncology 8:1, 15-21
CrossRef1523
Volker R. Jacobs. (2006) Current Status of Financing and Reimbursement of Trastuzumab (Herceptin<sup>®</sup>) for Adjuvant and Advanced Therapy of Breast Cancer in Germany. Breast Care 1:2, 86-94
CrossRef1524
2006. Trastuzumab. , 3480-3481.
CrossRef1525
Chantal Bernard-Marty, Fabienne Lebrun, Ahmad Awada, Martine J Piccart. (2006) Monoclonal Antibody-Based Targeted Therapy in Breast Cancer. Drugs 66:12, 1577-1591
CrossRef1526
Chad A. Livasy, F. Catrina Reading, Dominic T. Moore, John F. Boggess, Ruth A. Lininger. (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecologic Oncology 100:1, 101-106
CrossRef1527
Ja Seong Bae, Byung Joo Song, Mi la Kim, Seok Hyo Chang, Han Seong Kim, Woo Chan Park, Jeong Soo Kim, Sang Seol Jung. (2006) Clinicopathologic factor and Lymphovascular Invasion in Breast cancer. Journal of Breast Cancer 9:4, 317
CrossRef1528
Lars Sl??rdal, Olav Spigset. (2006) Heart Failure Induced by Non-Cardiac Drugs. Drug Safety 29:7, 567-586
CrossRef1529
Giampietro Gasparini, Raffaele Longo, Francesco Torino, Domenico Gattuso, Alessandro Morabito, Giuseppe Toffoli. (2006) Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology 57:1, 79-101
CrossRef1530
Greg L Plosker, Susan J Keam. (2006) Trastuzumab. Drugs 66:4, 449-475
CrossRef1531
Shunji Takahashi, Yoshinori Ito, Kiyohiko Hatake, Yoshikazu Sugimoto. (2006) Gene therapy for breast cancer. — review of clinical gene therapy trials for breast cancer and mdr1 gene therapy trial in cancer institute hospital. Breast Cancer 13:1, 8-15
CrossRef1532
Hidefumi Sasaki, Shigeki Shimizu, Katsuhiko Endo, Minoru Takada, Masaaki Kawahara, Hisaichi Tanaka, Akihide Matsumura, Keiji Iuchi, Hiroshi Haneda, Eriko Suzuki, Yoshihiro Kobayashi, Motoki Yano, Yoshitaka Fujii. (2006) EGFR and erbB2 mutation status in Japanese lung cancer patients. International Journal of Cancer 118:1, 180-184
CrossRef1533
Patrick J. Perik, Winette T. A. Van Der Graaf, Elisabeth G. E. De Vries, Frans Boomsma, Juergen Messerschmidt, Dirk J. Van Veldhuisen, Dirk T. Sleijfer, Jourik A. Gietema. (2006) Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncologica 45:2, 175-183
CrossRef1534
2006. Anthracyclines and related compounds. , 245-255.
CrossRef1535
Ali Badache, Anthony Gonçalves. (2006) The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia 11:1, 13-25
CrossRef1536
M.R. RASPOLLINI, T. SUSINI, G. AMUNNI, M. PAGLIERANI, F. CASTIGLIONE, F. GARBINI, C. CARRIERO, G. SCARSELLI, G.L. TADDEI. (2006) Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?. International Journal of Gynecological Cancer 16:1, 416-422
CrossRef1537
Wolfgang J. Köstler, Gernot Hudelist, Werner Rabitsch, Klaus Czerwenka, Ruth Müller, Christian F. Singer, Christoph C. Zielinski. (2006) Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 132:1, 9-18
CrossRef1538
Annette Lebeau. (2006) HER2 Testing in Breast Cancer: Opportunities and Challenges. Breast Care 1:2, 69-76
CrossRef1539
Clifford A Hudis. (2006) Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. Nature Clinical Practice Oncology 3:1, 12-13
CrossRef1540
Mohamed Bentires-Alj, Susana G Gil, Richard Chan, Zhigang C Wang, Yongping Wang, Naoko Imanaka, Lyndsay N Harris, Andrea Richardson, Benjamin G Neel, Haihua Gu. (2006) A role for the scaffolding adapter GAB2 in breast cancer. Nature Medicine 12:1, 114-121
CrossRef1541
N Lynn Henry, Kathleen M Diehl, Daniel F Hayes. (2006) Adjuvant systemic therapy for elderly women with breast cancer. Women's Health 2:1, 75-87
CrossRef1542
V Craig Jordan. (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology 147:S1, S269-S276
CrossRef1543
Deepali Sachdev, Douglas Yee. (2006) Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 27-39
CrossRef1544
Nina Ditsch, Sandra Rückert, Carolin Kümper, Miriam Lenhard, Steffen Kahlert, Ingo Bauerfeind, Klaus Friese, Michael Untch. (2006) Trastuzumab (Herceptin<sup>®</sup>): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation. Breast Care 1:2, 78-84
CrossRef1545
Debra Patt, Michelle Gauthier, Sharon Giordano. (2006) Paclitaxel in breast cancer. Women's Health 2:1, 11-21
CrossRef1546
Sun-Young Kong, Do Hoon Lee, Eun Sook Lee, Susan Park, Keun Seok Lee, Jungsil Ro. (2006) Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer. Cancer Research and Treatment 38:1, 35
CrossRef1547
Staffan Welin, Marie Louise Fjällskog, Jan Saras, Barbro Eriksson, Eva T. Janson. (2006) Expression of Tyrosine Kinase Receptors in Malignant Midgut Carcinoid Tumors. Neuroendocrinology 84:1, 42-48
CrossRef1548
M. Venturini, C. Bighin, S. Monfardini, F. Cappuzzo, N. Olmeo, A. Durando, F. Puglisi, O. Nicoletto, A. Lambiase, L. Mastro. (2006) Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment 95:1, 45-53
CrossRef1549
Daniele Santini, Bruno Vincenzi, Giuseppe Tonini. (2006) Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?. Women's Health 2:1, 1-3
CrossRef1550
Rose Marie Tyson, Dale F Kraemer, Matthew A Hunt, Leslie L Muldoon, Peter Orbay, Leeza Maron, Kristoph Jahnke, Edward A Neuwelt. (2006) The treatment of brain metastasis from breast cancer, role of blood–brain barrier disruption and early experience with trastuzumab. Therapy 3:1, 97-112
CrossRef1551
Max Mano. (2006) The burden of scientific progress: Growing inequalities in the delivery of cancer care. Acta Oncologica 45:1, 84-86
CrossRef1552
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology 3:1, 24-40
CrossRef1553
Jean-Marc Nabholtz, Joseph Gligorov. (2006) Taxane therapy for early stage breast cancer. Women's Health 2:1, 99-114
CrossRef1554
B??atrice Cl??menceau, G??raldine Gallot, R??gine Vivien, Jo??lle Gaschet, Mario Campone, Henri Vi??. (2006) Long-Term Preservation of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Natural Killer Cells Amplified In Vitro From the Peripheral Blood of Breast Cancer Patients After Chemotherapy. Journal of Immunotherapy 29:1, 53-60
CrossRef1555
Lajos Pusztai, Francisco J. Esteva. (2006) Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer. Cancer Investigation 24:2, 187-191
CrossRef1556
Michael Bilous, Adrienne Morey, Jane Armes, Margaret Cummings, Glenn Francis. (2006) Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology 38:2, 120-124
CrossRef1557
Sebastian F. Schoppmann, Raimund Jakesz. (2006) Early-Stage Breast Cancer – Highlights at ASCO 2006. Breast Care 1:4, 265-269
CrossRef1558
Jeffrey S. Ross, Karen E. Gray, Iain J. Webb, Gary S. Gray, Mark Rolfe, David P. Schenkein, David M. Nanus, Mathew I. Millowsky, Neil H. Bander. (2005) Antibody-based therapeutics: Focus on prostate cancer. Cancer and Metastasis Reviews 24:4, 521-537
CrossRef1559
Zeina A. Nahleh, Abdul-Rahman Jazieh. (2005) Multitargeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2???Positive Breast Cancer. American Journal of Clinical Oncology 28:6, 631-633
CrossRef1560
Carlynn Willmore, Joseph A Holden, Lester J Layfield. (2005) Correlation of HER2 Gene Amplification with Immunohistochemistry in Breast Cancer as Determined by a Novel Monoplex Polymerase Chain Reaction Assay. Applied Immunohistochemistry & Molecular Morphology 13:4, 333-341
CrossRef1561
Bryan T. Hennessy, Debra L. Smith, Prahlad T. Ram, Yiling Lu, Gordon B. Mills. (2005) Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery 4:12, 988-1004
CrossRef1562
Syed A Hussain, Daniel H Palmer, Andrea Stevens, David Spooner, Christopher J Poole, Daniel W Rea. (2005) Role of chemotherapy in breast cancer. Expert Review of Anticancer Therapy 5:6, 1095-1110
CrossRef1563
D JAGER, A KNUTH. (2005) Antibodies and vaccines–hope or illusion?. The Breast 14:6, 631-635
CrossRef1564
Suresh Ramalingam, Chandra P Belani. (2005) Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:15, 2667-2679
CrossRef1565
G. Kesava Reddy, Chris Schwab, Preeta Tyagi, Eric Nadler, Joyce A. O'Shaughnessy. (2005) 2005 Highlights From: ECCO 13—The European Cancer Conference, Paris, France October 30 to November 3, 2005. Clinical Breast Cancer 6:5, 380-384
CrossRef1566
Jeffery Peppercorn, Ann Partridge, Harold J. Burstein, Eric P. Winer. (2005) Standards for follow-up care of patients with breast cancer. The Breast 14:6, 500-508
CrossRef1567
Patrick Micke, Arne Östman. (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opinion on Therapeutic Targets 9:6, 1217-1233
CrossRef1568
H.J. Stemmler, S. Kahlert, O. Brudler, M. Beha, S. Müller, B. Stauch, V. Heinemann. (2005) High Efficacy of Gemcitabine and Cisplatin Plus Trastuzumab in Patients with HER2-overexpressing Metastatic Breast Cancer: A Phase II Study. Clinical Oncology 17:8, 630-635
CrossRef1569
Christian Doerig, Oliver Billker, David Pratt, Jane Endicott. (2005) Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1754:1-2, 132-150
CrossRef1570
Jonas Bergh. (2005) Adjuvant chemotherapy for breast cancer—“one fits all”?. The Breast 14:6, 564-569
CrossRef1571
Yingying Guo, Steven Shafer, Paul Weller, Jonathan Usuka, Gary Peltz. (2005) Pharmacogenomics and drug development. Pharmacogenomics 6:8, 857-864
CrossRef1572
Pinliang Hu, Jiannan Feng, Tao Zhou, Jianing Wang, Baofeng Jing, Ming Yu, Meiru Hu, Xuemin Zhang, Beifen Shen, Ning Guo. (2005) In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. Journal of Cellular Physiology 205:3, 335-343
CrossRef1573
Montse Verdú Artufel, Anna Colomer Valero, Ruth Román Lladó, Nadina Erill Sagalés, Miquel Calvo Llorca, Abelardo Moreno Carazo, Carlos Cordón Cardó, Xavier Puig Torrus. (2005) Protocolo de estudio molecular del oncogénHER2/neu en el carcinoma de mama. Clinical and Translational Oncology 7:11, 504-511
CrossRef1574
Victoria Villaflor, Philip Bonomi. (2005) Other Compounds and Targets in Non–Small Cell Lung Cancer. Seminars in Oncology 32, 30-36
CrossRef1575
Tetsuya Murakawa, Hitoshi Tsuda, Takao Tanimoto, Tetsuya Tanabe, Satoshi Kitahara, Osamu Matsubara. (2005) Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: Implication for a new therapeutic approach. Pathology International 55:12, 757-765
CrossRef1576
Christine Rebischung, Raphaëlle Barnoud, Laetitia Stéfani, Jean-Luc Faucheron, Mireille Mousseau. (2005) The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8:4, 249-252
CrossRef1577
Lee M. Krug, Vincent A. Miller, Jyoti Patel, John Crapanzano, Christopher G. Azzoli, Jorge Gomez, Mark G. Kris, Robert T. Heelan, Barbara Pizzo, Leslie Tyson, Christine Sheehan, Jeffrey S. Ross, Ennapadam Venkatraman. (2005) Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 104:10, 2149-2155
CrossRef1578
J. A. Menendez, L. Vellon, R. Colomer, R. Lupu. (2005) Effect of -Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. JNCI Journal of the National Cancer Institute 97:21, 1611-1615
CrossRef1579
Sheila E Taube, Jeffrey S Abrams. (2005) Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. Personalized Medicine 2:4, 363-369
CrossRef1580
Gregory M. Cote, Thomas A. Miller, Nathan K. LeBrasseur, Yukio Kuramochi, Douglas B. Sawyer. (2005) Neuregulin-1α and β isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Experimental Cell Research 311:1, 135-146
CrossRef1581
Vinod Ravi, Michael K. K. Wong. (2005) Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. Current Treatment Options in Oncology 6:6, 487-497
CrossRef1582
Maria D. Corte, Juan A. Rodil, Julio Vázquez, Lucia García, Juan C. Rodríguez, Miguel Bongera, José C. Fernández, Luis O. González, Ma Luz Lamelas, Maite Allende, José L. García-Muñiz, Antonio Fueyo, Francisco J. Vizoso. (2005) Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). Journal of Cancer Research and Clinical Oncology 131:11, 701-714
CrossRef1583
Raquel Prati, Sophia K. Apple, Jianbo He, Jeffrey A. Gornbein, Helena R. Chang. (2005) Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer. The Breast Journal 11:6, 433-439
CrossRef1584
A. Ocaña Fernández, M. Navarro Martín, J.J. Cruz Hernández. (2005) Afectación metastásica del sistema nervioso central en el cáncer de mama: papel del Herceptin. Revista Clínica Española 205:11, 553-555
CrossRef1585
Mani Mohindru, Amit Verma. (2005) Engineered antibodies act as targeted therapies in cancer treatment. The Indian Journal of Pediatrics 72:11, 943-947
CrossRef1586
E.A. EISENHAUER. (2005) Trial design for testing new therapies in ovarian cancer. International Journal of Gynecological Cancer 15:s3, 258-265
CrossRef1587
Junichi Kurebayashi. (2005) Resistance to endocrine therapy in breast cancer. Cancer Chemotherapy and Pharmacology 56:S1, 39-46
CrossRef1588
Sarah Bacus, Neil L Spector, Yosef Yarden. (2005) The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. Personalized Medicine 2:4, 301-315
CrossRef1589
Erinn Downs-Kelly, James Pettay, David Hicks, Marek Skacel, Brian Yoder, Lisa Rybicki, Jonathan Myles, Joseph Sreenan, Patrick Roche, Richard Powell, James Hainfeld, Thomas Grogan, Raymond Tubbs. (2005) Analytical Validation and Interobserver Reproducibility of EnzMet GenePro. The American Journal of Surgical Pathology 29:11, 1505-1511
CrossRef1590
Hong-Guang Xie, Felix W Frueh. (2005) Pharmacogenomics steps toward personalized medicine. Personalized Medicine 2:4, 325-337
CrossRef1591
Timothy J Parrett, Hai Yan. (2005) Digital karyotyping technology: exploring the cancer genome. Expert Review of Molecular Diagnostics 5:6, 917-925
CrossRef1592
Chiaki Okuse, Fumio Itoh. (2005) Current status of monoclonal antibodies as therapeutic agents for solid cancer. Journal of Gastroenterology 40:10, 1009-1011
CrossRef1593
Hortobagyi, Gabriel N., . (2005) Trastuzumab in the Treatment of Breast Cancer. New England Journal of Medicine 353:16, 1734-1736
Full Text1594
Romond, Edward H., Perez, Edith A., Bryant, John, Suman, Vera J., Geyer, Charles E. Jr., Davidson, Nancy E., Tan-Chiu, Elizabeth, Martino, Silvana, Paik, Soonmyung, Kaufman, Peter A., Swain, Sandra M., Pisansky, Thomas M., Fehrenbacher, Louis, Kutteh, Leila A., Vogel, Victor G., Visscher, Daniel W., Yothers, Greg, Jenkins, Robert B., Brown, Ann M., Dakhil, Shaker R., Mamounas, Eleftherios P., Lingle, Wilma L., Klein, Pamela M., Ingle, James N., Wolmark, Norman, . (2005) Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine 353:16, 1673-1684
Full Text1595
Piccart-Gebhart, Martine J., Procter, Marion, Leyland-Jones, Brian, Goldhirsch, Aron, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Bell, Richard, Jackisch, Christian, Cameron, David, Dowsett, Mitch, Barrios, Carlos H., Steger, Günther, Huang, Chiun-Shen, Andersson, Michael, Inbar, Moshe, Lichinitser, Mikhail, Láng, István, Nitz, Ulrike, Iwata, Hiroji, Thomssen, Christoph, Lohrisch, Caroline, Suter, Thomas M., Rüschoff, Josef, Sütő, Tamás, Greatorex, Victoria, Ward, Carol, Straehle, Carolyn, McFadden, Eleanor, Dolci, M. StellaGelber, Richard D., . (2005) Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine 353:16, 1659-1672
Full Text1596
Seth J. Corey. (2005) Targeted therapy: For kids, too. Pediatric Blood & Cancer 45:5, 623-634
CrossRef1597
Anna Berkenblit, Ursula A. Matulonis, Joan F. Kroener, Bruce J. Dezube, Gil N. Lam, Luceli C. Cuasay, Nils Brünner, Terence R. Jones, Michael H. Silverman, Michael A. Gold. (2005) Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecologic Oncology 99:1, 50-57
CrossRef1598
Serenella M. Pupa, Elda Tagliabue, Sylvie Ménard, Andrea Anichini. (2005) HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. Journal of Cellular Physiology 205:1, 10-18
CrossRef1599
Rene Bruno, Carla B. Washington, Jian-Feng Lu, Grazyna Lieberman, Ludger Banken, Pamela Klein. (2005) Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. Cancer Chemotherapy and Pharmacology 56:4, 361-369
CrossRef1600
Toshiyuki Sakaeda, Noboru Okamura, Akinobu Gotoh, Toshiro Shirakawa, Shuji Terao, Masahi Morioka, Kenji Tokui, Hisato Tanaka, Tsutomu Nakamura, Mariko Yagi, Yoshihiro Nishimura, Mitsuhiro Yokoyama, Katsuhiko Okumura. (2005) EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients. Pharmaceutical Research 22:10, 1757-1761
CrossRef1601
Chris Schwab, Eric Nadler, Joyce A. O'Shaughnessy. (2005) Analysis of Cardiac Toxicity in Phase III Adjuvant Trastuzumab Trials. Clinical Breast Cancer 6:4, 299-301
CrossRef1602
Makoto Suzuki, Hisayuki Shigematsu, Kenzo Hiroshima, Toshihiko Iizasa, Yukio Nakatani, John D. Minna, Adi F. Gazdar, Takehiko Fujisawa. (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Human Pathology 36:10, 1127-1134
CrossRef1603
Christina H. Yeon, Mark D. Pegram. (2005) Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Investigational New Drugs 23:5, 391-409
CrossRef1604
Robert J. Weil, Diane C. Palmieri, Julie L. Bronder, Andreas M. Stark, Patricia S. Steeg. (2005) Breast Cancer Metastasis to the Central Nervous System. The American Journal of Pathology 167:4, 913-920
CrossRef1605
, , M. Ruhul Quddus, C. James Sung, Cunxian Zhang, Terese Pasqueriello, Meryle Eklund, Margaret M. Steinhoff. (2005) Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy. Breast Cancer 12:4, 294-298
CrossRef1606
Alessandro D. Santin, Stefania Bellone, Sue Van Stedum, Wendy Bushen, Michela Palmieri, Eric R. Siegel, Luis E. De Las Casas, Juan J. Roman, Alexander Burnett, Sergio Pecorelli. (2005) Amplification of c-erbB2 oncogene. Cancer 104:7, 1391-1397
CrossRef1607
Stamatis-Nick C. Liossis, George C. Tsokos. (2005) Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology 116:4, 721-729
CrossRef1608
Michael I. Koukourakis, John Manavis, Costantinos Simopoulos, Vasilis Liberis, Alexandra Giatromanolaki, Efthimios Sivridis. (2005) Hypofractionated Accelerated Radiotherapy With Cytoprotection Combined With Trastuzumab, Liposomal Doxorubicine, and Docetaxel in c-erbB-2???Positive Breast Cancer. American Journal of Clinical Oncology 28:5, 495-500
CrossRef1609
Christiane Langer, Renzo Canetta, Robert Martell. 2005. Anticancer Drugs. , 401-419.
CrossRef1610
Wenle Xia, Catherine M Gerard, Leihua Liu, Nathalie M Baudson, Thierry L Ory, Neil L Spector. (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:41, 6213-6221
CrossRef1611
Klaus Pantel, Ute Woelfle. (2005) Detection and molecular characterisation of disseminated tumour cells: Implications for anti-cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1756:1, 53-64
CrossRef1612
Dalia M. Abd El-Rehim, Graham Ball, Sarah E. Pinder, Emad Rakha, Claire Paish, John F.R. Robertson, Douglas Macmillan, Roger W. Blamey, Ian O. Ellis. (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer 116:3, 340-350
CrossRef1613
Raffit Hassan, Robert J Kreitman, Ira Pastan, Mark C Willingham. (2005) Localization of Mesothelin in Epithelial Ovarian Cancer. Applied Immunohistochemistry & Molecular Morphology 13:3, 243-247
CrossRef1614
Erinn Downs-Kelly, Brian J Yoder, Mark Stoler, Raymond R Tubbs, Marek Skacel, Thomas Grogan, Patrick Roche, David G Hicks. (2005) The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast. The American Journal of Surgical Pathology 29:9, 1221-1227
CrossRef1615
Sridhar K. Rabindran. (2005) Antitumor activity of HER-2 inhibitors. Cancer Letters 227:1, 9-23
CrossRef1616
Jay S. Dela Cruz, Sherie L. Morrison, Manuel L. Penichet. (2005) Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 23:39, 4793-4803
CrossRef1617
Noël Dybdal, Grazyna Leiberman, Steven Anderson, Bryan McCune, Alex Bajamonde, Robert L. Cohen, Robert D. Mass, Corsee Sanders, Michael F. Press. (2005) Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab. Breast Cancer Research and Treatment 93:1, 3-11
CrossRef1618
Susan E. Moody, Denise Perez, Tien-chi Pan, Christopher J. Sarkisian, Carla P. Portocarrero, Christopher J. Sterner, Kathleen L. Notorfrancesco, Robert D. Cardiff, Lewis A. Chodosh. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:3, 197-209
CrossRef1619
Laurence Delacroix, Dominique Begon, Guillaume Chatel, Pascale Jackers, Rosita Winkler. (2005) Distal ERBB2 Promoter Fragment Displays Specific Transcriptional and Nuclear Binding Activities in ERBB2 Overexpressing Breast Cancer Cells. DNA and Cell Biology 24:9, 582-594
CrossRef1620
Ian E Smith, Susan G Cross. (2005) Trastuzumab. Women's Health 1:2, 161-169
CrossRef1621
Gregory P Adams, Louis M Weiner. (2005) Monoclonal antibody therapy of cancer. Nature Biotechnology 23:9, 1147-1157
CrossRef1622
Hirofumi Asakura, Hitoshi Takashima, Masahiro Mitani, Reiji Haba, Reiko Seo, Koiku Yokoe, Yoshihiro Toyama, Motoomi Ohkawa. (2005) Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine. International Journal of Clinical Oncology 10:4, 285-288
CrossRef1623
K. Spiekermann, W. Hiddemann. (2005) Molekulare Zielstrukturen in der Onkologie. Der Internist 46:8, 847-860
CrossRef1624
Ralf-Dieter Hofheinz, Senta Ulrike Gnad-Vogt, Ulrich Beyer, Andreas Hochhaus. (2005) Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs 16:7, 691-707
CrossRef1625
Peter Blower, Ronald de Wit, Susan Goodin, Matti Aapro. (2005) Drug–drug interactions in oncology: Why are they important and can they be minimized?. Critical Reviews in Oncology/Hematology 55:2, 117-142
CrossRef1626
Jean-Marc Nabholtz, Joseph Gligorov. (2005) Docetaxel in the treatment of breast cancer: current experience and future prospects. Expert Review of Anticancer Therapy 5:4, 613-633
CrossRef1627
Emer O Hanrahan, Bryan T Hennessy, Vicente Valero. (2005) Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opinion on Pharmacotherapy 6:9, 1477-1491
CrossRef1628
J AHN, S KIM, H SOHN, J LEE, Y KANG, W KUNKIM. (2005) Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. The Breast 14:4, 304-309
CrossRef1629
Michele Gallucci, Roberta Merola, Costantino Leonardo, Enzo Maria Ruggeri, Anna Maria Cianciulli. (2005) Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU International 96:3, 440-440
CrossRef1630
Britta Weigelt, Johannes L. Peterse, Laura J. van't Veer. (2005) Breast cancer metastasis: markers and models. Nature Reviews Cancer 5:8, 591-602
CrossRef1631
Jean-marc Nabholtz, Joseph Gligorov. (2005) Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opinion on Pharmacotherapy 6:9, 1555-1564
CrossRef1632
Antonio Jimeno, Manuel Hidalgo. (2005) Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. Expert Review of Anticancer Therapy 5:4, 727-735
CrossRef1633
Donal J Brennan, Sallyann L O’Brien, Ailís Fagan, Aedín C Culhane, Desmond G Higgins, Michael J Duffy, William M Gallagher. (2005) Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opinion on Biological Therapy 5:8, 1069-1083
CrossRef1634
Kelly K. Hunt, Khandan Keyomarsi. (2005) Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology 15:4, 319-326
CrossRef1635
S. Merkelbach-Bruse, R. Büttner. (2005) Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. Der Onkologe 11:8, 873-888
CrossRef1636
Doroshow, James H., . (2005) Targeting EGFR in Non–Small-Cell Lung Cancer. New England Journal of Medicine 353:2, 200-202
Full Text1637
Krause, Daniela S., Van Etten, Richard A., . (2005) Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine 353:2, 172-187
Full Text1638
L Gibault, J-P Metges, V Conan-Charlet, P Lozac'h, M Robaszkiewicz, C Bessaguet, N Lagarde, A Volant. (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. British Journal of Cancer 93:1, 107-115
CrossRef1639
S-T Lim, E-H Wong, K-L Chuah, S-S Leong, W-T Lim, M-H Tay, C-K Toh, E-H Tan. (2005) Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. British Journal of Cancer 93:1, 23-28
CrossRef1640
Antonio Verdoliva, Daniela Marasco, Antonia De Capua, Angela Saporito, Piero Bellofiore, Vincenzo Manfredi, Roberto Fattorusso, Carlo Pedone, Menotti Ruvo. (2005) A New Ligand for Immunoglobulin G Subdomains by Screening of a Synthetic Peptide Library. ChemBioChem 6:7, 1242-1253
CrossRef1641
Erika Nordberg, Ann-Charlott Steffen, Mikael Persson, Åsa L Sundberg, Jörgen Carlsson, Bengt Glimelius. (2005) Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. European Journal of Nuclear Medicine and Molecular Imaging 32:7, 771-777
CrossRef1642
Simone Mocellin, Mario Lise, Donato Nitti. (2005) Targeted therapy for colorectal cancer: mapping the way. Trends in Molecular Medicine 11:7, 327-335
CrossRef1643
Carsten T. Viehl, Michelle Becker-Hapak, Jason S. Lewis, Yoshiyuki Tanaka, Udaya K. Liyanage, David C. Linehan, Timothy J. Eberlein, Peter S. Goedegebuure. (2005) A Tat Fusion Protein–Based Tumor Vaccine for Breast Cancer. Annals of Surgical Oncology 12:7, 517-525
CrossRef1644
George Fountzilas, Dimitrios Pectasides, Anna Kalogera-Fountzila, Dimosthenis Skarlos, Haralambos P. Kalofonos, Christos Papadimitriou, Dimitrios Bafaloukos, Stefanos Lambropoulos, Savvas Papadopoulos, Helen Kourea, Christos Markopoulos, Helen Linardou, Dimitrios Mavroudis, Evangelos Briasoulis, Nicholaos Pavlidis, Evangelia Razis, Paraskevas Kosmidis, Helen Gogas. (2005) Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Research and Treatment 92:1, 1-9
CrossRef1645
Masaya Nomura, Yoshifumi Inoue, Shigeo Fujita, Jun Sakao, Masaki Hirota, Shigeo Souda, Masato Ohshima. (2005) Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer 12:3, 226-230
CrossRef1646
David G. Cox, Susan E. Hankinson, David J. Hunter. (2005) The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenetics and Genomics 15:7, 447-450
CrossRef1647
Wolfgang J. Köstler, Thomas Brodowicz, Gernot Hudelist, Margaretha Rudas, Reinhard Horvat, Günther G. Steger, Christian F. Singer, Johannes Attems, Werner Rabitsch, Negar Fakhrai, Katarzyna Elandt, Christoph Wiltschke, Michael Hejna, Christoph C. Zielinski. (2005) The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. Journal of Cancer Research and Clinical Oncology 131:7, 420-428
CrossRef1648
Alessandro D. Santin, Stefania Bellone, Sue Van Stedum, Wendy Bushen, Luis E. De Las Casas, Soheila Korourian, Erming Tian, Juan J. Roman, Alexander Burnett, Sergio Pecorelli. (2005) Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecologic Oncology 98:1, 24-30
CrossRef1649
Shahram Hedjazifar, Lachmi E. Jenndahl, Hiroaki Shimokawa, Dan Baeckström. (2005) PKB mediates c-erbB2-induced epithelial β1 integrin conformational inactivation through Rho-independent F-actin rearrangements. Experimental Cell Research 307:1, 259-275
CrossRef1650
Shigehira Saji, Masayo Kawakami, Shin-ichi Hayashi, Nobuyuki Yoshida, Makiko Hirose, Shin-ichiro Horiguchi, Akihiro Itoh, Nobuaki Funata, Stuart L Schreiber, Minoru Yoshida, Masakazu Toi. (2005) Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24:28, 4531-4539
CrossRef1651
Ana M. Gonzalez-Angulo, Kristine Broglio, Shu-Wan Kau, Yesmin Eralp, Julie Erlichman, Vicente Valero, Richard Theriault, Daniel Booser, Aman U. Buzdar, Gabriel N. Hortobagyi, Banu Arun. (2005) Women age ≤ 35 years with primary breast carcinoma. Cancer 103:12, 2466-2472
CrossRef1652
D. A. Haas-Kogan, M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, M. S. Berger, D. Stokoe. (2005) Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib. JNCI Journal of the National Cancer Institute 97:12, 880-887
CrossRef1653
Julien Dômont, Jean-Charles Soria, Thierry Le Chevalier. (2005) Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer. Seminars in Oncology 32:3, 279-283
CrossRef1654
Chris Schwab, Joyce A. O'Shaughnessy. (2005) Advances in the Adjuvant Treatment of HER2-Overexpressing Breast Cancer with the Anti-HER2 Antibody Trastuzumab. Clinical Breast Cancer 6:2, 108-111
CrossRef1655
Michelle Boyar, Daniel P. Petrylak. (2005) Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials. Current Oncology Reports 7:3, 207-214
CrossRef1656
Pequita Loring, Robert Cummins, Anthony O???Grady, Elaine W Kay. (2005) HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization. Applied Immunohistochemistry & Molecular Morphology 13:2, 194-200
CrossRef1657
Fabrice Barlesi, Cecile Tchouhadjian, Christophe Doddoli, Patrick Villani, Laurent Greillier, Jean-Pierre Kleisbauer, Pascal Thomas, Philippe Astoul. (2005) Gefitinib (ZD1839, IressaR) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundamental and Clinical Pharmacology 19:3, 385-393
CrossRef1658
Robert E Brown. (2005) Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Review of Proteomics 2:3, 337-348
CrossRef1659
Riccardo Ponzone, Piero Sismondi. (2005) Selected highlights from the 27th San Antonio Breast Cancer Symposium. Expert Opinion on Pharmacotherapy 6:7, 1257-1267
CrossRef1660
Jeffrey P. MacKeigan, Leon O. Murphy, John Blenis. (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biology 7:6, 591-600
CrossRef1661
Kenji Tamura, Masahiro Fukuoka. (2005) Gefitinib in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:6, 985-993
CrossRef1662
Hitoshi Tsuda, Yoichi Tani, Joel Weisenberger, Shigehiro Kitada, Tadashi Hasegawa, Tetsuya Murata, Seiichi Tamai, Setsuo Hirohashi, Osamu Matsubara, Tsuneo Natori. (2005) Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Science 96:6, 333-339
CrossRef1663
Sameer Sharma, Kunle Odunsi. (2005) Targeted therapy for epithelial ovarian cancer. Expert Opinion on Therapeutic Targets 9:3, 501-513
CrossRef1664
A. Gonçalves, P. Viens, H. Sobol, D. Maraninchi, F. Bertucci. (2005) Altérations moléculaires des cancers du sein : applications cliniques et nouveaux outils d'analyse. La Revue de Médecine Interne 26:6, 470-478
CrossRef1665
Jean-Marc Nabholtz, Joseph Gligorov. (2005) The role of taxanes in the treatment of breast cancer. Expert Opinion on Pharmacotherapy 6:7, 1073-1094
CrossRef1666
Renata Duchnowska, Cezary Szczylik. (2005) Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treatment Reviews 31:4, 312-318
CrossRef1667
S. Siberil, C.-A. Dutertre, C. Boix, J.-L. Teillaud. (2005) Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, beaucoup d'ingénierie, et … quelques succès cliniques. Transfusion Clinique et Biologique 12:2, 114-122
CrossRef1668
Nicholas W Choong, Patrick C Ma, Ravi Salgia. (2005) Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion on Therapeutic Targets 9:3, 533-559
CrossRef1669
Jonathan S MARVIN, Zhenping ZHU. (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacologica Sinica 26:6, 649-658
CrossRef1670
S Rueckert, I Ruehl, S Kahlert, G Konecny, M Untch. (2005) A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opinion on Biological Therapy 5:6, 853-866
CrossRef1671
Dawn N. Waterhouse, Tetyana Denyssevych, Norma Hudon, Stephen Chia, Karen A. Gelmon, Marcel B. Bally. (2005) Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels. Pharmaceutical Research 22:6, 915-922
CrossRef1672
Filippo Montemurro, Stefania Redana, Giorgio Valabrega, Massimo Aglietta. (2005) Controversies in breast cancer: adjuvant and neoadjuvant therapy. Expert Opinion on Pharmacotherapy 6:7, 1055-1072
CrossRef1673
Rohit Bhargava, Priti Lal, Beiyun Chen. (2005) HER-2/neu and Topoisomerase IIa Gene Amplification and Protein Expression in Invasive Breast Carcinomas: Chromogenic In Situ Hybridization and Immunohistochemical Analyses. American Journal of Clinical Pathology 123:6, 889-895
CrossRef1674
A. Schneeweiss, C. Sohn. (2005) Systemische Therapie des Mammakarzinoms. Der Onkologe 11:6, 693-704
CrossRef1675
Volker Heinemann. (2005) Gemcitabine in metastatic breast cancer. Expert Review of Anticancer Therapy 5:3, 429-443
CrossRef1676
Ryungsa Kim, Kazuaki Tanabe, Manabu Emi, Yoko Uchida, Tetsuya Toge. (2005) Modulation of tamoxifen sensitivity by antisenseBcl-2 and trastuzumab in breast carcinoma cells. Cancer 103:10, 2199-2207
CrossRef1677
Mark Richter, Hongtao Zhang. (2005) Receptor-Targeted Cancer Therapy. DNA and Cell Biology 24:5, 271-282
CrossRef1678
Carmel T. Chan, Marianne Z. Metz, Susan E. Kane. (2005) Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Research and Treatment 91:2, 187-201
CrossRef1679
Yun Gong, Daniel J. Booser, Nour Sneige. (2005) Comparison ofHER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:9, 1763-1769
CrossRef1680
F. Hilpert, A. Heiser, D. Kabelitz, J. Pfisterer, W. Jonat. (2005) Immuntherapie gynäkologischer Malignome. Der Onkologe 11:5, 530-535
CrossRef1681
Angelika B. Riemer, Georg Kraml, Otto Scheiner, Christoph C. Zielinski, Erika Jensen-Jarolim. (2005) Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition. Molecular Immunology 42:9, 1121-1124
CrossRef1682
Norbert Arens, Uwe Bleyl, Ralf Hildenbrand. (2005) HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Archiv 446:5, 489-496
CrossRef1683
H.-J. Lück. (2005) Therapie des metastasierten Mammakarzinoms. Der Gynäkologe 38:5, 425-431
CrossRef1684
Ying Tang, Deborah Scollard, Paul Chen, Judy Wang, Claire Holloway, Raymond M. Reilly. (2005) Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine Communications 26:5, 427-432
CrossRef1685
Osamu Sato, Takuro Wada, Akira Kawai, Umio Yamaguchi, Atsushi Makimoto, Yasuo Kokai, Toshihiko Yamashita, Hirokazu Chuman, Yasuo Beppu, Yoichi Tani, Tadashi Hasegawa. (2005) Expression of epidermal growth factor receptor,ERBB2 andKIT in adult soft tissue sarcomas. Cancer 103:9, 1881-1890
CrossRef1686
Nancy E. Hynes, Heidi A. Lane. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 5:5, 341-354
CrossRef1687
Makoto Kubo, Takashi Morisaki, Kotaro Matsumoto, Akira Tasaki, Naoki Yamanaka, Hiroshi Nakashima, Hideo Kuroki, Katsuya Nakamura, Masafumi Nakamura, Mitsuo Katano. (2005) Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunology, Immunotherapy 54:5, 468-476
CrossRef1688
Liana Adam, Wassim Kassouf, Colin P.N. Dinney. (2005) Clinical Applications for Targeted Therapy in Bladder Cancer. Urologic Clinics of North America 32:2, 239-246
CrossRef1689
G. Sauer, R. Kreienberg. (2005) Neue molekulare Therapiekonzepte beim Mammakarzinom. Der Gynäkologe 38:5, 432-438
CrossRef1690
Truls Gardmark, Kenneth Wester, Manuel de la Torre, Jorgen Carlsson, Per-Uno Malmstrom. (2005) Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU International 95:7, 982-986
CrossRef1691
A D Santin, F Zhan, S Cane', S Bellone, M Palmieri, M Thomas, A Burnett, J J Roman, M J Cannon, J Shaughnessy, S Pecorelli. (2005) Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal of Cancer 92:8, 1561-1573
CrossRef1692
Giorgio Valabrega, Filippo Montemurro, Ivana Sarotto, Annalisa Petrelli, Patrizia Rubini, Carlo Tacchetti, Massimo Aglietta, Paolo Maria Comoglio, Silvia Giordano. (2005) TGFα expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24:18, 3002-3010
CrossRef1693
K Mimura, K Kono, M Hanawa, F Mitsui, H Sugai, N Miyagawa, A Ooi, H Fujii. (2005) Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. British Journal of Cancer 92:7, 1253-1260
CrossRef1694
G Bussolati, F Montemurro, L Righi, M Donadio, M Aglietta, A Sapino. (2005) A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. British Journal of Cancer 92:7, 1261-1267
CrossRef1695
M. Stern, R. Herrmann. (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology 54:1, 11-29
CrossRef1696
Alberto Ocaña, César A. Rodríguez, Juan J. Cruz. (2005) Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. Clinical and Translational Oncology 7:3, 99-100
CrossRef1697
G. Kesava Reddy, Angelia D. Gibson, Tara Beers Gibson, Chris Schwab, Joyce A. O'Shaughnessy, Sara Mariani. (2005) 2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004. Clinical Breast Cancer 6:1, 15-22
CrossRef1698
Kerstin Heselmeyer-Haddad, Kathrin Sommerfeld, Nicole M. White, Nadia Chaudhri, Larry E. Morrison, Nallasivam Palanisamy, Zhen Yuan Wang, Gert Auer, Winfried Steinberg, Thomas Ried. (2005) Genomic Amplification of the Human Telomerase Gene (TERC) in Pap Smears Predicts the Development of Cervical Cancer. The American Journal of Pathology 166:4, 1229-1238
CrossRef1699
Michelle E Melisko, Sandeep Kunwar, Michael Prados, Mitchel S Berger, John W Park. (2005) Brain metastases of breast cancer. Expert Review of Anticancer Therapy 5:2, 253-268
CrossRef1700
Simone Diermeier, Gábor Horváth, Ruth Knuechel-Clarke, Ferdinand Hofstaedter, János Szöllősi, Gero Brockhoff. (2005) Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Experimental Cell Research 304:2, 604-619
CrossRef1701
Johnny Hyde, D. Scott McMeekin. (2005) Targeted therapies for gynecologic malignancies. Current Treatment Options in Oncology 6:2, 121-132
CrossRef1702
Rosalyn D. Blumenthal, Lou Osorio, Marianne K. Hayes, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg. (2005) Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunology, Immunotherapy 54:4, 315-327
CrossRef1703
Masakazu Toi, Yuji Takebayashi, Louis W. Chow. (2005) Translational research in breast cancer. Breast Cancer 12:2, 86-90
CrossRef1704
W. R. Sellers, M. Meyerson. (2005) EGFR Gene Mutations: A Call for Global x Global Views of Cancer. JNCI Journal of the National Cancer Institute 97:5, 326-328
CrossRef1705
Antonio Jimeno, Manuel Hidalgo. (2005) Blockade of epidermal growth factor receptor (EGFR) activity. Critical Reviews in Oncology/Hematology 53:3, 179-192
CrossRef1706
Alessandro D. Santin, Stefania Bellone, Eric R. Siegel, Michela Palmieri, Maria Thomas, Martin J. Cannon, Helen H. Kay, Juan J. Roman, Alexander Burnett, Sergio Pecorelli. (2005) Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal of Obstetrics and Gynecology 192:3, 813-818
CrossRef1707
Kalliopi P. Siziopikou, Saba Khan. (2005) Correlation of HER2 Gene Amplification With Expression of the Apoptosis-Suppressing Genes bcl-2 and bcl-x-L in Ductal Carcinoma in Situ of the Breast. Applied Immunohistochemistry & Molecular Morphology 13:1, 14-18
CrossRef1708
Mustafa Erman, Dominique Grunenwald, Frederique Penault-Llorca, Julien Grenier, Benjamin Besse, Pierre Validire, Luc Morat, Philippe Girard, Thierry Le Chevalier, Laure Sabatier, Jean-Charles Soria. (2005) Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47:3, 315-323
CrossRef1709
David G. Hicks, Raymond R. Tubbs. (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathology 36:3, 250-261
CrossRef1710
Karen Seiter. (2005) Toxicity of the topoisomerase II inhibitors. Expert Opinion on Drug Safety 4:2, 219-234
CrossRef1711
Ernst Lengyel, Dieter Prechtel, James H. Resau, Katja Gauger, Anita Welk, Kristina Lindemann, Georgia Salanti, Thomas Richter, Beatrice Knudsen, George F. Vande Woude, Nadia Harbeck. (2005) C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer 113:4, 678-682
CrossRef1712
Tobias Zellweger, Christoph Ninck, Michael Bloch, Martina Mirlacher, Pasi A. Koivisto, Heikki J. Helin, Michael J. Mihatsch, Thomas C. Gasser, Lukas Bubendorf. (2005) Expression patterns of potential therapeutic targets in prostate cancer. International Journal of Cancer 113:4, 619-628
CrossRef1713
J.C. Torrego García, J.L. Puertas Álvarez, A. Reyes García, A. Fernández Renedo. (2005) Cáncer de mama: evolución de una paciente durante 17 años. Medicine - Programa de Formación Médica Continuada Acreditado 9:26, 1737-1740
CrossRef1714
Max S. Mano, Jim Cassidy, Peter Canney. (2005) Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treatment Reviews 31:1, 35-48
CrossRef1715
Raoul Tibes, Jonathan Trent, Razelle Kurzrock. (2005) TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS*. Annual Review of Pharmacology and Toxicology 45:1, 357-384
CrossRef1716
Grace Callagy, Paul Pharoah, Suet-Feung Chin, Trogon Sangan, Yataro Daigo, Lucy Jackson, Carlos Caldas. (2005) Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. The Journal of Pathology 205:3, 388-396
CrossRef1717
Zsuzsanna Varga, Rosmarie Caduff, Bernhard Pestalozzi. (2005) Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Archiv 446:2, 136-141
CrossRef1718
Christine Le Roy, Jeffrey L. Wrana. (2005) Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nature Reviews Molecular Cell Biology 6:2, 112-126
CrossRef1719
Patrick J. Perik, Elisabeth G.E. de Vries, Jourik A. Gietema, Winette T.A. van der Graaf, Dirk Th. Sleijfer, Albert J.H. Suurmeijer, D.J. van Veldhuisen. (2005) The dilemma of the strive for apoptosis in oncology: mind the heart. Critical Reviews in Oncology/Hematology 53:2, 101-113
CrossRef1720
Francesco Caponigro, Maria Basile, Vincenzo de Rosa, Nicola Normanno. (2005) New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17???18 June 2004. Anti-Cancer Drugs 16:2, 211-221
CrossRef1721
Marisa F. Siebel, Hyman B. Muss. (2005) The influence of aging on the early detection, diagnosis, and treatment of breast cancer. Current Oncology Reports 7:1, 23-30
CrossRef1722
Tara Beers Gibson, Nancy Price, G. Kesava Reddy, Joyce A. O'Shaughnessy. (2005) 2004 Highlights from: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2004. Clinical Breast Cancer 5:6, 413-420
CrossRef1723
C.A. Rodríguez Sánchez. (2005) Cáncer de mama (y II). Estrategias terapéuticas. Medicine - Programa de Formación Médica Continuada Acreditado 9:26, 1692-1703
CrossRef1724
Wolfgang J. K??stler, G??nther G. Steger, Michael Krainer, Gabriela V. Kornek, Gottfried J. Locker, Thomas Brodowicz, Christine Marosi, Christian F. Singer, Gernot Hudelist, Werner Rabitsch, Christoph Wiltschke, Christoph C. Zielinski. (2005) Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs 16:2, 185-190
CrossRef1725
Toni M Dando, Gillian M Keating. (2005) Liposomal Doxorubicin. American Journal of Cancer 4:3, 193-206
CrossRef1726
Alexandros Ardavanis, Dimitrios Tryfonopoulos, G. Orfanos, Mihalis Karamouzis, Andreas Scorilas, A. Alexopoulos, Gerassimos Rigatos. (2005) Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Onkologie 28:11, 558-564
CrossRef1727
Julie R. Gralow. (2005) Optimizing the treatment of metastatic breast cancer. Breast Cancer Research and Treatment 89:S1, S9-S15
CrossRef1728
J.-Y. Blay. (2005) Médicaments actuels et optimisation. Annales Pharmaceutiques Françaises 63:1, 17-24
CrossRef1729
Hans-Joachim Stemmler, Steffen Kahlert, Wolfgang Siekiera, Michael Untch, Bernhard Heinrich, Volker Heinemann. (2005) Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC). Onkologie 28:11, 582-586
CrossRef1730
William J. Gradishar. (2005) The future of breast cancer: the role of prognostic factors. Breast Cancer Research and Treatment 89:S1, S17-S26
CrossRef1731
P.A. FUTREAL, R. WOOSTER, M.R. STRATTON. (2005) Somatic Mutations in Human Cancer: Insights from Resequencing the Protein Kinase Gene Family. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 43-49
CrossRef1732
Paul Workman. (2005) Genomics and the second golden era of cancer drug development. Molecular BioSystems 1:1, 17
CrossRef1733
Yoichi Tani, Yutaka Hatanaka, Kaoru Hashizume. (2005) Development of Precise Pharmocodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. ACTA HISTOCHEMICA ET CYTOCHEMICA 38:3, 209-216
CrossRef1734
Max Mano, Ghislaine Fraser, Pauline McIlroy, Lynne Stirling, Helen MacKay, Diana Ritchie, Peter Canney. (2005) Locally advanced breast cancer in octogenarian women. Breast Cancer Research and Treatment 89:1, 81-90
CrossRef1735
R. BENEZRA, E. HENKE, A. CIARROCCHI, M. RUZINOVA, D. SOLIT, N. ROSEN, D. NOLAN, V. MITTAL, P. DE CANDIA. (2005) Induction of Complete Regressions of Oncogene-induced Breast Tumors in Mice. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 375-381
CrossRef1736
George Youssef, Matthew Links. (2005) The Prevention and Management of Cardiovascular Complications of Chemotherapy in Patients with Cancer. American Journal of Cardiovascular Drugs 5:4, 233-243
CrossRef1737
Anders Ullén, Lena Lennartsson, Ulrika Harmenberg, Bo Lennernäs, Khairul Majumder, Anders R. Holmberg, Sten Nilsson, Göran P. Elmberger. (2005) Prostate cancer cell lines lack amplification: Overexpression of HER2. Acta Oncologica 44:5, 490-495
CrossRef1738
Masahide KUROKI, Hirotomo SHIBAGUCHI, Motomu KUROKI. (2005) Present Status and Perspectives of Antibody Therapy against Cancer. Japanese Journal of Complementary and Alternative Medicine 2:1, 15-21
CrossRef1739
Maria Rosaria Raspollini, Tommaso Susini, Gianni Amunni, Milena Paglierani, Antonio Taddei, Mauro Marchionni, Gianfranco Scarselli, Gian Luigi Taddei. (2005) COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?. Gynecologic Oncology 96:1, 159-167
CrossRef1740
L.D. Locati, G. Rinaldi, P. Bossi, G.P. Dagrada, P. Quattrone, G. Cantú, L. Licitra. (2005) Herceptin® plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncology 41:1, 97-98
CrossRef1741
A.N.J. TUTT, C.J. LORD, N. MCCABE, H. FARMER, N. TURNER, N.M. MARTIN, S.P. JACKSON, G.C.M. SMITH, A. ASHWORTH. (2005) Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 139-148
CrossRef1742
Fabio Puglisi, Martine Piccart. (2005) Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story?. Onkologie 28:11, 547-549
CrossRef1743
Bruce A. Chabner, Thomas G. Roberts. (2005) Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer 5:1, 65-72
CrossRef1744
Hans-Joachim Stemmler, Petra Stieber, Dorit L
ssig, Volker Heinemann. (2005) Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab. Onkologie 28:2, 95-97
CrossRef1745
M. Amirrad, F. Al-Mulla, G. Varadharaj, B. John, T. Saji, J.T. Anim. (2005) <i>BRCA1</i> Gene Expression in Breast Cancer in Kuwait: Correlation with Prognostic Parameters. Medical Principles and Practice 14:2, 67-72
CrossRef1746
David S. Alberts, Franco M. Muggia, James Carmichael, Eric P. Winer, Mohammad Jahanzeb, Alan P. Venook, Keith M. Skubitz, Edgardo Rivera, Joseph A. Sparano, Nicholas J. Dibella, Simon J. Stewart, John J. Kavanagh, Alberto A. Gabizon. (2004) Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology 31, 53-90
CrossRef1747
John W. Park, Christopher C. Benz, Francis J. Martin. (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in Oncology 31, 196-205
CrossRef1748
Ferdinand Rombout, Leon Aarons, Mats Karlsson, Anthony Man, France Mentré, Peter Nygren, Amy Racine, Hans Schaefer, Jean-Louis Steimer, Iñaki Troconiz, Achiel van Peer, . (2004) Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool?. Journal of Pharmacokinetics and Pharmacodynamics 31:6, 419-440
CrossRef1749
Nicholas J. Robert, Charles L. Vogel, I. Craig Henderson, Joseph A. Sparano, Melvin R. Moore, Paula Silverman, Beth A. Overmoyer, Charles L. Shapiro, John W. Park, Gail T. Colbern, Eric P. Winer, Alberto A. Gabizon. (2004) The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in Oncology 31, 106-146
CrossRef1750
G. Y. Kim, Y. L. Oh. (2004) Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. Cytopathology 15:6, 315-320
CrossRef1751
David M. Vail, Michael A. Amantea, Gail T. Colbern, Francis J. Martin, Ralf A. Hilger, Peter K. Working. (2004) Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Seminars in Oncology 31, 16-35
CrossRef1752
Mark A Pearson, Doriano Fabbro. (2004) Targeting protein kinases in cancer therapy: a success?. Expert Review of Anticancer Therapy 4:6, 1113-1124
CrossRef1753
Adrian M Senderowicz. (2004) Targeting cell cycle and apoptosis for the treatment of human malignancies. Current Opinion in Cell Biology 16:6, 670-678
CrossRef1754
L. M. Rodrigues, M. Stubbs, S. P. Robinson, B. Newell, J. Mansi, J. R. Griffiths. (2004) The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. Magnetic Resonance Materials in Physics, Biology and Medicine 17:3-6, 260-270
CrossRef1755
Luanda P. Grazette, Wolfgang Boecker, Takashi Matsui, Marc Semigran, Thomas L. Force, Roger J. Hajjar, Anthony Rosenzweig. (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes. Journal of the American College of Cardiology 44:11, 2231-2238
CrossRef1756
Michael S. Ewer, Francis J. Martin, I. Craig Henderson, Charles L. Shapiro, Robert S. Benjamin, Alberto A. Gabizon. (2004) Cardiac safety of liposomal anthracyclines. Seminars in Oncology 31, 161-181
CrossRef1757
Lajos Pusztai, Roman Rouzier, Peter Wagner, W. Fraser Symmans. (2004) Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. Drug Resistance Updates 7:6, 325-331
CrossRef1758
Jonathan M. Yingling, Kerry L. Blanchard, J. Scott Sawyer. (2004) Development of TGF-β signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery 3:12, 1011-1022
CrossRef1759
C. London. (2004) Kinase inhibitors in cancer therapy. Veterinary and Comparative Oncology 2:4, 177-193
CrossRef1760
Rohit Bhargava, Priti Lal, Beiyun Chen. (2004) Feasibility of Using Tissue Microarrays for the Assessment of HER-2 Gene Amplification by Fluorescence In Situ Hybridization in Breast Carcinoma. Diagnostic Molecular Pathology 13:4, 213-216
CrossRef1761
Kathryn A Phillips, Stephanie L Van Bebber. (2004) A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5:8, 1139-1149
CrossRef1762
R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, D. P. Harkin. (2004) The Role of BRCA1 in the Cellular Response to Chemotherapy. JNCI Journal of the National Cancer Institute 96:22, 1659-1668
CrossRef1763
Barbara Weir, Xiaojun Zhao, Matthew Meyerson. (2004) Somatic alterations in the human cancer genome. Cancer Cell 6:5, 433-438
CrossRef1764
Yan M. Li, Yong Pan, Yongkun Wei, Xiaoyun Cheng, Binhua P. Zhou, Ming Tan, Xiaoyan Zhou, Weiya Xia, Gabriel N. Hortobagyi, Dihua Yu, Mien-Chie Hung. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:5, 459-469
CrossRef1765
Mohammed Kashani-Sabet. (2004) Non-viral delivery of ribozymes for cancer gene therapy. Expert Opinion on Biological Therapy 4:11, 1749-1755
CrossRef1766
Shinobu Umemura, R. Yoshiyuki Osamura. (2004) Utility of immunohistochemistry in breast cancer practice. Breast Cancer 11:4, 334-338
CrossRef1767
Annemarie Larkin, Lorraine O'Driscoll, Susan Kennedy, Rachel Purcell, Elizabeth Moran, John Crown, Michael Parkinson, Martin Clynes. (2004) Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. International Journal of Cancer 112:2, 286-294
CrossRef1768
O. Brummer, H.-E. Stegner, G. Böhmer, H. Kühnle, K.-U. Petry. (2004) HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecologic Oncology 95:2, 336-340
CrossRef1769
Jeffrey L. Benovic, Adriano Marchese. (2004) A new key in breast cancer metastasis. Cancer Cell 6:5, 429-430
CrossRef1770
Anna Bafico, Guizhong Liu, Luba Goldin, Violaine Harris, Stuart A. Aaronson. (2004) An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6:5, 497-506
CrossRef1771
Nguyen-Hai Nam, Sungsoo Lee, Guofeng Ye, Gongqin Sun, Keykavous Parang. (2004) ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorganic & Medicinal Chemistry 12:22, 5753-5766
CrossRef1772
Sherene Loi, Marc Buyse, Christos Sotiriou, Fatima Cardoso. (2004) Challenges in breast cancer clinical trial design in the postgenomic era. Current Opinion in Oncology 16:6, 536-541
CrossRef1773
Nao Suzuki, Daisuke Aoki, Yutaka Tamada, Nobuyuki Susumu, Kimiko Orikawa, Katsumi Tsukazaki, Motoko Sakayori, Atsushi Suzuki, Takeshi Fukuchi, Makio Mukai, Kyoko Kojima-Aikawa, Isao Ishida, Shiro Nozawa. (2004) HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecologic Oncology 95:2, 290-298
CrossRef1774
William R. Sellers, Alex Matter. 2004. Cancer Drug Development in the Modern Era. .
CrossRef1775
Dalit Barkan, Cristina Montagna, Thomas Ried, Jeffrey E. Green. 2004. Mammary Gland Cancer. .
CrossRef1776
Nagahiro Saijo. (2004) What are the reasons for negative phase III trials of molecular-target-based drugs?. Cancer Science 95:10, 772-776
CrossRef1777
Takayuki Okamoto, Yohei Mukai, Yasuo Yoshioka, Hiroko Shibata, Maki Kawamura, Yoko Yamamoto, Shinsaku Nakagawa, Haruhiko Kamada, Takao Hayakawa, Tadanori Mayumi, Yasuo Tsutsumi. (2004) Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. Biochemical and Biophysical Research Communications 323:2, 583-591
CrossRef1778
Alison L. Jones, Brian Leyland-Jones. (2004) Optimizing treatment of HER2-positive metastatic breast cancer. Seminars in Oncology 31, 29-34
CrossRef1779
José Baselga, Jean-Jacques Body. (2004) Introduction. Seminars in Oncology 31, 1-3
CrossRef1780
Richard Bell, Shail Verma, Michael Untch, David Cameron, Ian Smith. (2004) Maximizing clinical benefit with trastuzumab. Seminars in Oncology 31, 35-44
CrossRef1781
Edith A. Perez, Lajos Pusztai, Marc van De Vijver. (2004) Improving patient care through molecular diagnostics. Seminars in Oncology 31, 14-20
CrossRef1782
José Baselga, Luca Gianni, Charles Geyer, Edith A. Perez, Alessandro Riva, Christian Jackisch. (2004) Future options with trastuzumab for primary systemic and adjuvant therapy. Seminars in Oncology 31, 51-57
CrossRef1783
David Cameron, Richard Bell. (2004) Optimizing treatment for patients with breast cancer. Seminars in Oncology 31, 4-5
CrossRef1784
Yosef Yarden, José Baselga, David Miles. (2004) Molecular approach to breast cancer treatment. Seminars in Oncology 31, 6-13
CrossRef1785
Jake Lokich. (2004) Tumor Response and Survival End Points in Clinical Trials. American Journal of Clinical Oncology 27:5, 494-496
CrossRef1786
Soo Jung Gong, Choon Jo Jin, Sun Young Rha, Hyun Cheol Chung. (2004) Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Letters 214:2, 215-224
CrossRef1787
Steven D Heys, Tarun Sarkar, Andrew W Hutcheon. (2004) Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opinion on Pharmacotherapy 5:10, 2147-2157
CrossRef1788
Ali Ziada, Albaha Barqawi, L. Michael Glode, Marileila Varella-Garcia, Frances Crighton, Susan Majeski, Mark Rosenblum, Madeleine Kane, Lin Chen, E. David Crawford. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. The Prostate 60:4, 332-337
CrossRef1789
Andrew V. Schally, Attila Nagy. (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends in Endocrinology & Metabolism 15:7, 300-310
CrossRef1790
Robin L Jones, Gerald J Berry, Robert D Rubens, David W Miles. (2004) Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. The Lancet Oncology 5:9, 575-577
CrossRef1791
Drew Pardoll, James Allison. (2004) Cancer immunotherapy: breaking the barriers to harvest the crop. Nature Medicine 10:9, 887-892
CrossRef1792
Marjolijn N Lub-de Hooge, Jos G W Kosterink, Patrick J Perik, Hugo Nijnuis, Ly Tran, Joost Bart, Albert J H Suurmeijer, Steven Jong, Pieter L Jager, Elisabeth G E Vries. (2004) Preclinical characterisation of 111 In-DTPA-trastuzumab. British Journal of Pharmacology 143:1, 99-106
CrossRef1793
Patrizia Casalini, Marilena V. Iorio, Enrico Galmozzi, Sylvie M
CrossRef1794
Richard Weinshilboum, Liewei Wang. (2004) Pharmacogenomics: bench to bedside. Nature Reviews Drug Discovery 3:9, 739-748
CrossRef1795
Mikihiko Kimura, Hitoshi Tsuda, Daisaku Morita, Takashi Ichikura, Sho Ogata, Shinsuke Aida, Yutaka Yoshizumi, Tadaaki Maehara, Hidetaka Mochizuki, Osamu Matsubara. (2004) A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Archiv 445:3, 255-262
CrossRef1796
Rose Lai, Chau T. Dang, Mark G. Malkin, Lauren E. Abrey. (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:4, 810-816
CrossRef1797
Pier Franco Conte, Valentina Guarneri, Paolo Bruzzi, Tiziana Prochilo, Barbara Salvadori, Angelo Bolognesi, Daniela Aldrighetti, Marco Venturini, Riccardo Rosso, Serafina Mammoliti, Flavio Carnino, Piergiorgio Giannessi, Massimo Costantini, Alfredo Moyano, Editta Baldini, . (2004) Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. Cancer 101:4, 704-712
CrossRef1798
G. E. Konecny, C. Thomssen, H. J. Luck, M. Untch, H.-J. Wang, W. Kuhn, H. Eidtmann, A. d. Bois, S. Olbricht, D. Steinfeld, V. Mobus, G. v. Minckwitz, S. Dandekar, L. Ramos, G. Pauletti, M. D. Pegram, F. Janicke, D. J. Slamon. (2004) HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute 96:15, 1141-1151
CrossRef1799
Yasir H Ibrahim, Douglas Yee. (2004) Insulin-like growth factor-I and cancer risk. Growth Hormone & IGF Research 14:4, 261-269
CrossRef1800
Yoichi Nagata, Keng-Hsueh Lan, Xiaoyan Zhou, Ming Tan, Francisco J. Esteva, Aysegul A. Sahin, Kristine S. Klos, Ping Li, Brett P. Monia, Nina T. Nguyen, Gabriel N. Hortobagyi, Mien-Chie Hung, Dihua Yu. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:2, 117-127
CrossRef1801
Nancy Price, G. Kesava Reddy, Preeta Tyagi, Vinay K. Jain, Joyce A. O'Shaughnessy. (2004) 2004 Highlights from: Third Annual Future of Breast Cancer: An International Congress, Southampton, Bermuda, July 2004. Clinical Breast Cancer 5:3, 172-176
CrossRef1802
Mani Mohindru, Amit Verma. (2004) Kinase inhibitors translate lab discoveries into exciting new cures for cancers. The Indian Journal of Pediatrics 71:8, 713-718
CrossRef1803
Alessandro D Santin, Stefania Bellone, Timothy J O’Brien, Sergio Pecorelli, Martin J Cannon, Juan J Roman. (2004) Current treatment options for endometrial cancer. Expert Review of Anticancer Therapy 4:4, 679-689
CrossRef1804
S. Korfee, T. Gauler, R. Hepp, C. Pöttgen, W. Eberhardt. (2004) New targeted treatments in lung cancer — overview of clinical trials. Lung Cancer 45, S199-S208
CrossRef1805
Barbara G. Beatty, Ronald Bryant, Weichen Wang, Takamaru Ashikaga, Pamela C. Gibson, Gladwyn Leiman, Donald L. Weaver. (2004) HER-2/neu Detection in Fine-Needle Aspirates of Breast Cancer Fluorescence In Situ Hybridization and Immunocytochemical Analysis. American Journal of Clinical Pathology 122:2, 246-255
CrossRef1806
Shaker Abuharbeid, Jürgen Apel, Martin Sander, Babette Fiedler, Martin Langer, Mary-Lou Zuzarte, Frank Czubayko, Achim Aigner. (2004) Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochemical and Biophysical Research Communications 321:2, 403-412
CrossRef1807
Yutaka Okawa, Katsuki Sugiyama, Keisuke Aiba, Akio Hirano, Shinji Uno, Takeshi Hagino, Kazumi Kawase, Hisashi Shioya, Kazuhiko Yoshida, Masao Kobayashi, Noriko Usui, Tadashi Kobayashi. (2004) Successful combination therapy with trastuzumab and paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer. Breast Cancer 11:3, 309-312
CrossRef1808
Akira Ito, Yuko Kuga, Hiroyuki Honda, Hiroyuki Kikkawa, Atsushi Horiuchi, Yuji Watanabe, Takeshi Kobayashi. (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Letters 212:2, 167-175
CrossRef1809
Alessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, Massimo Fanelli, Francesco Ferraù, Livia De Sio, Maria Angela Castellana, Vito Lorusso, Domenico Priolo, Stefano Vitale, Roberta Sarmiento, Salvatore Lo Vullo, Luigi Mariani, Giampietro Gasparini. (2004) Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer. Breast Cancer Research and Treatment 86:3, 249-258
CrossRef1810
Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Goi Sakamoto. (2004) Reproducible Immunohistochemical Criteria Based on Multiple Raters’ Judgments for Expression of Thymidine Phosphorylase in Breast Cancer Tissue. Breast Cancer Research and Treatment 86:3, 215-223
CrossRef1811
X Sastre-Garau, P Genin, A Rousseau, A Al Ghuzlan, A Nicolas, P Freneaux, C Rosty, B Sigal-Zafrani, J Couturier, J-P Thiery, H Magdelenat, A Vincent-Salomon. (2004) Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. Histopathology 45:2, 142-147
CrossRef1812
Cunningham, David, Humblet, Yves, Siena, Salvatore, Khayat, David, Bleiberg, Harry, Santoro, Armando, Bets, Danny, Mueser, Matthias, Harstrick, Andreas, Verslype, Chris, Chau, Ian, Van Cutsem, Eric, . (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New England Journal of Medicine 351:4, 337-345
Full Text1813
A J Clayton, S Danson, S Jolly, W D J Ryder, P A Burt, A L Stewart, P M Wilkinson, R S Welch, B Magee, G Wilson, A Howell, A M Wardley. (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. British Journal of Cancer
CrossRef1814
Ana M. Gonzalez-Angulo, Savitri Krishnamurthy, Yuko Yamamura, Kristine R. Broglio, Lajos Pusztai, Aman U. Buzdar, Gabriel N. Hortobagyi, Francisco J. Esteva. (2004) Lack of association between amplification ofher-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101:2, 258-263
CrossRef1815
W. R. Parulekar, E. A. Eisenhauer. (2004) Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. JNCI Journal of the National Cancer Institute 96:13, 990-997
CrossRef1816
Tetsuya Hamaguchi, Yasuhiro Matsumura, Yukihiro Nakanishi, Kei Muro, Yasuhide Yamada, Yasuhiro Shimada, Kuniaki Shirao, Hisae Niki, Saiko Hosokawa, Toshiaki Tagawa, Tadao Kakizoe. (2004) Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Science 95:7, 608-613
CrossRef1817
Brigitte M. Pützer, Matthias Drosten. (2004) The RET proto-oncogene: a potential target for molecular cancer therapy. Trends in Molecular Medicine 10:7, 351-357
CrossRef1818
Volkmar Müller, Isabell Witzel, Hans Joachim Lück, Günter Köhler, Gunther von Minckwitz, Volker Möbus, Daniel Sattler, Waldemar Wilczak, Thomas Löning, Fritz Jänicke, Klaus Pantel, Christoph Thomssen. (2004) Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer. Breast Cancer Research and Treatment 86:1, 9-18
CrossRef1819
Anthony Rhodes, Duncan Borthwick, Rob Sykes, Salam Al-Sam, Angelo Paradiso. (2004) The Use of Cell Line Standards to Reduce HER-2/neu Assay Variation in Multiple European Cancer Centers and the Potential of Automated Image Analysis to Provide for More Accurate Cut Points for Predicting Clinical Response to Trastuzumab. American Journal of Clinical Pathology 122:1, 51-60
CrossRef1820
Robin L Jones, Ian E Smith. (2004) Efficacy and safety of trastuzumab. Expert Opinion on Drug Safety 3:4, 317-327
CrossRef1821
Felix W Frueh, David Gurwitz. (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5:5, 571-579
CrossRef1822
Shigeto Ueda, Sho Ogata, Hitoshi Tsuda, Nobuaki Kawarabayashi, Mikihiko Kimura, Yoshiaki Sugiura, Seiichi Tamai, Osamu Matsubara, Kazuo Hatsuse, Hidetaka Mochizuki. (2004) The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness. Pancreas 29:1, e1-e8
CrossRef1823
John E. Robison, Laurent Perreard, Philip S. Bernard. (2004) State of the science: molecular classifications of breast cancer for clinical diagnostics. Clinical Biochemistry 37:7, 572-578
CrossRef1824
David W Grainger. (2004) Controlled-release and local delivery of therapeutic antibodies. Expert Opinion on Biological Therapy 4:7, 1029-1044
CrossRef1825
Boris Freidlin, Edward L. Korn. (2004) A testing procedure for survival data with few responders. Statistics in Medicine 23:11, 1818-1823
CrossRef1826
T SUTER, N COOKBRUNS, C BARTON. (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. The Breast 13:3, 173-183
CrossRef1827
Hans Wildiers, Robert Paridaens. (2004) Taxanes in elderly breast cancer patients. Cancer Treatment Reviews 30:4, 333-342
CrossRef1828
Kati P Porkka, Tapio Visakorpi. (2004) Molecular Mechanisms of Prostate Cancer. European Urology 45:6, 683-691
CrossRef1829
Robert Roskoski. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications 319:1, 1-11
CrossRef1830
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef1831
K.T. Papazisis, T. Habeshaw, D.W. Miles. (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice 58:6, 581-586
CrossRef1832
Carlos L. Arteaga, Jose Baselga. (2004) Tyrosine kinase inhibitors. Cancer Cell 5:6, 525-531
CrossRef1833
MATTHEW H.T. BUI, HARRI VISAPAA, DAVID SELIGSON, HYUNG KIM, KEN-RYU HAN, YUNDA HUANG, STEVE HORVATH, ERIC J. STANBRIDGE, AARNO PALOTIE, ROBERT A. FIGLIN, ARIE S. BELLDEGRUN. (2004) PROGNOSTIC VALUE OF CARBONIC ANHYDRASE IX AND KI67 AS PREDICTORS OF SURVIVAL FOR RENAL CLEAR CELL CARCINOMA. The Journal of Urology 171:6, 2461-2466
CrossRef1834
Snehal M Bhoola, Ronald D Alvarez. (2004) Novel therapies for recurrent ovarian cancer management. Expert Review of Anticancer Therapy 4:3, 437-448
CrossRef1835
Robert S. Kerbel, Barton A. Kamen. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 4:6, 423-436
CrossRef1836
Green, Mark R., . (2004) Targeting Targeted Therapy. New England Journal of Medicine 350:21, 2191-2193
Full Text1837
Daniela Montagna, Roberta Schiavo, Nadia Gibelli, Paolo Pedrazzoli, Roberto Tonelli, Sara Pagani, Elisa Assirelli, Franco Locatelli, Andrea Pession, Vittorio Fregoni, Elisa Montini, Gian Antonio Da Prada, Salvatore Siena, Rita Maccario. (2004) Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. International Journal of Cancer 110:1, 76-86
CrossRef1838
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, D. J. Slamon. (2004) Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. JNCI Journal of the National Cancer Institute 96:10, 739-749
CrossRef1839
G. W. Sledge. (2004) HERe-2 Stay: The Continuing Importance of Translational Research in Breast Cancer. JNCI Journal of the National Cancer Institute 96:10, 725-727
CrossRef1840
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, A. Riva, S. Blitz, M. F. Press, D. Reese, M.-A. Lindsay, D. J. Slamon. (2004) Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI Journal of the National Cancer Institute 96:10, 759-769
CrossRef1841
J Carlsson, H Nordgren, J Sjöström, K Wester, K Villman, N O Bengtsson, B Ostenstad, H Lundqvist, C Blomqvist. (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. British Journal of Cancer
CrossRef1842
M Coelho, P Gauthier, M Pugnière, F Roquet, A Pèlegrin, I Navarro-Teulon. (2004) Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. British Journal of Cancer 90:10, 2032-2041
CrossRef1843
Maria Theodoulou, Clifford Hudis. (2004) Cardiac profiles of liposomal anthracyclines. Cancer 100:10, 2052-2063
CrossRef1844
Lisa G. Horvath, Susan M. Henshall, James G. Kench, Jennifer J. Turner, David Golovsky, Phillip C. Brenner, Gordon F. O'Neill, Raji Kooner, Phillip D. Stricker, John J. Grygiel, Robert L. Sutherland. (2004) Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. The Prostate 59:3, 234-242
CrossRef1845
Primo N. Lara, Karen Giselle Chee, Jeff Longmate, Christopher Ruel, Frederick J. Meyers, Carl R. Gray, Regina Gandour Edwards, Paul H. Gumerlock, Przemyslaw Twardowski, James H. Doroshow, David R. Gandara. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma. Cancer 100:10, 2125-2131
CrossRef1846
A D Santin, F Zhan, S Bellone, M Palmieri, S Cane, M Gokden, J J Roman, T J O'Brien, E Tian, M J Cannon, J Shaughnessy, S Pecorelli. (2004) Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal of Cancer 90:9, 1814-1824
CrossRef1847
Priti Lal, Paulo A. Salazar, Clifford A. Hudis, Marc Ladanyi, Beiyun Chen. (2004) HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization : A Single-Institution Experience of 2,279 Cases and Comparison of Dual-Color and Single-Color Scoring. American Journal of Clinical Pathology 121:5, 631-636
CrossRef1848
Kenneth Bloom, Douglas Harrington. (2004) Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy. American Journal of Clinical Pathology 121:5, 620-630
CrossRef1849
R. D. Snyder. (2004) New concepts in breast cancer therapy. Internal Medicine Journal 34:5, 266-269
CrossRef1850
Marion Harris. (2004) Monoclonal antibodies as therapeutic agents for cancer. The Lancet Oncology 5:5, 292-302
CrossRef1851
P.K Julka, D.N Sharma, P Mukhopadhyay, G.K Rath. (2004) Trastuzumab and Docetaxel for Metastatic Breast Cancer: An Experience from a Cancer Centre in India. Clinical Oncology 16:2, 115-118
CrossRef1852
C COOGAN. (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:4, 786-790
CrossRef1853
Z Varga, J Zhao, C Ohlschlegel, B Odermatt, P U Heitz. (2004) Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44:4, 332-338
CrossRef1854
M Parton. (2004) High incidence of HER-2 positivity in inflammatory breast cancer. The Breast 13:2, 97-103
CrossRef1855
Tadashi Ikeda, Hiromitsu Jinno, Masaki Kitajima. (2004) The evolution of primary chemotherapy in breast cancer treatment. Breast Cancer 11:2, 148-155
CrossRef1856
Christian Rudlowski, Nicolaus Friedrichs, Andree Faridi, Lazlo Füzesi, Roland Moll, Gunther Bastert, Werner Rath, Reinhard Büttner. (2004) Her-2/neu Gene Amplification and Protein Expression in Primary Male Breast Cancer. Breast Cancer Research and Treatment 84:3, 215-223
CrossRef1857
Ralph G Zinner, Bonnie S Glisson, Frank V Fossella, Katherine M.W Pisters, Merril S Kies, Pamela M Lee, Erminia Massarelli, Bradley Sabloff, Herbert A Fritsche, Jae Y Ro, Nelson G Ordonez, Hai T Tran, Ying Yang, Terry L Smith, Robert D Mass, Roy S Herbst. (2004) Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44:1, 99-110
CrossRef1858
Matthew C Franklin, Kendall D Carey, Felix F Vajdos, Daniel J Leahy, Abraham M de Vos, Mark X Sliwkowski. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:4, 317-328
CrossRef1859
Juan Ángel Fresno Vara, Enrique Casado, Javier de Castro, Paloma Cejas, Cristóbal Belda-Iniesta, Manuel González-Barón. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews 30:2, 193-204
CrossRef1860
Evangelia Razis, George Fountzilas. (2004) Continuation of Trastuzumab Beyond Disease Progression: More Questions Than Answers. Clinical Breast Cancer 5:1, 59-62
CrossRef1861
G. Kesava Reddy, Preeta Tyagi, Vinay K. Jain, Joyce O'Shaughnessy. (2004) 2003 Highlights from: 26th Annual San Antonio Breast Cancer Symposium San Antonio, Texas, December 2003. Clinical Breast Cancer 5:1, 22-28
CrossRef1862
Virginia Kaklamani, Ruth M O’Regan. (2004) New targeted therapies in breast cancer. Seminars in Oncology 31, 20-25
CrossRef1863
Akemi Kataoka, Mayumi Ishida, Shigeru Murakami, Shinji Ohno. (2004) Sensitization of chemotherapy by anti-HER. Breast Cancer 11:2, 105-115
CrossRef1864
(2004) A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF–Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Human Gene Therapy 15:3, 313-337
CrossRef1865
Nour Sneige. (2004) Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: Current issues and future directions. Diagnostic Cytopathology 30:3, 158-165
CrossRef1866
Martine Extermann. (2004) Management issues for elderly patients with breast cancer. Current Treatment Options in Oncology 5:2, 161-169
CrossRef1867
Yong Li, Paul J Cozzi, Chang F Qu, David Y Zhang, Syed M Abbas Rizvi, Chand Raja, Barry J Allen. (2004) Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate. Cancer Letters 205:2, 161-171
CrossRef1868
Andreas Schneeweiss, Sema Kolay, Sebastian Aulmann, Gunter von Minckwitz, Julie Torode, Maria Koehler, Gunther Bastert. (2004) Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib (‘Iressa’, ZD1839). Anti-Cancer Drugs 15:3, 235-238
CrossRef1869
Thomas Holbro, Nancy E. Hynes. (2004) E
RB B RECEPTORS : Directing Key Signaling Networks Throughout Life. Annual Review of Pharmacology and Toxicology 44:1, 195-217
CrossRef1870
Elizabeth Half, Russell Broaddus, Kathleen D. Danenberg, Peter V. Danenberg, Gregory D. Ayers, Frank A. Sinicrope. (2004) HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. International Journal of Cancer 108:4, 540-548
CrossRef1871
W LESLIE, P BONOMI. (2004) Novel treatments in non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 245-267
CrossRef1872
M.P Decatris, S Sundar, K.J O’Byrne. (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treatment Reviews 30:1, 53-81
CrossRef1873
Mitchell E Gross, Ronald L Shazer, David B Agus. (2004) Targeting the HER-kinase axis in cancer. Seminars in Oncology 31, 9-20
CrossRef1874
Lise Mette Gjerdrum, Boe Sandahl Sorensen, Eigil Kjeldsen, Flemming Brandt Sorensen, Ebba Nexo, Stephen Hamilton-Dutoit. (2004) Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma. The Journal of Molecular Diagnostics 6:1, 42-51
CrossRef1875
Gabriel N Hortobagyi. (2004) Opportunities and challenges in the development of targeted therapies. Seminars in Oncology 31, 21-27
CrossRef1876
Laura Biganzoli, Alessandro Minisini, Matti Aapro, Angelo Di Leo. (2004) Chemotherapy for metastatic breast cancer. Current Opinion in Obstetrics and Gynecology 16:1, 37-41
CrossRef1877
Carlos L Arteaga, Cristina I Truica. (2004) Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Seminars in Oncology 31, 3-8
CrossRef1878
T.B. Hartmann, D. Thiel, R. Dummer, D. Schadendorf, S. Eichmuller. (2004) SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. British Journal of Dermatology 150:2, 252-258
CrossRef1879
Reiko F. Irie, David W. Ollila, Steven O’Day, Donald L. Morton. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunology, Immunotherapy 53:2, 110-117
CrossRef1880
Reade B Roberts, Carlos L Arteaga, David W Threadgill. (2004) Modeling the cancer patient with genetically engineered mice. Cancer Cell 5:2, 115-120
CrossRef1881
Yuhong Lu, Xiaolin Zi, Michael Pollak. (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer 108:3, 334-341
CrossRef1882
Marsha A. Moses, Jay Harper, Cecilia A. Fernández. (2004) A role for antiangiogenic therapy in breast cancer. Current Oncology Reports 6:1, 42-48
CrossRef1883
Eundeok Chang, Anhi Lee, Eunjung Lee, Hekyung Lee, Okran Shin, Sejeong Oh, Changsuk Kang. (2004) HER-2/ neu Oncogene Amplification by Chromogenic in situ Hybridization in 130 Breast Cancers Using Tissue Microarray and Clinical Follow-up Studies. Journal of Korean Medical Science 19:3, 390
CrossRef1884
Diana Lüftner. (2004) Breast cancer patients should not live without a HER-2/neu tissue result — But how safe can they live with it?. Wiener Klinische Wochenschrift 116:1-2, 3-5
CrossRef1885
Zee-Wan Wong, Steven J. Phillips, Matthew J. Ellis. (2004) Dramatic Response of Choroidal Metastases from Breast Cancer to a Combination of Trastuzumab and Vinorelbine. The Breast Journal 10:1, 54-56
CrossRef1886
Patrick Micke, Jan Georg Hengstler, Heidi Albrecht, Andreas Faldum, Fernando Bittinger, Kai Becker, Rainer Wiewrodt, Berthold Fischer, Roland Buhl. (2004) c-kit Expression in Adenocarcinomas of the Lung. Tumor Biology 25:5-6, 235-242
CrossRef1887
Sharon H. Giordano, Aman U. Buzdar, Terry L. Smith, Shu-Wan Kau, Ying Yang, Gabriel N. Hortobagyi. (2004) Is breast cancer survival improving?. Cancer 100:1, 44-52
CrossRef1888
Jeffrey S. Ross, David P. Schenkein, Robert Pietrusko, Mark Rolfe, Gerald P. Linette, James Stec, Nancy E. Stagliano, Geoffrey S. Ginsburg, W. Fraser Symmans, Lajos Pusztai, Gabriel N. Hortobagyi. (2004) Targeted Therapies for Cancer 2004. American Journal of Clinical Pathology 122:4, 598-609
CrossRef1889
Katsumasa Kuroi, Kojiro Shimozuma. (2004) Neurotoxicity of taxanes: Symptoms and quality of life assessment. Breast Cancer 11:1, 92-99
CrossRef1890
Corrado D'Arrigo, Ian S. Fentiman. (2004) Pathology of breast carcinoma. International Journal of Clinical Practice 58:1, 29-34
CrossRef1891
Tomi K Sawyer. (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opinion on Investigational Drugs 13:1, 1-19
CrossRef1892
Jeffrey S Ross. (2004) Targeted Therapy for Cancer. American Journal of Cancer 3:4, 205-214
CrossRef1893
Susanne Taucher, Margaretha Rudas, Robert M. Mader, Michael Gnant, Peter Dubsky, Sebastian Roka, Thomas Bachleitner, Daniela Kandioler, Günther Steger, Martina Mittlböck, Raimund Jakesz. (2004) Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wiener Klinische Wochenschrift 116:1-2, 26-31
CrossRef1894
Melody Cobleigh, John C. Somberg. (2004) A Case of Herceptin Cardiotoxicity. American Journal of Therapeutics 11:1, 74-76
CrossRef1895
Dolly Varshney, Yvonne Y. Zhou, Stephen A. Geller, Randa Alsabeh. (2004) Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay. American Journal of Clinical Pathology 121:1, 70-77
CrossRef1896
Masakazu Toi, Masahiro Takada, Hiroko Bando, Kazumi Toyama, Hiroyasu Yamashiro, Shinichiro Horiguchi, Shigehira Saji. (2004) Current status of antibody therapy for breast cancer. Breast Cancer 11:1, 10-14
CrossRef1897
D. Mavroudis, N. Malamos, A. Polyzos, Ch. Kouroussis, Ch. Christophilakis, I. Varthalitis, N. Androulakis, K. Kalbakis, G. Milaki, V. Georgoulias. (2004) Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology 67:3-4, 250-256
CrossRef1898
Jin-Hee Ahn, Sung-Bae Kim, Sei-Hyun Ahn, Gyung-Yub Gong, Myung-Ju Ahn, Yoon-Koo Kang, Jung-Shin Lee, Woo Kun Kim. (2004) Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma. Cancer Research and Treatment 36:3, 192
CrossRef1899
Christophe Rosty, J??r??me Couturier, Anne Vincent-Salomon, Pascal Genin, Paul Fr??neaux, Brigitte Sigal-Zafrani, Xavier Sastre-Garau. (2004) Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix. International Journal of Gynecological Pathology 23:1, 13-17
CrossRef1900
Filippo Montemurro, Giorgio Valabrega, Massimo Aglietta. (2004) Trastuzumab-based combination therapy for breast cancer. Expert Opinion on Pharmacotherapy 5:1, 81-96
CrossRef1901
Joanna Jasinska, Stefan Wagner, Christian Radauer, Roland Sedivy, Thomas Brodowicz, Christoph Wiltschke, Heimo Breiteneder, Hubert Pehamberger, Otto Scheiner, Ursula Wiedermann, Christoph C. Zielinski. (2003) Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. International Journal of Cancer 107:6, 976-983
CrossRef1902
G. E. Konecny. (2003) Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention?. CancerSpectrum Knowledge Environment 95:24, 1813-1815
CrossRef1903
Maria Theodoulou, Andrew D Seidman. (2003) Cardiac effects of adjuvant therapy for early breastcancer. Seminars in Oncology 30:6, 730-739
CrossRef1904
NATASHA J. CAPLEN, SPYRO MOUSSES. (2003) Short Interfering RNA (siRNA)-Mediated RNA Interference (RNAi) in Human Cells. Annals of the New York Academy of Sciences 1002:1, 56-62
CrossRef1905
Kaoru Hashizume, Yutaka Hatanaka, Yuki Kamihara, Tomoyuki Kato, Sakae Hata, Shizuka Akashi, Toshihiko Kato, Junichi Koyatsu, Yoichi Tani, Masahiko Tsujimoto, Hitoshi Tsuda. (2003) Interlaboratory Comparison in HercepTest Assessment of HER2 Protein Status in Invasive Breast Carcinoma Fixed With Various Formalin-based Fixatives. Applied Immunohistochemistry & Molecular Morphology339-344
CrossRef1906
Edward L. Nelson, Darue Prieto, Terri G. Alexander, Peter Pushko, Loreen A. Lofts, Jonathan O. Rayner, Kurt I. Kamrud, Bolyn Fralish, Jonathan F. Smith. (2003) Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-tumor Immunity to the ‘Self’ tumor-associated antigen, neu in a Rat Mammary Tumor Model. Breast Cancer Research and Treatment 82:3, 169-183
CrossRef1907
Yukinori Inadome, Masayuki Noguchi. (2003) Selection of Higher Molecular Weight Genomic DNA for Molecular Diagnosis From Formalin-Fixed Material. Diagnostic Molecular Pathology 12:4, 231-236
CrossRef1908
Bert H O’Neil, Richard M Goldberg. (2003) Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opinion on Investigational Drugs 12:12, 1939-1949
CrossRef1909
Yoav Avidor, Nicola J. Mabjeesh, Haim Matzkin. (2003) Biotechnology and Drug Discovery: From Bench to Bedside. Southern Medical Journal 96:12, 1174-1186
CrossRef1910
Sabine Merkelbach-Bruse, Eva Wardelmann, Peter Behrens, Inge Losen, Reinhard Buettner, Nicolaus Friedrichs. (2003) Current Diagnostic Methods of HER-2/neu Detection in Breast Cancer With Special Regard to Real-Time PCR. The American Journal of Surgical Pathology 27:12, 1565-1570
CrossRef1911
Michael A. Danso, Andrew D. Seidman. (2003) HER2-Overexpressing Metastatic Breast Cancer: The Role of Trastuzumab Regimens. Clinical Breast Cancer 4:5, 338-339
CrossRef1912
Dale Porter, Kornelia Polyak. (2003) Cancer target discovery using SAGE. Expert Opinion on Therapeutic Targets 7:6, 759-769
CrossRef1913
Marc Azemar, Sirus Djahansouzi, Elke Jäger, Christine Solbach, Mathias Schmidt, Alexander B. Maurer, Klaus Mross, Clemens Unger, Gunter von Minckwitz, Peter Dall, Bernd Groner, Winfried S. Wels. (2003) Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2. Breast Cancer Research and Treatment 82:3, 155-164
CrossRef1914
S Lo. (2003) Novel systemic therapies for breast cancer. Surgical Oncology 12:4, 277-287
CrossRef1915
Kazuya Kuraoka, Shunji Matsumura, Yoichi Hamai, Kei Nakachi, Kazue Imai, Keisuke Matsusaki, Naohide Oue, Reiko Ito, Hirofumi Nakayama, Wataru Yasui. (2003) A single nucleotide polymorphism in the transmembrane domain coding region ofHER-2 is associated with development and malignant phenotype of gastric cancer. International Journal of Cancer 107:4, 593-596
CrossRef1916
Ilka B. Fuchs, Solveig Landt, Helmut Bueler, Uwe Kuehl, Sarah Coupland, Anke Kleine-Tebbe, Werner Lichtenegger, Gerhard Schaller. (2003) Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™). Breast Cancer Research and Treatment 82:1, 23-28
CrossRef1917
M.R Kelly, M.J Kerin. (2003) The value of axillary lymphadenectomy. European Journal of Surgical Oncology (EJSO) 29:9, 701-702
CrossRef1918
Carlo Riccardo Rossi, Simone Mocellin, Roberto Mencarelli, Mirto Foletto, Pierluigi Pilati, Donato Nitti, Mario Lise. (2003) Gastrointestinal stromal tumors: From a surgical to a molecular approach. International Journal of Cancer 107:2, 171-176
CrossRef1919
Charles L. Vogel, Sandra X. Franco. (2003) Clinical Experience with Trastuzumab (Herceptin). The Breast Journal 9:6, 452-462
CrossRef1920
Y. Niibe, T. Nakano, T. Ohno, Y. Suzuki, K. Oka, H. Tsujii. (2003) Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. International Journal of Gynecological Cancer 13:6, 849-855
CrossRef1921
H. T. See, J. J. Kavanagh, W. Hu, R. C. Bast. (2003) Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer 13:6, 701-734
CrossRef1922
Cecilia Bozzetti, Nicola Personeni, Rita Nizzoli, Annamaria Guazzi, Marcella Flora, Cristina Bassano, Francesca Negri, Eugenia Martella, Nadia Naldi, Vittorio Franciosi, Stefano Cascinu. (2003) HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 99:5, 310-315
CrossRef1923
Catalina Falo, Abelardo Moreno, Belen Lloveras, Agn??s Figueras, Mar Varela, Agust??n Escobedo. (2003) Algorithm for the Diagnosis of HER-2/ neu Status in Breast-Infiltrating Carcinomas. American Journal of Clinical Oncology 26:5, 465-470
CrossRef1924
J. Lucas Inman, Tim Kute, Wain White, Mark Pettenati, Edward A. Levine. (2003) Absence of HER2 overexpression in metastatic malignant melanoma. Journal of Surgical Oncology 84:2, 82-88
CrossRef1925
Ruey Ho Kao, Giulio Francia, Richard Poulsom, Andrew M. Hanby, Ian R. Hart. (2003) Application of differential display, with in situ hybridization verification, to microscopic samples of breast cancer tissue. International Journal of Experimental Pathology 84:5, 207-212
CrossRef1926
Robert Haddad, A.Dimitrios Colevas, Jeffrey F Krane, Dennis Cooper, Bonnie Glisson, Philip C Amrein, Linda Weeks, Rosemary Costello, Marshall Posner. (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncology 39:7, 724-727
CrossRef1927
S.M. Ali, H.A. Harvey, Allan Lipton. (2003) Metastatic Breast Cancer. Clinical Orthopaedics and Related Research 415, S132-S137
CrossRef1928
Stefania Bellone, Michela Palmieri, Murat Gokden, Jabbar Joshua, Juan J Roman, Sergio Pecorelli, Martin J Cannon, Alessandro D Santin. (2003) Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 91:1, 231-240
CrossRef1929
E. M. Connolly, E. Gaffney, J. V. Reynolds. (2003) Gastrointestinal stromal tumours. British Journal of Surgery 90:10, 1178-1186
CrossRef1930
Antony W Burgess, Hyun-Soo Cho, Charles Eigenbrot, Kathryn M Ferguson, Thomas P.J Garrett, Daniel J Leahy, Mark A Lemmon, Mark X Sliwkowski, Colin W Ward, Shigeyuki Yokoyama. (2003) An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell 12:3, 541-552
CrossRef1931
O. Guntinas-Lichius, C. Wittekindt. (2003) The Role of Growth Factors for Disease and Therapy in Diseases of the Head and Neck. DNA and Cell Biology 22:9, 593-606
CrossRef1932
P. Sapra, T.M. Allen. (2003) Ligand-targeted liposomal anticancer drugs. Progress in Lipid Research 42:5, 439-462
CrossRef1933
J Kim. (2003) Targeted therapies for the treatment of cancer. The American Journal of Surgery 186:3, 264-268
CrossRef1934
Daniel R Nathanson, Garrett M Nash, Beiyun Chen, William Gerald, Philip B Paty. (2003) Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. Journal of the American College of Surgeons 197:3, 419-425
CrossRef1935
Kimimasa Saito, Kan Takeda, Kyoko Imanaka-Yoshida, Hiroshi Imai, Takao Sekine, Yuko Kamikura. (2003) Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Annals of Nuclear Medicine 17:6, 481-488
CrossRef1936
M Mitchell. (2003) Immunotherapy as part of combinations for the treatment of cancer. International Immunopharmacology 3:8, 1051-1059
CrossRef1937
John Crown. (2003) Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?. The Lancet 362:9385, 677-678
CrossRef1938
David R Spigel. (2003) HER2 and surgery: more questions to answer. The Lancet 362:9383, 502-503
CrossRef1939
David H. Johnson. (2003) Targeted therapy in non-small cell lung cancer: myth or reality. Lung Cancer 41, 3-8
CrossRef1940
D. Lüftner, A. Jung, P. Schmid, R. Geppert, E. Kienle, K.D. Wernecke, K. Possinger. (2003) Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients. Breast Cancer Research and Treatment 80:3, 245-255
CrossRef1941
AM Jubb, TH Landon, J Burwick, TQ Pham, GD Frantz, B Cairns, P Quirke, FV Peale, KJ Hillan. (2003) Quantitative analysis of colorectal tissue microarrays by immunofluorescence andin situ hybridization. The Journal of Pathology 200:5, 577-588
CrossRef1942
Oliver M Fischer, Sylvia Streit, Stefan Hart, Axel Ullrich. (2003) Beyond Herceptin and Gleevec. Current Opinion in Chemical Biology 7:4, 490-495
CrossRef1943
Corey J Langer. (2003) Role of targeted therapy in non-small cell lung cancer: hype or hope?. Expert Review of Anticancer Therapy 3:4, 443-455
CrossRef1944
Rony Abou-Jawde, Toni Choueiri, Carlos Alemany, Tarek Mekhail. (2003) An overview of targeted treatments in cancer. Clinical Therapeutics 25:8, 2121-2137
CrossRef1945
Man-Hei Shiu. (2003) A surgeon's look at the treatment of cancer. Annals of the College of Surgeons Hong Kong 7:s2, B7-B17
CrossRef1946
J. Bellmunt, R. de Wit, S Albiol, J Tabernero, J Albanell, J Baselga. (2003) New drugs and new approaches in metastatic bladder cancer. Critical Reviews in Oncology/Hematology 47:2, 195-206
CrossRef1947
Heather DeGrendele, Angelia D. Gibson, Preeta Tyagi, Joyce A. O'Shaughnessy. (2003) 2003 Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois May 31 to June 3, 2003. Clinical Breast Cancer 4:3, 166-172
CrossRef1948
Daniel R. Nathanson, Alfred T. Culliford, Jinru Shia, Beiyun Chen, Matthew D'Alessio, Zhao-Shi Zeng, Garrett M. Nash, William Gerald, Francis Barany, Philip B. Paty. (2003) HER 2/neu expression and gene amplification in colon cancer. International Journal of Cancer 105:6, 796-802
CrossRef1949
Andrew W. Millar, Kevin P. Lynch. (2003) Rethinking clinical trials for cytostatic drugs. Nature Reviews Cancer 3:7, 540-545
CrossRef1950
Jamila K Adam, Bharti Odhav, Kanti D Bhoola. (2003) Immune responses in cancer. Pharmacology & Therapeutics 99:1, 113-132
CrossRef1951
Paolo Giovanni Nuciforo, Caterina Pellegrini, Roberta Fasani, Marco Maggioni, Guido Coggi, Antonina Parafioriti, Silvano Bosari. (2003) Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Human Pathology 34:7, 639-645
CrossRef1952
Janet E Dancey, Boris Freidlin. (2003) Targeting epidermal growth factor receptor—are we missing the mark?. The Lancet 362:9377, 62-64
CrossRef1953
Christopher S. Foster, Christine M. Gosden, Youqiang Ke. (2003) Her2/neu expression in cancer: the pathologist as diagnostician or prophet?. Human Pathology 34:7, 635-638
CrossRef1954
Srikala S Sridhar, Lesley Seymour, Frances A Shepherd. (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. The Lancet Oncology 4:7, 397-406
CrossRef1955
V. Grunwald, M. Hidalgo. (2003) Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. JNCI Journal of the National Cancer Institute 95:12, 851-867
CrossRef1956
Johanna C. Bendell, Susan M. Domchek, Harold J. Burstein, Lyndsay Harris, Jerry Younger, Irene Kuter, Craig Bunnell, Montse Rue, Rebecca Gelman, Eric Winer. (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:12, 2972-2977
CrossRef1957
Ke Liu. (2003) The case for cancer immunotherapy. Drug Discovery Today 8:12, 530-531
CrossRef1958
Dan Ye, Anirban Maitra, Charles F. Timmons, Patrick J. Leavey, Raheela Ashfaq, Robert L. Ilaria,. (2003) The Epidermal Growth Factor Receptor HER2 Is Not a Major Therapeutic Target in Ewing Sarcoma. Journal of Pediatric Hematology/Oncology 25:6, 459-466
CrossRef1959
Rita Nahta, Gabriel N Hortobagyi, Francisco J Esteva. (2003) Novel pharmacological approaches in the treatment of breast cancer. Expert Opinion on Investigational Drugs 12:6, 909-921
CrossRef1960
M Tanskanen, T Jahkola, S Asko-Seljavaara, J Jalkanen, J Isola. (2003) HER2 oncogene amplification in extramammary Paget's disease. Histopathology 42:6, 575-579
CrossRef1961
Michael Untch, Nina Ditsch, Kerstin Hermelink. (2003) Immunotherapy: new options in breast cancer treatment. Expert Review of Anticancer Therapy 3:3, 403-408
CrossRef1962
Cora N. Sternberg, Nicholas J. Vogelzang. (2003) Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical Reviews in Oncology/Hematology 46, 105-115
CrossRef1963
J. Bellmunt, M. Hussain, C.P. Dinney. (2003) Novel approaches with targeted therapies in bladder cancer. Critical Reviews in Oncology/Hematology 46, 85-104
CrossRef1964
Jin-Shing Chen, Kengli Lan, Mien-Chie Hung. (2003) Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates 6:3, 129-136
CrossRef1965
Shahla Masood. (2003) The Expanding Role of Pathologists in the Diagnosis and Management of Breast Cancer: Worldwide Excellence in Breast Pathology Program. The Breast Journal 9:s2, S94-S97
CrossRef1966
Chien-Hsin Lee, Michael Hsiao, Yun-Long Tseng, Fu-Hsiung Chang. (2003) Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody. Journal of Biomedical Science 10:3, 337-344
CrossRef1967
Federico Cappuzzo, Stefania Bartolini, Lucio Crinò. (2003) Emerging drugs for non-small cell lung cancer. Expert Opinion on Emerging Drugs 8:1, 179-192
CrossRef1968
A. Vincent-Salomon, G. MacGrogan, J. Couturier, L. Arnould, S. Mathoulin-Pelissier. (2003) Re: HER2 Testing in the Real World. JNCI Journal of the National Cancer Institute 95:8, 628-628
CrossRef1969
M Dowsett, J Bartlett, IO Ellis, J Salter, M Hills, E Mallon, AD Watters, T Cooke, C Paish, PM Wencyk, SE Pinder. (2003) Correlation between immunohistochemistry (HercepTest) and fluorescencein situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. The Journal of Pathology 199:4, 418-423
CrossRef1970
Fan Zhang, Ying Yang, Terry Smith, Shu-Wan Kau, Judy M. McConathy, Francisco J. Esteva, Henry M. Kuerer, W. Fraser Symmans, Aman U. Buzdar, Gabriel N. Hortobagyi, Lajos Pusztai. (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:7, 1758-1765
CrossRef1971
Edward A. Sausville, Yusri Elsayed, Manish Monga, George Kim. (2003) S
IGNAL TRANSDUCTION –DIRECTED CANCER TREATMENTS *. Annual Review of Pharmacology and Toxicology 43:1, 199-231
CrossRef1972
Tero A.H. Järvinen, Edison T. Liu. (2003) Her-2/neu and Topoisomerase iiα in Breast Cancer. Breast Cancer Research and Treatment 78:3, 299-311
CrossRef1973
William J. Gradishar. (2003) Adjuvant systemic therapy of early stage breast cancer. Current Treatment Options in Oncology 4:2, 141-150
CrossRef1974
Martin J Edelman. (2003) Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?. Expert Review of Anticancer Therapy 3:2, 127-129
CrossRef1975
Simon Willis, Anne-Marie Hutchins, Fleur Hammet, John Ciciulla, Wee-Kheng Soo, David White, Peter van der Spek, Michael A. Henderson, Kurt Gish, Deon J. Venter, Jane E. Armes. (2003) Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes, Chromosomes and Cancer 36:4, 382-392
CrossRef1976
Masato Takahashi, Ken-ichi Inoue, Ryoichi Goto, Motoshi Tamura, Kazunori Taguchi, Hiromasa Takahashi, Hiroaki Suzuki, Katsushige Yamashiro, Masami Ogita. (2003) Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: A case report. Breast Cancer 10:2, 170-174
CrossRef1977
Keiichiro Tada, Yoshinori Ito, Kiyohiko Hatake, Taeko Okudaira, Jun-ichiro Watanabe, Masahiro Arakawa, Masayo Miyazato, Tetsuya Irie, Nobuyuki Mizunuma, Syunji Takahashi, Keisuke Aiba, Noboru Horikoshi, Fujio Kasumi. (2003) Severe infusion reaction induced by trastuzumab: A case report. Breast Cancer 10:2, 167-169
CrossRef1978
Prema P Peethambaram, William A Cliby, Gregory Lubiniecki, Amy C Clayton, Patrick C Roche, Stephen J Iturria, Lynn C Hartmann, Ingegerd Hellström, Scott E Strome. (2003) Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Gynecologic Oncology 89:1, 99-104
CrossRef1979
Jeffrey S. Ross, MD, Karen Gray, PhD, Gary S. Gray, PhD, Peter J. Worland, PhD, Mark Rolfe, PhD. (2003) Anticancer Antibodies. American Journal of Clinical Pathology 119:4, 472-485
CrossRef1980
I. Garc
CrossRef1981
Lloyd R Kelland. (2003) Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opinion on Investigational Drugs 12:3, 413-421
CrossRef1982
Grace Callagy, Elena Cattaneo, Yataro Daigo, Lisa Happerfield, Lynda G. Bobrow, Paul D. P. Pharoah, Carlos Caldas. (2003) Molecular Classification of Breast Carcinomas Using Tissue Microarrays. Diagnostic Molecular Pathology 12:1, 27-34
CrossRef1983
Harold J. Burstein. (2003) Trastuzumab in Combination with Chemotherapy. Breast Cancer Research and Treatment 81:S1, 69-72
CrossRef1984
John Crown, Mark Pegram. (2003) Platinum–Taxane Combinations in Metastatic Breast Cancer: An Evolving Role in the Era of Molecularly Targeted Therapy. Breast Cancer Research and Treatment 79:S1, 11-18
CrossRef1985
Alessandro D. Santin. (2003) HER2/neu overexpression: has the Achilles’ heel of uterine serous papillary carcinoma been exposed?. Gynecologic Oncology 88:3, 263-265
CrossRef1986
Lubos Petruzelka. (2003) Role of Taxanes. Breast Cancer Research and Treatment 81:S1, 17-24
CrossRef1987
Annemieke Dols, Sybren L. Meijer, Hong-Ming Hu, Vivian Goodell, Mary L. Disis, Silvia von Mensdorff-Pouilly, Rene Verheijen, W. Gregory Alvord, John W. Smith, Walter J. Urba, Bernard A. Fox. (2003) Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells. Journal of Immunotherapy 26:2, 163-170
CrossRef1988
Alasdair Breckenridge. (2003) For the good of the patient: risks and benefits of medicines. Pharmacoepidemiology and Drug Safety 12:2, 145-150
CrossRef1989
Tania Crombet, Leonel Torres, Elia Neninger, Mauricio Catalá, María E. Solano, Alejandro Perera, Olga Torres, Normando Iznaga, Franz Torres, Rolando Pérez, Agustín Lage. (2003) Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer. Journal of Immunotherapy 26:2, 139-148
CrossRef1990
S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, A. Tefferi. (2003) Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice. Mayo Clinic Proceedings 78:3, 307-317
CrossRef1991
Hyun-Soo Cho, Karen Mason, Kasra X. Ramyar, Ann Marie Stanley, Sandra B. Gabelli, Dan W. Denney, Daniel J. Leahy. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:6924, 756-760
CrossRef1992
Margaret von Mehren, Gregory P. Adams, Louis M. Weiner. (2003) Monoclonal Antibody Therapy for Cancer. Annual Review of Medicine 54:1, 343-369
CrossRef1993
Judith Clancy Keen, Nancy E. Davidson. (2003) The biology of breast carcinoma. Cancer 97:S3, 825-833
CrossRef1994
Patricia S Steeg, Diane Palmieri, Taoufik Ouatas, Massimiliano Salerno. (2003) Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. Cancer Letters 190:1, 1-12
CrossRef1995
Lois M. Witters, Samuel M. Santala, Linda Engle, Vernon Chinchilli, Allan Lipton. (2003) Decreased Response to Paclitaxel Versus Docetaxel in HER-2/neu Transfected Human Breast Cancer Cells. American Journal of Clinical Oncology 26:1, 50-54
CrossRef1996
Amy D'Orazio, Joyce A. O'Shaughnessy, Vinay K. Jain, George W. Sledge. (2003) The Addition of Carboplatin to Trastuzumab/Paclitaxel Improves Efficacy in HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer 3:6, 378-380
CrossRef1997
Filippo Montemurro, Gabriella Choa, Roberto Faggiuolo, Elisa Sperti, Antonio Capaldi, Michela Donadio, Monica Minischetti, Attilio Salomone, Guido Vietti-Ramus, Oscar Alabiso, Massimo Aglietta. (2003) Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer. American Journal of Clinical Oncology 26:1, 95-97
CrossRef1998
Jeffrey S Ross, Karen Gray, David Schenkein, Barry Greene, Gary S Gray, Jeanine Shulok, Peter J Worland, Abbie Celniker, Mark Rolfe. (2003) Antibody-based therapeutics in oncology. Expert Review of Anticancer Therapy 3:1, 107-121
CrossRef1999
Scott A Armstrong, Andrew L Kung, Meghann E Mabon, Lewis B Silverman, Ronald W Stam, Monique L Den Boer, Rob Pieters, John H Kersey, Stephen E Sallan, Jonathan A Fletcher, Todd R Golub, James D Griffin, Stanley J Korsmeyer. (2003) Inhibition of FLT3 in MLL. Cancer Cell 3:2, 173-183
CrossRef2000
Soumitra Basu, Adegboyega K. Oyelere. 2003. Application of Recombinant DNA Technology in Medicinal Chemistry and Drug Discovery. .
CrossRef2001
Paul S. Mischel, Timothy F. Cloughesy. (2003) Targeted Molecular Therapy of GBM. Brain Pathology 13:1, 52-61
CrossRef2002
Hans Wildiers, Martin S Highley, Ernst A de Bruijn, Allan T van Oosterom. (2003) Pharmacology of Anticancer Drugs in the Elderly Population. Clinical Pharmacokinetics 42:14, 1213-1242
CrossRef2003
Jeffrey S. Ross, Geoffrey S. Ginsburg. (2003) The Integration of Molecular Diagnostics With Therapeutics. American Journal of Clinical Pathology 119:1, 26
CrossRef2004
Laura G Est??vez, Andrew D Seidman. (2003) HER2-Positive Breast Cancer. American Journal of Cancer 2:3, 169-179
CrossRef2005
Laura Assersohn, Stephen R D Johnston. (2003) Postmenopausal Metastatic Breast Cancer. American Journal of Cancer 2:2, 95-109
CrossRef2006
Stuart J. Schnitt. (2003) Pharmacopathology. The American Journal of Surgical Pathology 27:1, 121-123
CrossRef2007
Robert C. Bast, Gordon B. Mills. (2003) General Keynote: Molecular Therapeutics and Pharmocogenomics. Gynecologic Oncology 88:1, S84-S87
CrossRef2008
Shin-ichi NIHIRA. (2003) Development of HER2-specific humanized antibody Herceptin (trastuzumab).. Folia Pharmacologica Japonica 122:6, 504-514
CrossRef2009
P. Nygren, R. Larsson. (2003) Overview of the clinical efficacy of investigational anticancer drugs. Journal of Internal Medicine 253:1, 46-75
CrossRef2010
h. iwamoto, h. fukasawa, t. honda, s. hirata, k. hoshi. (2003) HER-2/neu expression in ovarian clear cell carcinomas. International Journal of Gynecological Cancer 13:1, 28-31
CrossRef2011
Laura Biganzoli, Tanja Cufer, Peter Bruning, Robert E. Coleman, Luc Duchateau, Bernardo Rapoport, Marianne Nooij, Fran
CrossRef2012
Jonathan S. Berek, Oliver Dorigo, Brigit Schultes, Christopher Nicodemus. (2003) Specific Keynote: Immunological Therapy for Ovarian Cancer. Gynecologic Oncology 88:1, S105-S109
CrossRef2013
Peter J. Worland, PhD, Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD, Jeffrey S. Ross, MD. (2003) Anticancer Antibodies. American Journal of Clinical Pathology 119:4, 472
CrossRef2014
Jeffrey S. Ross, Geoffrey S. Ginsburg. (2003) The Integration of Molecular Diagnostics With Therapeutics. American Journal of Clinical Pathology 119:1, 26-36
CrossRef2015
Lorenza Rimassa, Carlo Carnaghi, Isabella Garassino, Piermario Salvini, Valeria Ginanni, Giuseppe Gullo, Emanuela Morenghi, Armando Santoro. (2003) Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer. Breast Cancer Research and Treatment 77:2, 185-188
CrossRef2016
Yuji Yoshiyama, Takashi Sugiyama, Motoko Kanke. (2003) Cardiotoxicity of Trastuzumab (Herceptin) in Chick Embryos. Biological & Pharmaceutical Bulletin 26:6, 893-895
CrossRef2017
Snezana Susnjar, Zora Neskovic-Konstantinovic, Ljiljana Stamatovic, Suzana Vasovic, Miroslav Strbac, Dragica Nikolic-Vukosavljevic, Dana Jovanovic. (2003) Združeni sadržaj receptora za estrogen i progesteron u predviđanju odgovora na hemioterapiju i hormonsku terapiju u karcinomu dojke. Srpski arhiv za celokupno lekarstvo 131:11-12, 443-448
CrossRef2018
Volkmar M??ller, Klaus Pantel. (2003) Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors. American Journal of Cancer 2:2, 77-86
CrossRef2019
Gerald Batist, Jeremy Barton, Philip Chaikin, Christine Swenson, Lauri Welles. (2002) Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opinion on Pharmacotherapy 3:12, 1739-1751
CrossRef2020
Susan E Moody, Christopher J Sarkisian, Kristina T Hahn, Edward J Gunther, Steven Pickup, Katherine D Dugan, Nathalie Innocent, Robert D Cardiff, Mitchell D Schnall, Lewis A Chodosh. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2:6, 451-461
CrossRef2021
Markus Hoopmann, Mathias Warm, Peter Mallmann, Anke Thomas, Uwe-Jochen Göhring, Thomas Schöndorf. (2002) Tumor M2 pyruvate kinase – determination in breast cancer patients receiving trastuzumab therapy. Cancer Letters 187:1-2, 223-228
CrossRef2022
Hans-Joachim Lück, Henri Roché. (2002) Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Critical Reviews in Oncology/Hematology 44, 15-30
CrossRef2023
Isaac Cohen, Mary Tagliaferri, Debu Tripathy. (2002) Traditional Chinese medicine in the treatment of breast cancer. Seminars in Oncology 29:6, 563-574
CrossRef2024
Abbas Ghaderi, Mohammad Vasei, Sa Maleck-Hosseini, Behronz Gharesi-Fard, Maliheh Khodami, Mehrnoosh Doroudchi, Helmout Modjtahedi. (2002) The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathology & Oncology Research 8:4, 252-256
CrossRef2025
T Hoang. (2002) Novel therapies for lung cancer. Surgical Oncology 11:4, 229-241
CrossRef2026
Ye Zhang, Jiang Yu, Emmanual Unni, Tsang C. Shao, Bicheng Nan, Thiti Snabboon, Susan Kasper, Francesca Andriani, Larry Denner, Marco Marcelli. (2002) Monogene and Polygene Therapy for the Treatment of Experimental Prostate Cancers by Use of Apoptotic Genes bax and bad Driven by the Prostate-Specific Promoter ARR 2 PB. Human Gene Therapy 13:17, 2051-2064
CrossRef2027
Masaki Fujimura, Noriyuki Katsumata, Hiroshi Tsuda, Naoko Uchi, Satomi Miyazaki, Takao Hidaka, Masatoshi Sakai, Shigeru Saito. (2002) HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. Cancer Science 93:11, 1250-1257
CrossRef2028
Thomas A. Buchholz, David N. Stivers, James Stec, Mark Ayers, Edward Clark, Andrew Bolt, Aysegul A. Sahin, W. Fraser Symmans, Kenneth R. Hess, Henry M. Kuerer, Vicente Valero, Gabriel N. Hortobagyi, Lajos Pusztai. (2002) Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. The Cancer Journal 8:6, 461-468
CrossRef2029
Jeffrey S Ross, Geoffrey S Ginsburg. (2002) Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. Expert Review of Molecular Diagnostics 2:6, 531-541
CrossRef2030
Tania Crombet-Ramos, Janusz Rak, Rolando P
CrossRef2031
Katya M. Sanchez, Christopher J. Sweeney, Robert Mass, Michael O. Koch, George J. Eckert, William A. Geary, Lee Ann Baldridge, Shaobo Zhang, John N. Eble, Liang Cheng. (2002) Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer 95:8, 1650-1655
CrossRef2032
Leslie C. Lai. (2002) Role of Steroid Hormones and Growth Factors in Breast Cancer. Clinical Chemistry and Laboratory Medicine 40:10, 969-974
CrossRef2033
John W. Park, Michelle E. Michelle. (2002) Resistance to Trastuzumab: Mechanistic Uncertainties. Clinical Breast Cancer 3:4, 258-259
CrossRef2034
Clifford Hudis. (2002) Breast Cancer and Leukemia: The forest for the trees?. Annals of Surgical Oncology 9:8, 717-718
CrossRef2035
Andy Millar. (2002) Limitations of combination anti-angiogenesis and chemotherapy. Nature Reviews Cancer 2:10,
CrossRef2036
Deborah L. Keefe. (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:7, 1592-1600
CrossRef2037
Rosemary L. Balleine, Richard F. Kefford. (2002) Targeting molecular mechanisms in cancer. ANZ Journal of Surgery 72:10, 760-763
CrossRef2038
Fabio Calabrò, Cora N. Sternberg. (2002) Localized and locally advanced bladder cancer. Current Treatment Options in Oncology 3:5, 413-428
CrossRef2039
Fatima Cardoso, Martine J. Piccart, Virginie Durbecq, Angelo Di Leo. (2002) Resistance to Trastuzumab: A Necessary Evil or a Temporary Challenge?. Clinical Breast Cancer 3:4, 247-257
CrossRef2040
B MA, C BRITTEN, L SIU. (2002) Clinical trial designs for targeted agents. Hematology/Oncology Clinics of North America 16:5, 1287-1305
CrossRef2041
Kenji Akita, Hiroshi Inagaki, Shigeki Sato, Takashi Niimi, Hiroyoshi Maeda, Shigemitsu Ninomiya, Hiroyuki Achiwa, Haruhiko Kawaguchi, Yosuke Yamakawa, Yoshitaka Fujii, Shigeki Shimizu, Tadaaki Eimoto, Ryuzo Ueda. (2002) p185HER-2/neu and p21CIP1/WAF1 Expression in Primary Tumors and Lymph Node Metastases in Non-small Cell Lung Cancer. Cancer Science 93:9, 1007-1011
CrossRef2042
Ian E Smith. (2002) New drugs for breast cancer. The Lancet 360:9335, 790-792
CrossRef2043
Regina Gandour-Edwards, Primo N. Lara, Ann K. Folkins, Janine M. LaSalle, Laurel Beckett, Yueju Li, Frederick J. Meyers, Ralph DeVere-White. (2002) DoesHER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95:5, 1009-1015
CrossRef2044
Ingo K Mellinghoff, Charles L Sawyers. (2002) The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3:5, 603-623
CrossRef2045
David A. Katz. (2002) From bench to bedside: a diagnostics framework for pharmacogenetics research. Molecular Genetics and Metabolism 77:1-2, 57-60
CrossRef2046
F Salazar-Onfray, M López, A Lundqvist, A Aguirre, A Escobar, A Serrano, C Korenblit, M Petersson, V Chhajlani, O Larsson, R Kiessling. (2002) Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. British Journal of Cancer 87:4, 414-422
CrossRef2047
David B Agus, Robert W Akita, William D Fox, Gail D Lewis, Brian Higgins, Paul I Pisacane, Julie A Lofgren, Charles Tindell, Douglas P Evans, Krista Maiese, Howard I Scher, Mark X Sliwkowski. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:2, 127-137
CrossRef2048
Jeffrey S. Ross, Geoffrey S. Ginsburg. (2002) Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discovery Today 7:16, 859-864
CrossRef2049
Jose Baselga. (2002) A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2:2, 93-95
CrossRef2050
C. Kollmannsberger, F. Mayer, H. Pressler, S. Koch, L. Kanz, J. W. Oosterhuis, L. H. J. Looijenga, C. Bokemeyer. (2002) Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 95:2, 301-308
CrossRef2051
Jean-Pierre Mach. 2002. Tumours: Targeting of Monoclonal Antibodies for Imaging and Potential for Therapy. .
CrossRef2052
Raymond Tubbs, Marek Skacel, James Pettay, Richard Powell, Jonathan Myles, David Hicks, Joseph Sreenan, Patrick Roche, Mark H. Stoler, James Hainfeld. (2002) Interobserver Interpretative Reproducibility of GOLDFISH, A First Generation Gold-Facilitated Autometallographic Bright Field In Situ Hybridization Assay for HER-2/neu Amplification in Invasive Mammary Carcinoma. The American Journal of Surgical Pathology 26:7, 908-913
CrossRef2053
Ali M Ardekani, Lance A Liotta, Emanuel F Petricoin. (2002) Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Review of Molecular Diagnostics 2:4, 312-320
CrossRef2054
Yee-Lu Tham, Mario S Verani, Jenny Chang. (2002) Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer. Breast Cancer Research and Treatment 74:2, 131-134
CrossRef2055
Philip A Watson, Kwanghee Kim, Kai-Shun Chen, Michael N Gould. (2002) Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. Cancer Cell 2:1, 67-79
CrossRef2056
Ralph G. Zinner, Jeri Kim, Roy S. Herbst. (2002) Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37:1, 17-27
CrossRef2057
D. Gancberg. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Annals of Oncology 13:7, 1036-1043
CrossRef2058
Trisha Gura. (2002) Therapeutic antibodies: Magic bullets hit the target. Nature 417:6889, 584-586
CrossRef2059
S. Paik. (2002) Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. CancerSpectrum Knowledge Environment 94:11, 852-854
CrossRef2060
P. C. Roche. (2002) Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. CancerSpectrum Knowledge Environment 94:11, 855-857
CrossRef2061
J. A. Zujewski. (2002) "Build Quality in"--HER2 Testing in the Real World. CancerSpectrum Knowledge Environment 94:11, 788-789
CrossRef2062
Daniel F Hayes, Ann D Thor. (2002) c-erbB-2 in breast cancer: Development of a clinically useful marker. Seminars in Oncology 29:3, 231-245
CrossRef2063
Martin F Fey. (2002) Impact of the Human Genome Project on the clinical management of sporadic cancers. The Lancet Oncology 3:6, 349-356
CrossRef2064
Maurie Markman, Tarek M Mekhail. (2002) Paclitaxel in cancer therapy. Expert Opinion on Pharmacotherapy 3:6, 755-766
CrossRef2065
Lucio Crinò, Federico Cappuzzo. (2002) Present and future treatment of advanced non–small cell lung cancer. Seminars in Oncology 29:3, 9-16
CrossRef2066
Fred R. Hirsch, Wilbur A. Franklin, Paul A. Bunn. (2002) What is the role of HER-2/neu and trastuzumab (HERCEPTIN®) in lung cancer?. Lung Cancer 36:3, 263-264
CrossRef2067
R. I. NICHOLSON, I. R. HUTCHESON, M. E. HARPER, J. M. KNOWLDEN, D. BARROW, R. A. McCLELLAND, H. E. JONES, A. E. WAKELING, J.M. W. GEE. (2002) Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer. Annals of the New York Academy of Sciences 963:1, 104-115
CrossRef2068
Rajeev Gupta, Caroline L. Knight, Barbara J. Bain. (2002) Receptor tyrosine kinase mutations in myeloid neoplasms. British Journal of Haematology 117:3, 489-508
CrossRef2069
Elise R. Hoff, Raymond R. Tubbs, Jonathan L. Myles, Gary W. Procop. (2002) HER2/neu Amplification in Breast Cancer: Stratification by Tumor Type and Grade. American Journal of Clinical Pathology 117:6, 916-921
CrossRef2070
M Morris. (2002) Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surgical Oncology 11:1-2, 13-23
CrossRef2071
Primo N. Lara, Frederick J. Meyers, Carl R. Gray, Regina Gandour Edwards, Paul H. Gumerlock, Caren Kauderer, Garrett Tichauer, Przemyslaw Twardowski, James H. Doroshow, David R. Gandara. (2002) HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer 94:10, 2584-2589
CrossRef2072
F R Hirsch, M Varella-Garcia, W A Franklin, R Veve, L Chen, B Helfrich, C Zeng, A Baron, P A Bunn. (2002) Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. British Journal of Cancer 86:9, 1449-1456
CrossRef2073
Henry M. Kuerer, George E. Peoples, Aysegul A. Sahin, James L. Murray, S. Eva Singletary, Agapito Castilleja, Kelly K. Hunt, David M. Gershenson, Constantin G. Ioannides. (2002) Axillary Lymph Node Cellular Immune Response to HER-2/ neu Peptides in Patients with Carcinoma of the Breast. Journal of Interferon & Cytokine Research 22:5, 583-592
CrossRef2074
Jose Baselga, Larry Norton. (2002) Focus on breast cancer. Cancer Cell 1:4, 319-322
CrossRef2075
Steven A. Crone, You-Yang Zhao, Lian Fan, Yusu Gu, Susumu Minamisawa, Yang Liu, Kirk L. Peterson, Ju Chen, Ronald Kahn, Gianluigi Condorelli, John Ross Jr, Kenneth R. Chien, Kuo-Fen Lee. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine 8:5, 459-465
CrossRef2076
Yoav Avidor, Nicola J Mabjeesh, Isabel Pimenta, Haim Matzkin. (2002) Biotechnology and drug discovery—the future is here: a guide for the practicing urologist. Urology 59:5, 643-651
CrossRef2077
Ming Tan, Tong Jing, Keng-Hsueh Lan, Christopher L Neal, Ping Li, Sangkyou Lee, Dexing Fang, Yoichi Nagata, Jiaxin Liu, Ralph Arlinghaus, Mien-Chie Hung, Dihua Yu. (2002) Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. Molecular Cell 9:5, 993-1004
CrossRef2078
Jeremy Clark, Sandra Edwards, Megan John, Penny Flohr, Tony Gordon, Karine Maillard, Ian Giddings, Carolanne Brown, Azadeh Bagherzadeh, Colin Campbell, Janet Shipley, Richard Wooster, Colin S. Cooper. (2002) Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes, Chromosomes and Cancer 34:1, 104-114
CrossRef2079
Raymond Tubbs, James Pettay, Marek Skacel, Richard Powell, Mark Stoler, Patrick Roche, James Hainfeld. (2002) Gold-Facilitated in Situ Hybridization. The American Journal of Pathology 160:5, 1589-1595
CrossRef2080
Gilbert Spizzo, Peter Obrist, Christian Ensinger, Igor Theurl, Martina D
CrossRef2081
Anne Vincent-Salomon, Michel Jouve, Pascal Genin, Paul Fr
CrossRef2082
Helen K Chew. (2002) Medical Management of Breast Cancer: Today and Tomorrow. Cancer Biotherapy & Radiopharmaceuticals 17:2, 137-149
CrossRef2083
Jean-Marc A Nabholtz, David M Reese, Mary-Ann Lindsay, Alessandro Riva. (2002) Combination chemotherapy for metastatic breast cancer. Expert Review of Anticancer Therapy 2:2, 169-180
CrossRef2084
T Tejada-Berges, CO Granai, M Gordinier, W Gajewski. (2002) Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Review of Anticancer Therapy 2:2, 143-150
CrossRef2085
Kavita Maung, Lori Johnson, Joyce O'shaughnessy. (2002) 2001 Highlights from: San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-13, 2001, Focus on Novel Approaches in Breast Cancer. Clinical Breast Cancer 3:1, 21-25
CrossRef2086
P. Eliopoulos, M. Q. Mohammed, K. Henry, S. Retsas. (2002) Overexpression of HER-2 in thick melanoma. Melanoma Research 12:2, 139-145
CrossRef2087
Funda Meric, Mien-Chie Hung, Gabriel N Hortobagyi, Kelly K Hunt. (2002) HER2/neu in the management of invasive breast cancer. Journal of the American College of Surgeons 194:4, 488-501
CrossRef2088
Johann S. de Bono, Eric K. Rowinsky. (2002) The ErbB receptor family: a therapeutic target for cancer. Trends in Molecular Medicine 8:4, S19-S26
CrossRef2089
David R. Spigel, Harold J. Burstein. (2002) HER2 overexpressing metastatic breast cancer. Current Treatment Options in Oncology 3:2, 163-174
CrossRef2090
Tyler O Kirby, Ronald Alvarez, Warner Huh. (2002) Immunotherapy of ovarian cancer. Expert Opinion on Biological Therapy 2:4, 409-417
CrossRef2091
Yotaro Izumi, Lei Xu, Emmanuelle di Tomaso, Dai Fukumura, Rakesh K. Jain. (2002) Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416:6878, 279-280
CrossRef2092
Deepti Shukla, Ravindra Veeramachaneni, Fleurette Abreo, Mary Lowery Nordberg. (2002) HER-2/neu Status: Comparison of Quantitative Immunohistochemistry by Automated Cellular Imaging and Fluorescence In Situ Hybridization. Pathology Case Reviews 7:2, 75-80
CrossRef2093
Laura K Shawver, Dennis Slamon, Axel Ullrich. (2002) Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:2, 117-123
CrossRef2094
Brian Leyland-Jones. (2002) Trastuzumab: hopes and realities. The Lancet Oncology 3:3, 137-144
CrossRef2095
Tomohiro Akatsuka, Takuro Wada, Yasuo Kokai, Satoshi Kawaguchi, Kazuo Isu, Katsushige Yamashiro, Toshihiko Yamashita, Norimasa Sawada, Shinya Yamawaki, Seiichi Ishii. (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:5, 1397-1404
CrossRef2096
Andrea de Matteis, Francesco Nuzzo, Giuseppe D'Aiuto, Vincenzo Labonia, Gabriella Landi, Emanuela Rossi, Angelo Antonio Mastro, Gerardo Botti, Ermelinda De Maio, Francesco Perrone. (2002) Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer 94:4, 895-901
CrossRef2097
Michael J. Morris, Victor E. Reuter, W. Kevin Kelly, Susan F. Slovin, Kate Kenneson, David Verbel, Iman Osman, Howard I. Scher. (2002) HER-2 profiling and targeting in prostate carcinoma. Cancer 94:4, 980-986
CrossRef2098
Christopher G Azzoli, Lee M Krug, Vincent A Miller, Mark G Kris, Robert Mass. (2002) Trastuzumab in the treatment of non–small cell lung cancer. Seminars in Oncology 29:1, 59-65
CrossRef2099
Sanjay Goel, Sridhar Mani, Roman Perez-Soler. (2002) Tyrosine kinase inhibitors: A clinical perspective. Current Oncology Reports 4:1, 9-19
CrossRef2100
Bruce E Elliott, Wesley L Hung, Alexander H Boag, Alan B Tuck. (2002) The role of hepatocyte growth factor (scatter factor) in epithelialmesenchymal transition and breast cancer. Canadian Journal of Physiology and Pharmacology 80:2, 91-102
CrossRef2101
Robert A Wolff. (2002) Exploiting molecular targets in pancreatic cancer. Hematology/Oncology Clinics of North America 16:1, 139-157
CrossRef2102
Howard L McLeod. (2002) Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Review of Anticancer Therapy 2:1, 113-119
CrossRef2103
Edith A. Perez, Patrick C. Roche, Robert B. Jenkins, Carol A. Reynolds, Kevin C. Halling, James N. Ingle, Lester E. Wold. (2002) HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization. Mayo Clinic Proceedings 77:2, 148-154
CrossRef2104
E. A. Perez, P. C. Roche, R. B. Jenkins, C. A. Reynolds, K. C. Halling, J. N. Ingle, L. E. Wold. (2002) HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization. Mayo Clinic Proceedings 77:2, 148-154
CrossRef2105
Lyndsay Harris, Gerald Batist, Robert Belt, Douglas Rovira, Rudolph Navari, Nozar Azarnia, Lauri Welles, Eric Winer, . (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:1, 25-36
CrossRef2106
Joseph A. Sparano, David L. Brown, Antonio C. Wolff. (2002) Predicting Cancer Therapy???Induced Cardiotoxicity. Drug Safety 25:5, 301-311
CrossRef2107
Richard N. Re. (2002) The Origins of Intracrine Hormone Action. The American Journal of the Medical Sciences 323:1, 43-48
CrossRef2108
Kate McKeage, Caroline M. Perry. (2002) Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2*. American Journal of Cancer 1:3, 217-221
CrossRef2109
Romano Danesi, Stefano Fogli, Alessandra Gennari, Pierfranco Conte, Mario Del Tacca. (2002) Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. Clinical Pharmacokinetics 41:6, 431-444
CrossRef2110
Kate McKeage, Caroline M. Perry. (2002) Trastuzumab. Drugs 62:1, 209-243
CrossRef2111
Frances O'Malley. (2002) HER2 status in primary breast cancer and regional metastases are highly concordant. Advances in Anatomic Pathology 9:1, 74-75
CrossRef2112
Michael S. Simon, Dina Ibrahim, Lisa Newman, Miron Stano. (2002) Efficacy and Economics of Hormonal Therapies for Advanced Breast Cancer. Drugs & Aging 19:6, 453-463
CrossRef2113
Catherine Van Poznak, Andrew D. Seidman. 2002. Breast Cancer. , 287-299.
CrossRef2114
Esther Zwick, Johannes Bange, Axel Ullrich. (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine 8:1, 17-23
CrossRef2115
Mark Hartley, Paula Ghaneh, Robert Sutton, John P Neoptolemos, Conor J Magee. (2002) The role of adjuvant therapy for pancreatic cancer. Expert Opinion on Investigational Drugs 11:1, 87-107
CrossRef2116
Kimmo J. Savinainen, Outi R. Saramäki, Marika J. Linja, Ola Bratt, Teuvo L.J. Tammela, Jorma J. Isola, Tapio Visakorpi. (2002) Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer. The American Journal of Pathology 160:1, 339-345
CrossRef2117
Shinobu Umemura, Yasutomo Sekido, Hitoshi Itoh, R. Yoshiyuki Osamura. (2002) Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab). ACTA HISTOCHEMICA ET CYTOCHEMICA 35:2, 77-81
CrossRef2118
Jean-Emmanuel Kurtz, Patrick Dufour. (2002) Strategies for Improving Quality of Life in Older Patients with Metastatic Breast Cancer. Drugs & Aging 19:8, 605-622
CrossRef2119
Ronald de Wit, Joaquim Bellmunt. (2002) Chemotherapy in Metastatic Urothelial Cancer. American Journal of Cancer 1:1, 23-31
CrossRef2120
J. Albanell, J. Baselga. (2001) Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect. JNCI Journal of the National Cancer Institute 93:24, 1830-1832
CrossRef2121
Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, M. Pollak. (2001) Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). JNCI Journal of the National Cancer Institute 93:24, 1852-1857
CrossRef2122
Hitoshi Tsuda, Futoshi Akiyama, Hiroshi Terasaki, Tadashi Hasegawa, Masafumi Kurosumi, Mitsunobu Shimadzu, Shunji Yamamori, Goi Sakamoto. (2001) Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Cancer 92:12, 2965-2974
CrossRef2123
Thomas M Behr, Martin P Béhé. (2001) Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. Expert Review of Anticancer Therapy 1:4, 501-505
CrossRef2124
Giampietro Gasparini. (2001) Metronomic scheduling: the future of chemotherapy?. The Lancet Oncology 2:12, 733-740
CrossRef2125
A.J.E. Freebairn, A.T.J. Last, T.M. Illidge. (2001) Trastuzumab: Designer Drug or Fashionable Fad?. Clinical Oncology 13:6, 427-433
CrossRef2126
Edith A. Perez. (2001) The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies. Current Oncology Reports 3:6, 516-522
CrossRef2127
Stuart J. Schnitt, MD, Timothy W. Jacobs, MD. (2001) Current Status of HER2 Testing. American Journal of Clinical Pathology 116:6, 806-810
CrossRef2128
John Crown. (2001) A “bureausceptic” view of cancer drug rationing. The Lancet 358:9294, 1660
CrossRef2129
R BAST, G MILLS, R YOUNG. (2001) Translational research – traffic on the bridge. Biomedecine & Pharmacotherapy 55:9-10, 565-571
CrossRef2130
Antonio C. Wolff. (2001) Systemic therapy. Current Opinion in Oncology 13:6, 436-449
CrossRef2131
Wolfgang Hinterberger, Margareta Hinterberger-Fischer. (2001) Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy. Expert Opinion on Biological Therapy 1:6, 1029-1048
CrossRef2132
Jeffrey S Ross, Barry Greene. (2001) Targeted therapy in oncology: the agony and ecstasy of personalized medicine. Expert Review of Anticancer Therapy 1:3, 321-322
CrossRef2133
Gottfried Konecny. (2001) Commentary on “Platinum Compounds in the Treatment of Advanced Breast Cancer”. Clinical Breast Cancer 2:3, 209
CrossRef2134
Klaus Pantel, Marcus Otte. (2001) Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Seminars in Cancer Biology 11:5, 327-337
CrossRef2135
Shinobu Umemura, Goi Sakamoto, Hironobu Sasano, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yutaka Tokuda, Toru Watanabe, Masakazu Toi, Tadashi Hasegawa, R. Yoshiyuki Osamura. (2001) Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab). Breast Cancer 8:4, 316-320
CrossRef2136
C Chandra Kumar, Vincent Madison. (2001) Drugs targeted against protein kinases. Expert Opinion on Emerging Drugs 6:2, 303-315
CrossRef2137
Yutaka Tokuda, Yasuhiro Suzuki, Masatoshi Ohta, Yuki Saito, Mitsuhiro Kubota, Tomoo Tajima, Shinobu Umemura, R. Yoshiyuki Osamura. (2001) Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan. Breast Cancer 8:4, 310-315
CrossRef2138
(2001) Trastuzumab and Breast Cancer. New England Journal of Medicine 345:13, 995-998
Full Text2139
Noreen P. Dowd, Michael Scully, Sharon R. Adderley, Anthony J. Cunningham, Desmond J. Fitzgerald. (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. Journal of Clinical Investigation 108:4, 585-590
CrossRef2140
Richard Bell. (2001) Duration of therapy in metastatic breast cancer: management using Herceptin®. Anti-Cancer Drugs 12:7, 561-568
CrossRef2141
Ashwin Gollerkeri, Laurie Harrold, Michal Rose, Diwaker Jain, Barbara Ann Burtness. (2001) Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience. International Journal of Cancer 93:1, 139-141
CrossRef2142
E. Eisenhauer, J. Dancey. (2001) Impact of new non-cytotoxics in the treatment of ovarian cancer. International Journal of Gynecological Cancer 11:s1, 68-72
CrossRef2143
J.W. Park, D.B. Kirpotin, K. Hong, R. Shalaby, Y. Shao, U.B. Nielsen, J.D. Marks, D. Papahadjopoulos, C.C. Benz. (2001) Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release 74:1-3, 95-113
CrossRef2144
Kavita Maung, Joyce O'Shaughnessy. (2001) Recent Data with Trastuzumab/Chemotherapy Combinations in HER2-Overexpressing Breast Cancer. Clinical Breast Cancer 2:2, 107-109
CrossRef2145
M. Verrill. (2001) Anthracyclines in breast cancer: therapy and issues of toxicity. The Breast 10, 8-15
CrossRef2146
Paul A Clarke, Paul Workman. (2001) Innovative cancer drug targets: genomics, transcriptomics and clinomics. Expert Opinion on Pharmacotherapy 2:6, 911-915
CrossRef2147
Eisenhauer, Elizabeth A., . (2001) From the Molecule to the Clinic — Inhibiting HER2 to Treat Breast Cancer. New England Journal of Medicine 344:11, 841-842
Full Text2148
Heikki Joensuu, Sasa Dimitrijevic. (2001) Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours. Annals of Medicine 33:7, 451-455
CrossRef2149
Dawn N. Waterhouse, Paul G. Tardi, Lawrence D. Mayer, Marcel B. Bally. (2001) A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form. Drug Safety 24:12, 903-920
CrossRef
